BACKGROUND OF THE INVENTION Protein transport and secretion are essential for cellular function. Protein transport is mediated by a signal peptide located at the amino terminus of the protein to be transported or secreted.

The signal peptide is comprised of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory pathway or remain in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes.

Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Proteins that are retained in the plasma membrane contain one or more transmembrane domains, each comprised of about 20 hydrophobic amino acid residues. Proteins that are secreted from the cell are generally synthesized as inactive precursors that are activated by post-translational processing events during transit through the secretory pathway. Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal peptidase. Other events that may occur during protein transport include chaperone-dependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex. Examples of secretory proteins with amino terminal signal peptides are discussed below and include proteins with important roles in cell-to-cell signaling. Such proteins include transmembrane receptors and cell surface markers, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, neuropeptides, vasomediators, ion channels, transporters/pumps, and proteases. (Reviewed in Alberts, B. et al.

(1994) Molecular Biology of The Cell, Garland Publishing, New York NY, pp. 557-560, 582-592.) G-protein coupled receptors (GPCRs) comprise a superfamily of integral membrane proteins which transduce extracellular signals. Not all GPCRs contain N-terminal signal peptides. GPCRs include receptors for biogenic amines such as dopamine, epinephrine, histamine, glutamate (metabotropic-type), acetylcholine (muscarinic-type), and serotonin; for lipid mediators of inflammation such as prostaglandins, platelet activating factor, and leukotrienes; for peptide hormones such as calcitonin, C5a anaphylatoxin, follicle stimulating hormone, gonadotropin releasing hormone, neurokinin, oxytocin, and thrombin; and for sensory signal mediators such as retinal photopigments and olfactory stimulatory molecules. The structure of these highly conserved receptors consists of seven hydrophobic transmembrane regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. The N-terminus interacts with ligands, the disulfide bridges interact with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate second messengers such as cyclic AMP, phospholipase C, inositol triphosphate, or ion channels. (Reviewed in Watson, S. and Arkinstall, S.

(1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; and Bolander, F. F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176.) Other types of receptors include cell surface antigens identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)- based"shot gun"teclmiques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation"based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a"cluster of differentiation"or"CD" designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego CA, pp. 17-20.) Matrix proteins (MPs) are transmembrane and extracellular proteins which function in formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, MPs may be heavily glycosylated and may contain an Arginine-Glycine-Aspartate (RGD) tripeptide motif which may play a role in adhesive interactions. MPs include extracellular proteins such as fibronectin, collagen, galectin, vitronectin and its proteolytic derivative somatomedin B; and cell adhesion receptors such as cell adhesion molecules (CAMs), cadherins, and integrins. (Reviewed in Ayad, S. et al. (1994) The Extracellular Matrix Facts Book, Academic Press, San Diego CA, pp. 2- 16; Ruoslahti, E. (1997) Kidney Int. 51: 1413-1417; Sjaastad, M. D. and Nelson, W. J. (1997) BioEssays 19: 47-55.) Cytokines are secreted by hematopoietic cells in response to injury or infection. Interleukins, neurotrophins, growth factors, interferons, and chemokines all define cytokine families that work in conjunction with cellular receptors to regulate cell proliferation and differentiation. In addition, cytokines effect activities such as leukocyte migration and function, hematopoietic cell proliferation, temperature regulation, acute response to infection, tissue remodeling, and apoptosis.

Chemokines, in particular, are small chemoattractant cytokines involved in inflammation, leukocyte proliferation and migration, angiogenesis and angiostasis, regulation ofhematopoiesis, HIV infectivity, and stimulation of cytokine secretion. Chemokines generally contain 70-100 amino acids and are subdivided into four subfamilies based on the presence of conserved cysteine-based motifs.

(Callard, R. and Gearing, A. (1994) The Cytokine Facts Book, Academic Press, New York NY, pp.

181-190,210-213, 223-227.) Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with MPs for activity. Complex interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and ! differentiation factors act on cells in their local environment (paracrine signaling). There are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, insulin-like growth factor, and platelet-derived growth factor. The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs). Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytesj T- lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell, precursors. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin which function as hormones to regulate cellular functions other than proliferation.

Growth and differentiation factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of tumors. During hematopoiesis, growth factor misregulation can result in anemias, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes.

(Reviewed in Pimente, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor MI, pp. 1-9.) Proteolytic enzymes or proteases either activate or deactivate proteins by hydrolyzing peptide bonds. Proteases are found in the cytosol, in membrane-bound compartments, and in the extracellular space. The major families are the zinc, serine, cysteine, thiol, and carboxyl proteases.

Ion channels, ion pumps, and transport proteins mediate the transport of molecules across cellular membranes. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis. Symporters and antiporters transport ions and small molecules such as amino acids, glucose, and drugs. Symporters transport molecules and ions unidirectionally, and antiporters transport molecules and ions bidirectionally. Transporter superfamilies include facilitative transporters and active ATP-binding cassette transporters which are involved in multiple-drug resistance and the targeting of antigenic peptides to MHC Class I molecules. These transporters bind to a specific ion or other molecule and undergo a conformational change in order to transfer the ion or molecule across the membrane. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York NY, pp. 523-546.) Ion channels are formed by transmembrane proteins which create a lined passageway across the membrane through which water and ions, such as Na+, K+, Ca2+, and Cl-, enter and exit the cell.

For example, chloride channels are involved in the regulation of the membrane electric potential as well as absorption and secretion of ions across the membrane. Chloride channels also regulate the internal pH of membrane-bound organelles.

Ion pumps are ATPases which actively maintain membrane gradients. Ion pumps are classified as P, V, or F according to their structure and function. All have one or more binding sites for ATP in their cytosolic domains. The P-class ion pumps include Cal+ ATPase and Na+lK+ ATPase and function in transporting H+, Na+, K+, and Ca'ions. P-class pumps consist of two a and two P transmembrane subunits. The V-and F-class ion pumps have similar structures but transport only H+.

F class H+ pumps mediate transport across the membranes of mitochondria and chloroplasts, while V- class H+ pumps regulate acidity inside lysosomes, endosomes, and plant vacuoles.

A family of structurally related intrinsic membrane proteins known as facilitative glucose transporters catalyze the movement of glucose and other selected sugars across the plasma membrane. The proteins in this family contain a highly conserved, large transmembrane domain comprised of 12 a-helices, and several weakly conserved, cytoplasmic and exoplasmic domains.

(Pessin, J. E. and Bell, G. I. (1992) Annu. Rev. Physiol. 54: 911-930. ) Amino acid transport is mediated by Na+ dependent amino acid transporters. These transporters are involved in gastrointestinal and renal uptake of dietary and cellular amino acids and in neuronal reuptake of neurotransmitters. Transport of cationic amino acids is mediated by the system y+ family and the cationic amino acid transporter (CAT) family. Members of the CAT family share a high degree of sequence homology, and each contains 12-14 putative transmembrane domains. (Ito, K. and Groudine, M. (1997) J. Biol. Chem. 272: 26780-26786. ) Hormones are secreted molecules that travel through the circulation and bind to specific receptors on the surface of, or within, target cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category includes small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category includes hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines and peptide hormones such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotropic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biology, Scientific American Books Inc, New York NY, pp. 856-864.) Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C. R. et al. (1985) Endocrine Physiology. Oxford University Press, New York, NY, pp. 57-62.) The discovery of new secretory molecules satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, cell signaling and the expression of secretory molecules.

SUMMARY OF THE INVENTION The present invention relates to nucleic acid sequences comprising human polynucleotides encoding secretory polypeptides that contain signal peptides and/or transmembrane domains. These human polynucleotides (sptm) as presented in the Sequence Listing uniquely identify partial or full length genes encoding structural, functional, and regulatory polypeptides involved in cell signaling.

The invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161. In another alternative, the polynucleotide comprises at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d).

The invention further provides a composition for the detection of expression of secretory polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ 1D NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d); and a detectable label.

The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a polynucleotide sequence of a polyneucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ ID NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a) ; d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target, polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 30 contiguous nucleotides. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.

The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a secretory polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the secretory polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ NID NU : 1-161 ; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID N0 : 1-161 ; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii) ; and v) an RNA equivalent of i) through iv), and b) recovering the secretory polypeptide so expressed. The invention additionally provides a method wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324.

The invention also provides an isolated secretory polypeptide (SPTM) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-161. The invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324. The method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324.

The invention further provides a microarray wherein at least one element of the microarray is an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID N0 : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ BD NO : 1-161 ; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d).

The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.

Additionally, the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b) ; and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; iii) a polynucleotide complementary to the polynucleotide of i) ; iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ IID NO : 1-161 ; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO : 1-161 ; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and alternatively, the target polynucleotide comprises a polynucleotide sequence of a fragment of a polynucleotide selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

The invention further provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324. In one alternative, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324.

The invention further provides an isolated polynucleotide encoding a polypeptide selected'from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, b) a polypeptide comprising a naturally occurring amino acid. sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162- 324. In one alternative, the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ IOD NO : 1-161.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ IID NO : 162-324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID N0 : 162-324.

The invention further provides a composition comprising a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO : 162- 324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional SPTM, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ IOD NO : 162-324, c) a biologically active fragment of a polypeptide having an. amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional SPTM, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.

In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional SPTM, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO : 162-324. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

DESCRIPTION OF THE TABLES Table 1 shows the sequence identification numbers (SEQ ID NO : s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with the sequence identification numbers (SEQ ID NO : s) and open reading frame identification numbers (ORF IDs) corresponding to polypeptides encoded by the template ID.

Table 2 shows the sequence identification numbers (SEQ ID NO : s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated"start"and"stop" nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. For TM domains, the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of the cell membrane or organelle.

Table 3 shows the sequence identification numbers (SEQ ID NO : s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with the component sequence identification spans (component spans) corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the spans indicating the nucleotide positions along each template.

Table 4 shows the tissue distribution profiles for the templates of the invention.

Table 5 shows the sequence identification numbers (SEQ ID NO : s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the"start"and"stop"nucleotide positions of the polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

Table 6 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 6 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).

Table 7 shows the sequence identification numbers (SEQ ID NO : s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

DETAILED DESCRIPTION OF THE INVENTION Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.

The singular forms"a","an", and"the"include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Definitions As used herein, the lower case"sptm"refers to a nucleic acid sequence, while the upper case "SPTM"refers to an amino acid sequence encoded by sptm. A"full-length"sptm refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.

"Adjuvants"are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunological response.

"Allele"refers to an alternative form of a nucleic acid sequence. Alleles result from a "mutation, "a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic sptm.

An"allelic variant"is an alternative form of the gene encoding SPTM. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered"nucleic acid sequences encoding SPTM include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as SPTM or a polypeptide with at least one functional characteristic of SPTM. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding SPTM, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding SPTM. The encoded protein may also be"altered, "and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent SPTM. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of SPTM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonin. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

"Amino acid sequence"refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.

"Amplification"refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.

"Antibody'refers to intact molecules as well as to fragments thereof, such as Fab, F (ab') 2, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind SPTM polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e. g. , a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled, to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term"aptamer"refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e. g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U. S. Patent No.

5,270, 163), which selects for target-specific aptamer sequences from large combinatorial libraries.

Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e. g. , the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH2), which may improve a desired property, e. g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e. g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system.

Aptamers may be specifically cross-linked to their cognate ligands, e. g. , by photo-activation of a cross-linker. (See, e. g. , Brody, E. N. and L. Gold (2000) J. Biotechnol. 74: 5-13. ) The term"intramer"refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96: 3606-3610).

The term"spiegelmer"refers to an aptamer which includes L-DNA, L-RNA, or other left- handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

"Antisense sequence"refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified base.

"Antisense technology"refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.

A"bin"is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.

"Biologically active"refers to an amino acid sequence having a structural, regulatory, or biochemical function of, a naturally occurring amino acid sequence.

"Clone joining"is a process for combining gene bins based upon the bins'containing sequence : information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.

"Complementary"describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5'-A-G-T-3'pairs with its complement 3'-T-C-A-5').

A"component sequence"is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.

A"consensus sequence"or"template sequence"is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GELVIEW fragment assembly system (Genetics Computer Group (GCG), Madison WI) or using a relational database management system (RDMS).

"Conservative amino acid substitutions"are those substitutions that, when made, least interfere with the properties of the original protein, i. e. , the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.

Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gin, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Glu, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

"Deletion"refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.

"Derivative"refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.

"Differential expression"refers to increased or upregulated ; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons maybe carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

The terms"element"and"array element"refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term"modulate"refers to a change in the activity of SPTM. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of SPTM.

"E-value"refers to the statistical probability that a match between two sequences occurred by chance.

"Exon shuffling"refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A"fragment"is a unique portion of sptm or SPTM which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5,10, 15,16, 20,25, 30,40, 50,60, 75,100, 150,250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.

A fragment of sptm comprises a region of unique polynucleotide sequence that specifically identifies sptm, for example, as distinct from any other sequence in the same genome. A fragment of sptm is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish sptm from related polynucleotide sequences. The precise length of a fragment of sptm and the region of sptm to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SPTM is encoded by a fragment of sptm. A fragment of SPTM comprises a region of unique amino acid sequence that specifically identifies SPTM. For example, a fragment of SPTM is useful as an immunogenic peptide for the development of antibodies that specifically recognize SPTM. The precise length of a fragment of SPTM and the region of SPTM to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A"full length"nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a"full length" polypeptide.

"Hit"refers to a sequence whose annotation will be used to describe a given template.

Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.

"Homology"refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an sptm or between a reference amino acid sequence and a fragment of an SPTM.

"Hybridization"refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the"washing"step. The defined hybridization conditions include the annealing conditions and the washing step (s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i. e. , binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.

Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The T. is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning : A Laboratory Manual, 2nd ed. , vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0. 1% SDS, for 1 hour.

Alternatively, temperatures of about 65°C, 60°C, or 55°C may be used. SSC concentration may be varied from about 0.2 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 g/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.

Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA: DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.

"Immunologically active"or"immunogenic"describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.

"Immune response"can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e. g. , cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An"immunogenic fragment"is a polypeptide or oligopeptide fragment of SPTM which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term"immunogenic fragment"also includes any polypeptide or oligopeptide fragment of SPTM which can be useful in any of the antibody production methods disclosed herein or known in the art.

"Insertion" or "addition" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.

"Labeling"refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.

"Microarray"is any arrangement of nucleic acids, amino acids, antibodies, etc. , on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.

"Linkers"are short stretches of nucleotide sequence which may be added to a vector or an sptm to create restriction endonuclease sites to facilitate cloning."Polylinkers"are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5'or 3' overhangs (e. g., BamHI, EcoRI, and HindE) and those which provide blunt ends (e. g. , EcoRV, SnaBI, and StuI).

"Naturally occurring"refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.

"Nucleic acid sequence"refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense (complementary) strand.

"Oligomer"refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and 30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e. g. , primers for PCR, and are usually chemically synthesized.

"Operably linked"refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.

The phrases"percent identity"and"% identity", as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5: 151-153 and in Higgins, D. G. et al. (1992) CABIOS 8: 189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and"diagonals saved"=4. The"weighted"residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the"percent similarity"between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms can be used that are provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215: 403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http ://www. ncbi. nlm. nih. gov/BLAST/. The BLAST software suite includes various sequence analysis programs including"BLASTN, "that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called"BLAST 2 Sequences"that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences"can be accessed and used interactively at http://www. ncbi. nlm. nih. gov/gorf/bl2/. The "BLAST 2 Sequences"tool can be used for both BLASTN and BLASTP (discussed below).

BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use BLASTN with the"BLAST 2 Sequences"tool Version 2.0. 9 (May-07-1999) set at default parameters. Such default parameters may be, for example: Matrix : BLOSUM62 Rewardformatch : 1 Penalty for mismatch :-2 Open Gap: 5 and Extension Gap : 2 penalties Gap x drop-off.-50 Expect : 10 Word Size : 11 Filter : on Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases"percent identity'and"% identity", as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=l, gap penalty=3, window=5, and"diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the"percent similarity'between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the"BLAST 2 Sequences"tool Version 2.0. 9 (May-07-1999) with BLASTP set at default parameters. Such default parameters may be, for example: Matrix : BLOSUM62 Open Gap : 11 and Extension Gap : 1 penalty Gap x drop-off. 50 Expect : 10 Word Size : 3 Filter : 071 Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

"Post-translational modification"of an SPTM may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the SPTM.

"Probe"refers to sptm or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes."Primers"are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing.

The primer may then be extended along the target DNA strand by a DNA polymerase enzyme.

Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e. g. , by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20,30, 40,50, 60,70, 80,90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. , (1989, Molecular Cloning : A Laboratory Manual, 2nd ed. , vol. 1-3, Cold Spring Harbor Press, Plainview NY) ; Ausubel, F. M. et al. , (1999, Short Protocols in Molecular Biology, 4i ed. Greene Publ. John Wiley & Sons Assoc. & Wiley-Intersciences, New York NY); and Innis, M. et al. , (1990; PCR Protocols. A Guide to Methods and Applications, Academic Press, San Diego CA). PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a"mispriming library, "in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs. ) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

"Purified"refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.

A"recombinant nucleic acid"is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.

This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e. g. , by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence.

Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e. g. , based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

"Regulatory element"refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3'untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.

"Reporter"molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An"RNA equivalent, "in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

"Sample"is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e. g. , bodily fluids including, but not limited to, saliva, blood, and urine ; chromosome (s), organelles, or membranes isolated from a cell ; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).

"Specific binding"or"specifically binding"refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e. g. , the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope"A,"the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

"Substitution"refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.

"Substrate"refers to any suitable rigid or semi-rigid support including, e. g. , membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A"transcript image"or"expression profile"refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation"refers to a process by which exogenous DNA enters a recipient cell.

Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.

"Transformants"include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.

A"transgenic organism, "as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A"variant"of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the"BLAST 2 Sequences"tool Version 2. 0 : 9 (May- 07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. The variant may result in"conservative" amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an"allelic" (as defined above),"splice,""species,"or"polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base.

The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc. , Santa Clara CA; described in U. S. Patent Number 5, 837, 458; Chang, C. -C. et al. (1999) Nat. Biotechnol. 17: 793-797; Christians, F. C. et al. (1999) Nat.

Biotechnol. 17: 259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14: 315-319) to alter or improve the biological properties of SPTM, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through"artificial"breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

A"variant"of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the"BLAST 2 Sequences"tool Version 2.0. 9 (May- 07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into"consensus"or"template" sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 2. The sequence identification numbers (SEQ ID NO : s) corresponding to the template IDE are shown in column 1. Segments of the template sequences are defined by the"start"and"stop" nucleotide positions listed in columns 3 and 4. These segments, when translated in the reading frames indicated in column 5, have similarity to signal peptide (SP) or transmembrane (TM) domain consensus sequences, as indicated in column 6.

In yet another embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into"consensus"or"template" sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 7. The sequence identification numbers (SEQ ID NO : s) corresponding to the template IDs are shown in column 1. The template sequences have similarity to GenBank sequences, or'11its,"as designated by the GI Numbers in column 3. The statistical probability of each GenBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.

The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in cell signaling. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.

Derivation of Nucleic Acid Sequences cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc.

(Incyte), Palo Alto CA). Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.

Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepifheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HTJVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.

Sequencing of the cDNAs Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U. S.

Biochemical Corporation, Cleveland OH), Taq polymerase (Applied Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg MD), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double- stranded templates. Chain termination reaction products may be electrophoresed on urea- polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed.

Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno NV), Peltier thermal cycler (PTC200 ; MJ Research, Inc. (MJ Research), Watertown MA), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.

The nucleotide sequences of the Sequence Listing have been prepared by current, state-of- the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e. g. , those described in Ausubel, F. M. et al. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY ; and Sambrook, J. et al. (1989) Molecular Cloning. A LaboratorY Manual, Cold Spring Harbor Press, Plainview NY.) Assembly of cDNA Sequences Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as PBRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.

Alternatively, cDNA sequences are used as"component"sequences that are assembled into "template"or"consensus"sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e. g. , the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA).

A series of BLAST comparisons is performed and low-information segments and repetitive elements (e. g. , dinucleotide repeats, Alu repeats, etc. ) are replaced by"n's", or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i. e., nonfinal assembled sequences) containing queued sequences or the sequences themselves.

After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.

Once gene bins have been generated based upon sequence alignments, bins are"clone joined" based upon clone information. Clone joining occurs when the 5'sequence of one clone is present in one bin and the 3'sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are merged.

A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length.

With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete"second strand"synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art.

Extension may thus be used to achieve the full length coding sequence of a gene.

Analysis of the cDNA Sequences The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e. g. , Ausubel, 1997, supra, Chapter 7.7 ; Meyers, R. A. (Ed. ) (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853; and Table 6. ) These analyses comprise both reading frame determinations, e. g. , based on triplet codon periodicity for particular organisms (Fickett, J. W. (1982) Nucleic Acids Res. 10: 5303-5318); analyses of potential start and stop codons ; and homology searches.

Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S. F. (1993) J. Mol. Evol. 36: 290-300; Altschul, S. F. et al.

(1990) J. Mol. Biol. 215 : 403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85: 841-845). Using an appropriate search tool (e. g. , BLAST or FOAM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query sptm or SPTM of the present invention.

Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in"Relational Database for Storing Biomolecule Information," U. S. S. N. 08/947,845, filed October 9,1997 ; "Project-Based Full-Length Biomolecular Sequence Database, "U. S. Patent Number 5,953, 727; and"Relational Database and System for Storing Information Relating to Biomolecular Sequences, "U. S. S. N. 09/034,807, filed March 4,1998, all of which are incorporated by reference herein in their entirety.

Protein hierarchies can be assigned to the putative encoded polypeptide based on, e. g. , motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data,"U. S. Patent Number 6,023, 659, incorporated herein by reference.

Human Secretory Sequences The sptm of the present invention may be used for a variety of diagnostic and therapeutic purposes. For example, an sptm may be used to diagnose a particular condition, disease, or disorder associated with cell signaling. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphom, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune system disorder such as such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves'disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphom, leukemia, and myeloma; and a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinalhemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathy, myasthenia gravis, periodic paralysis, a mental disorder including mood, anxiety, and schizophrenic disorder, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder. The sptm can be used to detect the presence of, or to quantify the amount of, an sptm- related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given sptm can inhibit or inactivate a therapeutically relevant gene related to the sptm.

Analysis of sptm Expression Patterns The expression of sptm may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of sptm expression. For example, the level of expression of sptm may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess. the relative levels of sptm expression in fully or partially differentiated cells or tissues, to determine if changes in sptm expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the analysis of sptm expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.

Hybridization and Genetic Analysis The sptm, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The sptm may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the sptm allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the sptm of the Sequence Listing.

Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ID NO : 1-161 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.

Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ID NO : 1-161 and fragments thereof, can be identified using various conditions of stringency. (See, e. g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152: 399-407; Kimmel, A. R. (1987) Methods Enzymol. 152: 507-511. ) Hybridization conditions are discussed in"Definitions." A probe for use in Southern or northern hybridization may be derived from a fragment of an sptm sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing sptm. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e. g. , various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or W bonding procedures. Such an array may contain any number of sptm and may be produced by hand or by using available devices, materials, and machines.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e. g., Brennan, T. M. et al. (1995) U. S. Patent No. 5,474, 796; Schena, M. et al. (1996) Proc. Natl. Acad.

Sci. USA 93: 10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116 ; Shalon, D. et al. (1995) PCT application W095/35505 ; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94: 2150-2155; and Heller, M. J. et al. (1997) U. S. Patent No. 5,605, 662. ) Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, sptm may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e. g., 32P-ATP, Amersham Pharmacia Biotech).

Additionally the polynucleotides of SEQ ID NO : 1-161 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e. g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, suPra, Chapters 3,5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of sptm in order to analyze, e. g. , regulatory elements.

Genetic Mapping Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.

As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers.

(See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83: 7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site.

In another embodiment of the invention, sptm sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of sptm may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an sptm coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e. g. , human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) ; bacterial P1 constructions, or single chromosome cDNA libraries. (See, e. g. , Harrington, J. J. et al. (1997) Nat.

Genet. 15: 345-355; Price, C. M. (1993) Blood Rev. 7: 127-134; and Trask, B. J. (1991) Trends Genet.

7: 149-154. ) Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e. g. , Meyers, supra, pp. 965-968. ) Correlation between the location of sptm on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder.

The sptm sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.

In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e. g., ataxia-telangiectasia to llq22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation.

(See, e. g. , Gatti, R. A. et al. (1988) Nature 336: 577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc. , among normal, carrier, or affected individuals.

Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e. g. , translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome.

These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.

Diagnostic Uses The sptm of the present invention may be used to design probes useful in diagnostic assays.

Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of sptm expression. Labeled probes developed from sptm sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, sptm, or fragments or oligonucleotides derived from sptm, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If sptm expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.

The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of sptm expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the sptm that are specific to a given human tissue and have not been observed in GenBank or other genome databases.

Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months.

Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.

The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.

In a particular aspect, oligonucleotide primers derived from the sptm of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from sptm are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high- throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc. , San Diego CA).

DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e. g. , hair or skin, or body fluids, e. g. , blood, saliva, semen, etc. , can be amplified using, e. g. , PCR, to identify individuals. (See, e. g., Erlich, H.

(1992) PCR Technology, Freeman and Co. , New York, NY). Similarly, polynucleotides of the present invention can be used as polymorphic markers.

There is also a need for reagents capable of identifying the source of a particular tissue.

Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.

Disease Model Systems Using sptm The polynucleotides encoding SPTM or their mammalian homologs may be"knocked out"in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e. g. , U. S. Patent Number 5,175, 383 and U. S. Patent Number 5,767, 337. ) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e. g. , the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244: 1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue-or developmental stage-specific manner (Marth, J. D.

(1996) Clin. Invest. 97: 1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25: 4323-4330).

Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

The polynucleotides encoding SPTM may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al.

(1998) Science 282 : 1145-1147).

The polynucleotides encoding SPTM of the invention can also be used to create"knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin : technology, a region of sptm is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress sptm, resulting, e. g. , in the secretion of SPTM in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4: 55-74).

Screening Assays SPTM encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e. g. , receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e. g. , a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) Current Protocols in Immunology 1 (2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e. g. , the active site. In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.

An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.

Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay using, e. g. , a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e. g. , blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover, agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Transcript hnaging and Toxicological Testing Another embodiment relates to the use of sptm to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis, "U. S. Patent Number 5, 840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to cell signaling.

Transcript images which profile sptm expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect sptm expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile sptm expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24: 153- 159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113: 467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.

Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds.

While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29,2000, available at http://www. nichs. nih. gov/oc/news/toxchip. htm. ) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of SPTM encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for SPTM to quantify the levels of SPTM expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270: 103- 11; Mendoze, L. G. et al. (1999) Biotechniques 27: 778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol-or amino- reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18 : 533-537), so proteome toxicant signatures maybe useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample.

A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the SPTM encoded by polynucleotides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the SPTM encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Transcript images may be used to profile sptm expression in distinct tissue types. This process can be used to determine cell signaling activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of sptm expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments, for diseases which affect cell signaling activity.

Transcript images of cell lines can be used to assess cell signaling activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in cell signaling activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.

Antisense Molecules The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e. g. , Agrawal, S. , ed. (1996) Antisense Therapeutics, Humana Press Inc. , Totawa NJ; Alama, A. et al. (1997) Pharmacol. Res. 36 (3): 171-178 ; Crooke, S. T. (1997) Adv. Pharmacol.

40: 1-49; Sharma, H. W. and R. Narayanan (1995) Bioessays 17 (12): 1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62 (1) : 11-22. ) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e. g. , Rossi, J. J. et al. (1991) Antisense Res. Dev. 1 (3): 285-288 ; Lee, R. et al. (1998) Biochemistry 37 (3): 900-1010; Pardridge, W. M. et al. (1995) Proc. Natl. Acad. Sci. USA 92 (12): 5592-5596; and Nielsen, P. E. and Haaima ; G.

(1997) Chem. Soc. Rev. 96: 73-78. ) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.

The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by sptm. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by, transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e. g. , Agrawal, supra.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e. g., Slater, J. E., et al. (1998) J. Allergy Clin. Immunol. 102 (3): 469-475; and Scanlon, K. J. , et al. (1995) 9 (13): 1288-1296. ) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e. g., Miller, A. D. (1990) Blood 76: 271 ; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63 (3): 323-347. ) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e. g. , Rossi, J. J. (1995) Br. Med. Bull. 51 (1) : 217-225; Boado, R. J. et al. (1998) J. Pharm Sci. 87 (11): 1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25 (14): 2730-2736. ) Expression In order to express a biologically active SPTM, the nucleotide sequences encoding SPTM or fragments thereof may be inserted into an appropriate expression vector, i. e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding SPTM and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e. g. , Sambrook, supra, Chapters 4,8, 16, and 17 ; and Ausubel, supra, Chapters 9,10, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding SPTM. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e. g. , baculovirus) ; plant cell systems transformed with viral expression vectors (e. g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e. g. , Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e. g. , Sambrook, supra ; Ausubel, 1995, supra, Van Heeke, G. L and S. M. Schuster (1989) J. Biol. Chem. 264: 5503-5509; Bitter, G. A. et al. (1987) Methods Enzymol.

153: 516-544; Scorer, C. A. et al. (1994) Biotechnology 12: 181-184; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91 : 3224-3227 ; Sandig, V. et al. (1996) Hum. Gene Ther. 7: 1937-1945 ; Takamatsu, N. (1987) EMBO J. 6: 307-311; Coruzzi, G. et al. (1984) EMBO J. 3: 1671-1680; Broglie, R. et al. (1984) Science 224: 838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17: 85-105 ; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp.

191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81 : 3655-3659 ; and Harrington, J. J. et al. (1997) Nat. Genet. 15: 345-355. ) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e. g. , Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5 (6): 350-356; Yu, M. et al. , (1993) Proc. Natl. Acad. Sci. USA 90 (13): 6340-6344 ; Buller, R. M. et al. (1985) Nature 317 (6040): 813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31 (3): 219-226 ; and Verma, I. M. and N. Somia (1997) Nature 389: 239-242. ) The invention is not limited by the host cell employed.

For long term production of recombinant proteins in mammalian systems, stable expression of SPTM in cell lines is preferred. For example, sequences encoding SPTM can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e. g. , Wigler, M. et al.

(1977) Cell 11: 223-232; Lowy, I. et al. (1980) Cell 22: 817-823.; Wigler, M. et al. (1980) Proc. Natl.

Acad. Sci. USA 77: 3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150: 1-14; Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85 : 8047-8051; Rhodes, C. A. (1995) Methods Mol. Biol. 55: 121-131.) Therapeutic Uses of sptm The polynucleotides encoding SPTM of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e. g. , in the cases of severe combined immunodeficiency (SCm)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288: 669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al.

(1995) Science 270: 475-480 ; Bordignon, C. et al. (1995) Science 270: 470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75 : 207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6: 643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6: 667-703), thalassemias, familialhypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)); (ii) express a conditionally lethal gene product (e. g, in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e. g. , against human retroviruses, such as human immunodeficiency virus (ERV) (Baltimore, D. (1988) Nature 335 : 395-396 ; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93: 11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in sptm expression or regulation causes disease, the expression of sptm from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in sptm are treated by constructing mammalian expression vectors comprising sptm and introducing these vectors by mechanical means into sptm-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and Anderson, W. F. (1993) Annu. Rev. Biochem. 62: 191- 217; Ivics, Z. (1997) Cell 91: 501-510; Boulay, J-L. and Récipon, H. (1998) Curr. Opin. Biotechnol.

9: 445-450).

Expression vectors that may be effective for the expression of sptm include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). The sptm of the invention maybe expressed using (i) a constitutively active promoter, (e. g. , from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or-actin genes), (ii) an inducible promoter (e. g. , the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci.

U. S. A. 89: 5547-5551; Gossen, M. et al. , (1995) Science 268: 1766-1769; Rossi, F. M. V. and Blau, H. M. (1998) Curr. Opin. Biotechnol. 9: 451-456), commercially available in the T-REX plasmid (Invitrogen) ; the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND ; Invitrogen) ; the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and Blau, H. M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding SPTM from a normal individual.

Commercially available liposom transformation kits (e. g. , the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and Eb, A. J. (1973) Virology 52: 456-467), or by electroporation (Neumann, E. et al.

(1982) EMBO J. 1 : 841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to sptm expression are treated by constructing a retrovirus vector consisting of (i) sptm under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation.

Retrovirus vectors (e. g. , PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U. S. A. 92: 6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61: 1647-1650; Bender, M. A. et al. (1987) J. Virol. 61: 1639-1646; Adam, M. A. and Miller, A. D. (1988) J. Virol. 62: 3802-3806; Dull, T. et al. (1998) J. Virol. 72: 8463-8471; Zufferey, R. et al. (1998) J. Virol. 72: 9873-9880). U. S. Patent Number 5,910, 434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e. g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71: 7020-7029; Bauer, G. et al. (1997) Blood 89: 2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71: 4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. U. S. A. 95: 1201-1206; Su, L.

(1997) Blood 89: 2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver sptm to cells which have one or more genetic abnormalities with respect to the expression of sptm. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27: 263-268). Potentially useful adenoviral vectors are described in U. S. Patent Number 5,707, 618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19: 511-544 and Verma, I. M. and Somia, N. (1997) Nature 18: 389: 239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver sptm to target cells which have one or more genetic abnormalities with respect to the expression of sptm. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing sptm to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169 : 385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U. S. Patent Number 5,804, 413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U. S. Patent Number 5,804, 413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.

F. et al. 1999 J. Virol. 73: 519-532 and Xu, H. et al. , (1994) Dev. Biol. 163: 152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver sptm to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SPV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and Li, K-J. (1998) Curr. Opin. Biotech. 9: 464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e. g. , protease and polymerase).

Similarly, inserting sptm into the alphavirus genome in place of the capsid-coding region results in the production of a large number of sptm RNAs and the synthesis of high levels of SPTM in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228: 74-83). The wide host range of alphaviruses will allow the introduction of sptm into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are weR known to those with ordinary skill in the art.

Antibodies Anti-SPTM antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e. g., Pound J. D. (1998) Immunochemical Protocols, Humana Press, Totowa, NJ.

The amino acid sequence encoded by the sptm of the Sequence Listing may be analyzed by appropriate software (e. g. , LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C- terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation.

Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra, Chapter 11.7).

Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole limpet hemocyanin (KLH; Sigma, St. Louis MO) for antibody production. A peptide encompassing an antigenic region may be expressed from an sptm, synthesized as described above, or purified from human cells.

Procedures well known in the art may be used for the production of antibodies. Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.

In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1 % bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.

Antisera with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.

In another procedure, isolated and purified peptide may be used to immunize mice (about 100 yg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals'B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.

Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

Antibody fragments containing specific binding sites for an epitope may also be generated.

For example, such fragments include, but are not limited to, the F (ab) 2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F (ab') 2 fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra, Chaps. 45-47). Antibodies generated against polypeptide encoded by sptm can be used to purify and characterize full-length SPTM protein and its activity, binding partners, etc.

Assays Using Antibodies Anti-SPTM antibodies may be used in assays to quantify the amount of SPTM found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule.

Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the SPTM and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra).

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U. S. Ser. No. 60/349,946 and U. S. 60/349,413, are hereby expressly incorporated by reference.

EXAMPLES 1. Construction of cDNA Libraries RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly (A+) RNA was isolated using oligo d (T) -coupled paramagnetic particles (Promega Corporation (Promega), Madison WI), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e. g. , the POLY (A) PURE mRNA purification kit (Ambion, Inc., Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e. g. , Ausubel, 1997, supra, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d (T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e. g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XLl-Blue, XLl-BlueMRF, or SOLR from Stratagene or DH5a, I ? H10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD) ; and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R. E. A. L. PREP 96 plasmid purification kit (QIAGEN). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V. B. (1994) Anal. Biochem. 216: 1-14. ) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC- 200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale CA) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII IV. Assembly and Analysis of Sequences Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre- processing editing pathways to eliminate, e. g. , low quality 3'ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e. g. , dinucleotide repeats, Alu repeats, etc. ) were replaced by"n's", or masked, to prevent spurious matches.

Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTN (v. 1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the"forward" reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 3 along with their positions along the template nucleotide sequences.

Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STTTCHER/BXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.

Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5'sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.

The final assembled templates were subsequently annotated using the following procedure.

Template sequences were analyzed using BLASTN (v2.0, NCBI) versus gbpri (GenBank version 135)."Hits"were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i. e. a probability score, of < 1 x 10-8. The hits were subject to frameshift FASTx versus GENPEPT (GenBank version 135). (See Table 6). In this analysis, a homolog match was defined as having an E-value of < 1 x 10-1. The assembly method used above was described in"System and Methods for Analyzing Biomolecular Sequences,"U. S. S. N. 09/276, 534, filed March 25,1999, and the LIFESEQ Gold user manual (Incyte) both incorporated by reference herein.

Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e. g.,"Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data, "U. S. Patent Number 6,023, 659 ;"Relational Database for Storing Biomolecule Information, "U. S. S. N. 08/947, 845, filed October 9,1997 ; "Project-Based Full-Length Biomolecular Sequence Database, "U. S. Patent Number 5,953, 727 ; and"Relational Database and System for Storing Information Relating to Biomolecular Sequences,"U. S. S. N. 09/034,807, filed March 4,1998, all of which are incorporated by reference herein.

The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HUMER software package (available to the public from Washington University School of Medicine, St. Louis MO). (See also World Wide Web site http://pfam. wustl. edu/ for detailed descriptions of Pfam protein domains and families.) Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S. R. (1996) Curr. Opin. Str. Biol. 6: 361-365. ) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template sequences were also translated in all three forward reading frames, and each translation was searched against WHMMER, a program that uses a hidden Markov model (HUM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E. L. et al.

(1998) Proc. Sixth Intl. Conf. On Intelligent Systems for Mol. Biol. , Glasgow et al., eds., The Am.

Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT Press, Cambridge, MA, pp. 175-182. ) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 2.

The results of HMMER analysis as reported in Table 2 may support the results of BLAST analysis as reported in Table 7 or may suggest alternative or additional properties of template-encoded polypeptides not previously uncovered by BLAST or other analyses. Susan, Keep this paragraph ? Template sequences are further analyzed using the bioinformatics tools listed in Table 6, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

Template sequences may be further queried against public databases such as me GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.

The template sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 5. Alternatively, a polypeptide of the invention may begin at any of the methionine residues within the full length translated polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 135) ). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 5 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ ID NO:) for the polypeptide segments of the invention. Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the translated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog. Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog.

V. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e. g. , Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

The basis of the search is the product score, which is defined as: BLAST Score x Percent Identity 5 x minimum {length (Seq. 1), length (Seq. 2)} The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and-4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding SPTM are analyzed with respect to the tissue sources from which they were derived. Polynucleotide sequences encoding SPTM were assembled, at least in part, with overlapping Incyte cDNA sequences. Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue ; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system ; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed ; or urinary tract.

The number of libraries in each category for each polynucleotide sequence encoding SPTM is counted and divided by the total number of libraries across all categories for each polynucleotide sequence encoding SPTM. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category for each polynucleotide sequence encoding SPTM is counted and divided by the total number of libraries across all categories for each polynucleotide sequence encoding SPTM. The resulting percentages reflect the tissue-specific and disease-specific expression of cDNA encoding SPTM. Percentage values of tissue-specific expression are reported in. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VI. Tissue Distribution Profiling A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system ; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system ; liver; musculoskeletal system; nervous system; pancreas; respiratory system ; sense organs; skin; stomatognathic system; unclassified/mixed ; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA). shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 2, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of 210% are shown. A tissue distribution of"widely distributed"in column 2 indicates percentage values of <10% in all tissue categories.

VII. Transcript Image Analysis Transcript images are generated as described in Seilhamer et al. ,"Comparative Gene Transcript Analysis, "U. S. Patent Number 5,840, 484, incorporated herein by reference.

VIII. Extension of Polynucleotide Sequences and Isolation of a Full-length cDNA Oligonucleotide primers designed using an sptm of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5'extension of the template, and the other primer, to initiate 3'extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68 °C to about 72 °C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.

High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4) 2SO4, and B- mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec ; Step 3: 60°C, 1 min ; Step 4 : 68°C ; 2 min ; Step 5: Steps 2,3, and 4 repeated 20 times; Step 6: 68°C, 5 min ; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ are as follows : Step 1: 94°C, 3 min ; Step 2: 94°C, 15 sec ; Step 3: 57°C, 1 min ; Step 4: 68°C, 2 min ; Step 5 : Steps 2,3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well is determined by dispensing 100 stl PICOGREEN quantitation reagent (0. 25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA (TE) and 0. 5 nul of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning NY), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN n (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 Al to 10 Al aliquot of the reaction mixture is analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions are successful in extending the sequence.

The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones are related using T4 ligase (New England Biolabs, Inc. , Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37°C in 384-well plates in LB/2x carbenicillin liquid media.

The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min ; Step 2: 94°C, 15 sec ; Step 3: 60°C, 1 min ; Step 4 : 72°C, 2 min ; Step 5: steps 2,3, and 4 repeated 29 times; Step 6: 72°C, 5 min ; Step 7: storage at 4°C. DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethysulfoxide (1 : 2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, the sptm is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling of Probes and Southern Hybridization Analyses Hybridization probes derived from the sptm of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, y32P-ATP, alld 0. 5S One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 107 dpm/, ug/ml hybridization buffer and used in a typical membrane-based hybridization analysis.

The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0. 7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68 °C, and hybridization is carried out overnight at 68 °C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0. 1x saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.

X. Chromosome Mapping of sptm The cDNA sequences which were used to assemble SEQ ID NO : 1-161 are compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ ID NO : 1-161 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 6). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

The genetic map locations of SEQ ID NO : 1-161 are described as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination. ) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

XI. Microarray Analysis Probe Preparation from Tissue or Cell Samples Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA+ RNA is purified using the oligo (dT) cellulose method. Each polyA+ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/1 oligo-dT primer (21mer), IX first strand buffer, 0.03 units/jul RNase inhibitor, 500 M dATP, 500/M dGTP, 500 M dTTP, 40 uM dCTP, 40 jiM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA+ RNA with GEMBRIGHT kits (Incyte). Specific control polyA+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1: 100,000, 1: 10,000, 1: 1000,1 : 100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1: 3,3 : 1,1 : 10,10 : 1,1 : 25,25 : 1 (w/w) to sample mRNA differential expression patterns. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0. 5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA. Probes are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc.

(CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 y1 SX SSC/0.2% SDS.

Microarrav Preparation Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 tig.

Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Coming) are cleaned by ultrasound in 0. 1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester, PA), washed extensively in distilled water, and coated with 0. 05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807, 522, incorporated herein by reference. 1, ul of the array element DNA, at an average concentration of 100 ng/tl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are W-crosslinked using a STRATALINKER UV-crosslinker (Stratagene).

Microarrays are washed at room temperature once in 0. 2% SDS and three times in distilled water.

Non-specific binding sites are blocked by incubation of microarrays in 0. 2% casein in phosphate buffered saline (PBS) (Tropix, Inc. , Bedford, MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.

Hybridization Hybridization reactions contain 9, ul of probe mixture consisting of 0. 2 g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65° C for 5 minutes and is aliquote onto the microarray surface and covered with an 1. 8 cm2 coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 nul of 5x SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (1X SSC, 0. 1 % SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X SSC), and dried.

Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc. , Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc. , Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster- scanned past the objective. The 1.8 cm x 1, 8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.

Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1: 100,000. When two probes from different sources (e. g. , representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc. , Norwood, MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte Genomics). Array elements that exhibit at least about a two-fold change in expression, a signal-to-background ratio of at least about 2.5, and an element spot size of at least about 40%, are considered to be differentially expressed.

XII. Complementary Nucleic Acids Sequences complementary to the sptm are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used.

Appropriate oligonucleotides are designed from the sptm using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5'sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.

XIII. Expression of SPTM Expression and purification of SPTM is accomplished using bacterial or virus-based expression systems. For expression of SPTM in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the tip-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e. g., BL21 (DE3). Antibiotic resistant bacteria express SPTM upon induction with isopropyl beta-D- thiogalactopyranoside (IPTG). Expression of SPTM in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding SPTM by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frusiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.

Infection of the latter requires additional genetic modifications to baculovirus. (See e. g., Engelhard, supra ; and Sandig, supra.) In most expression systems, SPTM is synthesized as a fusion protein with, e. g., glutathione S- transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from SPTM at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester NY). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, Chapters 10 and 16). Purified SPTM obtained by these methods can be used directly in the following activity assay.

XIV. Demonstration of SPTM Activity An assay for SPTM activity measures the expression of SPTM on the cell surface. cDNA encoding SPTM is subcloned into an appropriate mammalian expression vector suitable for high levels of cDNA expression. The resulting construct is transfected into a nonhuman cell line such as NIH3T3. Cell surface proteins are labeled with biotin using methods known in the art.

Immunoprecipitations are performed using SPTM-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of SPTM expressed on the cell surface.

Alternatively, an assay for SPTM activity measures the amount of SPTM in secretory, membrane-bound organelles. Transfected cells as described above are harvested and lysed. The lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifugation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane-bound vesicles, and other secretory organelles. Itnmunoprecipitations from fractionated and total cell lysates are performed using SPTM-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The concentration of SPTM in secretory organelles relative to SPTM in total cell lysate is proportional to the amount of SPTM in transit through the secretory pathway.

XV. Functional Assays SPTM function is assessed by expressing sptm at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3. 1 (Invitrogen Corporation, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10, ut of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 ug of an additional plasmid containing sequences encoding a marker protein are co-transfected.

Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector.

Marker proteins of choice include, e. g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.

FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of SPTM on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding SPTM and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding SPTM and other genes of interest can be analyzed by northern analysis or microarray techniques.

XVI. Production of Antibodies SPTM substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e. g., Harrington, M. G. (1990) Methods Enzymol. 182: 488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the SPTM amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e. g. , Ausubel, 1995, supra, Chapter 11.) Typically, peptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinirnide ester (MBS) to increase immunogenicity. (See, e. g., Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio- iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-SPTM activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

XVII. Purification of Naturally Occurring SPTM Using Specific Antibodies Naturally occurring or recombinant SPTM is substantially purified by immunoaffinity chromatography using antibodies specific for SPTM. An immunoaffinity column is constructed by covalent coupling anti-SPTM antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing SPTM are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of SPTM (e. g. , high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/SPTM binding (e. g. , a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and SPTM is collected.

XVIII. Identification of Molecules Which Interact with SPTM SPTM, or biologically active fragments thereof, are labeled within Bolton-Hunter reagent.

(See, e. g. , Bolton, A. E. and W. M. Hunter (1973) Biochem. J. 133: 529-539. ) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled SPTM, washed, and any wells with labeled SPTM complex are assayed. Data obtained using different concentrations of SPTM are used to calculate values for the number, affinity, and association of SPTM with the candidate molecules.

Alternatively, molecules interacting with SPTM are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340: 245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH).

SPTM may also be used in the PATHCALLING process (CuraGen Corp. , New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U. S.

Patent No. 6,057, 101).

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.

Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Table 1 SE ID NO : Template ID SEQ ID NO : ORF ID 1 LG : 021674.23 : 2002JAN18 162 LG: 021674. 23. orf3 : 2002JAN 18 2 LG:1500085. 9 : 2002JAN18 163 LG: 1500085.9. orf3 : 2002JAN 18 3 LG:201545. 7 : 2002JAN18 164 LG:201545.7.orfl:2002JAN18 4 LG : 228868. 32 : 2002JAN18 165 LG:228868. 32. orf1 : 2002JAN 18 4 LG : 228868. 32 : 2002JAN18 166 LG:228868. 32. orf3: 2002JAN18 5 LG : 231319.2 : 2002JAN18 167 LG:231319.2. orf2: 2002JAN18 6 LG:245164. 1: 2002JAN18 168 LG:245164.1.orfl : 2002JAN 18 7 LG:7685619. 6 : 2002JAN18 169 LG:7685619.6.orf12:2002JAN18 8 LG : 7771153. 7: 2002JAN18 170 LG : 7771153. 7. orf2 : 2002JAN18 9 LG : 978820.7 : 2002JAN18 171 LG : 978820. 7. orf1 : 2002JAN18 10 LG : 024189. 1 : 2002JAN18 172 LG: 024189. 1. orf3 : 2002JAN18 11 LG : 222798. 12 : 2002JAN18 173 LG:222798.12.orf1: 2002JAN 18 12 LG : 233706. 19 : 2002JAN18 174 LG:233706. 19. orf3 : 2002JAN 18 13 LG: 404417.1 : 2002JAN 18 175 LG : 404417. l. orfl : 2002JAN 18 14 LG: 005369.4 : 2002JAN18 176 LG: 005369.4. orf1 : 2002JAN18 15 LG : 008434, 1: 2002JAN18 177 LG: 008434. 1. orf:2002JAN18 16 LG : 022943. 14 : 2002JAN 18 178 LG : 022943. 14. orf2: 2002JAN 18 17 LG : 026981.4 : 2002JAN18 179 LG:0269812.4.orf2:2002JAN18 18 LG : 054807.6 : 2002JAN18 180 LG : 054807. 6. orf2 : 2002JAN 18 19 LG : 063690.11 : 2002JAN 18 181 LG : 063690, 11. orf2 : 2002JAN 18 19 LG: 063690.11 : 2002JAN18 182 LG: 063690. 11. orf3 : 2002JAN18 20 LG : 068514.8 : 2002JAN18 183 LG: 068514. 8. orf1 : 2002JAN18 21 LG : 097147.4 : 2002JAN18 184 LG: 097147. 4. orf2: 2002JAN18 22 LG : 099622.1 : 2002JAN18 185 LG : 099622. 1. orfl : 2002JAN 18 23 LG : 1005046. 2: 2002JAN 18 186 LG : 1005046. 2. orf3 : 2002JAN 18 24 LG: 1040736.16 : 2002JAN 18 187 LG:1040736.126. orf2: 2002JAN 18 25 LG: 105937.16 : 2002JAN 18 188 LG : 105937. 16. orf2 : 2002JAN 18 26 LG : 1077405.2 : 2002JAN 18 189 LG:1077405. 2. orf3: 2002JAN 18 27 LG: 1084716.4 : 2002JAN18 190 LG : 1084716.4. orf2 : 2002JAN18 28 LG:1091759. 1 : 2002JAN18 191 LG:1091759.1.orf1:2002JAN18 29 LG : 1095157. 16: 2002JAN18 192. LG: 1095157. 16. orf3 : 2002JAN18 30 LG : 1096601. 118 : 2002JAN18 193 LG : 1096601. 118. orf3 : 2002JAN18 31 LG : 1099356. 5: 2002JAN18 194 LG : 1099356. 5. orf2 : 2002JAN 18 32 LG : 1100807.18 : 2002JAN 18 195 LG : 1100807.18. orf2: 2002JAN 18 33 LG : 1116310. 38: 2002JAN18 196 LG. 1116310. 38. orf3 : 2002JAN18 34 LG:1132386. 23: 2002JAN 18 197 LG : 1132386. 23. orf1: 2002JAN 18 35 LG:1134869. 44: 2002JAN 18 198 LG : 1134869. 44. orf1: 2002JAN 18 36 LG : 1135675. 15 : 2002JAN 18 199 LG : 1135675. 15. orf3 : 2002JAN 18 37 LG : 1285109. 14 : 2002JAN18 200 LG : 1285109.14. orf3: 2002JAN18 38 LG : 1329818. 9: 2002JAN18 201 LG:1329818.9.orf1:2002JAN18 39 LG:1377451. 48 : 2002JAN18 202 LG : 1377451. 48. orf2: 2002JAN 18 40 LG : 1383694. 5 : 2020JAN18 203 LG : 1383694. 5. orf1 : 2002JAN 18 41 LG : 1383725. 3 : 2002JAN18 204 LG : 1383725. 3. orf2: 2002JAN18 42 LG : 1394903.37:2002JAN18 205 LG : 1394903. 37. orf2 : 2002JAN 18 43 LG : 1398274. 13 : 2002JAN 18 206 LG:1398274.13. orf3 : 2002JAN 18 44 LG : 1398646. 12: 2002JAN 18 207 LG : 1398646. 12. orf2 : 2002JAN 18 45 LG : 1398955. 2 : 2002JAN18 208 LG : 1398955. 2. orf2 : 2002JAN 18 46 LG : 1452762. 26 : 2002JAN 18 209 LG : 1452762. 26. orf1 : 2002JAN 18 47 LG : 1452783.7 : 2002JAN18 210 LG : 1452783.7. orf1 : 2002JAN 18 48. LG : 1453027. 28 : 2002JAN18 211 LG : 1453027. 28. orf1 : 2002JAN 18 Table 1 SE ID NO : Template ID SEQ ID NO : ORF ID 49 LG : 1454967. 12 : 2002JAN 18 212 LG:1454967. 12. orf1: 2002JAN 18 50 LG:1466307.1:2002JAN18 213 LG:1466307.1.orf2: 2002JAN 18 51 LG : 149121. 24:2002JAN18 214 L:149121.24.orf1: 2002JAN 18 52 LG : 1500347.11:2002JAN18 215 LG:1500347.11.orf1:2002JAN18 53 LG : 1500433 15 : 2002JAN 18 216 LG : 1500433. 15. orf2 : 2002JAN 18 54 LG:1500434.6:2002JAN18 217 LG:1500434.6. orf3: 2002JAN 18 55 LG : 1501028. 9 : 2002JAN18 218 LG : 1501028. 9. orf1 : 2002JAN 18 56 LG : 1501710. 32 : 2002JAN18 219 LG:1501710.32. orf2 : 2002JAN18 57 LG : 1502217. 12 : 2002JAN18 220 LG : 1502217. 12, orf1 : 2002JAN 18 58 LG : 1502272, 38: 2002JAN18 221 LG : 1502272. 38. orf3: 2002JAN18 59 LG : 1502313. 3: 2002JAN18 222 LG:1502313.3.orf3:2002JAN18 60 LG : 1502474. 57 : 2002JAN18 223 LG:1502474. 57. orf2 : 2002JAN 18 61 LG:1502663. 27 : 2002JAN 18 224 LG : 1502663. 27. orf2 : 2002JAN 18 62 LG : 154608. 1 : 2002JAN 18 225 LG : 154608. 1. orf1 : 2002JAN 18 63 LG : 170235. 14: 2002JAN18 226 LG:170235.124.orf1: 2002JAN 18 64 LG : 170604.1 : 2002JAN 18 227 LG : 170604. 1. orf2 : 2002JAN 18 65 LG : 171629. 1: 2002JAN18 228 LG : 171629.1. orf3 : 2002JAN18 66 LG : 172411. 1: 2002JAN18 229 LG:172411.1.orf3:2002JAN18 67 LG:173356. 1: 2002JAN18 230 LG:173356.1.orf3 : 2002JAN18 68 LG:193755.18: 2002JAN 18 231 LG : 193755. 18. orf2 : 2002JAN 18 69 LG : 196620. 12 : 2002JAN18 232 LG : 196620. 12. orf1 : 2002JAN18 70 LG : 197624. 1: 2002JAN 18 233 LG : 197624. 1. orf3 : 2002JAN 18 71 LG : 197634, 69 : 2002JAN18 234 LG: 197634.69. orf2: 2002JAN 18 72 LG: 198680.1 : 2002JAN 18 235 LG:198680.1. orf3 : 2002JAN 18 73 LG : 201188. 2 : 2002JAN18 236 LG : 201188. 2. orf2 : 2002JAN18 74 LG : 201887. 16: 2002JAN 18 237 LG : 201887, 16.orf1 : 2002JAN 18 75 LG : 208134. 1: 2002JAN 18 238 : 208134. 1. orf2 : 2002JAN 18 76 LG: 209924. 5 : 2002JAN18 239LG : 209924. 5. orf2 : 2002JAN 18 77 LG : 223060. 1: 2002JAN18 240 LG:223060.1.orf1 : 2002JAN 18 78 LG : 227583. 2: 2002JAN18 241 LG : 227583. 2. orf2 : 2002JAN 18 79 LG : 230149.12 : 2002JAN18 242 LG : 230149. 12. orf1 : 2002JAN18 80 LG : 230509. 30: 2002JAN18 243 LG: 230509.30. orf2 : 2002JAN 18 81 LG : 230923.1 : 2002JAN18 244 LG:230923.1.orf3:2002JAN18 82 LG : 232307.11 : 2002JAN18 245 LG : 232307. 11.orf1:2002JAN18 83 LG : 232415.30 : 2002JAN18 246 LG : 232415. 30. orf2 : 2002JAN18 84 LG : 234121.5 : 2002JAN 18 247 LG : 234121, 5. orf3 : 2002JAN 18 85 LG:235713. 10:2002JAN18 248 LG : 235713. 10.orf1:2002JAN18 86 LG:236340.12:2002JAN18 249 LG : 236340. 12. orf3: 2002JAN18 87 LG : 236386.2 : 2002JAN18 250 LG: 236386. 2. orf3: 2002JAN18 88 LG: 239601.22 : 2002JAN 18 251 LG : 239601, 22.of1: 2002JAN 18 89 LG : 239673. 8: 2002JAN18 252 LG:239673.8.orf3:2002JAN18 90 LG : 249905.45 : 2002JAN 18 253 LG : 249905.45.orf2 : 2002JAN 18 91 LG : 250038.3:2002JAN18 254 LG:250038.3.orf3.orf3:2002JAN18 92 LG: 252800.19 : 2002JAN18 255 LG : 252800. 19.orf3:2002JAN18 93 LG:253580.6 : 2002JAN18 256 LG : 253580. 6. orf1 : 2002JAN 18 94 LG : 271509. 8: 2002JAN18 257 LG : 271509. 8. orf2 : 2002JAN 18 95 LG:277161. 30: 2002JAN18 258 LG:277161.30.orf3:2002JAN18 96 LG : 330739. 4 : 2002JAN18 259 LG : 330739. 4. orf1 : 2002JAN 18 97 LG : 331470. 6 : 2002JAN18 260 LG:331470. 6. orf1 : 2002JAN 18 98 LG:331661. 1 : 2002JAN18 261 LG:331661.1.orf2:2002JAN18 Table 1 SEQ ID NO : Template ID SEQ ID NO : ORF ID 99 LG:332032.17:2002JAN18 262 LG : 332032. 17. orf2 : 2002JAN 18 100 LG : 332431. 2 : 2002JAN18 263 LG : 332431, 2. orf1 : 2002JAN18 101 LG: 335173.4;2002JAN18 264 LG : 335173.4.orf3:2002JAN18 102 LG : 336529@3 : 2002JAN18 265 LG : 336529. 3. orf3 : 2002JAN 18 103 LG:338001. 2 : 2002JAN18 266 LG : 338001. 2. orf2: 2002JAN18 104 LG:338469. 4 : 2002JAN18 267 LG: 338469. 4. orf2 : 2002JAN 18 105 LG : 344659. 1 : 2002JAN18 268 LG : 344659. 1. orf1:2002JAN18 106 LG: 345278.38 : 2002JAN18 269 LG:345278.38.orf1 : 2002JAN 18 107 LG : 346657. 13: 2002JAN18 270 LG : 346657. 13. orf3 : 2002JAN 18 108 LG:348101. 16 : 2002JAN18 271 LG: 348101. 16. orf3 : 2002JAN18 109 LG : 350827.10 : 2002JAN18 272 LG: 350827. 10. orf3 : 2002JAN 18 110 LG: 354580.28 : 2002JAN18 273 LG: 354580.28. orf1 : 2002JAN18 111 LG : 356006.3 : 2002JAN18 274 LG : 356006.3. orf3:2002JAN18 112 LG : 370212. 10:2002JAN18 275 LG: 370212. 10.orf1:2002JAN18 113 LG:373219.13:2002JAN18 276 LG:373219. 13. orf2 : 2002JAN18 114 LG : 399821. 22 : 2002JAN 18 277 LG : 399821. 22, orf3 : 2002JAN 18 115 LG: 400519. 1 : 2002JAN18 278 LG : 400519. 1. orf2 : 2002JAN18 116 LG : 402797. 1 : 2002JAN18 279 LG : 402797. 1. orf3: 2002JAN 18 117 LG : 402974. 1 : 2002JAN18 280 LG:402974.1. orf2 : 2002JAN18 118 LG: 403397.7 : 2002JAN18 281 LG : 403397.7. orf2: 2002JAN 18 1189 LG :404199.4:2002JAN18 282 LG:404199.4.orf1:2002JAN18 120 LG: 404482.7 : 2002JAN18 283 LG : 404482.7. orf3: 2002JAN18 121 LG : 406239. 1 : 2002JAN 18 284 LG : 406239. 1. orf2 : 2002JAN 18 122 LG : 407055*6 : 2002JAN18 285 LG : 407055*6. orfl : 2002JAN18 123 LG: 407485.1 : 2002JAN18 286 LG : 407485. 1. orf1 : 2002JAN 18 124 LG : 422048.46:2002JAN128 287 LG:422048.46.orf2:2002JAN18 125 LG:425448.18 : 2002JAN 18 288 LG : 425448, 18. orf3 : 2002JAN 18 126 LG : 435717, 5 : 2002JAN 18 289 LG : 435717. 5. orf 1 : 2002JAN 18 127 LG:451858. 13 : 2002JAN18 290 LG:451858.13.orf2 : 2002JAN18 128 LG : 462233. 20 : 2002JAN 18 291 LG : 462233. 20. orf3 : 2002JAN18 129 LG: 473880. 41 : 2002JAN18 292 LG:473880.41. orf3 : 2002JAN 18 130 LG:474421. 5: 2002JAN18 293 LG: 474421.5. orf3 : 2002JAN18 131 LG:481462.4:2002JAN18 294 LG:481462.4.orf2 : 2002JAN 18 132 LG: 7684981.2 : 2002JASN18 295 LG : 7684981. 2. orf12:2002JAN18 133 LG : 7690420.1 : 2002JAN18 296 LG : 7690420. 1. orf3 : 2002JAN 18 134 LG: 7691425.2 : 2002JAN18 297 LG:7691425.2.orf1 : 2002JAN 18 135 LG : 7692702. 1: 2002JAN18 298 LG: 7692702. 1. orf3 : 2002JAN18 136 LG: 7694388.21 : 2002JAN18 299 LG : 7694388. 21. orf2: 2002JAN18 137 LG : 7697322.7:2002JAN18 300 LG : 7697322.7. orf3 : 2002JAN18 138 LG: 7697347.3 : 2002JAN18 301LG : 7697347. 3. orf1 : 2002JAN 18 139 LG : 7698451. 18: 2002JAN18 302 LG : 7698451. 18. orf3:2002JAN18 140 LG:7698705. 7 : 2002JAN18 303 LG: 7698705. 7. orf2: 2002JAN18 141 CG. 7731829. 1: 2002JAN18 304 LG : 7731829.1.orf3:2002JAN18 142 LG : 7761659.11 : 2002JAN18 305 LG : 7761659. 11, orfl : 2002JAN 18 143 LG : 7761806.33 : 2002JAN18 306 LG:7761806.33. orf2: 2002JAN18 144 LG:7763039.6:2002JAN18 307 LG : 7763039.6.orf1:2002JAN18 145 LG : 7763254e5 : 2002JAN 18 308 LG : 7763254. 5. orf 1 : 2002JAN 18 146 LG : 7763421.8 : 2002JAN18 309 LG: 7763421.8. orf2 : 2002JAN18 147 LG : 7763437.104 : 2002JAN18 310 LG : 7763437.104. orf1 : 2002JAN18 148 LG:770095.2:2002JAN18 311 LG: 7770095.2. orf2 : 2002JAN18 Table 1 SEQ ID NO : Template ID SEQ ID NO : ORF ID 149 LG: 7770589.6 : 2002JAN18 312 LG:7770589.6.orf2 : 2002JAN18 150 LG:7770618.6:2002JAN18 313 LG : 7770618. 6. orf1 : 2002JAN18 151 LG : 7770900.9:2002JAN18 314 LG:7770900.9. orf3: 2002JAN18 152 LG : 7771513. 22 : 2002JAN 18 315 LG : 7771513. 22. orf3 : 2002JAN18 153 LG : 899402.3:2002JAN18 316 LG:899402.3.orf2 : 2002JAN18 154 LG : 902699. 29 : 2002JAN18 317LG : 902699. 29. orf2 : 2002JAN 18 155 LG : 977532. 3 : 2002JAN18 318 LG : 977532.3.orf3:2002JAN18 156 LG:978729.5 :2002JAN18 319 LG: 978729. 5. orf1 : 2002JAN 18 157 LG:980200.9:2002JAN18 320 LG: 980200.9. orf2 : 2002JAN18 158 LG : 980859.5 : 2002JASN18 321 LG:980859.5. orf3: 2002JAN 18 159 LG: 982723.4 : 2002JAN18 322 LG : 982723. 4. orf3: 2002JAN18 160 LG : 986427.1 : 2002JAN 18 323 LG : 986427. 1, orf3 : 2002JAN 18 161 LG:996868.32:2002JAN18 324 LG : 996868.32. orf3 : 2002JAN18 Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 1 LG:021674. 23 : 2002JAN18 1 9 TM Extracellular JLG : 021674. 23: 2002JAN18 10 27 TM Transmembrane 1 LG:021674. 23 : 2002JAN18 28 146 TM Cytosollc 1 LG:021674. 23 : 2002JAN18 147 169 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 170 188 TM Extracellular 1 LG:021674. 23 : 2002JAN18 189 211 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 212 315 TM Cytosolic 1 LG : 021674. 23 : 2002JAN18 316 338 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 339 357 TM Extracellular 1 LG: 021674.23 : 2002JAN18 358 375 TM Transmembrane 1 LG:021674. 23: 2002JAN18 376 420 TM Cytosolic 1 LG:021674. 23 :2002JAN18 421 438 TM Transmembrane 1 LG: 021674. 23 : 2002JAN18 439 464 TM Extracellular 1 LG: 021674.23 : 2002JAN18 465 487 TM Transmembrane 1 LG : 021674.23 :2002JAN18 488 570 TM Cytosolic 1 LG:021674.23:2002JAN18 571 593 TM Transmembrane 1 LG : 021674, 23 : 2002JAN18 594 596 TM Extracellular 1 LG: 021674. 23: 2002JAN18 597 619 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 620 625 TM Cytosolic 1 LG : 021674. 23:2002JAN18 626 645 TM Transmembrane 1 LG: 021674. 23: 2002JAN18 646 664 TM Extracellular 1 LG: 021674.23 : 2002JAN18 665 687 TM Transmembrane 1 LG : 021674. 23:2002JAN18 688 706 TM Cytosolic 1 LG : 021674.23 : 2002JAN18 707 729 TM Transmembrane 1 LG : 021674, 23: 2002JAN18 730 799 TM Extracellular 1 LG : 021674. 23:2002JAN18 800 822 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 823 879 TM Cytosolic 1 LG: 021674.23 : 2002JAN18 880 902 TM Transmembrane 1 LG : 021674 23: 2002JAN128 903 906 TM Extracellular 1 LG : 021674.23 : 2002JAN18 907 929 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 930 941 TM Cytosolic I LG : 021674. 23 : 2002JAN18 942 964 TM Transmembrane 1 LG: 021674.23 : 2002JAN18 965 978 TM Extracellular 1 LG:021674. 23 :2002JAN18 979 1001 TM Transmembrane 1 LG: 021674.23 : 2002JAN18 1002 1106 TM Cytosolic 1 LG:021674. 23 : 2002JAN18 1 21 TM Extracellular 1 L:021674. 23 : 2002JAN18 22 44 TM Transmembrane 1 LG: 021674. 23: 2002JAN18 45 135 TM Cytosolic JLG : 021674. 23: 2002JAN18 136 158 TM Transmembrane 1 LG: 021674. 23 :2002JAN18 159 199 TM Extracellular 1 LG : 021674.23 : 2002JAN18 200 222 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 223 383 TM Cytosolic 1 LG : 021674.23 :2002JAN18 384 406 TM Transmembrane 1 LG:021674. 23 : 2002JAN18 407 430 TM Extracellular 1 LG : 021674. 23 : 2002jan18 431 453 TM Transmembrane 1 LG : 021674. 23: 2002JAN18 454 704 TM Cytosolic 1 LG: 021674. 23: 2002JAN18 705 727 TM Transmembrane 1 LG:021674.23:2002JAN18 728 777 TM Extracellular 1 LG:021674.23:2002JAN18 778 797 TM Transmembrane Table 2 SEQ ID Template ID Start STop Frame Domain Topology NO : Type 1 LG:021674. 23 : 2002JAN18 798 803 TM Cytosolic 1 LG:021674. 23 : 2002JAN18 804 822 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 823 826 TM Extracellular 1 LG : 021674. 23 : 2002JAN18 827 849 TM Transmembrane I LG : 021674.23 : 2002JAN18 850 890 TM Cytosolic 1 LG : 021674.23 : 2002JAN18 891 913 TM Transmembrane 1 LG:021674. 23 : 2002JAN18 914 917 TM Extracellular 1 LG:021674. 23 :2002JAN18 918 937 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 938 943 TM Cytosolic 1 LG : 021674. 23 : 2002JAN18 944 966 TM Transmembrane 1 LG : 021674. 23: 2002JAN18 967 975 TM Extracellular 1 LG:021674. 23 : 2002JAN18 976 995 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 996 1015 TM Cytosolic 1 LG:021674. 23 : 2002JAN18 1016 1038 TM Transmembrane 1 LG : 021674. 23 : 2002JAN18 1039 1105 TM Extracellular 1 LG : 021674. 23 : 2002JAN18 1 30 TM Extracellular 1 LG : 021674. 23: 2002JAN18 31 50 TM Transmembrane 1 LG: 021674.23 : 2002JAN18 51 96 TM Cytosolic 1 LG : 021674. 23: 2002JAN 18 97 119 TM Transmembrane 1 LG:021674. 23 :2002JAN18 120 566 TM Extracellular 1 LG : 021674.23 : 2002JAN18 567 589 TM Transmembrane 1 LG : 021674.23 : 2002JAN18 590 595 TM Cytosolic 1 LG : 021674.23 : 2002JAN18 596 618 TM Transmembrane 1 LG: : 021674.23 : 2002JAN18 619 664 TM Extracellular 1 LG:021674. 23: 2002JAN18 665 687 TM Transmembrane I LG : 021674.23 : 2002JAN18 688 706 TM Cytosolic 1 LG : 021674. 23 : 2002JAN18 707 729 TM Transmembrane 1 LG:021674. 23: 2002JAN18 730 769 TM Extracellular 1 LG : 021674.23 : 2002JAN18 770 792 TM Transmembrane I LG : 021674.23 : 2002JAN18 793 798 TM Cytosolic 1 LG : 021674.23 : 2002JAN18 799 821 TM Transmembrane 1 LG:021674. 23 :2002JAN18 822 1105 TM Extracellular 1 LG : 021674.23 : 2002JAN18 2404 2478 forward 1 SP LG : 021674. 23: 2002JAN18 2404 2463 forward 1 SP 1 LG:021674. 23: 2002JAN18 2404 2457 forward 1 SP 1 LG:021674. 23: 2002JAN18 2738 2803 forward 2 SP 1 LG : 021674.23 : 2002JAN18 2214 2264 forward 3 SP 1 LG : 021674.23 : 2002JAN18 2415 2483 forward 3 SP 1 LG:021674. 23: 2002JAN18 2214 2270 forward 3 SP LG : 021674. 23: 2002JAN18 2418 2489 forward 3 SP 2 LG:1500085. 9: 2002JAN18 1 69 TM Cytosolic 2 LG : 1500085. 9: 2002JAN18 1 68 TM Cytosolic 3 LG:201545. 7 : 2002JAN18 1 361 TM Extracellular 3 LG : 201545. 7: 2002JAN18 362 379 TM Transmembrane 3 LG : 201545. 7: 2002JAN18 380 454 TM Cytosolic 3 LG: 201545.7 : 2002JAN18 1083 1157 forward 3 SP 3 LG : 201545. 7 : 2002JAN18 1083 1151 forward 3 SP 3 LG:201545. 7 :2002JAN18 1083 1139 forward 3 SP 3 LG:201545. 7: 2002JAN18 1083 1142 forward 3 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 3 LG : 201545.7 : 2002JAN18 84 164 forward 3 SP 4 LG : 228868. 32: 2002JAN18 1 14 TM Extracellular 4 LG:228868. 32: 2002JAN18 15 37 TM Transmembrane 4 LG:228868. 32: 2002JAN18 38 110 TM Cytosolic 4 LG:228868. 32 : 2002JAN18 111 133 TM Transmembrane 4 LG:228868.32:2002JAN18 134 346 TM Extracellular 4 LG: 228868.32 : 2002JAN18 1 44 TM Extracellular 4 LG : 228868. 32: 2002JAN18 45 67 TM Transmembrane 4 LG : 228868, 32 : 2002JAN18 b8 109 TM Cytosolic 4 LG:228868. 32 :2002JAN18 110 132 TM Transmembrane 4 LG:228868. 32: 2002JAN18 133 346 TM Extracellular 5 LG : 231319.2 : 2002JAN18 1 77 TM Cytosolic 5 LG:231319. 2: 2002JAN18 78 100 TM Transmembrane 5 LG : 231319.2 : 2002JAN18 101 114 TM Extracellular 5 LG:231319. 2 : 2002JAN18 115 136 TM Transmembrane 5 LG:231319. 2 : 2002JAN18 137 247 TM Cytosolic 5 LG : 231319. 2 : 2002JAN18 1 20 TM Cytosolic 5LG: 231319.2 : 2002JAN18 21 43 TM Transmembrane 5 LG : 231319. 2 : 2002JAN18 44 77 TM Extracellular 5 LG: 231319. 2:2002JAN18 78 100 TM Transmembrane 5 LG: 231319.2 : 2002JAN18 101 247 TM Cytosolic 5 LG : 231319.2 : 2002JAN18 1 49 TM Cytosolic 5 LG:231319 2: 2002JAN18 50 72 TM Transmembrane 5 LG : 231319. 2 : 2002JAN18 73 75 TM Extracellular 5 LG : 231319. 2: 2002JAN18 76 98 TM Transmembrane 5 LG : 231319.2 : 2002JAN18 99 246 TM Cytosolic 5 LG:231319. 2: 2002JAN18 220 294 forward 1 SP 5 LG : 231319.2 : 2002JAN18 220 297 forward 1 SP 5 LG : 231319.2 :2002JAN18 232 297 forward 1 SP 5 LG:231319. 2 :2002JAN18 165 242 forward 3 SP 5 LG : 231319.2 : 2002JAN18 165 242 forward 3 SP 6 LG : 245164.1 : 2002JAN18 1 1125 TM Extracellular 6 LG: 245164.1 : 2002JAN18 1126 1148 TM Transmembrane 6 LG : 245164.1 : 2002JAN 18 1149 1154 TM Cytosolic 6 LG:245164. 1 : 2002JAN18 1155 1177 TM Transmembrane 6 LG : 245164.1 : 2002JAN18 1178 1376 TM Extracellular 6 LG : 245164.1 : 2002JAN 18 1 157 TM Cytosolic 6 LG : 245164. 1 : 2002JAN18 158 180 TM Transmembrane 6 LG : 245164. 1 : 2002JAN18 181 999 TM Extracellular 6 LG:245164. 1: 2002JAN18 1000 1022 TM Transmembrane 6 LG: 245164.1 : 2002JAN18 1023 1099 TM Cytosolic 6 LG:245164. 1 : 2002JAN 18 1100 1122 TM Transmembrane 6 LG : 245164. 1 : 2002JAN18 1123 1253 TM Extracellular 6 LG:245164. 1: 2002JAN18 1254 1276 TM Transmembrane 6 LG : 245164.1 : 2002JAN 18 1277 1288 TM Cytosolic 6 LG:245164. 1 :2002JAN18 1289 1307 TM Transmembrane 6 LG : 245164.1 : 2002JAN18 1308 1326 TM Extracellular 6 LG : 2451641 2002JAN18 1327 1349 TM Transmembrane 6 LG:245164.1;2002JAN18 1350 1376 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 6 LG: 245164.1 : 2002JAN18 1762 1836 forward 1 SP 6 LG:245164. 1: 2002JAN18 1762 1827 forward 1 SP 7 LG: 7685619.6 : 2002JAN18 1 28 TM Cytosolic 7 LG : 7685619. 6 : 2002JAN18 29 51 TM Transmembrane 7 LG:7685619. 6: 2002JAN18 52 538 TM Extracellular 7 LG: 7685619.6 :2002JAN18 1387 1446 forward 1 SP 7 LG : 7685619. 6 : 2002JAN18 1387 1440 forward 1 SP 7 LG : 7685619. 6 : 2002JAN18 89 160 forward 2 SP 7 LG:7685619, 6 :2002JAN18 849 938 forward 3 SP 7 LG:7685619. 6 :2002JAN18 849 911 forward 3 SP 7 LG : 7685619. 6 : 2002JAN18 849 899 forward 3 SP 7LG: 7685619.6 :2002JAN18 849 914 forward 3 SP 7 LG: 7685619.6 : 2002JAN18 849 914 forward 3 SP 8 LG : 7771153. 7: 2002JAN18 1 136 TM Cytosolic 8 LG : 7771153. 7: 2002JAN18 137 159 TM Transmembrane 8 LG:7771153. 7 :2002JAN18 160 286 TM Extracellular 8 LG : 7771153. 7: 2002JAN18 98 172 forward 2 SP 9 LG:978820. 7 : 2002JAN18 1 9 TM Extracellular 9 LG : 978820. 7 2002JAN18 10 29 TM Transmembrane 9 LG:978820. 7 : 2002JAN18 30 54 TM Cytosolic 9 LG : 978820.7 : 2002JAN18 55 77 TM Transmembrane 9 LG:978820. 7 :2002JAN18 78 740 TM Extracellular 9 LG:978820. 7 : 2002JAN18 1 415 TM Extracellular 9LG:978820. 7 : 2002JAN18 416 438 TM Transmembrane 9 LG : 978820.7 : 2002JAN18 439 673 TM Cytosolic 9 LG : 978820. 7: 2002JAN18 674 696 TM Transmembrane 9 LG:978820. 7 :2002JAN18 697 739 TM Extracellular 9 LG : 978820. 7 : 2002JAN18 1 526 TM Extracellular 9 LG : 978820. 7: 2002JAN18 527 549 TM Transmembrane 9 LG : 978820.7 : 2002JAN18 550 676 TM Cytosolic 9 LG: 978820.7 :2002JAN18 677 699 TM Transmembrane 9 LG: 978820.7 : 2002JAN18 700 739 TM Extracellular 9 LG:978820. 7 : 2002JAN18 1577 1642 forward 2 SP 9 LG : 978820. 7: 2002JAN18 1577 1663 forward 2 SP 9 LG: 978820.7 : 2002JAN18 1577 1648 forward 2 SP 10 LG : 024189. 1: 2002JAN18 1 166 TM Cytosolic 10 LG 024189. 1 : 2002JAN18 167 189 TM Transmembrane 10 LG : 024189. 1 : 2002JAN18 190 203 TM Extracellular 10 LG 024189. 1 :2002JAN18 204 223 TM Transmembrane 10LG : 024189. 1 : 2002JAN18 224 656 TM Cytosolic 10 LG : 024189. 1: 2002JAN18 657 676 TM Transmembrane 10 LG :024189.1:2002JAN18 677 678 TM Extracellular 10 LG:024189.1:2002JAN18 469 558 forward 1 SP 10 LG:024189.1:2002JAN18 472 570 forward 1 SP 10 LG:024189.1:2002JAN18 587 667 forward 2 SP 10 LG : 024189. 1 : 2002JAN18 918 986 forward 3 SP 10 LG : 024189.1:2002JAN18 51 107 forward 3 SP 10 LG : 024189. 1 :2002JAN18 51 101 forward 3 SP 10 LG ; 024189. 1 : 2002JAN18 51 140 forward 3 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 10 LG: 024189.1 : 2002JAN18 51 134 fprward 3 SP 11 LG:222798. 12 : 2002JAN18 1824 1907 forward 3 SP 11 LG: 222798.12 : 2002JAN18 1824 1913 forward 3 SP 12 LG:233706. 19: 2002JAN18 376 486 forward 1 SP 13 LG : 404417. 1 : 2002JAN18 1 141 TM Extracellular 13 LG : 404417. 1: 2002JAN 18 142 164 TM Transmembrane 13 LG:404417. 1 : 2002JAN18 165 316 TM Cytosolic 13 LG: 404417.1 : 2002JAN18 55141 forward 1 SP 14 LG : 005369. 4 : 2002JAN18 1 135 TM Cytosolic 14 LG : 005369. 4 : 2002JAN18 136 158 TM Transmembrane 14 LG : 005369. 4 : 2002JAN 18 159 176 TM Extracellular 14 LG : 005369. 4 : 2002JAN 18 177 199 TM Transmembrane 14 LG: 005369.4 : 2002JAN 18 200 218 TM Cytosolic 14 LG : 005369. 4: 2002JAN 18 219 241 TM Transmembrane 14 LG : 005369. 4: 2002JAN18 242 876 TM Extracellular 14 LG : 005369. 4 : 2002JAN18 407 484 forward 2 SP 14 LG:005369. 4: 2002JAN18 1074 1172 forward 3 SP 14 LG: 005369.4 : 2002JAN18 1074 1172 forward 3 SP 14 LG:005369. 4: 2002JAN 18 1074 1172 forward 3 SP 15 LG: 008434.1 : 2002JAN 18 1 41 TM Extracellular 15 LG: 008434.1 : 2002JAN18 42 64 TM Transmembrane 15 LG: 008434.1 : 2002JAN18 65 120 TM Cytosolic 15 LG: 008434.1 : 2002JAN 18 1 30 TM Cytosolic 15 LG: 008434.1 : 2002JAN 18 31 53 TM Transmembrane 15 LG : 008434. 1 : 2002JAN 18 54 91 TM Extracellular 15 LG: 008434.1 : 2002JAN18 92 114 TM Transmembrane 15 LG:008434. 1 : 2002JAN18 115 119 TM Cytosolic 15 LG: 008434.1 : 2002JAN 18 94 156 forward 1 SP 16 LG : 022943. 14 : 2002JAN 18 1 9 TM Extracellular 16 LG:022943. 14: 2002JAN18 10 32 TM Transmembrane 16 LG : 022943.14 : 2002JAN18 33 157 TM Cytosolic 16 LG : 022943.14 : 2002JAN18 158 177 TM Transmembrane 16 LG:022943. 14: 2002JAN 18 178 194 TM Extracellular 16 LG:022943. 14: 2002JAN 18 1 6 TM Cytosolic 16 LG:022943. 14 : 2002JAN18 7 29 TM Transmembrane 16 LG:022943. 14 : 2002JAN18 30 108 TM Extracellular 16 LG : 022943. 14 : 2002JAN18 109 131 TM Transmembrane 16 LG: 022943.14 : 2002JAN 18 132 194 TM Cytosolic 16 LG : 022943. 14 : 2002JAN18 8 76 forward 2 SP 16 LG:022943. 14 : 2002JAN18 8 70 forward 2 SP 16 LG : 022943.14 : 2002JAN18 8 85 forward 2 SP 16 LG:022943. 14 : 2002JAN 18 8 73 forward 2 SP 16 LG:022943. 14: 2002JAN18 8 76 forward 2 SP 17 LG: 026981.4 : 2002JAN18 1 51 TM Cytosolic 17 LG : 026981.4 : 2002JAN18 52 74 TM Transmembrane 17 LG : 026981. 4: 2002JAN 18 75 359 TM Extracellular 17 LG:026981. 4: 2002JAN18 407 505 forward 2 SP 17 LG : 026981. 4: 2002JAN 18 419 490 forward 2 SP 17 LG: 026981.4 : 2002JAN18 419 496 forward 2 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 17 LG : 026981. 4 : 2002JAN18 419 484 forward 2 SP 17 LG: 026981.4 : 2002JAN18 419 496 forward 2 SP 18 LG: 054807.6 : 2002JAN18 1 206 TM Extracellular 18 LG:054807. 6: 2002JAN18 207 224 TM Transmembrane 18 LG: 054807.6 : 2002JAN18 225 345 TM Cytosolic 18 LG: 054807.6 : 2002JAN18 346 365 TM Transmembrane 18 LG:054807. 6: 2002JAN18 366 368 TM Extracellular 18 LG : 054807. 6 :2002JAN18 369 388 TM Transmembrane 18 LG:054807. 6: 2002JAN18 389 400 TM Cytosolic 18 LG:054807. 6 2002JAN18 401 423 TM Transmembrane 18 LG : 054807. 6 :2002JAN18 424 473 TM Extracellular 18 LG: 054807.6 :2002JAN18 474 496 TM Transmembrane 18 LG:054807. 6 : 2002JAN18 497 566 TM Cytosolic 18 LG:054807. 6 :2002JAN18 567 589 TM Transmembrane 18 LG : 054807. 6 : 2002JAN18 590 592 TM Extracellular 18 LG : 054807. 6 2002JAN18 593 615 TM Transmembrane 18 LG : 054807.6 : 2002JAN18 616 709 TM Cytosolic 18 LG : 054807. 6 : 2002JAN18 710 732 TM Transmembrane 18 LG : 054807.6 : 2002JAN18 733 830 TM Extracellular 18 LG : 054807.6 : 2002JAN18 1 441 TM Extracellular 18 LG: 054807.6 : 2002JAN18 442 464 TM Transmembrane 18 LG: 054807. 6: 2002JAN18 465 476 TM Cytosolic 18 LG:054807. 6: 2002JAN18 477 499 TM Transmembrane 18 LG : 054807.6 : 2002JAN18 500 707 TM Extracellular 18 LG : 054807. 6: 2002JAN18 708 725 TM Transmembrane 18 LG : 054807. 6: 2002JAN18 726 766 TM Cytosolic 18 LG : 054807.6 : 2002JAN 18 767 789 TM Transmembrane 18 LG : 054807. 6: 2002JAN18 790 803 TM Extracellular 18 LG : 054807. 6: 2002JAN18 804 823 TM Transmembrane 18 LG : 054807. 6: 2002JAN18 824 829 TM Cytosolic 18 LG : 054807. 6 : 2002JAN18 1 268 TM Extracellular 18 LG : 054807, 6 : 2002JAN18 269 291 TM Transmembrane 18 LG : 054807. 6 : 2002JAN18 292 342 TM Cytosolic 18 LG : 054807. 6 : 2002JAN18 343 365 TM Transmembrane 18 LG : 054807. 6 : 2002JAN18 366 448 TM Extracellular 18 LG:054807. 6: 2002JAN18 449 471 TM Transmembrane 18 LG : 054807.6 : 2002JAN18 472 477 TM Cytosolic 18 LG: 054807.6 : 2002JAN18 478 500 TM Transmembrane 18 LG :054807. 6: 2002JAN18 501 504 TM Extracellular 18 LG : 054807.6 : 2002JAN18 505 527 TM Transmembrane 18 LG: 054807. 6: 2002JAN18 528 565 TM Cytosolic 18 LG:054807. 6 : 2002JAN18 566 588 TM Transmembrane 18 LG: 054807.6 : 2002JAN18 589 591 TM Extracellular 18 LG: 054807. 6 : 2002JAN18 592 611 TM Transmembrane 18 LG : 054807.6 : 2002JAN18 612 707 TM Cytosolic 18 LG : 054807. 6: 2002JAN18 708 727 TM Transmembrane 18 LG : 054807. 6 : 2002JAN18 728 829 TM Extracellular 18 LG : 054807.6 : 2002JAN18 1967 2035 forward 2 SP 18 LG:054807.6:2002JAN18 1710 1769 forward 3 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 18 LG : 054807. 6 : 2002JAN18 1710 1763 forward 3 SP 18 LG : 054807. 6: 2002JAN18 1710 1763 forward 3 SP 18 LG : 054807. 6 : 2002JAN18 1710 1775 forward 3 SP 19 LG : 063690.11 : 2002JAN 18 1 84 TM Cytosolic 20 LG:068514. 8 : 2002JAN18 1 206 TM Extracellular 20 LG : 068514. 8 : 2002JAN18 207 229 TM Transmembrane 20 LG : 068514. 8 : 2002JAN18 230 259 TM Cytosolic 20 LG : 068514. 8: 2002JAN18 260 279 TM Transmembrane 20 LG: 068514.8 : 2002JAN18 280 902 TM Extracellular 20 LG:068514. 8: 2002JAN18 903 925 TM Transmembrane 20 LG : 068514.8 : 2002JAN18 926 936 TM Cytosolic 20 LG:068514. 8 : 2002JAN18 937 959 TM Transmembrane 20 LG:068514. 8 :2002JAN18 960 978 TM Extracellular 20LG:068514. 8 :2002JAN18 979 1001 TM Transmembrane 20 LG : 068514. 8 : 2002JAN18 1002 1072 TM Cytosolic 20 LG: 068514.8 : 2002JAN18 1 869 TM Extracellular 20 LG:068514. 8: 2002JAN18 870 892 TM Transmembrane 20 LG : 068514. 8 : 2002JAN18 893 975 TM Cytosolic 20 LG : 068514. 8 : 2002JAN18 976 998 TM Transmembrane 20 LG:068514. 8 : 2002JAN18 999 1007 TM Extracellular 20 LG:068514.; 8 2002JAN18 1008 1030 TM Transmembrane 20 LG : 068514. 8: 2002JAN18 1031 1071 TM Cytosolic 20LG: 068514.8 : 2002JAN18 2920 3000 forward 1 SP 20 LG : 068514. 8 : 2002JAN18 2920 2982 forward 1 SP 20 LG: 068514.8 : 2002JAN18 2920 2994 forward 1 SP 20 LG : 068514. 8 : 2002JAN18 2455 2511 forward 1 SP 20 LG:068514. 8 :2002JAN18 2920 2988 forward 1 SP 20 LG: 068514.8 : 2002JAN18 182 274 forward 2 SP 21 LG:097147. 4 : 2002JAN18 1 398 TM Extracellular 21 LG:097147. 4: 2002JAN18 399 421 TM Transmembrane 21 LG: 097147.4 : 2002JAN18 422 453 TM Cytosolic 21 LG:097147. 4 : 2002JAN18 454 476 TM Transmembrane 21 LG : 097147.4 : 2002JAN18 477 725 TM Extracellular 21 LG : 097147.4 : 2002JAN18 1 237 TM Cytosolic 21 LG:097147. 4: 2002JAN18 238 260 TM Transmembrane 21 LG : 097147.4 : 2002JAN18 261 296 TM Extracellular 21 LG :097147. 4 : 2002JAN18 297 319 TM Transmembrane 21LG: 097147.4 : 2002JAN18 320 387 TM Cytosolic 21LG : 097147. 4 : 2002JAN18 388 410 TM Transmembrane 21 LG: 097147.4 : 2002JAN18 411 458 TM Extracellular 21 LG: 097147.4 : 2002JAN18 459 481 TM Transmembrane 21 LG: 097147.4 : 2002JAN18 482 507 TM Cytosolic 21 LG:097147. 4 : 2002JAN18 508 530 TM Transmembrane 21 LG : 097147. 4 : 2002JAN18 531 725 TM Extracellular 21 LG:097147. 4: 2002JAN18 1 214 TM Cytosolic 21 LG : 097147. 4: 2002JAN18 215 237 TM Transmembrane 21 LG : 097147. 4: 2002JAN18 238 241 TM Extracellular 21 LG:097147. 4 :2002JAN18 242 264 TM Transmembrane 21 LG : 097147. 4: 2002JAN 8 265 384 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 21LG : 097147. 4 : 2002JAN18 385 407 TM Transmembrane 21 LG : 097147.4 : 2002JAN18 408 457 TM Extracellular 21 LG:097147. 4 : 2002JAN18 458 480 TM Transmembrane 21 LG:097147. 4 : 2002JAN18 481 510 TM Cytosolic 21 LG:097147. 4: 2002JAN18 511 533 TM Transmembrane 21 LG: 097147.4 : 2002JAN18 534 572 TM Extracellular 21 LG:097147. 4 :2002JAN18 573 592 TM Transmembrane 21 LG : 097147.4 : 2002JAN18 593 724 TM Cytosolic 21 LG:097147. 4 : 2002JAN18 808 882 forward 1 SP 21 LG : 097147, 4 : 2002JAN18 808 888 forward 1 SP 21 LG: 097147.4 : 2002JAN18 513 560 forward 3 SP 22 LG:099622. 1: 2002JAN 18 1 183 TM Cytosolic 23 LG:1005046. 2: 2002JAN18 1 1650 TM Extracellular 23 LG : 1005046. 2 : 2002JAN18 1651 1673 TM Transmembrane 23 LG:1005046. 2: 2002JAN 18 1674 1722 TM Cytosolic 23 LG:1005046. 2 : 2002JAN 18 1723 1740 TM Transmembrane 23 LG: 1005046.2 : 2002JAN18 1741 1810 TM Extracellular 23 LG:1005046. 2 : 2002JAN18 1811 1833 TM Transmembrane 23 LG : 1005046. 2: 2002JAN18 1834 1862 TM Cytosolic 23 LG:1005046. 2 : 2002JAN18 1 44 TM Cytosolic 23 LG:1005046. 2: 2002JAN18 45 67 TM Transmembrane 23 LG:1005046. 2: 2002JAN18 68 359 TM Extracellular 23 LG : 1005046. 2: 2002JAN18 360 382 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 383 388 TM Cytosolic 23 LG1005046. 2 :2002JAN18 389 411 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 412 415 TM Extracellular 23 LG : 1005046.2 : 2002JAN18 416 438 TM Transmembrane 23 LG : 1005046. 2: 2002JAN18 439 464 TM Cytosolic 23 LG:1005046. 2: 2002JAN18 465 484 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 485 493 TM Extracellular 23 LG:1005046. 2 :2002JAN18 494 516 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 517 577 TM Cytosolic 23 LG:1005046. 2 :2002JAN18 578 600 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 601 834 TM Extracellular 23 LG:1005046. 2 :2002JAN18 835 857 TM Transmembrane 23 LG : 1005046. 2: 2002JAN18 858 863 TM Cytosolic 23 LG : 1005046. 2: 2002JAN18 864 886 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 887 895 TM Extracellular 23 LG : 1005046. 2 : 2002JAN18 896 918 TM Transmembrane 23 LG : 1005046. 2 : 2002JAN18 919 938 TM Cytosolic 23 LG1005046. 2 : 2002JAN18 939 961 TM Transmembrane 23 LG:1005046. 2 : 2002JAN18 962 1862 TM Extracellular 23 LG : 1005046. 2: 2002JAN18 4717 4812 forward 1 SP 23 LG : 1005046. 2 : 2002JAN18 4717 4812 forward 1 SP 23 LG : 1005046.2 : 2002JAN18 3742 3795 forward 1 SP 23 LG : 1005046, 2: 2002JAN18 2918 3001 forward 2 SP 23 LG:1005046. 2: 2002JAN18 2918 2983 forward 2 SP 23 LG : 1005046. 2 : 2002JAN18 2918 3001 forward 2 SP 23 LG:1005046.2:2002JAN18 2918 3001 forward 2 SP Table 2 SEQ ID Template ID |Start Stop Frame Domain Topology NO: T e 23 LG:1005046. 2: 2002JAN18 2918 2977 forward 2 SP 23 LG : 1005046. 2 : 2002JAN18 2897 2977 forward 2 SP 23 LG:1005046. 2: 2002JAN18 2918 2983 forward 2 SP 24 LG:1040736. 16 : 2002JAN 18 1 524 TM Extracellular 24 LG:1040736. 16: 2002JAN 18 525 547 TM Transmembrane 24 LG:1040736. 16 : 2002JAN 18 548 578 TM Cytosolic 24 LG : 1040736. 16 : 2002JAN18 112 174 forward 1 SP 24 LG:1040736. 16 : 2002JAN18 1265 1315 forward 2 SP 25 LG:105937.16:2002JAN18 1 875 TM Extracellular 25 LG : 105937. 16: 2002JAN 18 876 898 TM Transmembrane 25 LG:105937. 16: 2002JAN 18 899 926 TM Cytosolic 25 LG : 105937, 16 : 2002JAN 18 1 872 TM Extracellular 25 LG:105937. 16 : 2002JAN 18 873 895 TM Transmembrane 25 LG : 105937. 16: 2002JAN18 896 925 TM Cytosolic 25 LG:105937.16:2002JAN18 2623 2685 forward 1 SP 25LG : 105937. 16 : 2002JAN18 2611 2679 forward 1 SP 25 LG:105937. 16: 2002JAN18 431 511 forward 2 SP 25 LG:105937. 16 : 2002JAN 18 1506 1583 forward 3 SP 25 LG : 105937.16:2002JAN18 2607 2660 forward 3 SP 26 LG:1077405. 2: 2002JAN18 1 222 TM Extracellular 26 LG: 1077405.2 : 2002JAN18 223 245 TM Transmembrane 26 LG:1077405. 2 : 2002JAN18 246 299 TM Cytosolic 26 LG:1077405. 2: 2002JAN18 300 322 TM Transmembrane 26LG : 1077405. 2 : 2002JAN 18 323 366 TM Extracellular 26 LG:1077405. 2 : 2002JAN18 679 750 forward 1 SP 26 LG:1077405. 2 2002JAN18 900 974 forward 3 SP 27 LG:1084716. 4: 2002JAN18 1 779 TM Extracellular 27 LG:1084716. 4: 2002JAN18 780 802 TM Transmembrane 27 LG:1084716. 4 : 2002JAN 18 803 827 TM Cytosolic 27 LG:1084716. 4 : 2002JAN18 1 524 TM Cytosolic 27 LG:1084716.4:2002JAN18 525 547 TM Transmembrane 27 LG : 1084716. 4:2002JAN18 548 827 TM Ectracellular 28 LG: 1091759.1 : 2002JAN18 1 16 TM Cytosolic 28 LG : 1091759. 1 :2002JAN18 17 36 TM Transmembrane 28 LG:1091759. 1 : 2002JAN18 37 278 TM Extracellular 28 LG:1091759. 1 : 2002JAN18 1 11 TM Cytosolic 28 LG:1091759. 1 2002JAN18 12 31 TM Trunsmembrane 28 LG:1091759. 1: 2002JAN 18 32 277 TM Extracellular 28 LG:1091759. 1 :2002JAN18 1 14 TM Extracellular 28 LG:1091759. 1 :2002JAN18 15 37 TM Transmembrane 28 LG:1091759. 1 : 2002JAN18 38 189 TM Cytosolic 28 LG : 1091759. 1: 2002JAN18 190 212 TM Transmembrane 28 LG:1091759. 1 :2002JAN18 213 238 TM Extracellular 28 LG:1091759.1:2002JAN18 239 261 TM Transmembrane 28 LG:1091759. 1: 2002JAN18 262 277 TM Cytosolic 29 LG : 1095157. 16 : 2002JAN18 1 53 TM Cytosolic 29 LG : 1095157. 16: 2002JAN18 54 76 TM Transmembrane 29 LG : 1095157. 16 : 2002JAN18 77 1053 TM Extracellular 29LG : 1095157. 16 : 2002JAN18 2644 2718 forward 1 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 29 LG:1095157. 16 : 2002JAN18 1654 1755 forward 1 SP 29 LG:1095157. 16 : 2002JAN18 2644 2712 forward 1 SP 29 LG:1091517.16:2002JAN18 172 246 forward 1 SP 29 LG:1091517.16:2002JAN18 2422 2481 forward 1 SP 29 LG : 1095157. 16 : 2002JAN18 1661 1732 forward 2 SP 29 LG:1095157. 16 : 2002JAN18 1661 1732 forward 2 SP 29 LG : 1095157. 16 : 2002JAN18 1661 1711 forward 2 SP 29 LG : 1095157. 16: 2002JAN18 1526 1639 forward 2 SP 29 LG : 1095157. 16 : 2002JAN18 1661 1726 forward 2 SP 29 LG:1095157. 16 : 2002JAN18 2256 2321 forward 3 SP 30 LG : 1096601.118:2002JAN18 1 4 TM Extracellular 30 LG : 1096601.118:2002JAN18 5 27 TM Transmembrane 30 LG : 1096601. 118 : 2002JAN18 28 160 TM Cytosolic 31 LG : 1099356. 5 : 2002JAN18 922 1032 forward 1 SP 31 LG : 1099356. 5 :2002JAN18 952 1026 forward 1 SP 31 LG : 1099356. 5: 2002JAN18 952 1032 forward 1 SP 31 LG: 1099356. 5 : 2002JAN18 946 1026 forward 1 SP 31 LG: 1099356.5 : 2002JAN18 964 1026 forward 1 SP 31 LG : 1099356.5 : 2002JAN18 955 1032 forward 1 SP 31 LG:1099356. 5: 2002JAN18 964 1032 forward 1 SP 31 LG1099356. 5 : 2002JAN18 955 1020 forward 1 SP 31 LG : 1099356. 5 : 2002JAN18 973 1029 forward 1 SP 31 LG : 1099356. 5: 2002JAN18 614 664 forward 2 SP 31 LG 1099356. 5: 2002JAN18 591 686 forward 3 SP 32 LG : 1100807. 18 : 2002JAN18 1 390 TM Extracellular 32 LG : 1100807. 18: 2002JAN18 391 413 TM Transmembrane 32 LG : 1100807. 18 : 2002JAN18 414 659 TM Cytosolic 32 LG:1100807. 18: 2002JAN 18 660 679 TM Transmembrane 32 LG:1100807. 18 :2002JAN18 680 715 TM Extracellular 32 LG : 1100807. 18 : 2002JAN18 1177 1245 forward 1 SP 32 LG:1100807.18:2002JAN18 1177 1242 forward 1 SP 32 LG:1100807. 18: 2002JAN18 1177 1251 forward 1 SP 32 LG : 1100807. 18 : 2002JAN18 1177 1251 forward 1 SP 32 LG : 1100807.18:2002JAN18 1981 2052 forward 1 SP 32 LG : 1100807. 18 : 2002JAN18 1520 1597 forward 2 SP 32 LG : 1100807. 18: 2002JAN18 686 757 forward 2 SP 32 LG:1100807. 18 : 2002JAN18 1182 1244 forward 3 SP 32 LG:1100807. 18 :2002JAN18 1182 1247 forward 3 SP 32 LG : 1100807. 18: 2002JAN18 1182 1226 forward 3 SP 32 LG : 1100807. 18 : 2002JAN18 1182 1250 forward 3 SP 32 LG:1100807. 18 : 2002JAN18 1182 1244 forward 3 SP 33 LG : in6310. 38: 2002JAN18 1 323 TM Extracellular 33 LG:1116310. 38 :2002JAN18 324 346 TM Transmembrane 33 LG:1116310.38:2002JAN18 347 443 TM Cytosolic 34 LG:1132386.23:2002JAN18 1 363 TM Extracellular 34 LG : 1132386 23 : 2002JAN18 364 386 TM Transmembrane 34 LG : 1132386. 23 : 2002JAN18 387 514 TM Cytosolic 34 LG:1132386. 23 :2002JAN18 515 537 TM Transmembrane 34 LG : 1132386 23 : 2002JAN18 538 556 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain topology NO: T e 34 LG:1132386. 23 : 2002JAN18 557 579 TM Transmembrane 34 LG : 1132386. 23 : 2002JAN18 580 585 TM Cytosolic 34 LG : 1132386. 23 : 2002JAN18 586 608 TM Transmembrane 34 LG : I 132386. 23: 2002JAN18 609 612 TM Extracellular 34 LG : 1132386. 23 : 2002JAN18 613 632 TM Transmembrane 34 LG : 1132386. 23 : 2002JAN18 633 728 TM Cytosolic 34 LG : 1132386. 23 : 2002JAN18 729 751 TM Transmembrane 34 LG : 1132386. 23: 2002JAN 18 752 786 TM Extracellular 34 LG : 1132386. 23 :2002JAN18 1 512 TM Extracellular 34 LG:1132386. 23 ;2002JAN18 513 535 TM Transmembrane 34 LG : 1132386. 23: 2002JAN18 536 614 TM Cytosolic 34 LG:1132386. 23 : 2002JAN18 615 637 TM Transmembrane 34 LG : 1132386. 23 :2002JAN18 638 702 TM Extracellular 34 LG : I 132386. 23 :2002JAN18 703 725 TM Transmembrane 34 LG:1132386. 23 : 2002JAN18 726 736 TM Cytosolic 34 LG : 1132386. 23: 2002JAN18 737 759 TM Transmembrane 34 LG : 1132386. 23 : 2002JAN18 760 786 TM Extracellular 34 LG:1132386. 23: 2002JAN 18 1 533 TM Extracellular 34 LG : 1132386. 23 : 2002JAN 18 534 556 TM Transmembrane 34 LG : I 132386. 23 : 2002JAN18 557 568 TM Cytosolic 34 LG : 1132386. 23 :2002JAN18 569 591 TM Transmembrane 34 LG : 1132386. 23 : 2002JAN18 592 610 TM Extracellular 34 LG:1132386. 23 :2002JAN18 611 633 TM Transmembrane 34 LG:1132386. 23 : 2002JAN18 634 786 TM Cytosolic 34 LG : 1132386. 23 : 2002JAN18 1762 1839 forward 1 SP 34 LG:1132386. 23 : 2002JAN18 1099 1152 forward 1 SP 34 LG : 1132386. 23: 2002JAN18 1762 1845 forward 1 SP 34 LG : 1132386. 23 : 2002JAN18 444 503 forward 3 SP 35 LG : I 134869. 44 2002JAN18 1 61 TM Cytosolic 36 LG : 1135675. 15 : 2002JAN18 1 400 TM Extracellular 36 LG : 1135675. 15 :2002JAN18 401 423 TM Transmembrane 34 LG:1132386. 15: 2002JAN18 424 684 TM Cytosolic 36 LG : 1135675. 15: 2002JAN18 685 707 TM Transmembrane 36 LG : 1135675. 15 : 2002JAN18 708 1042 TM Extracellular 36 LG : 1135675. 15 : 2002JAN18 1127 1213 forward 2 SP 36LG : 1135675. 15 : 2002JAN 18 138 191 forward 3 SP 37 LG : 1285109.14 : 2002JAN18 1 4 TM Cytosolic 37 LG:1285109. 14: 2002JAN18 5 27 TM Transmembrane 37 LG : 1285109. 14 : 2002JAN 18 28 483 TM Extracellular 37 LG : 1285109. 14: 2002JAN18 1 6 TM Cytosolic 37 LG : 1285109. 14 : 2002JAN18 7 29 TM Transmembrane 37 LG : 1285109. 14 :2002JAN18 30 61 TM Extracellular 37 LG: 1285109.14 : 2002JAN18 62 84 TM Transmembrane 37 LG : 1285109. 14 : 2002JAN18 85 427 TM Cytosolic 37 LG : 1285109. 14 : 2002JAN18 428 450 TM Transmembrane 37 LG:1285109.14:2002JAN18 451 459 TM Extracellular 37 LG : 1285109. 14:2002JAN18 460 479 TM Transmembrane 37 LG : 1285109.14 : 2002JAN18 480 483 TM Cytosolic 37 LG : 1285109. 14 : 2002JAN18 607 672 forward 1 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 37 LG:1285109. 14: 2002JAN18 1317 1364 forward 3 SP 37 LG : 1285109. 14 : 2002JAN18 1317 1379 forward 3 SP 37 LG : 1285109.14 : 2002JAN18 1317 1376 forward 3 SP 38 LG:1329818. 9 : 2002JAN18 1 54 TM Extracellular 38 LG : 1329818. 9 : 2002JAN18 55 77 TM Transmembrane 38 LG:1329818. 9 : 2002JAN18 78 169 TM Cytosolic 38 LG:1329818. 9 :2002JAN18 170 192 TM Transmembrane 38 LG:1329818. 9 : 2002JAN 18 193 201 TM Extracellular 38 LG:1329818. 9 :2002JAN18 202 224 TM Transmembrane 38 LG : 1329818. 9 : 2002JAN18 225 271 TM Cytosolic 38 LG : 1329818. 9 : 2002JAN18 272 294 TM Transmembrane 38 LG:1329818.9:2002JAN18 295 636 TM Extracellular 38 LG:1329818. 9 : 2002JAN18 637 659 TM Transmembrane 38 LG:1329818. 9: 2002JAN18 660 679 TM Cytosolic 38 LG:1329818. 9: 2002JAN18 680 702 TM Transmembrane 38 LG:1329818. 9 : 2002JAN18 703 809 TM Extracellular 38 LG:1329818.9:2002JAN18 1 573 TM Extracellular 38 LG:1329818. 9 :2002JAN18 574 596 TM Transmembrane 38 LG : 1329818. 9 : 2002JAN18 597 608 TM Cytosolic 38 LG : 1329818. 9 : 2002JAN18 609 631 TM Transmembrane 38 LG:1329818. 9 : 2002JAN18 632 719 TM Extracellular 38 LG : 1 329818. 9: 2002JAN18 720 742 TM Transmembrane 38 LG : 1329818. 9 : 2002JAN18 743 809 TM Cytosolic 38 LG : 1329818. 9: 2002JAN18 842 898 forward 2 SP 38 LG:1329818. 9 : 2002JAN18 1904 1966 forward 2 SP 38 LG : 1329818. 9 : 2002JAN18 1904 1960 forward 2 SP 38 LG : 1329818. 9 : 2002JAN18 1904 1975 forward 2 SP 39 LG:1377451. 48 : 2002JAN18 1 82 TM Cytosolic 39 LG:1377451. 48: 2002JAN18 83 105 TM Transmembrane 39 LG:1377451. 48 :2002JAN18 106 510 TM Extracellular 39 LG : 1377451. 48 : 2002JAN 18 1068 1157 forward 3 SP 39 LG:1377451. 48: 2002JAN18 186 299 forward 3 SP 39 LG:1377451. 48: 2002JAN18 234 299 forward 3 SP 39 LG:1377451. 48 2002JAN18 252 299 forward 3 SP 39 LG:1377451. 48 : 2002JAN18 246 299 forward 3 SP 39 LG : 1377451. 48: 2002JAN18 246 302 forward 3 SP 40 LG : 1383694. 5: 2002JAN18 1 42 TM Cytosolic 41 LG : 1383725. 3: 2002JAN 18 1 41 TM Cytosolic 41 LG:1383725. 3 ; 2002JAN18 42 64 TM Transmembrane 41 LG: 1383725. 3: 2002JAN18 65 67 TM Extracellular 41 LG:1383725. 3 : 2002JAN 18 68 90 TM Transmembrane 41 LG:1383725. 3: 2002JAN18 91 109 TM Cytosolic 41 LG : 1383725. 3 : 2002JAN18 110 132 TM Transmembrane 41 LG : 1383725. 3 : 2002JAN18 133 182 TM Extracellular 41 LG:1383725. 3 : 2002JAN18 183 205 TM Transmembrane 41 LG:1383725. 3: 2002JAN18 206 209 TM Cytosolic 41 LG1383725 3 2002JAN18 210 232 TM Transmembrane 41 LG:1383725. 3 :2002JAN18 233 314 TM Extracellular 41 LG:1383725. 3 :2002JAN18 315 337 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 41 LG:1383725. 3 : 2002JAN18 338 353TMCytosoi ! c 41 LG:1383725.3:2002JAN18 354 376 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 377 1011 TM Extracellular 41 LG:1383725. 3 : 2002JAN18 1012 1034 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 1035 1086 TM Cytosolic 41 LG:1383725. 3 : 2002JAN18 1 32 TM Extracellular 41 LG:1383725. 3 : 2002JAN 18 33 55 TM Transmembrane 41 LG:1383725. 3: 2002JAN18 56 66 TM Cytosolic 41 LG:1383725. 3 : 2002JAN18 67 89 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 90 178 TM Extracellular 41 LG : 1383725. 3 : 2002JAN18 179 201 TM Transmembrane 41 LG:1383725. 3: 2002JAN18 202 221 TM Cytosolic 41 LG : 1383725. 3 : 2002JAN18 222 244 TM Transmembrane 41 LG : 1383725. 3: 2002JAN18 245 314 TM Extracellular 41 LG : 1383725. 3 : 2002JAN18 315 337 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 338 357 TM Cytosolic 41 LG:1383725. 3 : 2002JAN18 358 380 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 381 1086 TM Extracellular 41 LG:1383725. 3 : 2002JAN18 1 38 TM Cytosolic 41 LG : 1383725. 3: 2002JAN18 39 61 TM Transmembrane 41 LG. 1383725. 3 :2002JAN18 62 194 TM Extracellular 41 LG : 1383725. 3 : 2002JAN18 195 217 TM Transmembrane 41 LG : 1383725. 3: 2002JAN18 218 223 TM Cytosolic 41 LG : 1383725. 3 : 2002JAN18 224 242 TM Transmembrane 41 LG:1383725. 3 : 2002JAN 18 243 261 TM Extracellular 41 LG:1383725. 3 : 2002JAN18 262 284 TM Transmembrane 41 LG : 1383725. 3 : 2002JAN18 285 348 TM Cytosolic 41 LG: 1383725.3 : 2002JAN18 349 371 TM Transmembrane 41 LG:1383725. 3 : 2002JAN18 372 1053 TM Extracellular 41 LG : 1383725. 3 : 2002JAN18 1054 1073 TM Transmembrane 41 LG : 1383725. 3: 2002JAN18 1074 1085 TM Cytosolic 41 LG:1383725. 3: 2002JAN18 1042 1116 forward 1 SP 41 LG:1383725. 3 : 2002JAN18 2383 2475 forward 1 SP 41 LG : 1383725. 3 : 2002JAN18 1042 1122 forward 1 SP 41 LG : 1383725. 3: 2002JAN18 2383 2448 forward 1 SP 42 LG:1394903. 37 : 2002JAN18 1 19 TM Extracellular 42 LG:1394903. 37 : 2002JAN 18 20 42 TM Transmembrane 42 LG:1394903. 37 : 2002JAN18 43 210 TM Cytosolic 42 LG:1394903. 37: 2002JAN18 211 233 TM Transmembrane 42 LG : 1394903. 37 : 2002JAN18 234 752 TM Extracellular 42 LG : 1394903. 37 : 2002JAN18 391 444 forward 1 SP 42 LG:1394903. 37 : 2002JAN 18 623 724 forward 2 SP 42 LG:1394903. 37 : 2002JAN18 680 724 forward 2 SP 42 LG:1394903. 37 :2002JAN18 680 730 forward 2 SP 43 LG : 1398274. 13: 2002JAN18 1 9 TM Extracellular 43 LG : 1398274. 13 : 2002JAN18 10 32 TM Transmembrane 43 LG:1398274. 13 : 2002JAN 18 33 36 TM Cytosolic 43 LG:1398274. 13: 2002JAN18 37 54 TM Transmembrane 43 LG:1398274. 13 : 2002JAN 18 55 901 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 43 LG:1398274. 13: 2002JAN18 902 924 TM Transmembrane 43 LG:1398274. 13: 2002JAN18 925 973 TM Cytosolic 43 LG:1398274. 13: 2002JAN18 974 996 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 997 1299 TM Extracellular 43 LG : 1398274. 13 : 2002JAN18 1300 1322 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 1323 1342 TM Cytosolic 43 LG:1398274. 13: 2002JAN18 1343 1365 TM Transmembrane 43 LG:1398274. 13: 2002JAN18 1366 1582 TM Extracellular 43 LG:1398274.13:2002JAN18 1 4 TM Extracellular 43 LG:1398274. 13: 2002JAN18 5 27 TM Transmembrane 43 LG:1398274. 13: 2002JAN 18 28 33 TM Cytosolic 43 LG : 1398274. 13: 2002JAN18 34 56 TM Transmembrane 43 LG:1398274.13:2002JAN18 57 498 TM Extracellular 43 LG:1398274. 13 : 2002JAN18 499 516 TM Transmembrane 43 LG : 1398274. 13 : 2002JAN18 517 522 TM Cytosolic 43 LG : 1398274. 13 : 2002JAN18 523 545 TM Transmembrane 43 LG: 1398274.13 : 2002JAN18 546 891 TM Extracellular 43 LG : 1398274. 13: 2002JAN18 892 914 TM Transmembrane 43 LG:1398274. 13 : 2002JAN18 915 934 TM Cytosolic 43 LG:1398274. 13 : 2002JAN18 935 952 TM Transmembrane 43 LG:1398274. 13: 2002JAN18 953 961 TM Extracellular 43 LG:1398274.13:2002JAN18 962 984 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 985 1349 TM Cytosolic 43 LG : 1398274. 13 : 2002JAN 18 1350 13872 TM Transmembrane 43 LG:1398274. 13 : 2002JAN18 1373 1582 TM Extracellular 43 LG:1398274. 13 :2002JAN18 1 236 TM Extracellular 43 LG:1398274. 13 :2002JAN18 237 259 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 260 353 TM Cytosolic 43 LG:1398274. 13 :2002JAN18 354 376 TM Transmembrane 43 LG:1398274. 13 :2002JAN18 377 390 TM Extracellular 43 LG : 1398274. 13: 2002JAN18 391 413 TM Transmembrane 43 LG : 1398274. 13 : 2002JAN18 414 448 TM Cytosolic 3 LG:1398274. 13 : 2002JAN 18 449 471 TM Transmembrane 43 LG:1398274. 13 : 2002JAN 18 472 485 TM Extracellular 43 LG:1398274.13:2002JAN18 486 508 TM Transmembrane 43 LG:1398274.13:2002JAN18 509 520 TM Cytosolic 43 LG : 1398274.13 : 2002JAN18 521 538 TM Transmembrane 43 LG:1398274. 13: 2002JAN18 539 754 TM Extracellular 43 LG : 1398274. 13: 2002JAN18 755 774 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 775 802 TM Cytosolic 43 LG : 1398274. 13 : 2002JAN18 803 825 TM Transmembrane 43 LG : 1398274. 13:2002JAN18 826 839 TM Extracellular 43 LG : 1398274. 13: 2002JAN18 840 862 TM Transmembrane 43 LG : 1398274. 13: 2002JAN18 863 894 TM Cytosolic 43 LG : 1398274. 13: 2002JAN18 895 914 TM Transmembrane 43 LG : 1398274. 13 : 2002JAN 18 9l 5 1286 TM Extracellular 43 LG : 1398274.13 : 2002JAN18 1287 1309 TM Transmembrane 43 LG : 1398274, 13 : 2002JAN18 1310 1320 TM Cytosolic 43 LG:1398274. 13: 2002JAN18 1321 1343 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 43 LG:1398274. 13 : 2002JAN18 1344 1352 TM Extracellular 43 LG : 139827413 : 2002JAN18 1353 1375 TM Transmembrane 43 LG : 1398274. 13 : 2002JAN18 1376 1581 TM Cytosolic 43 LG : 1398274. 13 : 2002JAN18 2791 2865 forward 1 SP 43 LG:1398274.13:2002JAN18 3307 3360 forward 1 SP 43 LG : 1398274. 13: 2002JAN18 3785 3883 forward 2 SP 43 LG:1398274. 13 : 2002JAN18 3785 3877 forward 2 SP 43 LG : 1398274. 13: 2002JAN18 33 86 forward 3 SP 43 LG:1398274. 13 : 2002JAN18 1056 1121 forward 3 SP 43 LG : 1398274. 13 : 2002JAN18 27 80 forward 3 SP 43 LG:1398274. 13 : 2002JAN 18 33 80 forward 3 SP 44 LG:1398646. 12 :2002JAN18 1 754 TM Extracellular 44 LG : 1398646, 12 :2002JAN18 755 777 TM Transmembrane 44 LG : 1398646. 12 : 2002JAN18 778 886 TM Cytosolic 44 LG: 1398646.12 : 2002JAN18 1 759 TM Extracellular 44 LG : 1398646. 12 : 2002JAN18 760 782 TM Transmembrane 44 LG : 1398646. 12: 2002JAN18 783 793 TM Cytosolic 44 LG:1398646. 12: 2002JAN18 794 816 TM Transmembrane 44 LG : 1398646. 12: 2002JAN18 817 830 TM Extracellular 44 LG : 1398646. 12 : 2002JAN18 831 848 TM Transmembrane 44 LG : 1398646. 12: 2002JAN18 849 885 TM Cytosolic 44 LG: 1398646.12 : 2002JAN18 1 104 TM Cytosolic 44 LG : 1398646. 12 : 2002JAN 18 105 127 TM Transmembrane 44 LG: 1398646.12 : 2002JAN18 128 506 TM Extracellular 44 LG:1398646. 12 : 2002JAN 18 507 526 TM Transmembrane 44 LG:1398646. 12 : 2002JAN18 527 758 TM Cytosolic 44 LG:1398646. 12: 2002JAN18 759 781 TM Transmembrane 44 LG : 1398646. 12: 2002JAN18 782 795 TM Extracellular 44 LG:1398646. 12 : 2002JAN18 796 818 TM Transmembrane 44 LG : 1398646. 12 : 2002JAN18 819 885 TM Cytosolic 44 LG:1398646. 12: 2002JAN18 2407 2472 forward 1 SP 44 LG:1398646. 12: 2002JAN18 2249 2317 forward 2 SP 44 LG : 1398646. 12 :2002JAN18 2249 2311 forward 2 SP 45 LG:1398955. 2 : 2002JAN18 1 1296 TM Extracellular 45 LG:1398955. 2 : 2002JAN18 1297 1316 TM Transmembrane 45 LG:1398955. 2: 2002JAN18 1317 1320 TM Cytosolic 45 LG : 1398955. 2 : 2002JAN18 1321 1343 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1344 1674 TM Extracellular 45 LG:1398955. 2 :2002JAN18 1675 1697 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1698 1713 TM Cytosolic 45 LG:1398955. 2 : 2002JAN18 1 1321 TM Extracellular 45 LG:1398955. 2 : 2002JAN18 1322 1344 TM Transmembrane 45 LG:1398955. 2: 2002JAN18 1345 1516 TM Cytosolic 45 LG : 1398955. 2 : 2002JAN18 15i7 1639 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1540 1542 TM Extracellular 45 LG:1398955. 2 : 2002JAN18 1543 1565 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1566 1636 TM Cytosolic 45 LG:1398955. 2 : 2002JAN18 1637 1659 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1660 1712 TM Extracellular Table 2 SEQ ID Template ID |Start Stop Frame Domain Topology NO : T e 45 LG : 1398955. 2 : 2002JAN18 1 961 TM Extracellular 45 LG:1398955. 2 : 2002JAN18 962 979 TM Transmembrane 45 LG:1398955. 2: 2002JAN18 980 1134 TM Cytosolic 45 LG:1398955. 2 :2002JAN18 1135 1157 TM Transmembrane 45 LG:1398955. 2 : 2002JAN18 1158 1171 TM Extracellular 45 LG:1398955. 2 : 2002JAN 18 1172 1194 TM Transmembrane 45 LG:1398955. 2 : 2002JAN 18 1195 1303 TM Cytosolic 45 LG:1398955. 2 :2002JAN18 1304 1326 TM Transmembrane 45 LG : 1398955. 2 : 2002JAN18 1327 1712 TM Extracellular 45 LG : 1398955. 2 : 2002JAN18 2012 2071 forward 2 SP 45 LG : 1398955. 2: 2002JAN18 2012 2077 forward 2 SP 45 LG:1398955. 2 : 2002JAN18 2012 2074 forward 2 SP 45 LG:1398955. 2: 2002JAN18 2012 2077 forward 2 SP 45 LG : 1398955. 2: 2002JAN18 4133 4210 forward 2 SP 45 LG:1398955. 2 : 2002JAN 18 3909 3956 forward 3 SP 45 LG:1398955. 2: 2002JAN18 1812 1886 forward 3 SP 45 LG : 1398955. 2 : 2002JAN 18 1812 1880 forward 3 SP 45 LG:1398955. 2 :2002JAN18 1812 1865 forward 3 SP 45 LG:1398955. 2: 2002JAN18 1812 1892 forward 3 SP 45 LG:1398955. 2 : 2002JAN18 1812 1886 forward 3 SP 46 LG : 1452762. 26 : 2002JAN18 1 20 TM Cytosolic 46 LG:1452762. 26: 2002JAN18 21 40 TM Transmembrane 46 LG : 1452762. 26: 2002JAN18 41 81 TM Extracellular 46 LG:1452762. 26 :2002JAN18 82 104 TM Transmembrane 46 LG : 1452762.26 : 2002JAN18 105 123 TM Cytosolic 46 LG:1452762. 26 : 2002JAN 18 124 146 TM Transmembrane 46 LG:1452762. 26 : 2002JAN 18 147 378 TM Extracellular 46 LG : 1452762. 26 : 2002JAN18 1 20 TM Cytosolic 46 LG:1452762. 26 :2002JAN18 21 40 TM Transmembrane 46 LG:1452762. 26: 2002JAN18 41 43 TM Extracellular 46 LG:1452762. 26 : 2002JAN18 44 61 TM Transmembrane 46 LG:1452762. 26: 2002JAN18 62 81 TM Cytosolic 46 LG:1452762. 26 : 2002JAN18 82 104 TM Transmembrane 46 LG : 1452762. 26: 2002JAN18 105 172 TM Extracellular 46 LG : 1452762. 26: 2002JAN18 173 195 TM Transmembrane 46 LG : 1452762. 26 : 2002JAN18 196 201 TM Cytosolic 46 LG:1452762. 26 :2002JAN18 202 224 TM Transmembrane 46 LG: 1452762.26 : 2002JAN18 225 259 TM Extracellular 46 LG:1452762. 26 :2002JAN18 260 282 TM Transmembrane 46 LG:1452762. 26: 2002JAN18 283 294 TM Cytosolic 46 LG : 1452762. 26 2002JAN18 295 317 TM Transmembrane 46 LG : 1452762. 26: 2002JAN18 318 326 TM Extracellular 46 LG : 1452762. 26 : 2002JAN18 327 349 TM Transmembrane 46 LG:1452762. 26 : 2002JAN18 350 377 TM Cytosolic 46 LG:1452762. 26 : 2002JAN18 1 198 TM Extracellular 46 LG:1452762. 26 2002JAN18 199 221 TM Transmembrane 46 LG : 1452762. 26 : 2002JAN18 222 241 TM Cytosolic 46 LG:1452762. 26 : 2002JAN18 242 264 TM Transmembrane 46 LG : 1452762. 26: 2002JAN18 265 335 TM Extracellular Table 2 SEQ ID Template ID |Start Stop Frame Domain Topology NO: Type 46 LG:1452762. 26 : 2002JAN18 336 358 TM Transmembrane 46 LG : 1452762. 26 : 2002JAN18 359 377 TM Cytosolic 46 LG:1452762. 26 : 2002JAN18 583 636 forward 1 SP 46 LG : 1452762. 26 : 2002JAN18 854 928 forward 2 SP 46 LG : 1452762. 26: 2002JAN18 854 934 forward 2 SP 46 LG : 1452762, 26 : 2002JAN18 854 934 forward 2 SP 47 LG:1452783. 7: 2002JAN 18 1 867 TM Extracellular 47 LG: 1452783.7 : 2002JAN 18 868 890 TM Transmembrane 47 LG : 1452783. 7 :2002JAN18 891 909 TM Cytosolic 47 LG : 1452783.7 : 2002JAN18 910 932 TM Transmembrane 47 LG : 1452783. 7 : 2002JAN18 933 1028 TM Extracellular 47 LG:1452783.7:2002JAN18 1 756 TM Extracellular 47 LG : 1452783. 7 : 2002JAN18 757 779 TM Transmembrane 47 LG:1452783. 7 : 2002JAN18 780 861 TM Cytosolic 47 LG: 1452783.7 :2002JAN18 862 884 TM Transmembrane 47 LG : 1452783. 7: 2002JAN18 885 903 TM Extracellular 47 LG:1452783. 7 : 2002JAN18 904 926 TM Transmembrane 47 LG : 1452783. 7: 2002JAN18 927 932 TM Cytosolic 47 LG : 1452783. 7 : 2002JAN18 933 955 TM Transmembrane 47 LG:1452783. 7 : 2002JAN18 956 969 TM Extracellular 47 LG : 1452783. 7 : 2002JAN18 970 992 TM Transmembrane 47 LG : 1452783. 7 :2002JAN18 993 1027 TM Cytosolic 47 LG : 1452783.7 : 2002JAN18 2365 2427 forward 1 SP 47 LG : 1452783. 7: 2002JAN18 2365 2430 forward 1 SP 47 LG:1452783. 7: 2002JAN18 2365 2433 forward 1 SP 47 LG:1452783. 7: 2002JAN18 284 337 forward 2 SP 47 LG:1452783. 7 : 2002JAN18 284 343 forward 2 SP 47 LG:1452783. 7 : 2002JAN18 2259 2303 forward 3 SP 47 LG : 1452783. 7 : 2002JAN18 2259 2309 forward 3 SP 47 LG: 1452783.7 2002JAN18 2259 2324 forward 3 SP 47 LG : 1452783.7 : 2002JAN18 318 380 forward 3 SP 47 LG : 1452783. 7 : 2002JAN18 318 377 forward 3 SP 47 LG : 1452783. 7: 2002JAN18 2259 2336 forward 3 SP 47 LG: 1452783.7 : 2002JAN18 318 380 forward 3 SP 47 LG:1452783. 7 : 2002JAN18 318 374 forward 3 SP 48 LG : 1453027. 28: 2002JAN18 1 69 TM Cytosolic 48 LG : 1453027. 28: 2002JAN18 70 92 TM Transmembrane 48 LG : 1453027. 28: 2002JAN18 93 272 TM Extracellular 48 LG ; 1453027. 28 : 2002JAN18 1 70 TM Extracellular 48 LG : 1453027. 28 :2002JAN18 71 93 TM Transmembrane 48 LG : 1453027. 28 : 2002JAN18 94 113 TM Cytosolic 48 LG : 1453027. 28 : 2002JAN18 114 136 TM Transmembrane 48 LG : 1453027. 28: 2002JAN18 137 272 TM Extracellular 48 LG : 1453027. 28: 2002JAN18 415 492 forward 1 SP 48 LG : 1453027. 28 : 2002JAN18 415 486 forward 1 SP 48 LG:1453027. 28 : 2002JAN18 415 492 forward 1 SP 48 LG : 1453027, 28: 2002JAN18 415 492 forward 1 SP 48 LG : 1453027. 28 : 2002JAN18 415 477 forward 1 SP 48 LG : 1453027. 28: 2002JAN18 353 412 forward 2 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 48 LG : 1453027. 28: 2002JAN18 315 413 forward 3 SP 48 LG : 1453027. 28: 2002JAN18 315 395 forward 3 SP 48 LG : 1453027.28:2002JAN18 315 392 forward 3 SP 49 LG : 1454967. 12: 2002JAN18 1 1331 TM Extracellular 49 LG : 1454967. 12: 2002JAN18 1332 1354 TM Transmembrane 49 LG : 1454967. 12 : 2002JAN18 1355 1358 TM Cytosolic 49 LG:1454967. 12: 2002JAN18 1359 1376 TM Transmembrane 49 LG : 1454967. 12: 2002JAN18 1377 1385 TM Extracellular 49 LG : 1454967.12 :2002JAN18 1386 1408 TM Transmembrane 49 LG : 1454967.12 : 2002JAN18 1409 1429 TM Cytosolic 49 LG: 1454967.12 : 2002JAN18 1 50 TM extracellular 49 LG:1454967. 12 : 2002JAN 18 51 68 TM Transmembrane 49 LG : 1454967. 12 : 2002JAN18 69 339 TM Cytosolic 49 LG:1454967. 12 : 2002JAN18 340 362 TM Transmembrane 49 LG: 1454967.12 : 2002JAN18 363 1428 TM Extracellular 49 LG: 1454967.12 : 2002JAN18 3676 3762 forward 1 SP 49 LG : 1454967. 12 : 2002JAN18 3676 3765 forward 1 SP 49 LG : 1454967. 12 :2002JAN18 3676 3762 forward 1 SP 49 LG:1454967. 12 : 2002JAN18 1003 1077 forward 1 SP 49 LG : 1454967. 12: 2002JAN18 1003 1077 forward 1 SP 49 LG:1454967. 12 : 2002JAN18 1012 1071 forward 1 SP 49 LG: 1454967.12 : 2002JAN18 1015 1074 forward 1 SP 49 LG : 1454967.12 : 2002JAN18 158 214 forward 2 SP 49 LG : 1454967. 12: 2002JAN18 1130 1231 forward 2 SP 49 LG : 1454967. 12: 2002JAN18 158 223 forward 2 SP 49 LG:1454967.12:2002JAN18 158 217 forward 2 SP 49 LG : 1454967. 12 : 2002JAN18 758 838 forward 2 SP 49 LG : 1454967.12:2002JAN18 1011 1094 forward 3 SP 49 LG:1454967. 12 : 2002JAN18 1011 1085 forward 3 SP 49 LG : 1454967. 12 :2002JAN18 1011 1079 forward 3 SP 49 LG : 1454967. 12: 2002JAN18 1011 1094 forward 3 SP 49 LG:1454967. 12: 2002JAN18 1011 1070 forward 3 SP 50 LG:1466307. 1 :2002JAN18 1 50 TM Extracellular 50 LG:1466307. 1 2002JAN18 51 73 TM Transmembrsne 50 LG : 1466307.1 : 2002JAN18 74 166 TM Cytosolic 51 LG : 149121. 24: 2002JAN18 1 20 TM Cytosolic 51 LG : 149121. 24: 2002JAN 18 21 43 TM Transmembrane 51 LG:149121. 24: 2002JAN 18 44 1217 TM Extracellular 51 LG : 149121. 24 : 2002JAN18 337 411 forward 1 SP 51 LG : 149121. 24 : 2002JAN18 337 414 forward 1 SP 51 LG : 149121. 24 : 2002JAN18 1682 1750 forward 2 SP 51 LG:149121. 24 : 2002JAN18 1682 1744 forward 2 SP 51 LG : 149121. 24 : 2002JAN18 1682 1738 forward 2 SP 51 LG : 149121. 24 : 2002JAN18 1682 1747 forward 2 SP 52 LG : 1 500347. 11 : 2002JAN 18 1 45 TM Cytosolic 52 LG:1500347. 11: 2002JAN18 46 68 TM Transmembrane 52 LG:1500347.11:2002JAN18 69 136 TM Extracellular 52 LG:1500347.11:2002JAN18 137 159 TM Transmembrane 52LG : 1500347. n : 2002JAN18 160 216 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 52 LG:1500347.11:2002JAN18 106 186 forward 1 SP 52 LG:1500347.11:2002JAN18 106 183 forward 1 SP 52 LG:1500347. 11 : 2002JAN18 106 174 forward 1 SP 53 LG : 1500433. 15 : 2002JAN18 1 117 TM Cytosolic 53 LG : 1500433. 15 : 2002JAN 18 118 137 TM Transmembrane 53 LG : 1500433. 15: 2002JAN 18 138 338 TM Extracellular 53 LG : 1500433. 15 : 2002JAN18 472 519 forward 1 SP 53 LG:1500433.15:2002JAN18 472 531 forward 1 SP 53 LG : 1500433. 15 : 2002JAN18 344 409 forward 2 SP 53 LG: 1500433.15 :2002JAN18 344 403 forward 2 SP 53 LG:1500433. 15: 2002JAN18 344 406 forward 2 SP 54 LG:1500434. 6: 2002JAN 18 1 457 TM Extracellular 54 LG:1500434.6:2002JAN18 458 480 TM Transmembrane 54 LG : 1500434, 6 : 2002JAN18 481 683 TM Cytosolic 54 LG : 1500434. 6 : 2002JAN18 684 701 TM Transmembrane 54 LG : 1500434.6 : 2002JAN18 702 757 TM Extracellular 54 LG : I 500434. 6: 2002JAN18 758 780 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 781 821 TM Cytosolic 54 LG : 1500434.6 : 2002JAN18 822 844 TM Transmembrane 54 LG : 1500434.6 : 2002JAN18 845 871 TM Extracellular 54 LG : 1500434. 6 : 2002JAN18 872 894 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 895 938 TM Cytosolic 54 LG : 1500434.6 : 2002JAN18 939 961 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 962 975 TM Extracellular 54 LG:1500434. 6 :2002JAN18 976 998 TM Transmembrane 54 LG:1500434.6:2002JAN18 999 1004 TM Cytosolic 54 LG:1500434.6:2002JAN18 1005 1027 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 1028 1041 TM Extracellular 54 LG:1500434. 6 : 2002JAN18 1042 1064 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 1065 1229 TM Cytosolic 54 LG:1500434. 6 :2002JAN18 1230 1252 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 1253 1280 TM Extracellular 54 LG:1500434. 6 : 2002JAN18 1281 1303 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1304 1376 TM Cytosolic 54 LG:1500434.6:2002JAN18 1377 1399 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1400 1413 TM Extracellular 54 LG : 1500434.6:2002JAN18 1414 1436 TM Transmembrane 54 LG : 1500434. 6: 2002JAN18 1437 1518 TM Cytosolic 54 LG : 1500434. 6: 2002JAN18 1 706 TM Extracellular 54 LG : I 500434. 6 :2002JAN18 707 729 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 730 829 TM Cytosolic 4 LG : 1500434. 6 : 2002JAN18 830 852 TM Transmembrane 54 LG : 1500434. 6: 2002JAN18 853 866 TM Extracellular 54 LG : I 500434. 6 :2002JAN18 867 889 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 890 974 TM Cytosolic 54 LG:1500434. 6: 2002JAN18 975 997 TM Transmembrane 54 LG:1500434. 6: 2002JAN 18 998 1011 TM Extracellular 54 LG:1500434. 6 : 2002JAN 18 1012 1031 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 1032 1112 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 54 LG:1500434. 6 : 2002JAN18 1113 1135 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1136 1149 TM Extracellular 54 LG : 1500434. 6: 2002JAN18 1150 1172 TM Transmembrane 54 LG : 1500434. 6: 2002JAN 18 1173 1262 TM Cytosolic 54 LG : 1500434. 6 : 2002JAN 18 1263 1285 TM Transmembrane 54 LG: 1500434.6 : 2002JAN18 1286 1374 TM Extracellular 54 LG:1500434. 6 : 2002JAN18 1375 1397 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1398 1423 TM Cytosolic 54 LG:1500434. 6 2002JAN18 1424 1446 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 1447 1450 TM Extracellular 54 LG:1500434. 6: 2002JAN18 1451 1473 TM Transmembrane 54 LG : 1500434. 6: 2002JAN18 1474 1484 TM Cytosolic 54 LG : 1500434. 6 : 2002JAN18 1485 1507 TM Transmembrane 54 LG:1500434. 6 :2002JAN18 1508 1517 TM Extracellular 54 LG:1500434. 6 : 2002JAN 18 1 789 TM Extracellular 54 LG:1500434. 6: 2002JAN18 790 809 TM Transmembrane 54 LG : 1500434. 6: 2002JAN18 810 829 TM Cytosolic 54 LG:1500434. 6: 2002JAN18 830 852 TM Transmembrane 54 LG:1500434.6:2002JAN18 853 888 TM Extracellular 54 LG:1500434. 6: 2002JAN18 889 911 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 912 933 TM Cytosolic 54 LG : 1500434. 6 : 2002JAN18 934 956 TM Transmembrane 54 LG:1500434. 6 : 2002JAN 18 957 975 TM Extracellular 54 LG : 1500434. 6 : 2002JAN18 976 998 TM Transmembrane 54 LG:1500434. 6 : 2002JAN18 999 1010 TM Cytosolic 54 LG : 1500434. 6: 2002JAN18 1011 1033 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 1034 1241 TM Extracellular 54 LG : 1500434. 6: 2002JAN18 1242 1264 TM Transmembrane 54 LG : 1500434. 6 : 2002JAN18 1265 1276 TM Cytosolic 54 LG:1500434. 6 : 2002JAN 18 1277 1299 TM Transmembrane 54 LG:1500434. 6 : 2002JAN 18 1300 1338 TM Extracellular 54 LG:1500434. 6 : 2002JAN18 1339 1356 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1357 1423 TM Cytosolic 54 LG:1500434.6:2002JAN18 1424 1446 TM Transmembrane 54 LG : 1500434. 6: 2002JAN18 1447 1449 TM Extracellular 54 LG:1500434. 6 : 2002JAN18 1450 1467 TM Transmembrane 54 LG:1500434. 6: 2002JAN18 1468 1486 TM Cytosolic 54 LG:1500434. 6 : 2002JAN18 1487 1509 TM Transmembrane 54 LG:1500434.6 : 2002JAN18 1510 1517 TM Extracellular 54 LG:1500434.6:2002JAN18 412 501 forward 1 SP 54 LG:1500434. 6: 2002JAN18 2260 2331 forward 1 SP 54 LG : 1500434.6:2002JAN18 3034 3087 forward 1 SP 54 LG : 1500434. 6: 2002JAN18 2266 2331 forward 1 SP 54 LG : 1500434.6 : 2002JAN18 4272 4319 forward 3 SP 54 LG:1500434. 6 :2002JAN18 2370 2441 forward 3 SP 54 LG:1500434. 6: 2002JAN18 2370 2429 forward 3 SP 54 LG:1500434. 6: 2002JAN18 4272 4325 forward 3 SP 54 LG:1500434. 6: 2002JAN18 2370 2432 forward 3 SP 155 1 LG : 1501028. 9 :2002JAN18 1 24 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 55 LG : 1501028. 9 : 2002JAN18 25 47 TM Transmembrane 55 LG : 1501028.9 : 2002JAN18 48 53 TM Cytosolic 55 LG : 1501028. 9 : 2002JAN 18 54 73 TM Transmembrane 55 LG : 1501028. 9 : 2002JAN18 74 87 TM Extracellular 55 LG:1501028. 9: 2002JAN18 88 105 TM Transmembrane 55 LG:1501028. 9: 2002JAN18 106 198 TM Cytosolic 55 LG:1501028. 9 : 2002JAN18 1 28 TM Cytosolic 55 LG:1501028. 9 : 2002JAN18 29 51 TM Transmembrane 55 LG:1501028. 9 : 2002JAN18 52 70 TM Extracellular 55 LG:1501028. 9 :2002JAN18 71 93 TM Transmembrane 55 LG : 1501028. 9 : 2002JAN18 94 198 TM Cytosolic 55 LG : 1501028. 9 : 2002JAN18 52 123 forward 1 SP 55 LG:1501028. 9 : 2002JAN18 51 146 forward 3 SP 56 LG:1501710. 32 :2002JAN18 1 360 TM extracellular 56 LG:1501710. 32 :2002JAN18 361 380 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 381 632 TM Cytosolic 56 LG : 1 501710. 32 :2002JAN18 633 655 TM Transmembrane 56 LG:1501710. 32 :2002JAN18 656 669 TM Extracellular 56 LG:1501710. 32 : 2002JAN18 670 689 TM Transmembrane 56 LG : 1501710. 32: 2002JAN18 690 695 TM Cytosolic 56 LG:1501710. 32 : 2002JAN18 696 718 TM Transmembrane 56 LG:1501710. 32: 2002JAN18 719 748 TM Extracellular 56 LG:1501710. 32: 2002JAN18 749 771 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 772 791 TM Cytosolic 56 LG: 1501710.32 : 2002JAN18 792 814 TM Transmembrane 56 LG:1501710. 32: 2002JAN18 815 873 TM Extracellular 56 LG:1501710. 32 : 2002JAN18 874 896 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 897 1043 TM Cytosolic 56 LG : 1501710. 32 : 2002JAN18 1044 1066 TM Transmembrane 56 LG : 1501710.32 : 2002JAN18 1067 1277 TM Extracellular 56 LG : 1501710. 32 : 2002JAN18 1 483 TM Extracellular 56 LG:1501710. 32: 2002JAN18 484 506 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 507 526 TM Cytosolic 56 LG:1501710. 32 :2002JAN18 527 546 TM Transmembrane 56 LG:1501710. 32: 2002JAN18 547 618 TM Extracellular 56LG : 1501710. 32: 2002JAN18 619 636 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 637 642 TM Cytosolic 56 LG:1501710. 32: 2002JAN18 643 665 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 666 669 TM Extracellular 56 LG: 1501710.32 :2002JAN18 670 692 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 693 704 TM Cytosolic 56 LG:1501710. 32: 2002JAN18 705 727 TM Transmembrane 56 LG : 1501710.32 : 2002JAN18 728 754 TM Extracellular 56 LG1501710 32: 2002JAN18 755 777 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 778 912 TM Cytosolic 56 LG:1501710. 32 : 2002JAN18 913 935 TM Transmembrane 56 LG : 1501710 32: 2002JAN18 936 1277 TM Extracellular 56 LG : 1501710 32: 2002JAN18 1 357 TM Extracellular 56 LG1501710 32 2002JAN18 358 380 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 56 LG : 1501710. 32 : 2002JAN18 381 466 TM Cytosolic 56 LG:1501710. 32 : 2002JAN18 467 489 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 490 671 TM Extracellular 56 LG:1501710. 32: 2002JAN18 672 694 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 695 705 TM Cytosolic 56 LG:1501710. 32: 2002JAN18 706 728 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 729 747 TM Extracellular 56 LG:1501710. 32: 2002JAN18 748 770 TM Transmembrane 56 LG:1501710. 32 : 2002JAN18 771 782 TM Cytosolic 56 LG : 1501710.32 : 2002JAN 18 783 801 TM Transmembrane 56 LG:1501710. 32: 2002JAN 18 802 815 TM Extracellular 56 LG : 1501710. 32: 2002JAN 18 816 838 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 839 850 TM Cytosolic 56 LG : 1501710. 32 : 2002JAN18 851 873 TM Transmembrane 56 LG:1501710. 32: 2002JAN18 874 919 TM Extracellular 56 LG:1501710. 32 : 2002JAN18 920 942 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 943 948 TM Cytosolic 56 LG:1501710. 32 : 2002JAN18 949 971 TM Transmembrane 56 LG : 1501710. 32 : 2002JAN18 972 1277 TM Extracellular 56 LG:1501710. 32: 2002JAN18 2716 2802 forward 1 SP 56 LG : 1501710.32 : 2002JAN18 2025 2069 forward 3 SP 57 LG:1502217. 12: 2002JAN 18 1 60 TM Cytosolic 57 LG:1502217. 12: 2002JAN18 61 83 TM Transmembrane 57 LG : 1502217. 12: 2002JAN18 84 216 TM Extracellular 57 LG : 1502217. 12 : 2002JAN 18 217 239 TM Transmembrane 57 LG : 1502217.12 : 2002JAN18 240 251 TM Cytosolic 57 LG : 1502217. 12: 2002JAN 18 252 271 TM Transmembrane 57 LG : 1502217. 12: 2002JAN18 272 348 TM Extracellular 57 LG : 1502217. 12 : 2002JAN18 349 371 TM Transmembrane 57 LG : 1502217. 12 : 2002JAN 18 372 442 TM Cytosolic 57 LG : 1502217. 12 : 2002JAN 18 1 19 TM Cytosolic 57 LG : 1502217. 12 : 2002JAN18 20 39 TM Transmembrane 57 LG:1502217. 12 : 2002JAN 18 40 58 TM Extracellular 57 LG : 1502217. 12 : 2002JAN18 59 78 TM Transmembrane 57 LG:1502217. 12: 2002JAN18 79 84 TM Cytosolic 57 LG: 1502217.12 : 2002JAN 18 85 107 TM Transmembrane 57 LG : 1502217. 12: 2002JAN 18 108 442 TM Extracellular 57 LG : 1502217. 12: 2002JAN18 1030 1098 forward 1 SP 57 LG:1502217. 12: 2002JAN 18 1030 1104 forward 1 SP 57 LG : 1502217. 12 : 2002JAN18 1030 1116 forward 1 SP 57 LG : 1502217. 12: 2002JAN 18 1030 1095 forward 1 SP 57 LG : 1502217. 12 : 2002JAN 18 930 1013 forward 3 SP 58 LG : 1502272. 38 : 2002JAN18 1 1056 TM Extracellular 58 LG:1502272. 38: 2002JAN 18 1057 1079 TM Transmembrane 58 LG:1502272. 38 : 2002JAN18 1080 1229 TM Cytosolic 58 LG : 1502272. 38 : 2002JAN18 1 19 TM Extracellular 58 LG:1502272. 38 : 2002JAN 18 20 42 TM Transmembrane 58 LG:1502272. 38 : 2002JAN 18 43 48 TM Cytosolic 58 LG:1502272. 38 : 2002JAN18 49 71 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 58 LG:1502272. 38 :2002JAN18 72 1228 TM Extracellular 58 LG: 1502272.38 : 2002JAN18 1 58 TM Cytosolic 58 LG:1502272. 38 : 2002JAN18 59 81 TM Transmembrane 58 LG : 1502272. 38: 2002JAN18 82 1228 TM Extracellular 58 LG : 1502272. 38: 2002JAN18 1420 1491 forward 1 SP 58 LG : 1502272, 38 : 2002JAN18 3145 3240 forward 1 SP 58 LG : 1502272. 38 : 2002JAN18 3163 3219 forward 1 SP 58 LG:1502272. 38 : 2002JAN18 1420 1494 forward 1 SP 58 LG : 1502272.38:2002JAN18 3163 3237 forward 1 SP 58 LG: 1502272.38 : 2002JAN18 3145 3237 forward 1 SP 58 LG : 1502272.38:2002JAN18 485 541 forward 2 SP 58 LG:1502272. 38 :2002JAN18 2000 2065 forward 2 SP 58 LG : 1502272.38:2002JAN18 2831 2932 forward 2 SP 58 LG:1502272. 38 : 2002JAN18 2000 2065 forward 2 SP 58 LG : 1502272. 38 : 2002JAN18 1434 1487 forward 3 SP 59 LG:1502313. 3 : 2002JAN18 1 281 TM Cytosolic 59 LG : 1502313. 3 : 2002JAN18 282 304 TM Transmembrane 59 LG:1502313 3 : 2002JAN18 305 318 TM Extracellular 59 LG : 1502313. 3 :2002JAN18 1 281 TM Extracellular 59 LG : 1502313. 3: 2002JAN18 282 304 TM Transmembrane 59 LG:1502313. 3 : 2002JAN18 305 318 TM Cytosolic 60 LG : 1502474. 57: 2002JAN18 1 403 TM Extracellular 60 LG : 1502474. 57 : 2002JAN18 404 426 TM Transmembrane 60 LG:1502474. 57: 2002JAN18 427 582 TM Cytosolic 60 LG:1502474 57 : 2002JAN18 1 404 TM Extracellular 60 LG:1502474. 57 : 2002JAN18 405 427 TM Transmembrane 60 LG : 1502474.57 : 2002JAN18 428 581 TM Cytosolic 60 LG : 1502474. 57: 2002JAN18 1 95 TM Cytosolic 60 LG : 1502474. 57 : 2002JAN18 96 118 TM Transmembrane 60 LG:1502474.57:2002JAN18 119 581 TM Extracellular 60 LG : I 502474. 57 : 2002JAN18 221 295 forward 2 SP 60 LG:1502474.57:2002JAN18 221 304 forward 2 SP 61 LG:1502663. 27 : 2002JAN18 1 417 TM Cytosolic 61 LG:1502663. 27 :2002JAN18 418 440 TM Transmembrane 61 LG:1502663. 27 : 2002JAN18 441 492 TM Extracellular 61 LG : 1502663. 27: 2002JAN18 493 515 TM Transmembrane 61 LG : 1502663. 27 : 2002JAN18 516 579 TM Cytosolic 61 LG : 1502663. 272002JAN18 580 602 TM Transmembrane 61 LG : 1502663. 27 : 2002JAN18 603 875 TM Extracellular 61 LG : 1502663. 27 : 2002JAN18 876 898 TM Transmembrane 61 LG : 1502663. 27: 2002JAN18 899 1275 TM Cytosolic 61 LG:1502663. 27 :2002JAN18 1276 1298 TM Transmembrane 61 LG : 1502663. 27 : 2002JAN18 1299 1317 TM Extracellular 61 LG:1502663. 27 : 2002JAN18 1318 1340 TM Transmembrane 61 LG : 1502663. 27: 2002JAN18 1341 1472 TM Cytosolic 61 LG:1502663. 27 : 2002JAN18 1473 1495 TM Transmembrane 1502663. 27 2002JAN18 1496 1521 TM Extrscellular 61 LG:1502663. 27: 2002JAN18 1522 1544 TM Transmembrane 61 LG:1502663. 27 : 2002JAN18 1545 1570 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 61 LG : 1502663. 27 : 2002JAN18 1 1526 TM Extracellular 61 LG : 1502663. 27 : 2002JAN18 1527 1549 TM Transmembrane 61 LG:1502663. 27 : 2002JAN18 1550 1569 TM Cytosolic 61 LG:1502663. 27 : 2002JAN18 1 1268 TM Extracellular 61 LG:1502663. 27 : 2002JAN18 1269 1291 TM Transmembrane 61 LG:1502663. 27 :2002JAN18 1292 1403 TM Cytosolic 61 LG : 1502663. 27 : 2002JAN18 1404 1426 TM Transmembrane 61 LG:1502663. 27 : 2002JAN18 1427 1520 TM Extracellular 61 LG: 1502663.27 : 2002JAN18 1521 1543 TM Transmembrane 61 LG : 1502663. 27 : 2002JAN18 1544 1569 TM Cytosolic 61 LG:1502663. 27 : 2002JAN18 2710 2799 forward 1 SP 61 LG: 1502663. 27: 2002JAN18 3802 3894 forward 1 SP 61 LG : 1502663. 27 : 2002JAN18 3835 3885 forward 1 SP 61 LG: 1502663. 27 : 2002JAN18 4577 4651 forward 2 SP 61 LG:1502663. 27: 2002JAN18 4577 4651 forward 2 SP 61 LG:1502663. 27: 2002JAN18 3806 3883 forward 2 SP 61 LG:1502663. 27 : 2002JAN 18 4577 4636 forward 2 SP 61 LG:1502663. 27: 2002JAN18 4044 4115 forward 3 SP 62 LG:154608. 1 : 2002JAN18 1 100 TM Cytosolic 62 LG : 154608. 1 : 2002JAN18 101 123 TM Transmembrane 62 LG:154608. 1: 2002JAN18 124 256 TM Extracellular 62 LG:154608. 1 : 2002JAN 18 257 279 TM Transmembrane 62 LG : 154608. 1: 2002JAN18 280 367 TM Cytosolic 62 LG : 154608. 1 : 2002JAN18 1 9 TM Extracellular 62 LG:154608. 1: 2002JAN18 10 27 TM Transmembrane 62 LG:154608. 1: 2002JAN18 28 33 TM Cytosolic 62 LG: 154608.1 : 2002JAN18 34 51 TM Transmembrane 62 LG : 154608.1 : 2002JAN18 52 263 TM Extracellular 62 LG : 154608.1 : 2002JAN18 264 286 TM Transmembrane 62 LG : 154608. 1: 2002JAN18 287 305 TM Cytosolic 62 LG:154608. 1 : 2002JAN 18 306 28 TM Transmembrane 62 LG : 154608. 1: 2002JAN18 329 366 TM Extracellular 62 LG : 154608. 1: 2002JAN18 1 305 TM Extracellular 62 LG:154608. 1 :2002JAN18 306 328 TM Transmembrane 62 LG : 154608. 1 : 2002JAN18 329 366 TM Cytosolic 62 LG:154608. 1: 2002JAN18 592 666 forward 1 SP 63 LG : 170235. 14: 2002JAN 18 1 11 TM Cytosolic 63 LG:170235. 14: 2002JAN18 12 34 TM Transmembrane 63 LG:170235. 14 : 2002JAN18 35 177 TM Extracellular 63 LG : 170235. 14 : 2002JAN18 1 14 TM Extracellular 63 LG:170235. 14 : 2002JAN 18 15 37 TM Transmembrane 63 LG : 170234.14:2002JAN18 38 48 TM Cytosolic 63 LG:170235.14:2002JAN18 49 71 TM Transmembrane 63 LG : 170235. 14: 2002JAN 18 72 177 TM Extracellular 64 LG : 170604.1:2002JAN18 1 49 TM Cytosolic 64 LG:170604.1:2002JAN18 50 72 TM Transmembrane 64 LG : 1 70604. 1 : 2002JAN 18 73 550 TM Extracellular 64 LG:170604.1:2002JAN18 1 53 TM Cytosolic 64 LG:170604.1:2002JAN18 54 76 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 64 LG:170604. 1 :2002JAN18 77 550 TM Extracellular 64 LG:170604. 1 : 2002JAN 18 1410 1475 forward 3 SP 65 LG : 171629. 1: 2002JAN18 1 90 TM Extracellular 65 LG:171629. 1 : 2002JAN 18 91 113 TM Transmembrane 65 LG:171629. 1 : 2002JAN 18 114 351 TM Cytosolic 65 LG:171629. 1 : 2002JAN18 803 859 forward 2 SP 66 LG:172411. 1 : 2002JAN 18 1 680 TM Extracellular 66 LG:172411. 1 : 2002JAN18 681 703 TM Transmembrane 66 LG:172411. 1: 2002JAN 18 704 831 TM Cytosolic 66 LG : 172411. 1 : 2002JAN18 832 854 TM Transmembrane 66 LG:172411. 1 : 2002JAN18 855 1239 TM Extracellular 66 LG:172411. 1 : 2002JAN 18 1 531 TM Extracellular 66 LG172411 1 2002JAN18 532 554 TM Trunsmembrune 66 LG : 172411. 1: 2002JAN18 555 562 TM Cytosolic 66 LG : 172411. 1 : 2002JAN18 563 585 TM Transmembrane 66 LG : 172411. 1 : 2002JAN 18 586 1239 TM Extracellular 66 LG : 172411. 1: 2002JAN18 2764 2823 forward 1 SP 6 LG:172411. 1: 2002JAN18 2066 2131 forward 2 SP 66 LG : 172411. 1 : 2002JAN18 1602 1688 forward 3 SP 67 LG : 173356. 1 : 2002JAN18 18 319 TM Extracellular 67 LG:173356. 1 : 2002JAN 18 320 342 TM Transmembrane 67 LG:173356. 1 : 2002JAN 18 343 354 TM Cytosolic 67 LG : 173356. 1 : 2002JAN 18 355 372 TM Transmembrane 67 LG:173356. 1: 2002JAN 18 373 430 TM Extracellular 67 LG1733561 2002JAN18 431 453 TM Transmembrane 67 LG:173356. 1 : 2002JAN18 454 484 TM Cytosolic 67 LG1733561 2002JAN18 485 507 TM Transmembrane 67 LG : 173356. 1: 2002JAN18 508 511 TM Extracellular 67 LG:173356. 1 2002JAN18 512 534 TM Trsnsmembrane 67 LG : 173356. 1 : 2002JAN18 535 546 TM Cytosolic 67 LG:173356. 1 : 2002JAN 18 547 569 TM Transmembrane 67 LG:173356.1:2002JAN18 570 596 TM Extracellular 67LG : 173356. 1 : 2002JAN18 597 619 TM Transmembrane 67 LG : 1733561 : 2002JAN18 620 894 TM Cytosolic 67 LG:173356. 1 2002JAN18 895 917 TM Trsnsmembrane 67 LG:173356. 1 : 2002JAN18 918 972 TM Extracellular 67 LG:173356. 1 : 2002JAN 18 973 995 TM Transmembrane 67 LG:173356. 1: 2002JAN18 996 1015 TM Cytosolic 67 LG : 173356.1:2002JAN18 1 238 TM Cytosolic 67LG:173356.1:2002JAN18 239 261 TM Transmembrane 67 LG : 173356. 1 : 2002JAN18 262 355 TM Extracellular 67LG : 173356. 1 : 2002JAN18 356 378 TM Transmembrane 67 LG : 173356.1:2002JAN18 379 595 TM Cytosolic 67 LG:173356. 1 : 2002JAN18 596 618 TM Transmembrane 67 LG:173356.1:2002JAN18 619 1015 TM Extracellular 67 LG:173356.1:2002JAN18 1 329 TM Extracellular 67 LG:173356. 1 2002JAN18 330 352 TM Transmembrane 67 LG : 173356. 1 : 2002JAN18 353 404 TM Cytosolic 67 LG:173356.1:2002JAN18 405 427 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 67 LG:173356. 1 : 2002JAN 18 428 441 TM Extracellular 67 LG:173356. 1 : 2002JAN 18 442 464 TM Transmembrane 67 LG:173356. 1 : 2002JAN 18 465 476 TM Cytosolic 67 LG:173356. 1 :2002JAN18 477 499 TM Transmembrane 67 LG:173356. 1 : 2002JAN 18 500 545 TM Extracellular 67 LG:173356. 1 2002JAN18 546 568 TM Transmembrane 67 LG : 173356. 1 : 2002JAN18 569 912 TM Cytosolic 67 LG:173356. 1 : 2002JAN18 913 935 TM Transmembrane 67 LG:173356. 1 : 2002JAN18 936 949 TM Extracellular 67 LG : 173356. 1: 2002JAN18 950 972 TM Transmembrane 67 LG : 173356. 1: 2002JAN18 973 1014 TM Cytosolic 68 LG:193755. 18 : 2002JAN 18 1 11 TM Cytosolic 68 LG:193755. 18 : 2002JAN18 12 31 TM Transmembrane 68 LG:193755. 18 : 2002JAN18 32 40 TM Extracellular 68 LG:193755. 18 :2002JAN18 41 63 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 64 96 TM Cytosolic 68 LG:193755. 18 :2002JAN18 97 119 TM Transmembrane 68 LG : 193755. 18:2002JAN18 120 179 TM Extracellular 68 LG:193755. 18 :2002JAN18 180 199 TM Transmembrane 68 LG:193755. 18 :2002JAN18 200 257 TM Cytosolic 68 LG : 193755. 18: 2002JAN18 258 276 TM Transmembrane 68 LG:193755. 18 : 2002JAN18 277 290 TM Extracellular 68 LG:193755. 18 : 2002JAN 18 291 313 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 314 399 TM Cytosolic 68 LG:193755. 18 : 2002JAN18 400 422 TM Transmembrane 68 LG : 193755. 18: 2002JAN18 423 431 TM Extracellular 68 LG : 193755.18 : 2002JAN18 432 449 TM Transmembrane 68 LG : 193755. 18: 2002JAN18 450 460 TM Cytosolic 68 LG : 193755. 18 : 2002JAN18 461 480 TM Transmembrane 68 LG:193755. 18 : 2002JAN18 481 499 TM Extracellular 68 LG:193755. 18 : 2002JAN18 500 522 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 523 534 TM Cytosolic 68 LG : 193755. 18 : 2002JAN18 535 557 TM Transmembrane 68 LG:193755. 18 : 2002JAN 18 558 571 TM Extracellular 68 LG:193755. 18 : 2002JAN 18 572 591 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 592 706 TM Cytosolic 68 LG:193755. 18 : 2002JAN 18 707 729 TM Transmembrane 68 LG:193755. 18 :2002JAN18 730 738 TM Extracellular 68 LG:193755. 18 :2002JAN18 739 761 TM Transmembrane 68 LG:193755. 18: 2002JAN18 762 899 TM Cytosolic 68 LG:193755. 18 : 2002JAN18 900 922 TM Transmembrane 68 LG : 193755. 18: 2002JAN18 923 933 TM Extracellular 68 LG:193755.18:2002JAN18 1 9 TM Extracellular 68 LG:193755. 18 :2002JAN18 10 29 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 30 176 TM Cytosolic 68 LG:193755.18:2002JAN18 177 199 TM Transmembrane 68 LG:193755.18:2002JAN18 200 501 TM Extracellular 68 LG:193755.18:2002JAN18 502 524 TM Transmembrane 68 LG : 193755 18: 2002JAN18 525 608 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 68 LG : 193755. 18 : 2002JAN18 609 631 TM Transmembrane 68 LG : 193755. 18 : 2002JAN 18 632 640 TM Extracellular 68 LG: 193755.18 : 2002JAN18 641 663 TM Transmembrane 68 LG:193755. 18: 2002JAN 18 664 719 TM Cytosolic 68 LG:193755. 18: 2002JAN 18 720 742 TM Transmembrane 68 LG:193755. 18 : 2002JAN 18 743 933 TM Extracellular 68 LG : 193755. 18: 2002JAN18 1 9 TM Extracellular 68 LG:193755. 18 : 2002JAN18 10 27 TM Transmembrane 68 LG : 193755.18 : 2002JAN18 28 38 TM Cytosolic 68 LG : 193755. 18 : 2002JAN 18 39 61 TM Transmembrane 68 LG : 193755. 18: 2002JAN18 62 300 TM Extracellular 68 LG : 193755. 18: 2002JAN 18 301 323 TM Transmembrane 68 LG:193755. 18: 2002JAN 18 324 397 TM Cytosolic 68 LG: 193755.18 : 2002JAN 18 398 415 TM Transmembrane 68 LG:193755. 18 : 2002JAN 18 416 434 TM Extracellular 68 LG:193755. 18 : 2002JAN 18 435 457 TM Transmembrane 68 LG:193755. 18 : 2002JAN18 458 469 TM Cytosolic 68 LG : 193755. 18 : 2002JAN18 470 492 TM Transmembrane 68 LG:193755. 18: 2002JAN18 493 496 TM Extracellular 68 LG:193755. 18 : 2002JAN18 497 519 TM Transmembrane 68 LG : 193755. 18 : 2002JAN18 520 614 TM Cytosolic 68 LG:193755. 18 : 2002JAN 18 615 634 TM Transmembrane 68 LG : 193755. 18 : 2002JAN 18 635 933 TM Extracellular 68 LG : 193755.18:2002JAN18 100 156 forward 1 SP 68 LG : 193755. 18: 2002JAN 18 106 156 forward 1 SP 68 LG : 193755. 18: 2002JAN18 100 165 forward 1 SP 68 LG : 193755.18:2002JAN18 100 177 forward 1 SP 68 LG: 193755.18 : 2002JAN18 100 177 forward 1 SP 68 LG:193755. 18 : 2002JAN18 100 177 forward 1 SP 86 LG:193755. 18 : 2002JAN18 100 177 forward 1 SP 86 LG:193755. 18: 2002JAN 18 100 162 forward 1 SP 68 LG : 193755. 18 : 2002JAN18 100 159 forward 1 SP 68 LG : 193755. 18 : 2002JAN18 1290 1352 forward 3 SP 69 LG : 196620. 12: 2002JAN18 1 1028 TM Extracellular 69 LG:1956620. 12 : 2002JAN 18 1029 1051 TM Transmembrane 69 LG:196620. 12 : 2002JAN 18 1052 1111 TM Cytosolic 69 LG : 196620. 12 : 2002JAN 18 1112 1134 TM Transmembrane 69 LG : 196620. 12 : 2002JAN18 1135 1449 TM Extracellular 69 LG : 196620. 12 : 2002JAN 18 1 1011 TM Extracellular 69 LG : 196620. 12 : 2002JAN18 1012 1031 TM Transmembrane 69 LG : 196620.12:2002JAN18 1032 1032 TM Cytosolic 69 LG : 196620. 12 : 2002JAN18 1033 1055 TM Transmembrane 69 LG : 196620. 12 : 2002JAN 18 1056 1449 TM Extracellular 69 LG : 196620 12 : 2002JAN18 2354 2443 forward 2 SP 69 LG:196620. 12 : 2002JAN 18 4173 4262 forward 3 SP 70 LG : 197624, 1 : 2002JAN18 1 273 TM Extracellular 70 LG : 197624. 1 : 2002JAN 18 274 296 TM Transmembrane 70 LG:197624.1: 2002JAN 18 297 302 TM Cytosolic 70 LG : 197624 1: 2002JAN 18 303 325 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 70 LG:197624. 1 : 2002JAN 18 326 399 TM Extracellular 70 LG:197624. 1 : 2002JAN18 400 417 TM Transmembrane 70 LG:197624. 1 : 2002JAN 18 418 433 TM Cytosolic 70 LG:197624. 1 : 2002JAN18 1 264 TM Extracellular 70 LG : 197624. 1 : 2002JAN18 265 287 TM Transmembrane 70 LG:197624. 1 :2002JAN18 288 299 TM Cytosolic 70 LG: 197624.1 : 2002JAN18 300 322 TM Transmembrane 70 LG:197624. 1 : 2002JAN 18 323 341 TM Extracellular 70 LG:197624. 1 : 2002JAN18 342 361 TM Transmembrane 70 LG:197624. 1 : 2002JAN 18 362 385 TM Cytosolic 70 LG:197624. 1 : 2002JAN 18 386 405 TM Transmembrane 70 LG : 197624. 1 : 2002JAN18 406 433 TM Extracellular 70 LG:197624. 1 :2002JAN18 1 273 TM Extracellular 70LG : 197624. 1 :2002JAN18 274 291 TM Transmembrane 70 LG:197624. 1: 2002JAN18 292 297 TM Cytosolic 70 LG:197624. 1 :2002JAN18 298 317 TM Transmembrane 70 LG:197624. 1: 2002JAN18 318 393 TM Extracellular 70 LG:197624. 1 : 2002JAN18 394 416 TM Transmembrane 70 LG:197624. 1 2002JAN18 417 433 TM Cytosolic 71 LG:197634. 69: 2002JAN18 1 127 TM Cytosolic 71 LG : 197634. 69 :2002JAN18 128 147 TM Transmembrane 71 LG : 197634. 69: 2002JAN18 148 156 TM Extracellular 71 LG : I 97634. 69 :2002JAN18 157 179 TM Transmembrane 71 LG : 197634. 69 : 2002JAN18 180 260 TM Cytosolic 71 LG:197634. 69: 2002JAN18 7 99 forward 1 SP 72 LG : 198680. 1 : 2002JAN18 1 261 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 262 284 TM Transmembrane 72 LG:198680 1: 2002JAN18 285 309 TM Extracellular 72 LG:198680. 1 : 2002JAN18 310 332 TM Transmembrane 72 LG : 198680.1 : 2002JAN18 333 412 TM Cytosolic 72 LG:198680. 1 : 2002JAN18 413 435 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 436 1017 TM Extracellular 72 LG: 198680.1 : 2002JAN18 1018 1040 TM Transmembrane 72 LG : 198680. 1: 2002JAN18 1041 1041 TM Cytosolic 72 LG:198680. 1 : 2002JAN 18 1042 1064 TM Transmembrane 72 LG:198680. 1 : 2002JAN 18 1065 1073 TM Extracellular 72 LG:19860. 1 :2002JAN18 1074 1096 TM Transmembrane 72 LG : 198680.1 : 2002JAN18 1097 1116 TM Cytosolic 72 LG : 198680. 1 : 2002JAN18 1117 1139 TM Transmembrane 72 LG : 198680. 1: 2002JAN18 1140 1158 TM Extracellular 72 LG : 198680. 1: 2002JAN18 1159 1181 TM Transmembrane 72 LG:198680. 1 : 2002JAN18 1182 1193 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 1194 1213 TM Transmembrane 72 LG:198680.1:2002JAN18 1214 1222 TM Extracellular 72 LG:198680. 1 :2002JAN18 1223 1245 TM Transmembrane 72 LG:198680.1:2002JAN18 1246 1247 TM Cytosolic 72 LG:198680. 1 : 2002JAN 18 1 947 TM Extracellular 72 LG:198680. 1 : 2002JAN 18 948 970 TM Transmembrane 72 LG:198680. 1 :2002JAN18 971 982 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 72 LG : 198680. 1 : 2002JAN 18 983 1000 TM Transmembrane 72 LG : 198680. 1 : 2002JAN 18 1001 1014 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 1015 1037 TM Transmembrsne 72 LG : 198680. 1: 2002JAN 18 1038 1041 TM Cytosolic 72 LG : 198680. 1 : 2002JAN 18 1042 1064 TM Transmembrane 72LG : 198680. 1 : 2002JAN 18 1065 1078 TM Extracellular 72 LG : 198680. 1: 2002JAN 18 1079 1096 TM Transmembrane 72 LG : 198680. 1: 2002JAN 18 1097 1128 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 1129 1151 TM Transmembrane 72 LG : 198680. 1: 2002JAN18 1152 1160 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 1161 1183 TM Transmembrane 72 LG : 198680. 1: 2002JAN18 1184 1187 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 1188 1210 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1211 1219 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 1220 1242 TM Transmembrane 72 LG:198680. 1: 2002JAN18 1243 1246 TM Cytosolic 72 LG : 198680. 1 : 2002JAN18 1 320 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 321 343 TM Transmembrane 72 LG : 198680. 1: 2002JAN18 344 411 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 412 434 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 435 1030 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 1031 1053 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1054 1132 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 1133 1155 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1156 1158 TM Extracellular 72 LG : 198680. 1: 2002JAN18 1159 1180 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1181 1186 TM Cytosolic 72 LG : 198680. 1: 2002JAN18 1187 1206 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1207 1220 TM Extracellular 72 LG : 198680. 1 : 2002JAN18 1221 1243 TM Transmembrane 72 LG : 198680. 1 : 2002JAN18 1244 1246 TM Cytosolic 72 LG : 198680. 1 : 2002JAN18 3569 3625 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 3569 3628 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 3569 3643 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 2822 2911 forward 2 SP 72 LG:198680. 1 : 2002JAN18 3560 3631 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 3569 3622 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 3560 3637 forward 2 SP 72 LG:198680. 1 : 2002JAN18 3560 3628 forward 2 SP 72 LG : 198680. 1: 2002JAN18 3560 3625 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 3569 3622 forward 2 SP 72 LG : 198680. 1 : 2002JAN18 1755 1799 forward 3 SP 73 LG : 201188.2:2002JAN18 1 767 TM Extracellular 73 LG : 201188. 2: 2002JAN18 768 790 TM Transmembrane 73 LG : 201188. 2: 2002JAN18 791 848 TM Cytosolic 73 LG : 201188. 2: 2002JAN18 849 871 TM Transmembrane 73 LG : 201188. 2: 2002JAN18 872 890 TM Extracellular 73 LG : 201188.2 : 2002JAN18 891 913 TM Transmembrane 73 LG : 201188. 2: 2002JAN18 914 925 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 73 LG:201188. 2 2002JAN18 926 948 TM Transmembrsne 73 LG:201188. 2 :2002JAN18 949 1435 TM Extracellular 74 LG : 201887. 16: 2002JAN18 1 11 TM Cytosolic 74 LG : 201887. 16 : 2002JAN 18 12 34 TM Transmembrane 74 LG : 201887.16 : 2002JAN 18 35 656 TM Extracellular 74 LG:201887. 16 : 2002JAN 18 657 679 TM Transmembrane 74 LG : 201887. 16: 2002JAN18 680 774 TM Cytosolic 74 LG : 201887, 16 : 2002JAN18 775 797 TM Transmembrane 74 LG:201887. 16 :2002JAN18 798 820 TM Extracellular 74 LG:201887. 16 :2002JAN18 1 525 TM Extracellular 74 LG : 201887, 16 : 2002JAN 18 526 548 TM Transmembrane 74 LG : 201887. 16 : 2002JAN18 549 656 TM Cytosolic 74 LG:201887. 16 : 2002JAN18 657 679 TM Transmembrane 74 LG : 201887.16 : 2002JAN18 680 716 TM Extracellular 74 LG:201887. 16 :2002JAN18 717 739 TM Transmembrane 74 LG : 201887. 16: 2002JAN18 740 774 TM Cytosolic 74 LG:201887,. 16 :2002JAN18 775 794 TM Transmembrane 74 LG : 201887. 16 : 2002JAN18 795 819 TM Extracellular 74 LG : 201887. 16 : 2002JAN18 2353 2397 forward 1 SP 75 LG : 208134. 1: 2002JAN18 1 58 TM Extracellular 75 LG: 208134. 1:2002JAN18 59 81 TM Transmembrane 75 LG : 208134.1 : 2002JAN 18 82 92 TM Cytosolic 75 LG : 208134. 1: 2002JAN 18 93 115 TM Transmembrane 75 LG:208134. 1 :2002JAN18 116 134 TM Extracellular 75 LG:208134. 1 :2002JAN18 135 157 TM Transmembrane 75 LG : 208134.1 : 2002JAN18 158 280 TM Cytosolic 75 LG : 208134. 1 : 2002JAN18 281 303 TM Transmembrane 75 LG : 208134.1 : 2002JAN18 304 306 TM Extracellular 75 LG:208134. 1 : 2002JAN18 307 329 TM Transmembrane 75 LG: 208134.1 : 2002JAN18 330 531 TM Cytosolic 75 LG:208134. 1 : 2002JAN 18 532 554 TM Transmembrane 75 LG:208134. 1 :2002JAN18 555 568 TM Extracellular 75 LG:208134. 1 2002JAN18 569 591 TM Transmembrane 75 LG : 208134. 1 : 2002JAN18 592 611 TM Cytosolic 75 LG:208134. 1 : 2002JAN18 612 634 TM Transmembrane 75 LG:208134. 1 :2002JAN18 635 670 TM Extracellular 75 LG:208134. 1 : 2002JAN18 671 690 TM Transmembrane 75 LG : 208134. 1 : 2002JAN18 691 821 TM Cytosolic 75 LG:208134. 1 :2002JAN18 822 844 TM Transmembrane 75 LG : 208134. 1 :2002JAN18 845 960 TM Extracellular 75 LG:208134.1:2002JAN18 1 527 TM Extracellular 75 LG:208134. 1: 2002JAN18 528 550 TM Transmembrane 75 LG : 208134. 1:2002JAN18 551 576 TM Cytosolic 75 LG : 208134.1 : 2002JAN18 577 599 TM Transmembrane 75 LG:208134. 1 : 2002JAN18 600 608 TM Extracellular 75 LG:208134.1:2002JAN18 609 631 TM Transmembrane 75 LG 208134. 1 2002JAN18 632 665 TM Cytosolic 75 LG:208134.1:2002JAN18 666 688 TM Transmembrane 75 LG: 208134.1 :2002JAN18 689 923 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 75 LG : 208134. 1 : 2002JAN18 924 946 TM Transmembrane 75 LG : 208134. 1:2002JAN18 947 960 TM Cytosolic 75 LG : 208134.1 : 2002JAN 18 1 3 TM Extracellular 75 LG : 208134.1 : 2002JAN18 4 23 TM Transmembrane 75 LG : 208134. 1: 2002JAN18 24 246 TM Cytosolic 75 LG : 208134. 1: 2002JAN18 247 267 TM Transmembrane 75 LG: 208134.1 : 2002JAN18 268 305 TM Extracellular 75 LG : 208134. 1:2002JAN18 306 328 TM Transmembrane 75 LG : 208134. 1: 2002JAN18 329 336 TM Cytosolic 75 LG:208134. 1 : 2002JAN18 337 359 TM Transmembrane 75 LG 2081341 2002JAN18 360 539 TM Extracellular 75 LG 2081341 2002JAN18 540 562 TM Transmembrane 75 LG:208134.1:2002JAN18 563 574 TM Cytosolic 75 LG : 208134. 1 : 2002JAN18 575 597 TM Transmembrane 75 LG : 208134. 1 : 2002JAN18 598 616 TM Extracellular 75 LG: 208134.1 : 2002JAN18 617 639 TM Transmembrane 75 LG : 208134.1 : 2002JAN18 640 811 TM Cytosolic 75 LG : 208134. 1: 2002JAN18 812 831 TM Transmembrane 75 LG: 208134.1 : 2002JAN18 832 960 TM Extracellular 75 LG:208134. 1 : 2002JAN18 1756 1824 forward 1 SP 75 LG : 208134. 1 : 2002JAN18 1756 1818 forward 1 SP 75 LG:208134.1:2002JAN18 557 628 forward 2 SP 75 LG:208134.1:2002JAN18 557 622 forward 2 SP 75 LG : 208134. 1 : 2002JAN18 557 619 forward 2 SP 75 LG : 208134. 1 : 2002JAN18 557 622 forward 2 SP 75 LG 208134. 1 :2002JAN18 557 616 forward 2 SP 76 LG : 209924. 5 : 2002JAN18 1 124 TM Extracellular 76 LG 209924 5 :2002JAN18 125 147 TM Transmembrane 76 LG:209924.5:2002JAN18 148 312 TM Cytosolic 76 LG 209924 52002JAN18 313 335 TM Transmembrane 76 LG : 209924. 5 : 2002JAN18 336 349 TM Extracellular 76 LG : 209924. 5 :2002JAN18 350 372 TM Transmembrane 76 LG:209924. 5 : 2002JAN18 373 390 TM Cytosolic 77 LG : 223060. 1: 2002JAN18 1 173 TM Extracellular 77 LG:223060. 1 :2002JAN18 174 196 TM Transmembrane 77 LG : 223060.1 : 2002JAN18 197 669 TM Cytosolic 77 LG : 223060, 1 : 2002JAN 18 670 692 TM Transmembrane 77 LG: 223060.1 : 2002JAN18 693 728 TM Extracellular 77 LG:223060. 1 : 2002JAN18 729 751 TM Transmembrane 77 LG : 223060. 1 : 2002JAN18 752 877 TM Cytosolic 77 LG : 223060. 1: 2002JAN 18 1 139 TM Extracellular 77 LG:223060.1:2002JAN18 140 157 TM Transmembrane 77 LG : 223060. 1: 2002JAN18 158 169 TM Cytosolic 77 LG:223060.1:2002JAN18 170 192 TM Transmembrane 77 LG:223060.1:2002JAN18 193 877 TM Extracellular 78 LG : 227583. 2 :2002JAN18 1 88 TM Extracellular 78 LG : 227583. 2 : 2002JAN18 89 108 TM Transmembrane 78 LG:227583.2:2002JAN18 109 205 TM Cytosolic 78 LG 227583. 2 :2002JAN18 206 228 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 78 LG:227583. 2 :2002JAN18 229 242 TM Extracellular 78 LG : 227583. 2 : 2002JAN18 243 265 TM Transmembrane 78 LG:227583. 2 :2002JAN18 266 344 TM Cytosolic 78 LG:227583. 2: 2002JAN18 1 30 TM Cytosolic 78 LG:227583.2:L2002JAN18 31 53 TM Transmembrane 78 LG : 227583. 2: 2002JAN18 54 62 TM Extracellular 78 LG : 227583, 2 :2002JAN18 63 85 TM Transmembrane 78 LG : 227583. 2: 2002JAN18 86 89 TM Cytosolic 78 LG : 227583. 2 : 2002JAN18 90 112 TM Transmembrane 78 LG : 227583.2 : 2002JAN18 113 223 TM Extracellular 78 LG : 227583. 2 : 2002JAN 18 224 246 TM Transmembrane 78 LG : 227583.2 : 2002JAN18 247 284 TM Cytosolic 78 LG : 227583. 2: 2002JAN18 285 307 TM Transmembrane 78 LG : 227583. 2 : 2002JAN18 308 344 TM Extracellular 78 LG : 227583. 2 : 2002JAN18 1 64 TM Extracellular 78 LG:227583. 2 : 2002JAN18 65 82 TM Transmembrane 78 LG : 227583.2 : 2002JAN 18 83 88 TM Cytosolic 78 LG : 227583.2 : 2002JAN18 89 108 TM Transmembrane 78 LG : 227583. 2: 2002JAN18 109 144 TM Extracellular 78 LG: 227583.2 : 2002JAN18 145 164 TM Transmembrane 78 LG: 227583.2 : 2002JAN18 165 205 TM Cytosolic 78 LG : 227583. 2 2002JAN18 206 223 TM Transmembrane 78 LG : 227583. 2: 2002JAN18 224 237 TM Extracellular 78 LG:227583.2:2002JAN18 238 260 TM Transmembrane 78 LG : 227583. 2: 2002JAN18 261 344 TM Cytosolic 78 LG:227583. 2 : 2002JAN18 329 391 forward 2 SP 78 LG : 227583. 2 : 2002JAN18 329 397 forward 2 SP 78 LG : 227583. 2 :2002JAN18 264 347 forward 3 SP 79 LG : 230149.12 : 2002JAN18 1 89 TM Cytosolic 79 LG:230149. 12 : 2002JAN 18 90 112 TM Transmembrane 79 LG : 230149. 12: 2002JAN18 113 150 TM Extracellular 79 LG:230149. 12 : 2002JAN 18 i 51 173 TM Transmembrane 79 LG : 230149. 12:2002JAN18 174 249 TM Cytosolic 79 LG: 230149.12 : 2002JAN18 1 29 TM Cytosolic 79 LG:230149. 12 : 2002JAN18 30 49 TM Transmembrane 79 LG : 230149. 12 : 2002JAN18 50 112 TM Extracellular 79 LG : 230149. 12 : 2002JAN18 113 135 TM Transmembrane 79 LG : 230149. 12 : 2002JAN18 136 150 TM Cytosolic 79 LG:230149. 12 : 2002JAN18 151 173 TM Transmembrane 79 LG:230149. 12 : 2002JAN18 174 249 TM Extracellular 79 LG : 230149. 12 : 2002JAN18 68 133 forward 2 SP LG : 230149. 12 :2002JAN18 68 139 forward 2 SP 80 LG:230509. 30 :2002JAN18 1 598 TM Extracellular 80 LG : 230509.30:2002JAN18 599 616 TM Transmembrane 80 LG : 230509. 30:2002JAN18 617 921 TM Cytosolic 80 LG:230509. 30 : 2002JAN18 922 944 TM Transmembrane 80 LG:230509. 30 : 2002JAN 18 945 985 TM Extracellular 81 LG 230923 1 : 2002JAN 18 1 Extracellular 81 LG:230923. 1 : 2002JAN18 961 983 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: T e 81 LG : 230923. 1: 2002JAN18 984 1079 TM Cytosolic 81 LG : 230923.1 : 2002JAN18 1080 1099 TM Transmembrane 81 LG : 230923.1 : 2002JAN18 1100 1108 TM Extracellular 81 LG: 230923.1 : 2002JAN18 1109 1128 TM Transmembrane 81 LG : 230923. 1 : 2002JAN 18 1129 1138 TM Cytosolic 81 LG : 230923. 1 : 2002JAN18 1 957 TM Extracellular 81 LG : 230923. 1: 2002JAN 18 958 980 TM Transmembrane 81 LG: 230923.1 : 2002JAN18 981 1014 TM Cytosolic 81 LG:230923. 1: 2002JAN18 1015 1037 TM Transmembrane 81 LG : 230923. 1 : 2002JAN 18 1038 1078 TM Extracellular 81 LG : 230923. 1 : 2002JAN 18 1079 1101 TM Transmembrane 81 LG : 230923. 1 : 2002JAN 18 1102 1112 TM Cytosolic 81 LG: 230923.1 : 2002JAN 18 1113 1135 TM Transmembrane 81 LG:230923. 1 : 2002JAN18 1136 1137 TM Extracellular 81 LG : 230923.1 : 2002JAN18 2872 2937 forward 1 SP 81 LG: 230923.1 : 2002JAN18 2872 2928 forward 1 SP 81 LG : 230923. 1 : 2002JAN18 2872 2946 forward 1 SP 81 LG : 230923. 1: 2002JAN18 2872 2934 forward 1 SP 81 LG: 230923.1 : 2002JAN18 1540 1605 forward 1 SP 81 LG : 230923. 1: 2002JAN18 2872 2919 forward 1 SP 81 LG : 230923.1 : 2002JAN18 1540 1602 forward 1 SP 81 LG: 230923.1 : 2002JAN18 1535 1597 forward 2 SP 81 LG : 230923.1 : 2002JAN18 2867 2932 forward 2 SP 81 LG : 230923. 1 : 2002JAN18 1535 1630 forward 2 SP 81 LG : 230923. 1 : 2002JAN18 2853 2939 forward 3 SP 81 LG : 230923.1 : 2002JAN18 2877 2936 forward 3 SP 81 LG: 230923. 1: 2002JAN18 300 401 forward 3 SP 81 LG : 230923.1 : 2002JAN18 2853 2924 forward 3 SP 82 LG: 232307.11 : 2002JAN 18 1 1532 TM Extracellular 82 LG: 232307. 11 : 2002JAN18 1533 1555 TM Transmembrane 82 LG: 232307.11 : 2002JAN 18 1556 1557 TM Cytosolic 82 LG : 232307.11 : 2002JAN18 2095 2148 forward 1 SP 82 LG : 232307. 11: 2002JAN18 2095 2166 forward 1 SP 82 LG : 232307. 11 : 2002JAN 18 3304 3366 forward 1 SP 82 LG : 232307.11 : 2002JAN18 3263 3322 forward 2 SP 2 LG: 232307. 11 : 2002JAN18 2427 2501 forward 3 SP 82 LG: 232307.11 : 2002JAN18 2427 2507 forward 3 SP 83 LG:232415. 30 : 2002JAN18 1 63 TM Extracellular 83 LG:232415. 30 : 2002JAN18 64 86 TM Transmembrane 83 LG: 232415.30 : 2002JAN18 87 255 TM Cytosolic 83 LG : 232415.30 : 2002JAN18 256 278 TM Transmembrane 83 LG : 232415.30 : 2002JAN18 279 301 TM Extracellular 83 LG : 232415. 30 : 2002JAN 18 1 260 TM Cytosolic 83 LG: 232415.30 : 2002JAN18 261 283 TM Transmembrane 83 LG : 232415. 30: 2002JAN18 284 301 TM Extracellular 83 LG : 232415. 30 : 2002JAN18 772 828 forward 1 SP 83 LG: : 232415. 30: 2002JAN18 772 831 forward 1 SP 84 LG : 234121.5 : 2002JAN18 1 915 TM Extracellular 84 LG:234121. 5 : 2002JAN18 916 938 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: T e 84 LG : 234121. 5 : 2002JAN18 939 1050 TM Cytosolic 84 LG : 234121. 5 : 2002JAN18 1051 1073 TM Transmembrane 84 LG:234121. 5: 2002JAN18 1074 1092 TM Extracellular 84 LG:234121. 5 : 2002JAN18 1093 1115 TM Transmembrane 84 LG : 234121.5 : 2002JAN18 1116 1224 TM Cytosolic 84 LG:234121. 5 2002JAN18 1225 1244 TM Transmembrane 84 LG:234121. 5 :2002JAN18 1245 1293 TM Extracellular 84 LG:234121. 5 : 2002JAN18 1294 1313 TM Transmembrane 84 LG:234121 5 : 2002JAN18 1314 1393 TM Cytosolic 84 LG : 234121.5 : 2002JAN18 1 1091 TM Extracellular 84 LG : 234121. 5: 2002JAN18 1092 1114 TM Transmembrane 84 LG : 234121. 5: 2002JAN18 1115 1165 TM Cytosolic 84 LG : 234121. 5 : 2002JAN18 1166 1185 TM Transmembrane 84 LG : 234121. 5 :2002JAN18 1186 1317 TM Extracellular 84 LG:234121. 5 :2002JAN18 1318 1340 TM Transmembrane 84 LG : 234121. 5 : 2002JAN18 1341 1393 TM Cytosolic 84 LG:234121. 5 : 2002JAN18 1 1161 TM Extracellular 84 LG:234121. 5 : 2002JAN18 1162 1181 TM Transmembrane 84 LG : 234121. 5: 2002JAN18 1182 1393 TM Cytosolic 84 LG : 234121. 5: 2002JAN18 3289 3381 forward 1 SP 84 LG: 234121.5 : 2002JAN18 3289 3336 forward 1 SP 84 LG:234121. 5 : 2002JAN18 875 943 forward 2 SP 84 LG:234121.5:2002JAN18 860 940 forward 2 SP 84 LG : 234121. 5 :2002JAN18 875 940 forward 2 SP 84 LG : 234121. 5 : 2002JAN18 875 949 forward 2 SP 84 LG : 234121.5 : 2002JAN18 875 934 forward 2 SP 84 LG:234121. 5 :2002JAN18 860 934 forward 2 SP 84 LG : 234121.5 : 2002JAN18 875 931 forward 2 SP 84 LG : 234121. 5 : 2002JAN18 860 949 forward 2 SP 84 LG : 234121. 5: 2002JAN18 875 937 forward 2 SP 84 LG:234121. 5 : 2002JAN18 875 940 forward 2 SP 84 LG:234121. 5 : 2002JAN18 3858 3944 forward 3 SP 85 LG : 235713.10 : 2002JAN18 1 132 TM Cytosolic 85 LG:235713. 10 :2002JAN18 133 155 TM Transmembrane 85 LG:235713. 10 :2002JAN18 156 174 TM Extracellular 85 LG : 235713. 10 :2002JAN18 175 197 TM Transmembrane 85 LG : 235713. 10 : 2002JAN18 198 262 TM Cytosolic 85 LG:235713. 10 : 2002JAN 18 263 285 TM Transmembrane 85 LG:235713. 10 :2002JAN18 286 316 TM Extracellular 85 LG : 235713. 10 : 2002JAN18 317 339 TM Transmembrane 85 LG:235713. 10: 2002JAN18 340 459 TM Cytosolic 85 LG:235713. 10 : 2002JAN18 460 482 TM Transmembrane 85 LG:235713. 10 : 2002JAN18 483 523 TM Extracellular 85 LG:135713. 10 2002JAN18 524 541 TM Trunsmembrane 85 LG : 235713. 10: 2002JAN18 542 657 TM Cytosolic 85 LG : 235713.10 : 2002JAN18 658 680 TM Transmembrane 85 LG:235713. 10: 2002JAN18 681 816 TM Extracellular 85 LG:235713. 10 : 2002JAN18 1 252 TM Cytosolic 8t LG:235713. 10 ; 2002JAN18 253 275 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 85 LG : 235713. 10: 2002JAN18 276 816 TM Extracellular 85 LG: 235713.10 : 2002JAN18 1571 1618 forward 2 SP 85 LG:235713. 10 @2002JAN18 42 104 forward 3 SP 85 LG : 235713. 10 : 2002JAN 18 42 107 forward 3 SP 85 LG : 235713. 10 : 2002JAN18 42 131 forward 3 SP 85 LG : 235713. 10: 2002JAN18 42 101 forward 3 SP 86 LG : 236340. 12 : 2002JAN18 1 607 TM Extracellular 86 LG:236340. 12 : 2002JAN18 608 630 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 631 641 TM Cytosolic 86 LG : 236340.12 : 2002JAN18 642 664 TM Transmembrane 86 LG : 236340 12: 2002JAN18 665 668 TM Extracellular 86 LG: 236340.12 : 2002JAN18 669 691 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 692 902 TM Cytosolic 86 LG:236340. 12: 2002JAN 18 903 921 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 922 930 TM Extracellular 86 LG : 236340. 12: 2002JAN 18 931 953 TM Transmembrane 86 LG:236340.12:2002JAN18 954 1181 TM Cytosolic 86 LG : 236340.12 : 2002JAN18 1182 1204 TM Transmembrane 86 LG: 236340.12 : 2002JAN18 1205 1238 TM Extracellular 86 LG:236340. 12 : 2002JAN18 1239 1258 TM Transmembrane 86 LG : 236340. 12: 2002JAN 18 1259 1317 TM Cytosolic 86 LG : 236340. 12: 2002JAN18 1318 1340 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 1341 1382 TM Extracellular 86 LG : 236340 12 : 2002JAN18 1383 1400 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 1401 1404 TM Cytosolic 86 LG: 236340.12 : 2002JAN18 1405 1422 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 1423 1423 TM Extracellular 86 LG : 236340. 12 : 2002JAN18 1 588 TM Extracellular 86 LG:236340. 12: 2002JAN18 589 611 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 612 653 TM Cytosolic 86 LG: 236340.12 : 2002JAN18 654 676 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 677 1423 TM Extracellular 86 LG : 236340, 12: 2002JAN18 1 809 TM Extracellular 86 LG:236340. 12: 2002JAN18 810 832 TM Transmembrane 86 LG:236340. 12: 2002JAN18 833 930 TM Cytosolic 86 LG:236340.12 : 2002JAN 18 931 953 TM Transmembrane 86 LG : 236340. 12 : 2002JAN18 954 1002 TM Extracellular 86 LG : 236340. 12 : 2002JAN 18 1003 1020 TM Transmembrane 86 LG : 236340.12 : 2002JAN18 1021 1239 TM Cytosolic 86 LG:236340.12:2002JAN18 1240 1262 TM Transmembrane 86 LG:236340. 12 : 2002JAN18 1263 1276 TM Extracellular 86 LG : 236340. 12 : 2002JAN18 1277 1299 TM Transmembrane 86 LG:236340.12:2002JAN18 1300 1423 TM Cytosolic 86 LG : 236340. 12 : 2002JAN18 1894 1944 forward 1 SP 86 LG:236340. 12: 2002JAN18 995 1054 forward 2 SP 86 LG:236340. 12 : 2002JAN18 1415 1474 forward 2 SP 87 LG:236386.2:2002JAN18 1 730 TM Extracellular 87 LG:236386.2:2002JAN18 731 753 TM Transmembrane 87 LG:236386. 2: 2002JAN18 754 759 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 87 LG: 236386.2 : 2002JAN18 760 782 TM Transmembrane 87 LG : 236386. 2 : 2002JAN18 783 1557 TM Extracellular 87 LG:236386. 2 : 2002JAN18 2041 2106 forward 1 SP 87 LG: 236386.2 : 2002JAN18 2041 2094 forward 1 SP 87 LG : 236386. 2 : 2002JAN18 2016 2108 forward 3 SP 88 LG:239601. 22 : 2002JAN18 1 12 TM Cytosolic 88 LG:239601. 22: 2002JAN18 13 30 TM Transmembrane 88 LG : 239601. 22 : 2002JAN18 31 55 TM Extracellular 88 LG : 239601. 22 : 2002JAN18 56 78 TM Transmembrane 88 LG: 239601.22 : 2002JAN18 79 170 TM Cytosolic 88 LG:239601. 22: 2002JAN18 171 190 TM Transmembrane 88 LG : 239601. 22: 2002JAN18 191 243 TM Extracellular 88 LG : 239601. 22 : 2002JAN18 244 266 TM Transmembrane 88 LG : 239601.22 : 2002JAN18 267 292 TM Cytosolic 88 LG:239601. 22: 2002JAN18 293 315 TM Transmembrane 88 LG : 239601.22 : 2002JAN18 316 329 TM Extracellular 88 LG:239601. 22 : 2002JAN18 330 352 TM Transmembrane 88 LG:239601. 22 : 2002JAN18 353 364 TM Cytosolic 88 LG : 239601. 22 : 2002JAN18 365 387 TM Transmembrane 88 LG : 239601. 22 : 2002JAN18 388 995 TM Extracellular 88 LG : 239601.22 : 2002JAN18 1 54 TM Extracellular 88 LG : 239601.22 : 2002JAN18 5 77 TM Transmembrane 88 LG:239601. 22 : 2002JAN18 78 165 TM Cytosolic 88 LG : 239601.22 : 2002JAN 18 166 188 TM Transmembrane 88 LG:239601. 22: 2002JAN 18 189 303 TM Extracellular 88 LG: 239601.22 : 2002JAN 18 304 326 TM Transmembrane 88 LG : 239601.22 : 2002JAN 18 327 374 TM Cytosolic 88 LG : 239601.22 : 2002JAN18 375 397 TM Transmembrane 88 LG: 239601.22 : 2002JAN 18 398 406 TM Extracellular 88 LG : 239601. 22: 2002JAN 18 407 429 TM Transmembrane 88 LG : 239601. 22: 2002JAN18 430 578 TM Cytosolic 88 LG:239601. 22: 2002JAN18 579 601 TM Transmembrane 88 LG : 239601. 22: 2002JAN18 602 995 TM Extracellular 88 LG : 239601. 22 : 2002JAN18 1 14 TM Extracellular 88 LG : 239601. 22 : 2002JAN18 15 37 TM Transmembrane 88 LG: 239601.22 : 2002JAN18 38 41 TM Cytosolic 88 LG : 239601. 22 : 2002JAN18 42 64 TM Transmembrane 88 LG : 239601. 22: 2002JAN 18 65 174 TM Extracellular 88 LG : 239601. 22 : 2002JAN 18 175 197 TM Transmembrane 88 LG:239601. 22 : 2002JAN18 198 235 TM Cytosolic 88 LG : 239601. 22 : 2002JAN18 236 258 TM Transmembrane 88 LG:239601. 22 : 2002JAN18 259 308 TM Extracellular 88 LG : 239601.22 : 2002JAN 18 309 331 TM Transmembrane 88 LG : 239601. 22 : 2002JAN18 332 351 TM Cytosolic 88 LG:239601. 22 : 2002JAN18 352 374 TM Transmembrane 88 LG : 239601.22 : 2002JAN18 375 378 TM Extracellular 88 LG: 239601.22 : 2002JAN18 379 401 TM Transmembrane 88 LG : 239601.22 : 2002JAN18 402 412 TM Cytosolic 88 LG : 239601. 22 : 2002JAN18 413 435 TM Transmembrane Table 2 SEQ ID |Template ID Start Stop Frame Domain Topology NO: Type 88 LG : 239601.22 : 2002JAN18 436 995 TM Extracellular 88 LG : 239601, 22 :2002JAN18 477 563 forward 3 SP 88 LG : 239601.22 : 2002JAN18 477 563 forward 3 SP 88 LG: 239601.22 : 2002JAN18 477 551 forward 3 SP 89 LG:239673. 8 : 2002JAN18 1 279 TM Extracellular 89 LG : 239673. 8 : 2002JAN18 280 302 TM Transmembrane 89 LG:239673. 8 : 2002JAN18 303 570 TM Cytosolic 89 LG : 239673. 8: 2002JAN18 571 593 TM Transmembrane 89 LG:239673. 8: 2002JAN18 594 925 TM Extracellular 89 LG : 239673.8 : 2002JAN18 1 143 TM Cytosolic 89 LG : 239673. 8 2002JAN18 144 163 TM Transmembrane 89 LG : 239673. 8 :2002JAN18 164 172 TM Extracellular 89 LG : 239673.8 : 2002JAN18 173 195 TM Transmembrane 89 LG: 239673.8 : 2002JAN18 196 201 TM Cytosolic 89 LG:239673. 8 :2002JAN18 202 224 TM Transmembrane 89 LG : 239673. 8 : 2002JAN18 225 228 TM Extracellular 89 LG:239673. 8 : 2002JAN18 229 246 TM Transmembrane 89 LG:239673.8:2002JAN18 247 278 TM Cytosolic 89 LG : 239673. 8 :2002JAN18 279 301 TM Transmembrane 89 LG:239673. 8 :2002JAN18 302 925 TM Extracellular 89 LG : 239673.8 : 2002JAN18 1165 1224 forward 1 SP 89 LG: 239673. 8 : 2002JAN18 1165 1218 forward 1 SP 89 LG:239673.8:2002JAN18 1165 1251 forward 1 SP 89 LG:239673. 8 :2002JAN18 371 439 forward 2 SP 89 LG:239673. 8 : 2002JAN18 669 755 forward 3 SP 89 LG: 239673.8 : 2002JAN18 669 761 forward 3 SP 89 LG : 239673. 8: 2002JAN18 543 605 forward 3 SP 89 LG : 239673.8 : 2002JAN18 543 599 forward 3 SP 90 LG:249905. 45 : 2002JAN18 1 469 TM Extracellular 90LG : 249905. 45 : 2002JAN18 470 492 TM Transmembrane 90 LG : 249905.45 : 2002JAN18 493 536 TM Cytosolic 90 LG : 249905. 45 : 2002JAN18 537 559 TM Transmembrane 90 LG:249905. 45 : 2002JAN18 560 835 TM Extracellular 90 LG:249905. 45 : 2002JAN18 1 450 TM Extracellular 90 LG:249905. 45 :2002JAN18 451 473 TM Transmembrane 90 LG:249905. 45: 2002JAN18 474 614 TM Cytosolic 90 LG:249905. 45 :2002JAN18 615 637 TM Transmembrane 90 LG:249905. 45 :2002JAN18 638 640 TM Extracellular 90 LG:249905. 45 : 2002JAN18 641 660 TM Transmembrane 90 LG : 249905.45 : 2002JAN18 661 813 TM Cytosolic 90 LG : 249905. 45: 2002JAN18 814 833 TM Transmembrane 90 LG:249905. 45 :2002JAN18 834 835 TM Extracellular 90 LG:249905. 45 2002JAN18 2163 2231 forward 3 SP 91 LG:250038. 3 : 2002JAN 18 1 2110 TM Extracellular 91 LG:250038. 3 :2002JAN18 2111 2133 TM Transmembrane 91 LG : 250038.3 : 2002JAN18 2134 2159 TM Cytosolic 91 LG : 250038. 3 : 2002JAN18 2160 2178 TM Transmembrane 91 LG:250038.3:2002JAN18 2179 2187 TM Extracellular 91 LG:250038.3:2002JAN18 2188 2210 TM Transmembrane Table 2 SEQtD TemptateiD Start Stop Frame Domain Topotogy NO : Type 91 LG: 250038.3 : 2002JAN18 2211 2221 TM Cytosolic 91 LG: 250038, 3: 2002JAN18 2222 2244 TM Transmembrane 91 LG: 250038.3 : 2002JAN18 2245 2245 TM Extracellular 91 LG : 250038.3 : 2002JAN18 1486 1575 forward 1 SP 91 LG : 250038.3 : 2002JAN18 5953 6024 forward 1 SP 91 LG:250038. 3 : 2002JAN18 886 948 forward 1 SP 91 LG : 250038. 3 : 2002JAN18 5465 5527 forward 2 SP 91 LG: 250038.3 : 2002JAN18 5465 5533 forward 2 SP 91 LG: 250038.3 : 2002JAN18 5456 5524 forward 2 SP 91 LG: 250038.3 : 2002JAN18 755 808 forward 2 SP 91 LG : 250038, 3: 2002JAN18 869 940 forward 2 SP 91 LG : 250038. 3: 2002JAN18 5465 5512 forward 2 SP 91 LG : 250038, 3 : 2002JAN18 6003 6077 forward 3 SP 91 LG : 250038. 3 : 2002JAN18 5814 5906 forward 3 SP 92 LG : 252800.19 : 2002JAN18 1 41 TM Cytosolic 92 LG: 252800.19 : 2002JAN18 42 64 TM Transmembrane 92 LG:252800. 19: 2002JAN18 65 113 TM Extracellular 92 LG : 252800.19 : 2002JAN18 114 136 TM Transmembrane 92 LG: 252800.19 : 2002JAN18 137 201 TM Cytosolic 93 LG : 253580. 6 : 2002JAN18 1 3 TM Extracellular 93 LG : 253580, 6 : 2002JAN18 4 21 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 22 356 TM Cytosolic 93 LG : 253580, 6: 2002JAN18 357 379 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 380 383 TM Extracellular 93 LG : 253580, 6: 2002JAN18 384 406 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 407 450 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 451 473 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 474 508 TM Extracellular 93 LG: 253580.6 : 2002JAN18 509 531 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 532 693 TM Cytosolic 93 LG: 253580.6 : 2002JAN18 694 716 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 717 735 TM Extracellular 93 LG:253580. 6 : 2002JAN18 736 758 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 759 769 TM Cytosolic 93 LG:253580. 6: 2002JAN18 770 792 TM Transmembrane 93 LG : 253580, 6 : 2002JAN18 793 813 TM Extracellular 93 LG : 253580, 6 : 2002JAN18 814 831 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 832 867 TM Cytosolic 93 LG : 253580.6 : 2002JAN18 868 885 TM Transmembrane 93 LG : 253580, 6 : 2002JAN18 886 1451 TM Extracellular 93 LG : 253580.6 : 2002JAN18 1452 1474 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 1475 1525 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 1526 1548 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 1549 1557 TM Extracellular 93 LG: 253580.6 : 2002JAN18 1558 1580 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 1581 1588 TM Cytosolic 93 LG: 253580.6 : 2002JAN18 219 TM Extracellular 93 LG : 253580.6 : 2002JAN18 220 242 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 243 302 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 93 LG:253580. 6 : 2002JAN18 303 325 TM Transmembrane 93 LG:253580.6:2002JAN18 326 354 TM Extracellular 93 LG:253580. 6 :2002JAN18 355 377 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 378 383 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 384 401 TM Transmembrane 93 LG253580. 6 2002JAN18 402 405 TM Extracellular 93 LG : 253580. 6 : 2002JAN18 406 428 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 429 450 TM Cytosolic 93 LG : 253580. 6 :2002JAN18 451 473 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 474 584 TM Extracellular 93 LG:253580. 6 :2002JAN18 585 607 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 608 619 TM Cytosolic 93 LG:253580. 6 :2002JAN18 620 642 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 643 700 TM Extracellular 93 LG: 253580.6 : 2002JAN18 701 723 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 724 735 TM Cytosolic 93 LG:253580.6:2002JAN18 736 755 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 756 769 TM Extracellular 93 LG:253580. 6 : 2002JAN18 770 790 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 791 863 TM Cytosolic 93 LG : 253580.6 : 2002JAN18 864 886 TM Transmembrane 93 LG:253580.6:2002JAN18 887 1250 TM Extracellular 93 LG:253580. 6 :2002JAN18 1251 1273 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 1274 1346 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 1347 1369 TM Transmembrane 93 LG:253580. 6 :2002JAN18 1370 1458 TM Extracellular 93 LG:253580. 6 :2002JAN18 1459 1478 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 1479 1498 TM Cytosolic 93 LG: 253580.6 : 2002JAN18 1499 1521 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 1522 1540 TM Extracellular 93 LG : 253580.6 : 2002JAN18 1541 1563 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 1564 1588 TM Cytosolic 93 LG : 253580. 6: 2002JAN18 1 118 TM Cytosolic 93 LG:253580. 6 2002JAN18 119 141 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 142 217 TM Extracellular 93 LG : 253580. 6: 2002JAN18 218 235 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 236 304 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 305 327 TM Transmembrane 93 LG : 253580. 6 2002JAN18 328 330 TM Extracellular 93 LG : 253580. 6 :2002JAN18 331 348 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 349 354 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 355 377 TM Transmembrane 93 LG : 253580. 6 :2002JAN18 378 386 TM Extracellular 93 LG:253580. 6 :2002JAN18 387 409 TM Transmembrane 93 LG: 253580.6 : 2002JAN18 410 447 TM Cytosolic 93 LG : 253580. 6 2002JAN18 448 470 TM Transmembrane 93 LG : 253580.6 : 2002JAN18 471 583 TM Extracellular 93 LG253580. 6 2002JAN18 584 606 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 607 612 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 93 LG : 253580, 6 2002JAN18 613 635 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 636 747 TM Extracellular 93 LG : 253580.6 : 2002JAN18 748 770 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 771 821 TM Cytosolic 93 LG:253580. 6 2002JAN18 822 844 TM Transmembrane 93 LG:253580. 6 : 2002JAN18 845 863 TM Extracellular 93 LG : 253580, 6 : 2002JAN18 864 886 TM Transmembrane 93 LG : 253580. 6 : 2002JAN18 887 1022 TM Cytosolic 93 LG:253580. 6 : 2002JAN18 1023 1045 TM Transmembrane 93 LG:253580. 6 :2002JAN18 1046 1546 TM Extracellular 93 LG : 253580. 6: 2002JAN18 1547 1569 TM Transmembrane 93 LG : 253580. 6: 2002JAN18 1570 1588 TM Cytosolic 93 LG:253580. 6: 2002JAN18 4390 4443 forward 1 SP 93 LG:253580.6:2002JAN18 4007 4084 forward 2 SP 93 LG:253580. 6: 2002JAN18 3749 3832 forward 2 SP 93 LG:253580. 6 : 2002JAN18 4520 4570 forward 2 SP 93 LG:253580. 6 2002JAN18 4520 4594 forward 2 SP 93 LG:253580. 6 :2002JAN18 3749 3802 forward 2 SP 93 LG : 253580.6 : 2002JAN18 3528 3575 forward 3 SP 94 LG:271509.8:2002JAN18 1 865 TM Extracellular 94 LG:271509. 8 : 2002JAN18 866 885 TM Transmembrane 94 LG : 271509.8 : 2002JAN18 886 1047 TM Cytosolic 94 LG : 271509. 8 : 2002JAN18 1048 1070 TM Transmembrane 94 LG : 271509. 8 :2002JAN18 1071 1126 TM Extracellular 94 LG:271509. 8 2002JAN18 1127 1149 TM Transmembrane 94 LG : 271509.8 : 2002JAN 18 1150 1155 TM Cytosolic 94 LG : 271509. 8 : 2002JAN18 1156 1178 TM Transmembrane 94 LG:271509. 8 : 2002JAN18 1179 1400 TM Extracellular 94 LG:271509. 8 :2002JAN18 710 790 forward 2 SP 94 LG:271509. 8 :2002JAN18 2403 2456 forward 3 SP 94 LG : 271509. 8 : 2002JAN18 2403 2450 forward 3 SP 94 LG : 271509.8 : 2002JAN18 2280 2360 forward 3 SP 95 LG : 277161.30 : 2002JAN 18 1 186 TM Cytosolic 95 LG : 277161.30 : 2002JAN18 187 204 TM Transmembrane 95 LG : 277161. 30 : 2002JAN18 205 816 TM Extracellular 95 LG : 277161. 30 : 2002JAN18 1 661 TM Extracellular 95 LG : 277161.30 : 2002JAN18 662 684 TM Transmembrane 95 LG : 277161. 30 : 2002JAN18 685 730 TM Cytosolic 95 LG : 277161. 30: 2002JAN18 731 753 TM Transmembrane 95 LG : 277161, 30 : 2002JAN 18 754 762 TM Extracellular 95 LG:277161. 30 : 2002JAN18 763 780 TM Transmembrane 95 LG : 277161. 30: 2002JAN18 781 816 TM Cytosolic 95 LG:277161. 30 : 2002JAN18 2211 2279 forward 3 SP 96 LG : 330739.4 : 2002JAN18 1 130 TM Cytosolic 96 LG 3307394 2002JAN18 131 153 TM Transmembrane 96 LG:330739. 4: 2002JAN18 154 380 TM Extracellular 96 LG:330739. 4: 2002JAN18 619 708 forward 1 SP 97 LG : 331470. 6: 2002JAN18 1992 TM Extracellular 97 LG : 334170. 6 : 2002JAN18 1993 2015 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 97 LG : 331470. 6 : 2002JAN18 2016 2019 TM Cytosolic 97 LG:331470. 6 : 2002JAN18 2020 2037 TM Transmembrane 97 LG : 331470. 6 : 2002JAN18 2038 2409 TM Extracellular 97 LG:331470. 6 2002JAN18 1 1344 TM Extrscellular 97 LG:331470. 6 2002JAN18 1345 1362 TM Transmembrane 97 LG : 331470. 6: 2002JAN18 1363 1399 TM Cytosolic 97 LG:331470. 6 2002JAN18 1400 1422 TM Transmembrane 97 LG: 331470.6 : 2002JAN18 1423 2409 TM Extracellular 97 LG : 331470. 6 : 2002JAN18 4387 4452 forward 1 SP 97 LG : 331470. 6 : 2002JAN18 5329 5421 forward 1 SP 97 LG:331470. 6 : 2002JAN18 5368 5415 forward 1 SP 97 LG:331470. 6 : 2002JAN18 4387 4470 forward 1 SP 97 LG:331470. 6 :2002JAN18 5766 5840 forward 3 SP 97 LG:331470. 6 : 2002JAN18 5766 5840 forward 3 SP 97 LG: 331470.6 : 2002JAN18 5766 5828 forward 3 SP 97 LG : 331470.6 : 2002JAN18 4662 4781 forward 3 SP 97 LG:331470. 6 : 2002JAN18 5766 5846 forward 3 SP 98 LG : 331661. 1 2002JAN18 939 TM Extrscellular 98 LG:331661. 1 :2002JAN18 940 962 TM Transmembrane 98 LG : 331661.1 : 2002JAN18 963 999 TM Cytosolic 98 LG : 331661. 1 : 2002JAN18 250 327 forward 1 SP 98 LG:331661. 1: 2002JAN18 793 876 forward 1 SP 98 LG:331661. 1: 2002JAN18 793 882 forward 1 SP 98 LG : 331661. 1 : 2002JAN 18 250 318 forward 1 SP 98 LG:331661. 1 2002JAN18 250 324 forward 1 SP 98 LG:331661. 1 : 2002JAN 18 250 312 forward 1 SP 98 LG : 331661. 1: 2002JAN18 299 364 forward 2 SP 98 LG : 331661. 1: 2002JAN18 282 359 forward 3 SP 98 LG:331661. 1 :2002JAN18 288 350 forward 3 SP 99 LG : 332032.17 : 2002JAN18 1 254 TM Extracellular 99 LG : 332032.17 : 2002JAN18 255 277 TM Transmembrane 99 LG : 332032.17 : 2002JAN18 278 290 TM Cytosolic 99 LG : 332032.17 : 2002JAN18 1 256 TM Extracellular 99 LG : 332032. 17: 2002JAN18 257 274 TM Transmembrane 99 LG : 332032. 17 : 2002JAN18 275 290 TM Cytosolic 99 LG:332032. 17 : 2002JAN18 495 566 forward 3 SP 100 LG : 332431. 2: 2002JAN18 1 254 TM Cytosolic 100 LG: 332431.2 : 2002JAN18 255 277 TM Transmembrane 100 LG : 332431. 2 :2002JAN18 278 296 TM Extracellular 100 LG : 332431. 2 : 2002JAN18 297 319 TM Transmembrane 100 LG: 332431. 2: 2002JAN18 320 457 TM Cytosolic 100 LG : 332431. 2 :2002JAN18 458 480 TM Transmembrane 100 LG : 332431. 2 :2002JAN18 481 546 TM Extracellular 100 LG : 332431. 2 :2002JAN18 547 569 TM Transmembrane 100 LG: 332431. 2 : 2002JAN18 570 575 TM Cytosolic 100 LG: 332431. 2:2002JAN18 576 598 TM Transmembrane 100 LG:332431. 2 : 2002JAN18 599 645 TM Extracellular 100 LG : 332431. 2 : 2002JAN18 646 668 TM Transmembrane 100 LG : 332431. 2 : 2002JAN18 669 704 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 100 LG : 332431. 2 : 2002JAN 18 705 724 TM Transmembrane 100 LG : 332431.2 : 2002JAN18 725 760 TM Extracellular 100 LG: 332431. 2 : 2002JAN18 1 643 TM Extracellular 100 LG : 332431.2 : 2002JAN18 644 666 TM Transmembrane 100 LG : 332431.2 : 2002JAN18 667 707 TM Cytosolic 100 LG : 332431. 2 : 2002JAN18 708 725 TM Transmembrane 100 LG: 332431.2 : 2002JAN18 726 760 TM Extracellular 100 LG: 332431. 2: 2002JAN18 1 570 TM Extracellular 100 LG: 332431. 2: 2002JAN18 571 593 TM Transmembrane 100 LG : 332431. 2 : 2002JAN18 594 613 TM Cytosolic 100 LG : 332431. 2 : 2002JAN18 614 631 TM Transmembrane 100 LG: 332431.2 : 2002JAN18 632 759 TM Extracellular 100 LG : 332431. 2 : 2002JAN18 748 810 forward 1 SP 100 LG : 332431.2 : 2002JAN18 748 825 forward 1 SP 100 LG : 332431.2 : 2002JAN18 748 813 forward 1 SP 100 LG: 332431.2 : 2002JAN18 748 819 forward 1 SP 101 LG: 335173, 4 ; 2002JAN18 1 351 TM Extracellular 101 LG: 335173.4 : 2002JAN18 352 374 TM Transmembrane 101 LG : 335173. 4: 2002JAN 18 375 380 TM Cytosolic 101 LG: 335173. 4 : 2002JAN18 381 403 TM Transmembrane 101 LG: 335173. 4: 2002JAN 18 404 458 TM Extracellular 101 LG : 335173.4 : 2002JAN18 664 735 forward 1 SP 101 LG : 335173. 4: 2002JAN18 664 729 forward 1 SP 101 LG : 335173. 4 : 2002JAN18 664 735 forward 1 SP 101 LG : 335173.4 : 2002JAN18 691 753 forward 1 SP 101 LG : 335173. 4: 2002JAN18 691 750 forward 1 SP 101 LG : 335173. 4: 2002JAN18 698 760 forward 2 SP 101 LG: 335173.4 : 2002JAN18 698 763 forward 2 SP 102 LG : 336529. 3: 2002JAN18 1 1123 TM Extracellular 102 LG : 336529. 3: 2002JAN18 1124 1146 TM Transmembrane 102 LG : 336529. 3 : 2002JAN18 1147 1468 TM Cytosolic 102 LG: 336529.3 : 2002JAN18 1469 1491 TM Transmembrane 102 LG: 336529.3 : 2002JAN18 1492 2658 TM Extracellular 102 LG : 336529.3 : 2002JAN18 1 1124 TM Extracellular 102 LG : 336529.3 : 2002JAN18 1125 1147 TM Transmembrane 102 LG: 336529. 3: 2002JAN18 1148 1272 TM Cytosolic 102 LG : 336529. 3 : 2002JAN18 1173 1295 TM Transmembrane 102 LG: 336529. 3 : 2002JAN18 1296 1349 TM Extracellular 102 LG : 336529. 3: 2002JAN18 1350 1372 TM Transmembrane 102 LG : 336529. 3: 2002JAN 18 1373 1422 TM Cytosolic 102 LG : 336529.3 : 2002JAN18 1423 1445 TM Transmembrane 102 LG : 336529.3 : 2002JAN18 1446 1470 TM Extracellular 102 LG: 336529.3 : 2002JAN18 1471 1493 TM Trasmembrane 102 LG : 336529.3 : 2002JAN18 1494 1675 TM Cytosolic 102 LG: 336529.3 : 2002JAN18 1676 1698 TM Transmembrane 102 LG: 336529. 3: 2002JAN18 1699 2657 TM Extracellular 102 LG: 336529.3 : 2002JAN18 1 1123 TM Extracellular 102 LG: 336529.3 : 2002JAN18 1124 1146 TM Transmembrane 102 LG : 336529 3: 2002JAN18 1147 1353 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 102 LG: 336529. 3 : 2002JAN18 1354 1371 TM Transmembrane 102 LG : 336529.3 : 2002JAN18 1372 1375 TM Extracellular 102 LG: 336529. 3: 2002JAN18 1376 1398 TM Transmembrane 102 LG : 336529. 3: 2002JAN18 1399 1468 TM Cytosolic 102 LG: 336529.3 : 2002JAN18 1469 1491 TM Transmembrane 102 LG: 336529.3 : 2002JAN18 1492 2657 TM Extracellular 102 LG : 336529. 3 :2002JAN18 1756 1824 forward 1 SP 102 LG : 336529.3 : 2002JAN18 1006 1053 forward 1 SP 102 LG : 336529.3 : 2002JAN18 4064 4135 forward 2 SP 102 LG : 336529. 3 : 2002JAN18 4064 4129 forward 2 SP 102 LG : 336529.3 : 2002JAN18 3174 3266 forward 3 SP 102 LG : 336529. 3 : 2002JAN18 3174 3269 forward 3 SP 103 LG: 338001. 2 : 2002JAN18 1 12 TM Extracellular 103 LG: 338001.2 : 2002JAN18 13 35 TM Transmembrane 103 LG: 338001. 2: 2002JAN18 36 128 TM Cytosolic 103 LG : 338001. 2 : 2002JAN18 129 151 TM Transmembrane 103 LG: 338001.2 : 2002JAN18 152 580 TM Extracellular 103 LG: 338001.2 : 2002JAN18 181 270 forward 1 SP 103 LG: 338001.2 : 2002JAN18 181 264 forward 1 SP 103 LG : 338001. 2: 2002JAN18 151 216 forward 1 SP 103 LG : 338001. 2 :2002JAN18 1079 1141 forward 2 SP 103 LG: 338001.2 : 2002JAN18 98 187 forward 2 SP 103 LG : 338001.2 : 2002JAN18 1079 1144 forward 2 SP 103 LG: 338001. 2: 2002JAN18 438 512 forward 3 SP 103 LG: 338001. 2 : 2002JAN18 438 503 forward 3 SP 103 LG : 338001. 2 : 2002JAN18 90 173 forward 3 SP 103 LG : 338001. 2 : 2002JAN18 438 509 forward 3 SP 103 LG: 338001. 2: 2002JAN 18 54 125 forward 3 SP 103 LG: 338001.2 : 2002JAN18 438 521 forward 3 SP 103 LG: 338001. 2 : 2002JAN18 438 497 forward 3 SP 103 LG : 338001. 2 :2002JAN18 438 521 forward 3 SP 104 LG : 338469.4 : 2002JAN18 1 502 TM Extracellular 104 LG: 338469. 4 : 2002JAN18 503 525 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 526 654 TM Cytosolic 104 LG : 338469. 4 : 2002JAN18 655 686 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 687 700 TM Extracellular 104 LG : 338469.4 : 2002JAN18 701 725 TM Transmembrane 104 LG : 338469. 4: 2002JAN18 724 734 TM Cytosolic 104 LG: 338469. 4:2002JAN18 735 757 TM Transmembrane 104 LG: 338469. 4: 2002JAN18 758 771 TM Extracellular 104 LG : 338469. 4 : 2002JAN18 772 794 TM Transmembrane 104 LG : 338469. 4 : 2002JAN18 795 805 TM Cytosolic 104 LG: 338469.4 : 2002JAN 18 806 828 TM Transmembrane 104 LG: 338469. 4 : 2002JAN18 829 837 TM Extracellular 104 LG: 338469.4 : 2002JAN18 838 860 TM Transmembrane 104 LG : 338469.4 : 2002JAN18 861 943 TM Cytosolic 104 LG: 338469.4 : 2002JAN18 944 966 TM Transmembrane 104 LG: 338469. 4: 2002JAN 18 967 979 TM Extracellular 104 LG:338469. 4 : 2002JAN18 1 656 TM Extracellular Table. 2. SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 104 LG : 338469. 4 :2002JAN18 657 679 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 680 699 TM Cytosolic 104 LG : 338469. 4 : 2002JAN18 700 722 TM Transmembrane 104 LG : 338469.4 : 2002JAN18 723 756 TM Extracellular 104 LG : 338469. 4 2002JAN18 757 779 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 780 806 TM Cytosolic 104 LG: 338469. 4 : 2002JAN18 807 829 TM Transmembrane 104 LG : 338469. 4: 2002JAN18 830 944 TM Extracellular 104 LG : 338469. 4 2002JAN18 945 967 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 968 978 TM Cytosolic 104 LG : 338469. 4 : 2002JAN18 1 129 TM Extracellular 104 LG : 338469. 4 :2002JAN18 130 152 TM Transmembrane 104 LG: 338469.4 : 2002JAN18 153 296 TM Cytosolic 104 LG : 338469. 4 : 2002JAN 18 297 319 TM Transmembrane 104 LG ;338469,4:2002JAN18 320 656 TM Extracellular 104 LG : 338469. 4 : 2002JAN18 657 679 TM Transmembrane 104 LG : 338469.4 :2002JAN18 680 699 TM Cytosolic 104 LG : 338469. 4 : 2002JAN 18 700 722 TM Transmembrane 104 LG : 338469. 4 : 2002JAN18 723 759 TM Extracellular 104 LG : 338469.4 :2002JAN18 760 779 TM Transmembrane 104 LG : 338469. 4 : 2002JAN18 780 938 TM Cytosolic 104 LG :338469. 4 : 2002JAN18 939 961 TM Transmembrane 104 LG: 338469. 4: 2002JAN18 962 978 TM Extracellular 104 LG : 338469. 4 : 2002JAN18 178 255 forward 1 SP 104 LG : 338469. 4 :2002JAN18 367 426 forward 1 SP 104 LG : 338469. 4 : 2002JAN18 367 462 forward 1 SP 104 LG : 338469. 4 :2002JAN18 178 255 forward 1 SP 104 LG: 338469.4 : 2002JAN18 2824 2877 forward 1 SP 104 LG: 338469. 4: 2002JAN18 367 432 forward 1 SP 104 LG : 338469. 4 : 2002JAN18 178 249 forward 1 SP 104 LG: 338469.4 : 2002JAN18 357 431 forward 3 SP 104 LG : 338469.4 : 2002JAN18 366 437 forward 3 SP 105 LG : 344659. 1 : 2002JAN18 1 547 TM Extracellular 105 LG : 344659. 1 : 2002JAN18 548 570 TM Transmembrane 105 LG: 344659.1 : 2002JAN18 571 574 TM Cytosolic 105 LG : 344659. 1 : 2002JAN18 575 597 TM Transmembrane 105 LG: 344659.1 : 2002JAN18 598 646 TM Extracellular 105 LG : 344659. 1 : 2002JAN18 647 669 TM Transmembrane 105 LG: 344659.1 : 2002JAN18 670 675 TM Cytosolic 105 LG : 344659. 1 : 2002JAN18 676 698 TM Transmembrane 105 LG: 344659. 1: 2002JAN18 699 1303 TM Extracellular 105 LG : 344659. 1 : 2002JAN18 1252 1323 forward 1 SP 105 LG : 344659. 1 :2002JAN18 1258 1323 forward 1 SP 105 LG : 344659.1 : 2002JAN18 88 180 forward 1 SP 105 LG : 344659.1 :2002JAN18 1261 1326 forward 1 SP 105 LG : 344659. 1: 2002JAN18 1261 1323 forward 1 SP 105 LG: 344659. 1 : 2002JAN18 1258 1329 forward 1 SP 105 LG : 344659. 1 : 2002JAN18 2631 2702 forward 3 SP 105 LG:344659.1;2002JAN18 2631 2708 forward 3 SP Table 2 SEQ ID |Template ID Start Stop Frame Domain Topology NO: T e 105 LG : 344659. 1 : 2002JAN18 2613 2726 forward 3 SP 105 LG : 344659.1 : 2002JAN18 2631 2702 forward 3 SP 106 LG : 345278. 38 : 2002JAN 18 1 105 TM Cytosolic 106 LG : 345278. 38:2002JAN18 106 128 TM Transmembrane 106 LG: 345278. 38: 2002JAN 18 129 720 TM Extracellular 106 LG: 345278.38 : 2002JAN 18 721 743 TM Transmembrane 106 LG : 345278. 38 : 2002JAN 18 744 755 TM Cytosolic 106 LG: 345278. 38 : 2002JAN 18 756 773 TM Transmembrane 106 LG : 345278.38 : 2002JAN 18 774 782 TM Extracellular 106 LG : 345278.38 : 2002JAN 18 783 805 TM Transmembrane 106 LG : 345278. 38 : 2002JAN18 806 813 TM Cytosolic 106 LG : 345278. 38 : 2002JAN 18 814 833 TM Transmembrane 106 LG: 345278. 38 : 2002JAN 18 834 836 TM Extracellular 106 LG: 345278.38 : 2002JAN 18 837 859 TM Transmembrane 106 LG : 345278. 38: 2002JAN 18 860 873 TM Cytosolic 106 LG: 345278.38 : 2002JAN 18 1 721 TM Extracellular 106 LG : 345278. 38: 2002JAN18 722 744 TM Transmembrane 106 LG: 345278. 38 : 2002JAN18 745 763 TM Cytosolic 106 LG: 345278. 38 :2002JAN18 764 786 TM Transmembrane 106 LG : 345278. 38: 2002JAN18 787 816 TM Extracellular 106 LG : 345278.38 : 2002JAN18 817 839 TM Transmembrane 106 LG : 345278. 38 : 2002JAN18 840 873 TM Cytosolic 106 LG : 345278. 38 : 2002JAN18 1 733 TM Extracellular 106 LG: 345278. 38: 2002JAN18 734 756 TM Transmembrane 106 LG: 345278.38 : 2002JAN18 757 836 TM Cytosolic 106 LG : 345278.38 : 2002JAN18 837 859 TM Transmembrane 106 LG : 345278. 38 : 2002JAN 18 860 873 TM Extracellular 106 LG : 345278. 38 : 2002JAN18 2048 2104 forward 2 SP 106 LG: 345278.38 : 2002JAN18 2030 2098 forward 2 SP 106 LG : 345278. 38 : 2002JAN18 2048 2098 forward 2 SP 106 LG : 345278. 38 : 2002JAN18 2030 2104 forward 2 SP 107 LG : 346657.13 : 2002JAN18 1 228 TM Cytosolic 107 LG: 346657.13 : 2002JAN18 229 251 TM Transmembrane 107 LG : 346657.13 : 2002JAN 18 252 295 TM Extracellular 107 LG : 346657. 13 : 2002JAN18 296 315 TM Transmembrane 107 LG : 346657.13 : 2002JAN18 316 465 TM Cytosolic 107 LG : 346657.13 : 2002JAN18 1 34 TM Cytosolic 107 LG : 346657.13 : 2002JAN18 3557TM ! Transmembrane 107 LG : 346657.13 : 2002JAN18 58 465 TM Extracellular 107 LG : 346657.13 : 2002JAN18 1 94 TM Extracellular 107 LG: 346657. 13 : 2002JAN 18 95 117 TM Transmembrane 107 LG : 346657. 13 : 2002JAN18 118 222 TM Cytosolic 107 LG : 346657.13 : 2002JAN18 223 245 TM Transmembrane 107 LG : 346657. 13 : 2002JAN 18 246 300 TM Extracellular 107 LG : 346657.13 : 2002JAN18 301 320 TM Transmembrane 107 LG: 346657.13 : 2002JAN18 321 464 TM Cytosolic 108 LG : 348101.16 : 2002JAN18 1 14 TM Extracellular 108 LG: 348101. 16 : 2002JAN 18 15 37 TM Transmembrane 108 LG : 348101.16 : 2002JAN18 38 95 TM Cytosolic Table 2 SEQ ID Template I Start Stop Frame Domain Topology NO: Type 108 LG: 348101. 16 : 2002JAN18 96 118 TM Transmembrane 108 LG ;348101. 16 :2002JAN18 119 137 TM Extracellular 108 LG : 348101. 16 : 2002JAN18 138 160 TM Transmembrane 108 LG : 348101. 16 : 2002JAN18 161 442 TM Cytosolic 108 LG : 348101. 16 : 2002JAN18 443 465 TM Transmembrane 108 LG :348101.16:2002JAN18 466 678 TM Extracellular 108 LG : 348101. 16 :2002JAN18 679 701 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 702 734 TM Cytosolic 108 LG :348101.16:2002JAN18 735 757 TM Transmembrane 108 LG :348101.16:2002JAN18 758 1459 TM Extracellular 108 LG : 348101. 16 :2002JAN18 1460 1482 TM Transmembrane 108 LG: 348101.16 : 2002JAN18 1483 1493 TM Cytosolic 108 LG : 348101. 16 :2002JAN18 1494 1511 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 1512 1517 TM Extracellular 108 LG : 348101. 16 :2002JAN18 1 14 TM Extracellular 108 LG: 348101. 16: 2002JAN 18 15 37 TM Transmembrane 108 LG: 348101. 16: 2002JAN18 38 91 TM Cytosolic 108 LG : 348101. 16 : 2002JAN18 92 114 TM Transmembrane 108 LG : 348101. 16 : 2002JAN18 115 128 TM Extracellular 108 LG: 348101. 16: 2002JAN18 129 151 TM Transmembrane 108 LG: 348101. 16: 2002JAN18 152 171 TM Cytosolic 108 LG: 348101. 16 : 2002JAN18 172 194 TM Transmembrane 108 LG : 348101. 16: 2002JAN18 195 281 TM Extracellular 108 LG :348101.16:2002JAN18 282 304 TM Transmembrane 108 LG :348101.16:2002JAN18 305 316 TM Cytosolic 108 LG : 348101. 16 : 2002JAN18 317 336 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 337 345 TM Extracellular 108 LG :348101.16:2002JAN18 346 365 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 366 438 TM Cytosolic 108 LG : 348101. 16 :2002JAN18 439 461 TM Transmembrane 108 LG : 348101. 16 : 2002JAN18 462 1517 TM Extracellular 108 LG : 348101. 16 : 2002JAN18 1 12 TM Cytosolic 108 LG : 348101. 16 : 2002JAN 18 13 35 TM Transmembrane 108 LG: 348101. 16 : 2002JAN 18 36 49 TM Extracellular 108 LG: 348101. 16: 2002JAN18 50 72 TM Transmembrane 108 LG: 348101. 16: 2002JAN18 73 92 TM Cytosolic 108 LG : 348101. 16 : 2002JAN 18 93 115 TM Transmembrane 108 LG : 348101. 16 : 2002JAN18 116 129 TM Extracellular 108 LG: 348101. 16 : 2002JAN18 130 152 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 153 164 TM Cytosolic 108 LG: 348101. 16 : 2002JAN18 165 187 TM Transmembrane 108 LG :348101.16:2002JAN18 188 440 TM Extracellular 108 LG : 348101. 16 :2002JAN18 441 463 TM Transmembrane 108 LG: 348101. 16 : 2002JAN18 464 614 TM Cytosolic 108 LG :348101.16:2002JAN18 615 634 TM Transmembrane 108 LG: 348101. 16: 2002JAN18 635 637 TM Extracellular 108 LG : 348101. 16 : 2002JAN18 638 660 TM Transmembrane 108 LG: 348101. 16: 2002JAN18 661 782 TM Cytosolic 108 LG:348101.16:2002JAN18 783 805 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 108 LG : 348101. 16 : 2002JAN 18 806 1517 TM Extracellular 108 LG : 348101. 16 : 2002JAN18 66 122 forward 3 SP 108 LG : 348101. 16 :2002JAN18 69 128 forward SP 108 LG : 348101.16 : 2002JAN18 57 122 forward 3 SP 109 LG : 350827. 10 2002JAN18 470 TM Extracellulur 109 LG : 350827. 10 :2002JAN18 471 493 TM Transmembrane 109 LG: 350827. 10: 2002JAN18 494 554 TM Cytosolic 109 LG : 350827. 10 : 2002JAN18 1 63 TM Cytosolic 109 LG : 350827. 10 : 2002JAN 18 64 86 TM Transmembrane 109 LG: 350827.10 : 2002JAN 18 87 95 TM Extracellular 109 LG: 350827.10 : 2002JAN18 96 118 TM Transmembrane 109 LG : 350827.10 : 2002JAN18 119 187 TM Cytosolic 109 LG : 350827. 10 :2002JAN18 188 210 TM Transmembrane 109 LG : 350827, 10 :2002JAN18 211 554 TM Extracellular 109 LG: 350827. 10: 2002JAN18 1 55 TM Cytosolic 109 LG: 350827. 10 : 2002JAN18 56 78 TM Transmembrane 109 LG : 350827. 10 :2002JAN18 79 554 TM Extracellular 110 LG: 354580.28 : 2002JAN18 1 87 TM Cytosolic 110 LG: 354580.28 : 2002JAN 18 88 110 TM Transmembrane 110 LG : 354580.28 : 2002JAN18 111 129 TM Extracellular 110 LG : 354580. 28 :2002JAN18 130 152 TM Transmembrane 110 LG: 354580.28 : 2002JAN18 153 568 TM Cytosolic 110 LG: 354580. 28 : 2002JAN18 569 591 TM Transmembrane 110 LG: 354580. 28 : 2002JAN18 592 637 TM Extracellular 110 LG : 354580. 28: 2002JAN18 1 86 TM Cytosolic 110 LG: 354580. 28: 2002JAN18 87 109 TM Transmembrane 110 LG : 354580. 28 : 2002JAN18 110 144 TM Extracellular 110 LG : 354580.28 : 2002JAN18 145 167 TM Transmembrane 110 LG : 354580. 28 : 2002JAN18 168 456 TM Cytosolic 110 LG: 354580.28 : 2002JAN18 457 479 TM Transmembrane 110 LG: 354580.28 : 2002JAN18 480 637 TM Extracellular 110 LG : 354580. 28 : 2002JAN18 1426 1500 forward 1 SP 110 LG : 354580. 28 :2002JAN18 1426 1494 forward 1 SP 110 LG : 354580. 28 :2002JAN18 1426 1503 forward 1 SP 110 LG : 354580.28 : 2002JAN18 1426 1500 forward 1 SP 110 LG: 354580.28 : 2002JAN18 1426 1506 forward 1 SP 110 LG: 354580.28 : 2002JAN18 1426 1509 forward 1 SP 111 LG : 356006.3 : 2002JAN18 1 11 TM Cytosolic 111 LG : 356006.3 : 2002JAN18 12 31 TM Transmembrane ill LG : 356006. 3: 2002JAN18 32 34 TM Extracellular ill LG: 356006.3 : 2002JAN18 35 57 TM Transmembrane 111 LG : 356006. 3: 2002JAN18 58 270 TM Cytosolic 112 LG: 370212. 10: 2002JAN18 1 563 TM Extracellular 112 LG :370212.10:2002JAN18 564 586 TM Transmembrane 112 LG: 370212. 10: 2002JAN18 587 598 TM Cytosolic 112 LG: 370212. 10 : 2002JAN18 599 621 TM Transmembrane 112 LG : 370212.10:2002JAN18 622 683 TM Extracellular 112 LG:370212.10 : 2002JAN18 684 706 TM Transmembrane 112 LG:370212.10:2002JAN18 707 821 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 112 LG : 370212. 10 : 2002JAN18 822 839 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 840 848 TM Extracellular 112 LG : 370212.10 : 2002JAN18 849 868 TM Transmembrane 112 LG: 370212. 10 : 2002JAN18 869 888 TM Cytosolic 112 LG: 370212.10 : 2002JAN18 889 911 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 912 1004 TM Extracellular 112 LG: 370212.10:2002JAN18 1005 1027 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 1028 1087 TM Cytosolic 112 LG : 370212. 10 : 2002JAN18 1088 1105 TM Transmembrane 112 LG: 370212. 10 : 2002JAN 18 1106 1170 TM Extracellular 112 LG : 370212.10 : 2002JAN18 1171 1193 TM Transmembrane 112 LG: 370212. 10 : 2002JAN18 1194 1213 TM Cytosolic 112 LG : 370212.10 : 2002JAN18 1214 1236 TM Transmembrane 112 LG: 370212. 10 : 2002JAN18 1237 1268 TM Extracellular 112 LG: 370212. 10 : 2002JAN18 1269 1291 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 1292 1316 TM Cytosolic 112 LG : 370212.10 : 2002JAN18 1317 1339 TM Transmembrane 112 LG: 370212.10 : 2002JAN 18 i 340 i 378 TM Extracellular 112 LG: 370212. 10: 2002JAN18 1379 1401 TM Transmembrane 112 LG: 370212. 10: 2002JAN18 1402 1572 TM Cytosolic 112 LG : 370212.10 : 2002JAN18 1573 1595 TM Transmembrane 112 LG: 370212. 10: 2002JAN18 1596 1629 TM Extracellular 112 LG : 370212. 10: 2002JAN18 557 TM Extracellular 112 LG : 370212. 10: 2002JAN18 558 580 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 581 729 TM Cytosolic 112 LG: 370212.10 : 2002JAN18 730 752 TM Transmembrane 112 LG : 370212. 10 : 2002JAN18 753 822 TM Extracellular 112 LG: 370212.10 : 2002JAN18 823 842 TM Transmembrane 112 LG : 370212. 10: 2002JAN18 843 951 TM Cytosolic 112 LG: 370212.10 : 2002JAN18 952 974 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 975 1004 TM Extracellular 112 LG: 370212.10 : 2002JAN18 1005 1027 TM Transmembrane 112 LG : 370212. 10 : 2002JAN18 1028 1151 TM Cytosolic 112 LG : 370212. 10 : 2002JAN18 1152 1174 TM Transmembrane 112 LG : 370212. 10: 2002JAN18 1175 1266 TM Extrracellular 112 LG : 370212. 10 : 2002JAN18 1267 1289 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1290 1307 TM Cytosolic 112 LG: 370212. 10 : 2002JAN18 1308 1330 TM Transmembrane 112 LG : 370212. 10:2002JAN18 1331 1582 TM Extracellular 112 LG: 370212. 10 : 2002JAN18 1583 1605 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1606 1628 TM Cytosolic 112 LG : 370212. 10: 2002JAN18 1 999 TM Extracellular 112 LG: 370212. 10: 2002JAN18 1000 1022 TM Transmembrane 112 LG : 370212. 10 : 2002JAN18 1023 1118 TM Cytosolic 112 LG: 370212. 10: 2002JAN18 1119 1141 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1142 1160 TM Extracellular 112 LG: 370212.10 : 2002JAN 18 1161 1183 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 1184 1231 TM Cytosolic 112 LG : 370212. 10: 2002JAN18 1232 1254 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 112 LG : 370212. 10 :2002JAN18 1255 1268 TM Extracellular 112 LG : 370212. 10 :2002JAN18 1269 1288 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 1289 1307 TM Cytosolic 112 LG : 370212. 10 :2002JAN18 1308 1325 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1326 1351 TM Extracellular 112 LG : 370212. 10 : 2002JAN18 1352 1374 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1375 1382 TM Cytosolic 112 LG: 370212. 10: 2002JAN18 1383 1405 TM Transmembrane 112 LG: 370212. 10: 2002JAN18 1406 1451 TM Extracellular 112 LG : 370212. 10 : 2002JAN18 1452 1474 TM Transmembrane 112 LG: 370212. 10: 2002JAN18 1475 1497 TM Cytosolic 112 LG : 370212. 10: 2002JAN18 1498 1520 TM Transmembrane 112 LG : 370212. 10 : 2002JAN18 1521 1534 TM Extracellular 112 LG: 370212.10 :2002JAN18 1535 1552 TM Transmembrane 112 LG : 370212.10 : 2002JAN18 1553 1571 TM Cytosolic 112 LG : 370212. 10 : 2002JAN18 1572 1594 TM Transmembrane 112 LG: 370212.10 : 2002JAN18 1595 1628 TM Extracellular 112 LG : 370212. 10 : 2002JAN 18 2020 2115 forward 1 SP 112 LG : 370212. 10 : 2002JAN 18 1784 1870 forward 2 SP 112 LG : 370212. 10 : 2002JAN18 3015 3071 forward 3 SP 112 LG : 370212. 10 : 2002JAN18 3015 3077 forward 3 SP 112 LG :370212. 10 :2002JAN18 3015 3065 forward 3 SP 112 LG : 370212, 10 :2002JAN18 3015 3083 forward 3 SP 113 LG : 373219. 13 : 2002JAN18 1 23 TM Extracellular 113 LG : 373219. 13 ; 2002JAN18 24 46 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 47 100 TM Cytosolic 113 LG: 373219.13 : 2002JAN18 101 120 TM Transmembrane 113 LG : 373219. 13: 2002JAN18 121 244 TM Extracellular 113 LG : 373219. 13 : 2002JAN18 245 267 TM Transmembrane 113 LG : 373219. 13: 2002JAN18 268 353 TM Cytosolic 113 LG :373219. 13 : 2002JAN 18 354 376 TM Transmembrane 113 LG : 373219.13 : 2002JAN18 377 413 TM Extracellular 113 LG : 373219. 13 :2002JAN18 414 436 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 437 461 TM Cytosolic 113 LG : 373219. 13 2002JAN18 462 484 TM Transmembrane 113 LG : 373219. 13 :2002JAN18 485 986 TM Extracellular 113 LG : 373219. 13: 2002JAN18 1 19 TM Extracellular 113 LG : 373219. 13 : 2002JAN18 20 42 TM Transmembrane 113 LG: 373219. 13: 2002JAN 18 43 229 TM Cytosolic 113 LG: 373219. 13: 2002JAN18 230 252 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 253 280 TM Extracellular 113 LG : 373219. 13 : 2002JAN 18 281 303 TM Transmembrane 113 LG : 373219.13 : 2002JAN18 304 440 TM Cytosolic 113 LG: 373219.13 : 2002JAN18 441 460 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 461 464 TM Extracellular 113 LG : 373219. 13 :2002JAN18 465 484 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 485 636 TM Cytosolic 113 LG: 373219.13 : 2002JAN18 637 659 TM Transmembrane 113 LG:373219.13:2002JAN18 660 703 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 113 LG : 373219. 13 2002JAN18 704 723 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 724 735 TM Cytosolic 113 LG:373219.13:2002JAN18 736 758 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 759 875 TM Extracellular 113 LG : 373219.13 : 2002JAN18 876 898 TM Transmembrane 113 LG: 373219. 13 : 2002JAN18 899 910 TM Cytosolic 113 LG : 373219. 13 : 2002JAN 18 911 933 TM Transmembrane 113 LG:373219. 13 : 2002JAN18 934 986 TM Extracellular 113 LG : 373219.13:2002JAN18 1 19 TM Cytosolic 113 LG :373219. 13 : 2002JAN 18 20 39 TM Transmembrane 113 LG: 373219. 13 : 2002JAN18 40 43 TM Extracelllar 113 LG: 373219.13 : 2002JAN18 44 66 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 67 223 TM Cytosolic 113 LG: 373219. 13: 2002JAN18 224 246 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 247 275 TM Extracellular 113 LG : 373219. 13 2002JAN18 276 298 TM Transmembrsne 113 LG : 373219.13 : 2002JAN18 299 327 TM Cytosolic 113 LG : 373219. 13 :2002JAN18 328 347 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 348 361 TM Extracellular 113 LG : 373219. 13 : 2002JAN18 362 384 TM Transmembrane 113 LG : 373219. 13: 2002JAN18 385 404 TM Cytosolic 113 LG : 373219. 13 : 2002JAN18 405 422 TM Transmembrane 113 LG : 373219. 13 : 2002JAN 18 423 426 TM Extracellular 113 LG : 373219. 13: 2002JAN18 427 449 TM Transmembrane 113 LG: 373219. 13: 2002JAN18 450 461 TM Cytosolic 113 LG : 373219. 13 2002JAN18 462 484 TM Trunsmembrane 113 LG: 373219. 13: 2002JAN18 485 488 TM Extracellular 113 LG : 373219. 13 : 2002JAN18 489 511 TM Transmembrane 113 LG: 373219.13 : 2002JAN18 512 515 TM Cytosolic 113 LG : 373219. 13 :2002JAN18 516 538 TM Transmembrane 113 LG: 373219.13 :2002JAN18 539 577 TM Extracellular 113 LG : 373219. 13 : 2002JAN18 578 600 TM Transmembrane 113 LG: 373219. 13: 2002JAN18 601 709 TM Cytosolic 113 LG: 373219. 13: 2002JAN18 710 732 TM Transmembrane 113 LG: 373219. 13: 2002JAN18 733 741 TM Extracellular 113 LG : 373219.13 : 2002JAN18 742 764 TM Transmembrane 113 LG : 373219. 13: 2002JAN18 765 873 TM Cytosolic 113 LG: 373219. 13: 2002JAN18 874 891 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 892 910 TM Extracellular 113 LG : 373219.13:2002JAN18 911 933 TM Transmembrane 113 LG : 373219. 13 : 2002JAN18 934 985 TM Cytosolic 113 LG : 373219. 13: 2002JAN18 1381 1443 forward 1 SP 114 LG : 399821. 22: 2002JAN18 1 401 TM Extracellular 114 LG : 399821. 22 :2002JAN18 402 424 TM Transmembrane 114 LG: 399821. 22:2002JAN18 425 444 TM Cytosolic 114 LG : 399821. 22 :2002JAN18 445 464 TM Transmembrane 114 LG : 399821. 22 :2002JAN18 465 1138 TM Extracellular 114 LG : 399821. 22 :2002JAN18 1139 1161 TM Transmembrane 114 LG:399821. 22 :2002JAN18 1162 1416 TM Cytosolic Table 2 SEQ ID Template ID |Start |Stop Frame Domain Topology NO: T e 114 LG : 399821, 22 : 2002JAN18 1417 1439 TM Transmembrane 114 LG : 399821, 22 : 2002JAN18 1440 1782 TM Extracellular 114 LG: 399821.22 : 2002JAN18 1783 1800 TM Transmembrane 114 LG: 399821, 22: 2002JAN18 1801 1810 TM Cytosolic 114 LG : 399821.22 : 2002JAN18 1 1781 TM Extracellular 114 LG : 399821. 22 :2002JAN18 1782 1804 TM Transmembrane 114 LG: 399821. 22 : 2002JAN18 1805 1810 TM Cytosolic 114 LG : 399821. 22 : 2002JAN18 4129 4194 forward 1 SP 114 LG : 399821. 22: 2002JAN18 2701 2763 forward 1 SP 114 LG: 399821. 22: 2002JAN18 2701 2793 forward 1 SP 114 LG: 399821. 22 : 2002JAN18 2701 2766 forward 1 SP 114 LG : 399821. 22 : 2002JAN18 3499 3567 forward 1 SP 114 LG : 399821. 22: 2002JAN18 4129 4176 forward 1 SP 114 LG : 399821. 22 : 2002JAN 18 2823 2894 forward 3 SP 114 LG : 399821. 22 : 2002JAN18 2823 2903 forward 3 SP 114 LG : 399821. 22: 2002JAN18 2499 2585 forward 3 SP 115 LG : 400519.1 : 2002JAN18 1 1992 TM Extracellular 115 LG: 400519.1 : 2002JAN18 1193 1212 TM Transmembrane 115 LG:400519. 1: 2002JAN18 1213 1240 TM Cytosolic 115 LG: 400519. 1 : 2002JAN18 1241 1263 TM Transmembrane 115 LG: 400519.1 : 2002JAN18 1264 1428 TM Extracellular 115 LG :400519. 1 :2002JAN18 1 619 TM Extracellular 115 LG :400519. 1 : 2002JAN18 620 637 TM Transmembrane 115 LG: 400519. 1 : 2002JAN18 638 643 TM Cytosolic 115 LG:400519. 1 :2002JAN18 644 666 TM Transmembrane 115 LG : 400519, 1 : 2002JAN18 667 720 TM Extracellular 115 LG: 400519, 1 : 2002JAN18 721 740 TM Transmembrane 115 LG : 400519.1 : 2002JAN18 741 812 TM Cytosolic 115 LG : 400519. 1 :2002JAN18 813 835 TM Transmembrane 115 LG: 400519, 1 : 2002JAN18 836 870 TM Extracellular 115 LG :400519. 1 : 2002JAN18 871 893 TM Transmembrane 115 LG: 400519. 1: 2002JAN18 894 897 TM Cytosolic 115 LG :400519. 1 : 2002JAN18 898 917 TM Transmembrane 115 LG: 400519. 1 : 2002JAN18 918 1004 TM Extracellular 115 LG : 400519. 1 :2002JAN18 1005 1027 TM Transmembrane 115 LG : 400519.1 : 2002JAN18 1028 1239 TM Cytosolic 115 LG :400519. 1 : 2002JAN18 1240 1262 TM Transmembrane 115 LG: 400519.1 : 2002JAN18 1263 1266 TM Extracellular 115 LG: 400519, 1: 2002JAN18 1267 1284 TM Transmembrane 115 LG : 400519, 1 : 2002JAN18 1285 1427 TM Cytosolic 115 LG : 400519. 1 : 2002JAN18 1 202 T Extracellular 115 LG : 400519.1 : 2002JAN18 203 225 TM Transmembrane 115 LG : 400519. 1: 2002JAN18 226 237 TM Cytosolic 115 LG : 400519. 1 : 2002JAN18 238 260 TM Transmembrane 115 LG : 400519. 1 : 2002JAN18 261 866 TM Extracellular 115 LG :400519 1 :2002JAN18 867 889 TM Transmembrane 115 LG : 400519. 1 : 2002JAN 18 890 1165 TM Cytosolic 115 LG : 400519. 1 2002JAN18 1166 1183 TM Transmembrane 115 LG:400519. 1 ; 2002JAN 18 1184 1192 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 115 LG : 400519. 1 : 2002JAN18 1193 1212 TM Transmembrane 115 LG : 400519.1 : 2002JAN18 1213 1241 TM Cytosolic 115 LG : 400519. 1 : 2002JAN18 1242 1264 TM Transmembrane 115 LG: 400519. 1 : 2002JAN18 1265 1427 TM Extracellular 115 LG 400519. 1 : 2002JAN18 3715 3774 forward 1 SP 115 LG : 400519. 1: 2002JAN18 3715 3777 forward 1 SP 115 LG : 400519. 1 : 2002JAN18 3711 3779 forward 3 SP 116 LG: 402797.1 : 2002JAN18 1 65 TM Cytosolic 116 LG : 402797. 1 : 2002JAN18 66 88 TM Transmembrane 116 LG: 402797. 1 : 2002JAN18 89 611 TM Extracellular 116 LG :402797. 1 : 2002JAN18 1577 1621 forward 2 SP 117 LG: 402974.1 : 2002JAN18 1 260 TM Extracellular 117 LG :402974. 1 :2002JAN18 261 283 TM Transmembrane 117 LG: 402974. 1 : 2002JAN18 284 289 TM Cytosolic 117 LG :402974. 1 : 2002JAN18 290 312 TM Transmembrane 117 LG: 402974. 1 : 2002JAN18 313 331 TM Extracellular 117 LG : 402974.1 : 2002JAN18 332 354 TM Transmembrane 117 LG : 402974. 1 : 2002JAN18 355 365 TM Cytosolic 117 LG : 402974.1 : 2002JAN18 366 388 TM Transmembrane 117 LG: 402974. 1 : 2002JAN18 389 726 TM Extracellular 117 LG: 402974. 1: 2002JAN18 1 258 TM Extracellular 117 LG : 402974. 1 : 2002JAN18 259 281 TM Transmembrane 117 LG: 402974.1 : 2002JAN18 282 292 TM Cytosolic 117 LG: 402974.1 : 2002JAN 18 293 315 TM Transmembrane 117 LG: 402974. 1 : 2002JAN18 316 369 TM Extracellular 117 LG : 402974. 1 : 2002JAN18 370 389 TM Transmembrane 117 LG : 402974. 1 : 2002JAN18 390 626 TM Cytosolic 117 LG : 402974.1 : 2002JAN18 627 646 TM Transmembrane 117 LG : 402974.1 : 2002JAN18 647 665 TM Extracellular 117 LG :402974. 1 : 2002JAN18 666 688 TM Transmembrane 117 LG : 402974. 1: 2002JAN18 689 726 TM Cytosolic 117 LG: 402974.1 : 2002JAN18 1120 1188 forward 1 SP 117 LG :402974. 1 :2002JAN18 1997 2065 forward 2 SP 117 LG: 402974.1 : 2002JAN18 1997 2056 forward 2 SP 117 LG : 402974.1 : 2002JAN18 1997 2053 forward 2 SP 117 LG : 402974. 1: 2002JAN18 1997 2071 forward 2 SP 117 LG : 402974. 1 : 2002JAN18 1997 2050 forward 2 SP 118 LG :403397. 7 : 2002JAN18 1 856 TM Extracellular 118 LG : 403397. 7 :2002JAN18 857 879 TM Transmembrane 118 LG: 403397. 7: 2002JAN18 880 980 TM Cytosolic 118 LG: 403397.7 : 2002JAN18 1 867 TM Extracellular 118 LG : 403397. 7 : 2002JAN18 868 890 TM Transmembrane 118 LG: 403397. 7: 2002JAN18 891 910 TM Cytosolic 118 LG: 403397.7 : 2002JAN18 911 933 TM Transmembrane 118 LG: 403397. 7: 2002JAN18 934 942 TM Extracellular 118 LG:403397. 7 : 2002JAN18 943 965 TM Transmembrane 118 LG: 403397.7 : 2002JAN18 966 980 TM Cytosolic 118 LG: 403397. 7 : 2002JAN18 1600 1668 forward 1 SP 118 LG :403397. 7 : 2002JAN 18 2816 2908 forward 2 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 118 LG: 403397, 7 : 2002JAN18 2816 2908 forward 2 SP 118 LG : 403397.7 : 2002JAN18 2816 2878 forward 2 SP 118 LG :403397. 7 :2002JAN18 1569 1628 forward 3 SP 118 LG :403397. 7 :2002JAN18 1569 1634 forward 3 SP 118 LG : 403397. 7:2002JAN18 1569 1640 forward 3 SP 118 LG : 403397.7 : 2002JAN18 1569 1640 forward 3 SP 118 LG :403397. 7 : 2002JAN18 1569 1640 forward 3 SP 119 LG : 404199. 4 : 2002JAN18 1 123 TM Extracellular 119 LG :404199. 4 :2002JAN18 124 146 TM Transmembrane 119 LG : 404199, 4: 2002JAN18 147 157 TM Cytosolic 119 LG: 404199. 4: 2002JAN18 158 180 TM Transmembrane 119 LG : 404199. 4 : 2002JAN 18 181 194 TM Extracellular 119 LG : 404199.4 : 2002JAN18 195 217 TM Transmembrane 119 LG : 404199, 4 : 2002JAN18 218 223 TM Cytosolic 119 LG: 404199. 4 : 2002JAN18 224 243 TM Transmembrane 119 LG :404199. 4 : 2002JAN 18 244 281 TM Extracellular 119 LG :404199. 4 :2002JAN18 282 304 TM Transmembrane 119 LG: 404199, 4 : 2002JAN18 305 316 TM Cytosolic 119 LG :404199. 4 :2002JAN18 317 339 TM Transmembrane 119 LG : 404199. 4 2002JAN18 340 937 TM Extracellular 119 LG: 404199. 4 : 2002JAN18 1 101 TM Cytosolic 119 LG : 404199. 4 2002JAN18 102 124 TM Transmembrane 119 LG : 404199. 4 : 2002JAN 18 125 791 TM Extracellular 119 LG :404199. 4 :2002JAN18 792 814 TM Transmembrane 119 LG: 404199.4 : 2002JAN18 815 834 TM Cytosolic 119 LG : 404199. 4 : 2002JAN 18 835 857 TM Transmembrane 119 LG : 404199. 4 :2002JAN18 858 937 TM Extracellular 119 LG : 404199, 4: 2002JAN18 1 844 TM Extracellular 119 LG : 404199. 4 :2002JAN18 845 867 TM Transmembrane 119 LG : 404199. 4: 2002JAN18 868 913 TM Cytosolic 119 LG : 404199.4 : 2002JAN18 914 936 TM Transmembrane 119 LG: 404199, 4: 2002JAN18 937 937 TM Extracellular 119 LG : 404199, 4 : 2002JAN18 370 453 forward 1 SP 119 LG : 404199. 4 : 2002JAN18 497 577 forward 2 SP 119 LG :404199. 4 :2002JAN18 497 571 forward 2 SP 119 LG :404199. 4 : 2002JAN18 497 577 forward 2 SP 119 LG : 404199, 4 : 2002JAN18 497 571 forward 2 SP 119 LG :404199. 4 :2002JAN18 497 562 forward 2 SP 119 LG :404199. 4 : 2002JAN18 971 1015 forward 2 SP 119 LG: 404199, 4 : 2002JAN18 497 568 forward 2 SP 119 LG : 404199, 4 : 2002JAN18 464 577 forward 2 SP 119 LG :404199. 4 :2002JAN18 971 1024 forward 2 SP 119 LG:404199.4:2002JAN18 497 553 forward 2 SP 119 LG :404199. 4 : 2002JAN18 497 559 forward 2 SP 119 LG : 404199. 4 : 2002JAN18 971 1030 forward 2 SP 119 LG : 404199, 4: 2002JAN18 549 671 forward 3 SP 119 LG: 404199, 4: 2002JAN18 312 374 forward 3 SP 119 LG : 404199. 4 : 2002JAN 18 312 389 forward 3 SP 119 LG : 404199. 4: 2002JAN18 312 389 forward 3 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 119 LG: 404199. 4 : 2002JAN18 312 389 forward 3 SP 119 LG : 404199. 4 : 2002JAN18 312 362 forward 3 SP 119 LG: 404199. 4: 2002JAN18 312 368 forward 3 SP 120 LG : 404482. 7: 2002JAN 18 1 392 TM Extracellular 120 LG : 404482.7 : 2002JAN18 393 415 TM Transmembrane 120 LG: 404482.7 : 2002JAN18 416 624 TM Cytosolic 120 LG :404482. 7 : 2002JAN18 625 647 TM Transmembrane 120 LG: 404482.7 : 2002JAN18 648 690 TM Extracellular 120 LG: 404482.7 : 2002JAN18 691 713 TM Transmembrane 120 LG : 404482. 7 : 2002JAN18 714 989 TM Cytosolic 120 LG : 404482.7 : 2002JAN18 990 1007 TM Transmembrane 120 LG :404482. 7 : 2002JAN18 1008 1008 TM Extracellular 120 LG : 404482. 7: 2002JAN18 1 221 TM Cytosolic 120 LG: 404482.7 : 2002JAN18 222 244 TM Transmembrane 120 LG: 404482. 7 : 2002JAN18 245 1008 TM Extracellular 120 LG: 404482. 7 : 2002JAN18 1 245 TM Cytosolic 120 LG : 404482. 7 :2002JAN18 246 268 TM Transmembrane 120 LG : 404482.7 : 2002JAN18 269 1007 TM Extracellular 121 LG : 406239. 1: 2002JAN18 1 278 TM Extracellular 121 LG :406239. 1 : 2002JAN18 279 301 TM Transmembrane 121 LG : 406239. 1 : 2002JAN18 302 321 TM Cytosolic 121 LG : 406239. 1 :2002JAN18 322 344 TM Transmembrane 121 LG : 406239. 1 : 2002JAN18 345 423 TM Extracellular 121 LG : 406239.1 : 2002JAN18 1035 1091 forward 3 SP 122 LG :407055 6 : 2002JAN 18 1 999 TM Extracellular 122 LG :407055. 6 :2002JAN18 1000 1022 TM Transmembrane 122 LG: 407055. 6: 2002JAN18 1023 1042 TM Cytosolic 122 LG: 407055.6 : 2002JAN18 1043 1065 TM Transmembrane 122 LG : 407055.6 : 2002JAN18 1066 1079 TM Extracellular 122 LG : 407055. 6 :2002JAN18 1080 1097 TM Transmembrane 122 LG: 407055. 6: 2002JAN18 1098 1180 TM Cytosolic 122 LG :407055.6:2002JAN18 1181 1200 TM Transmembrane 122 LG : 407055.6 : 2002JAN18 1201 1226 TM Extracellular 122 LG :407055. 6 :2002JAN18 1227 1249 TM Transmembrane 122 LG : 407055. 6 : 2002JAN18 1250 1290 TM Cytosolic 122 LG :407055. 6 2002JAN18 1050 TM Extrscellular 122 LG: 407055. 6 : 2002JAN18 1051 1073 TM Transmembrane 122 LG: 407055. 6 : 2002JAN18 1074 1237 TM Cytosolic 122 LG : 407055, 6 : 2002JAN18 1238 1260 TM Transmembrane 122 LG : 407055. 6 : 2002JAN18 1261 1290 TM Extracellular 122 LG: 407055. 6 : 2002JAN18 1 1224 TM Extracellular 122 LG :407055. 6 : 2002JAN18 1225 1247 TM Transmembrane 122 LG : 407055. 6: 2002JAN18 1248 1289 TM Cytosolic 122 LG: 407055. 6 : 2002JAN18 1449 1523 forward 3 SP 122 LG: 407055. 6: 2002JAN18 1449 1517 forward 3 SP 123 LG: 407485. 1: 2002JAN18 1 264 TM Cytosolic 123 LG : 407485. 1 : 2002JAN18 265 287 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 288 312 TM Extracellular 123 LG:407485.1:2002JAN18 313 335 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: T e 123 LG :407485. 1 : 2002JAN 18 336 339 TM Cytosolic 123 LG :407485.1:2002JAN18 340 362 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 363 404 TM Extracellular 123 LG :407485. 1 : 2002JAN18 405 427 TM Transmembrane 123 LG : 407485. 1: 2002JAN18 428 433 TM Cytosolic 123 LG: 407485.1 : 2002JAN18 434 456 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 457 1411 TM Extracellular 123 LG: 407485.1 : 2002JAN18 1412 1434 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1435 1609 TM Cytosolic 123 LG :407485. 1 2002JAN18 1610 1632 TM Transmembrane 123 LG :407485. 1 : 2002JAN 18 1633 1656 TM Extracellular 123 LG : 407485. 1 : 2002JAN 18 1657 1676 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 1677 1723 TM Cytosolic 123 LG :407485. 1 :2002JAN18 1724 1746 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1747 1836 TM Extracellular 123 LG :407485. 1 : 2002JAN18 1837 1859 TM Transmembrane 123 LG: 407485.1 : 2002JAN18 1860 1904 TM Cytosolic 123 LG : 407485.1 : 2002JAN18 1905 1927 TM Transmembrane 123 LG: 407485. 1 : 2002JAN18 1928 1936 TM Extracellular 123 LG :407485. 1 : 2002JAN 18 1937 1959 TM Transmembrane 123 LG : 407485. 1: 2002JAN18 1960 1970 TM Cytosolic 123 LG :407485. 1 :2002JAN18 1971 1993 TM Transmembrane 123 LG :407485. 1 : 2002JAN18 1994 2007 TM Extracellular 123 LG :407485. 1 :2002JAN18 2008 2027 TM Transmembrane 123 LG :407485. 1 : 2002JAN18 2028 2081 TM Cytosolic 123 LG :407485. 1 2002JAN18 936 TM Extrscellular 123 LG :407485.1:2002JAN18 937 959 TM Transmembrane 123 LG: 407485. 1:2002JAN18 960 979 TM Cytosolic 123 LG: 407485. 1:2002JAN18 980 1002 TM Transmembrane 123 LG 407485. 1 2002JAN18 1003 1161 TM Extracellular 123 LG 407485. 1 2002JAN18 1162 1184 TM Transmembrane 123 LG: 407485. 1:2002JAN18 1185 1584 TM Cytosolic 123 LG :407485.1:2002JAN18 1585 1602 TM Transmembrane 123 LG : 407485. 1:2002JAN18 1603 1621 TM Extracellular 123 LG : 407485. 1:2002JAN18 1622 1644 TM Transmembrane 123 LG : 407485. 1:2002JAN18 1645 1722 TM Cytosolic 123 LG: 407485. 1:2002JAN18 1723 1745 TM Transmembrane 123 LG 407485. 1 2002JAN18 1746 1779 TM Extrscellulur 123 LG : 407485. : 2002JAN18 1780 1802 TM Transmembrane 123 LG: 407485. 1:2002JAN18 1803 1836 TM Cytosolic 123 LG :407485.1:2002JAN18 1837 1859 TM Transmembrane 123 LG :407485.1:2002JAN18 1860 1873 TM Extracellular 123 LG: 407485.1 : 2002JAN18 1874 1891 TM Transmembrane 123 LG:407485.1 : 2002JAN18 1892 1897 TM Cytosolic 123 LG : 407485. 1 : 2002JAN18 1898 1920 TM Transmembrane 123 LG :407485.1:2002JAN18 1921 1952 TM Extracellular 123 LG :407485.1:2002JAN18 1953 1975 TM Transmembrane 123 LG:407485.1:2002JAN18 1976 1981 TM Cytosolic 123 LG:407485.1:2002JAN18 1982 2004 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 123 LG: 407485. 1 : 2002JAN18 2005 2032 TM Extracellular 123 LG : 407485.1 : 2002JAN18 2033 2055 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 2056 2080 TM Cytosolic 123 LG :407485. 1 : 2002JAN 18 1 486 TM Extracellular 123 LG :407485. 1 : 2002JAN18 487 506 TM Transmembrane 123 LG : 407485. 1: 2002JAN 18 507 512 TM Cytosolic 123 LG : 407485. 1 : 2002JAN18 513 532 TM Transmembrane 123 LG :407485. 1 : 2002JAN 18 533 741 TM Extracellular 123 LG : 407485. 1 : 2002JAN18 742 761 TM Transmembrane 123 LG : 407485. 1 : 2002JAN 18 762 800 TM Cytosolic 123 LG : 407485.1 : 2002JAN18 801 823 TM Transmembrane 123 LG: 407485. 1 : 2002JAN 18 824 982 TM Extracellular 123 LG :407485. 1 : 2002JAN18 983 1005 TM Transmembrane 123 LG: 407485. 1 : 2002JAN18 1006 1089 TM Cytosolic 123 LG :407485. 1 : 2002JAN18 1090 1112 TM Transmembrane 123 LG :407485. 1 : 2002JAN18 1113 1409 TM Extracellular 123 LG : 407485.1 : 2002JAN18 1410 1432 TM Transmembrane 123 LG : 407485. 1: 2002JAN18 1433 1472 TM Cytosolic 123 LG: 407485. 1: 2002JAN18 1473 1495 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 1496 1514 TM Extracellular 123 LG :407485. 1 : 2002JAN18 1515 1537 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1538 1548 TM Cytosolic 123 LG : 407485. 1 ; 2002JAN18 1549 1566 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1567 1619 TM Extracellular 123 LG :407485. 1 : 2002JAN 18 1620 1642 TM Transmembrane 123 LG: 407485. 1 : 2002JAN18 1643 1662 TM Cytosolic 123 LG : 407485. 1 :2002JAN18 1663 1685 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1686 1704 TM Extracellular 123 LG: 407485. 1: 2002JAN18 1705 1727 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 1728 1733 TM Cytosolic 123 LG: 407485. 1: 2002JAN18 1734 1756 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 1757 1778 TM Extracellular 123 LG : 407485. 1: 2002JAN18 1779 1798 TM Transmembrane 123 LG : 407485. 1 : 2002JAN18 1799 1977 TM Cytosolic 123 LG :407485. 1 : 2002JAN18 1978 2000 TM Transmembrane 123 LG :407485. 1 : 2002JAN 18 2001 2003 TM Extracellular 123 LG : 407485.1 : 2002JAN18 2004 2026 TM Transmembrane 123 LG : 407485.1 : 2002JAN18 2027 2080 TM Cytosolic 123 LG :407485. 1: 2002JAN18 148 243 forward 1 SP 123 LG: 407485.1 : 2002JAN18 2224 2277 forward 1 SP 123 LG : 407485.1 : 2002JAN18 2224 2280 forward 1 SP 123 LG : 407485.1 : 2002JAN18 2224 2283 forward 1 SP 123 LG : 407485.1 : 2002JAN18 1529 1609 forward 2 SP 123 LG: 407485. 1 : 2002JAN18 1524 1577 forward 3 SP 123 LG :407485. 1 :2002JAN18 1533 1577 forward 3 SP 124 LG: 422048. 46 : 2002JAN18 1 115 TM Extracellular 124 LG :422048. 46 :2002JAN18 116 138 TM Transmembrane 124 LG : 422048. 46: 2002JAN18 139 157 TM Cytosolic 124 LG:422048. 46 : 2002JAN18 158 180 TMTransmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 124 LG : 422048.46 : 2002JAN18 181 184 TM Extracellular 124 LG : 422048. 46: 2002JAN18 185 207 TM Transmembrane 124 LG : 422048. 46 : 2002JAN18 208 232 TM Cytosolic 124 LG : 422048. 46 :2002JAN18 233 255 TM Transmembrane 124 LG :422048. 46 :2002JAN18 256 376 TM Extracellular 124 LG : 422048. 46: 2002JAN18 1 138 TM Extracellular 124 LG :422048. 46 :2002JAN18 139 161 TM Transmembrane 124 LG : 422048. 46: 2002JAN18 162 181 TM Cytosolic 124 LG :422048. 46 :2002JAN18 182 199 TM Transmembrane 124 LG 422048. 462002JAN18 200 234 TM Extracellular 124 LG 422048. 462002JAN18 235 257 TM Transmembrane 124 LG : 422048. 46: 2002JAN18 258 376 TM Cytosolic 124 LG :422048. 46 :2002JAN18 1 130 TM Extracellular 124 LG :422048. 46 :2002JAN18 131 153 TM Transmembrane 124 LG : 422048.46 : 2002JAN18 154 164 TM Cytosolic 124 LG : 422048.46 : 2002JAN18 165 187 TM Transmembrane 124 LG: 422048.46 : 2002JAN18 188 375 TM Extracellular 125 LG: 425448.18 : 2002JAN18 1 305 TM Cytosolic 125 LG : 425448. 18 : 2002JAN 18 306 328 TM Transmembrane 125 LG : 425448. 18: 2002JAN18 329 1450 TM Extracellular 125 LG : 425448. 18 :2002JAN18 4071 4169 forward 3 SP 126 LG: 435717.5 : 2002JAN18 1 20 TM Cytosolic 126 LG : 435717. 5 : 2002JAN18 21 43 TM Transmembrane 126 LG: 435717.5 : 2002JAN18 44 721 TM Extracellular 126 LG : 435717. 5 : 2002JAN18 722 744 TM Transmembrane 126 LG : 435717.5 : 2002JAN18 745 750 TM Cytosolic 126 LG : 435717. 5 2002JAN18 751 773 TM Transmembrane 126 LG : 435717. 5 : 2002JAN18 774 963 TM Extracellular 126 LG: 435717.5 : 2002JAN18 1 14 TM Extracellular 126 LG: 435717.5 : 2002JAN 18 15 34 TM Transmembrane 126 LG: 435717. 5: 2002JAN18 35 71 TM Cytosolic 126 LG : 435717. 5 : 2002JAN 18 72 94 TM Transmembrane 126 LG : 435717. 5 :2002JAN18 95 113 TM Extracellular 126 LG : 435717.5 : 2002JAN18 114 136 TM Transmembrane 126 LG :435717. 5 : 2002JAN18 137 190 TM Cytosolic 126 LG : 435717. 5 :2002JAN18 191 213 TM Transmembrane 126 LG: 435717. 5 : 2002JAN18 214 401 TM Extracellular 126 LG : 435717. 5 : 2002JAN18 402 424 TM Transmembrane 126 LG: 435717.5 : 2002JAN18 425 685 TM Cytosolic 126 LG: 435717.5 : 2002JAN18 686 708 TM Transmembrane 126 LG : 435717. 5 : 2002JAN18 709 712 TM Extracellular 126 LG : 435717. 5 :2002JAN18 713 735 TM Transmembrane 126 LG : 435717. 5 : 2002JAN18 736 747 TM Cytosolic 126 LG : 435717. 5 :2002JAN18 748 770 TM Transmembrane 126 LG : 435717. 5: 2002JAN18 771 963 TM Extracellular 126 LG : 435717. 5: 2002JAN18 1 405 TM Extracellular 126 LG : 435717. 5 : 2002JAN18 406 428 TM Transmembrane 126 LG: 435717. 5 : 2002JAN18 429 480 TM Cytosolic 126 LG : 435717. 5 : 2002JAN18 481 503 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 126 LG : 435717. 5 :2002JAN18 504 607 TM Extracellular 126 LG : 435717. 5 :2002JAN18 608 625 TM Transmembrane 126 LG: 435717.5 : 2002JAN18 626 753 TM Cytosolic 126 LG : 435717. 5 : 2002JAN18 754 773 TM Transmembrane 126 LG : 435717. 5 : 2002JAN 18 774 963 TM Extracellular 126 LG : 435717. 5 : 2002JAN18 1438 1506 forward 1 SP 126 LG : 435717. 5 : 2002JAN18 2078 2137 forward 2 SP 126 LG : 435717.5 : 2002JAN18 608 685 forward 2 SP 126 LG: 435717.5 : 2002JAN18 608 685 forward 2 SP 127 LG : 451858. 13 2002JAN18 1 184 TM Extracellulur 127 LG : 451858.13 : 2002JAN18 185 207 TM Transmembrane 127 LG : 451858.13 : 2002JAN18 208 303 TM Cytosolic 127 LG : 451858. 13 : 2002JAN 18 304 326 TM Transmembrane 127 LG : 451858. 13: 2002JAN18 327 1225 TM Extracellular 127 LG: 451858.13 : 2002JAN18 1 187 TM Extracellular 127 LG: 451858.13 : 2002JAN18 188 207 TM Transmembrane 127 LG : 451858. 13 : 2002JAN18 208 472 TM Cytosolic 127 LG : 451858. 13 :2002JAN18 473 495 TM Transmembrane 127 LG : 451858. 13 :2002JAN18 496 724 TM Extracellular 127 LG : 451858. 13: 2002JAN18 725 747 TM Transmembrane 127 LG: 451858. 13: 2002JAN18 748 751 TM Cytosolic 127 LG : 451858. 13 :2002JAN18 752 774 TM Transmembrane 127 LG : 451858.13 : 2002JAN18 775 783 TM Extracellular 127 LG :451858.13:2002JAN18 784 806 TM Transmembrane 127 LG: 451858.13 : 2002JAN18 807 870 TM Cytosolic 127 LG : 451858. 13 :2002JAN18 871 888 TM Transmembrane 127 LG: 451858.13 : 2002JAN18 889 1225 TM Extracellular 127 LG: 451858.13 : 2002JAN18 1 683 TM Extracellular 127 LG : 451858. 13 : 2002JAN18 684 703 TM Transmembrane 127 LG: 451858.13 : 2002JAN18 704 723 TM Cytosolic 127 LG: 451858.13 : 2002JAN18 724 746 TM Transmembrane 127 LG : 451858. 13: 2002JAN18 747 755 TM Extracellular 127 LG : 451858. 13 : 2002JAN18 756 778 TM Transmembrane 127 LG : 451858. 13 : 2002JAN18 779 976 TM Cytosolic 127 LG : 451858. 13 : 2002JAN18 977 999 TM Transmembrane 127 LG : 451858.13 : 2002JAN18 1000 1038 TM Extracellular 127 LG : 451858.13 : 2002JAN18 1039 1061 TM Transmembrane 127 LG: 451858.13 : 2002JAN18 1062 1073 TM Cytosolic 127 LG : 451858. 13 :2002JAN18 1074 1093 TM Transmembrane 127 LG : 451858. 13 :2002JAN18 1094 1107 TM Extracellular 127 LG : 451858. 13 :2002JAN18 1108 1130 TM Transmembrane 127 LG : 451858.13 : 2002JAN18 1131 1195 TM Cytosolic 127 LG :451858 13 : 2002JAN 18 1196 1215 TM Transmembrane 127 LG : 451858. 13 :2002JAN18 1216 1225 TM Extracellular 127 LG : 451858. 13 :2002JAN18 773 853 forward 2 SP 127 LG: 451858. 13: 2002JAN18 2654 2728 forward 2 SP 127 LG :451858. 13 : 2002JAN18 1206 J268 forward 3 SP 127 LG :451858. 13 :2002JAN18 1368 1433 forward 3 SP 128 LG :462233. 20 :2002JAN18 1660 1737 forward 1 SP Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 128 LG :462233. 20 2002JAN18 1660 1731 forward 1 SP 128 LG : 462233. 20: 2002JAN18 1660 1731 forward 1 SP 128 LG: 462233. 20 : 2002JAN18 1660 1734 forward 1 SP 128 LG: 462233. 20: 2002JAN18 121 204 forward 1 SP 128 LG : 462233. 20: 2002JAN18 1660 1722 forward 1 SP 128 LG: 462233. 20: 2002JAN18 1660 1737 forward 1 SP 128 LG : 462233.20 : 2002JAN18 1660 1749 forward 1 SP 128 LG: 462233. 20: 2002JAN18 2508 2576 forward 3 SP 128 LG :462233. 20 :2002JAN18 1659 1748 forward 3 SP 128 LG: 462233.20 : 2002JAN18 2508 2573 forward 3 SP 128 LG: 462233. 20: 2002JAN18 2508 2567 forward 3 SP 128 LG : 462233. 20 : 2002JAN18 831 875 forward 3 SP 129 LG : 473880. 41 : 2002JAN18 1 36 TM Extracellular 129 LG : 473880. 41 :2002JAN18 37 59 TM Transmembrane 129 LG: 473880.41 : 2002JAN18 60 162 TM Cytosolic 129 LG: 473880. 41: 2002JAN18 163 180 TM Transmembrane 129 LG : 473880. 41: 2002JAN18 181 271 TM Extracellular 129 LG : 473880.41 : 2002JAN18 49117 forward I SP 129 LG: 473880.41 : 2002JAN18 49 111 forward 1 SP 129 LG : 473880. 41 : 2002JAN18 49 108 forward 1 SP 129 LG : 473880. 41 :2002JAN18 49 108 forward 1 SP 129 LG: 473880. 41 : 2002JAN 18 49 105 forward 1 SP 129 LG : 473880. 41 : 2002JAN18 49 114 forward 1 SP 129 LG : 473880.41 : 2002JAN 18 49 132 forward 1 SP 129 LG : 473880. 41 : 2002JAN18 477 542 forward 3 SP 129 LG : 473880. 41 : 2002JAN18 477 548 forward 3 SP 130 LG:474421.5:2002JAN18 1 63 TM Extracellular 130 LG : 474421. 5 : 2002JAN 18 64 86 TM Transmembrane 130 LG : 474421.5 : 2002JAN18 87 90 TM Cytosolic 130 LG: 474421.5 : 2002JAN 18 1 89 TM Cytosolic 131 LG: 481462. 4: 2002JAN18 1 38 TM Extraceullular 131 LG : 481462. 4 2002JAN18 39 61 TM Trsnsmembrane 131 LG: 481462.4 : 2002JAN18 62 211 TM Cytosolic 131 LG : 481462.4 : 2002JAN18 212 234 TM Transmembrane 131 LG: 481462.4 : 2002JAN18 235 238 TM Extracellular 131 LG : 481462. 4 : 2002JAN18 239 261 TM Transmembrane 131 LG:481462. 4 : 2002JAN18 262 327 TM Cytosolic 131 LG:481462. 4 :2002JAN18 328 345 TM Transmembrane 131 LG : 481462. 4: 2002JAN18 346 346 TM Extracellular 132 LG : 7684981. 2: 2002JAN18 1 615 TM Extracellular 132 LG :7684981.2:2002JAN18 616 633 TM Transmembrane 132 LG: 7684981.2 : 2002JAN18 634 752 TM Cytosolic 132 LG 7684981. 2 2002JAN18 753 772 TM Transmembrane 132 LG : 7684981. 2 :2002JAN18 773 786 TM Extracellular 132 LG : 7684981. 2 : 2002JAN18 787 807 TM Transmembrane 132 LG 7684981. 2 2002JAN18 808 905 TM Cytosotic 132 LG : 7684981. 2 : 2002JAN18 906 928TMTransmembrane 132 LG :7684981. 2 2002JAN18 929 971 TM Extracellular 132 LG : 7684981.2 : 2002JAN18 972 994 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 132 LG :7684981. 2 :2002JAN18 995 1000 TM Cytosolic 132 LG :7684981. 2 :2002JAN18 1001 1023 TM Transmembrane 132 LG : 7684981, 2: 2002JAN18 1024 1049 TM Extracellular 132 LG : 7684981, 2 :2002JAN18 1 1000 TM Extracellular 132 LG: 7684981, 2: 2002JAN18 1001 1023 TM Transmembrane 132 LG 7684981, 2 :2002JAN18 1024 1049 TM Cytosolic 132 LG :7684981. 2 :2002JAN18 1 789 TM Extracellular 132 LG :7684981. 2 : 2002JAN 18 790 812 TM Transmembrane 132 LG :7684981. 2 : 2002JAN18 813 914 TM Cytosolic 132 LG : 7684981. 2 : 2002JAN 18 915 937 TM Transmembrane 132 LG : 7684981, 2: 2002JAN18 938 964 TM Extracellular 132 LG :7684981. 2 : 2002JAN18 965 987 TM Transmembrane 132 LG: 7684981. 2 : 2002JAN18 988 1007 TM Cytosolic 132 LG :7684981.2:2002JAN18 1008 1027 TM Transmembrane 132 LG : 7684981. 2 :2002JAN18 1028 1049 TM Extracellular 132 LG: 7684981.2 : 2002JAN18 1028 1105 forward 2 SP 133 LG: 7690420, 1 : 2002JAN18 1 87 TM Cytosolic 134 LG: 7691425.2 : 2002JAN18 1 173 TM Cytosolic 134 LG: 7691425.2 : 2002JAN18 174 196 TM Transmembrane 134 LG : 7691425, 2: 2002JAN18 197 205 TM Extracellular 134 LG : 7691425, 2: 2002JAN18 206 228 TM Transmembrane 134 LG : 7691425.2 : 2002JAN18 229 337 TM Cytosolic 134 LG : 7691425, 2 : 2002JAN18 1 172 TM Cytosolic 134 LG :7691425. 2 :2002JAN18 173 192 TM Transmembrane 134 LG :7691425. 2 :2002JAN18 193 206 TM Extracellular 134 LG: 7691425. 2 : 2002JAN18 207 229 TM Transmembrane 134 LG: 7691425, 2 : 2002JAN18 230 337 TM Cytosolic 134 LG : 7691425.2 : 2002JAN18 503 577 forward 2 SP 134 LG: 7691425.2 : 2002JAN18 308 397 forward 2 SP 134 LG :7691425. 2 :2002JAN18 503 583 forward 2 SP 135 LG: 7692702, 1: 2002JAN18 1 6 TM Cytosolic 135 LG : 7692702, 1 :2002JAN18 7 29 TM Transmembrane 135 LG: 7692702. 1 : 2002JAN18 30 360 TM Extracellular 135 LG: 7692702, 1 : 2002JAN18 504 593 forward 3 P 136 LG: 7694388.21 : 2002JAN18 1 20 Tm Cytosolic 136 LG : 7694388, 21 :2002JAN18 21 42 TM Transmembrane 136 LG :7694388. 21 :2002JAN18 43 56 TM Extracellular 136 LG : 7694388, 21 :2002JAN18 57 79 TM Transmembrane 136 LG : 7694388. 21 : 2002JAN18 80 166 TM Cytolic 136 LG :7694388. 21 : 2002JAN18 167 189 TM Transmembrane 136 LG : 7694388.21 : 2002JAN18 190 203 TM Extracellular 136 LG:7694388. 21: 2002JAN18 204 226 TM Transmembrane 136 LG : 7694388. 21 : 2002JAN18 227 283 TM Cytosolic 136 LG : 7694388. 21 :2002JAN18 1 46 TM Cytosolic 136 LG : 7694388. 21 : 2002JAN18 47 69 TM Transmembrane 136 LG :7694388. 21 :2002JAN18 70 114 TM Extracellular 136 LG : 7694388. 21: 2002JAN18 115 137 TM Transmembrane 136 LG:7694388.21:2002JAN18 138 157 TM Cytosolic 136 LG 7694388, 21 : 2002JAN18 158 180TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 136 LG ;7694388. 21 :2002JAN18 181 204 TM Extracellular 136 LG : 7694388. 21 : 2002JAN18 205 227 TM Transmembrane 136 LG : 7694388. 21 : 2002JAN18 228 282 TM Cytosolic 136 LG : 7694388. 21: 2002JAN18 1 97 TM Cytosolic 136 LG : 7694388.21 : 2002JAN18 98 117 TM Transmembrane 136 LG : 7694388. 21 :2002JAN18 118 158 TM Extracellular 136 LG: 7694388.21 : 2002JAN18 159 181 TM Transmembrane 136 LG : 7694388. 21: 2002JAN18 182 201 TM Cytosolic 136 LG :7694388. 21 : 2002JAN18 202 224 TM Transmembrane 136 LG :7694388. 21 : 2002JAN18 225 238 TM Extrcellular 136 LG 7694388, 21 :2002JAN18 239 258 TM Transmembrane 136 LG : 7694388, 21 : 2002JAN18 259 282 TM Cytosolic 137 LG : 7697322. 7: 2002JAN18 1 1 TM Cytosolic 137 LG :7697322.7:2002JAN18 2 21 TM Transmembrane 137 LG :7697322. 7 : 2002JAN18 22 52 TM Extracellular 137 LG : 7697322. 7 :2002JAN18 53 75 TM Transmembrane 137 LG: 7697322.7 : 2002JAN 18 76 264 TM Cytosolic 137 LG: 7697322.7 : 2002JAN18 265 287 TM Transmembrane 137 LG :7697322.7:2002JAN18 288 326 TM Extracellular 137 LG : 7697322. 7: 2002JAN18 327 349 TM Transmembrane 137 LG : 7697322.7 : 2002JAN18 350 401 TM Cytosolic 137 LG :7697322. 7 :2002JAN18 402 424 TM Transmembrane 137 LG: 7697322. 7 : 2002JAN18 425 800 TM Extracellular 137 LG : 7697322. 7 :2002JAN18 1 56 TM Extracellular 137 LG :7697322. 7 :2002JAN18 57 79 TM Transmembrane 137 LG : 7697322.7 : 2002JAN18 80 91 TM Cytosolic 137 LG : 7697322.7 : 2002JAN18 92 109 TM Transmembrane 137 LG: 7697322.7 : 2002JAN18 110 169 TM Extracellular 137 LG: 7697322. 7: 2002JAN18 170 192 TM Transmembrane 137 LG: 7697322.7 : 2002JAN18 193 257 TM Cytosolic 137 LG : 7697322. 7 : 2002JAN18 258 280 TM Transmembrane 137 LG : 7697322. 7 : 2002JAN18 281 800 TM Extracellular 137 LG : 7697322.7 : 2002JAN18 1 4 TM Cytosolic 137 LG : 7697322. 7:$2002JAN18 5 27 TM Transmembrane 137 LG : 7697322. 7 :2002JAN18 28 59 TM Extracellular 137 LG: 7697322. 7: 2002JAN18 60 82 TM Transmembrane 137 LG: 7697322.7 : 2002JAN 18 83 94 TM Cytosolic 137 LG : 7697322, 7: 2002JAN18 95 117 TM Transmembrane 137 LG :7697322. 7 : 2002JAN18 118 131 TM Extracellular 137 LG : 7697322.7 : 2002JAN18 132 154 TM Transmembrane 137 LG : 7697322. 7: 2002JAN18 155 206 TM Cytosolic 137 LG: 7697322.7 : 2002JAN18 207 224 TM Transmembrane 137 LG:7697322.7:2002JAN18 225 254 TM Extracellular 137 LG : 7697322.7 : 2002JAN18 255 277 TM Transmembrane 137 LG : 7697322. 7 : 2002JAN18 278 311 TM Cytosolic 137 LG :7697322. 7 : 2002JAN18 312 334 TM Transmembrane 137 LG : 7697322. 7 : 2002JAN18 335 799 TM Extracellular 137 LG : 7697322. 7 : 2002JAN18 1283 1369 forward 2 SP 138 LG: 7697347.3 : 2002JAN18 1 241 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 138 LG :7697347. 3 :2002JAN18 242 264 TM Transmembrane 138 LG : 7697347, 3 : 2002JAN18 265 276 TM Cytosolic 138 LG : 7697347. 3 : 2002JAN18 277 299 TM Transmembrane 138 LG : 7697347. 3 : 2002JAN18 300 313 TM Extracellular 139 LG: 7698451.18 : 2002JAN18 1 158 TM Cytosolic 139 LG : 7698451.18 : 2002JAN18 1 157 TM Cytosolic 140 LG: 7698705.7 : 2002JAN18 1 94 TM Cytosolic 141 LG : 7731829. 1 :2002JAN18 1 29 TM Extracellular 141 LG : 7731829.1 : 2002JAN18 30 52 TM Transmembrane 141 LG: 7731829. 1 : 2002JAN18 53 56 TM Cytosolic 141 LG : 7731829. 1 : 2002JAN 18 57 79 TM Transmembrane 141 LG : 7731829, 1: 2002JAN 18 80 93 TM Extracellular 141 LG : 7731829, 1 : 2002JAN18 94 113 TM Transmembrane 141 LG : 7731829, 1: 2002JAN18 114 117 TM Cytosolic 141 LG :7731829.1:2002JAN18 118 140 TM Transmembrane 141 LG: 7731829.1 : 2002JAN18 141 154 TM Extracellular 141 LG :7731829. 1 : 2002JAN18 155 177 TM Transmembrane 141 LG: 7731829, 1 : 2002JAN18 178 230 TM Cytosolic 141 LG: 7731829.1 : 2002JAN18 1 6 TM Cytosolic 141 LG :7731829.1:2002JAN18 7 26 TM Transmembrane 141 LG : 7731829, 1: 2002JAN18 27 40 TM Extracellular 141 LG : 7731829. 1 2002JAN18 41 63 TM Trsnsmembrane 141 LG :7731829.1:2002JAN18 64 69 TM Cytosolic 141 LG : 7731829. 1 :2002JAN18 70 92 TM Transmembrane 141 LG : 7731829. 1 : 2002JAN 18 93 204 TM Extracellular 141 LG: 7731829.1 : 2002JAN18 205 227 TM Transmembrane 141 LG : 7731829.1 : 2002JAN18 228 230 TM Cytosolic 141 LG : 7731829. 1 :2002JAN18 1 37 TM Extracellular 141 LG : 7731829. 1 : 2002JAN18 38 60 TM Transmembrane 141 LG : 7731829.1 : 2002JAN18 61 72 TM Cytosolic 141 LG : 7731829. 1 :2002JAN18 73 95 TM Transmembrane 141 LG: 7731829. 1: 2002JAN18 96 229 TM Extracellular 141 LG: 7731829, 1 : 2002JAN18 343 390 forward 1 SP 142 LG: 7761659, 11 : 2002JAN 18 1 154 TM Extracellular 142 LG: 7761659.11 : 2002JAN18 155 177 TM Transmembrane 142 LG : 7761659. 11 : 2002JAN18 178 183 TM Cytosolic 142 LG : 7761659.11 : 2002JAN18 184 206 TM Transmembrane 142 LG: 7761659. 11 : 2002JAN18 207 209 TM Extracellular 142 LG : 7761659. 11 : 2002JAN18 210 232 TM Transmembrane 142 LG: 7761659.11 : 2002JAN18 233 253 TM Cytosolic 142 LG : 7761659. 11 : 2002JAN18 1 153 TM Extracellular 142 LG :7761659.11:2002JAN18 154 176 TM Transmembrane 142 LG: 7761659.11 : 2002JAN18 177 182 TM Cytosolic 142 LG:7761659.11:2002JAN18 183 205 TM Transmembrane 142 LG : 7761659. 11 : 2002JAN18 206 253 TM Extracellular 142 LG : 7761659. n : 2002JAN18 234 290 forward 3 SP 143 LG : 7761806, 33 : 2002JAN18 1 681 TM Extracellular 143 LG : 7761806.33:2002JAN18 682 704 TM Transmembrane 143 LG : 7761806. 33:2002JAN18 705 780 TM Cytosolic Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 143 LG :7761806.33:2002JAN18 781 803 TM Transmembrane 143 LG : 7761806. 33 : 2002JAN18 804 817 TM Extracellular 143 LG : 7761806. 33 : 2002JAN18 818 840 TM Transmembrane 143 LG : 7761806. 33 : 2002JAN18 841 848 TM Cytosolic 143 LG : 7761806. 33 :2002JAN18 715 774 forward 1 SP 143 LG:7761806. 33: 2002JAN18 715 780 forward 1 SP 143 LG :7761806.33:2002JAN18 715 780 forward 1 SP 143 LG : 7761806. 33 : 2002JAN18 715 777 forward 1 SP 143 LG: 7761806, 33 : 2002JAN18 450 533 forward 3 SP 143 LG : 7761806. 33 :2002JAN18 1404 1502 forward 3 SP 143 LG : 7761806. 33 : 2002JAN18 1404 1484 forward 3 SP 144 LG : 7763039. 6 2002JAN18 567 TM Extrscellular 144 LG : 7763039. 6 2002JAN18 568 590 TM Transmembrane 144 LG : 7763039. 6 : 2002JAN18 591 810 TM Cytosolic 144 LG: 7763039. 6 : 2002JAN18 1 35 TM Cytosolic 144 LG :7763039.6:2002JAN18 36 58 TM Transmembrane 144 LG: 7763039, 6: 2002JAN 18 59 61 TM Extracellular 144 LG : 7763039. 6 : 2002JAN18 62 81 TM Transmembrane 144 LG : 7763039.6 : 2002JAN18 82 446 TM Cytosolic 144 LG: 7763039. 6 : 2002JAN18 447 469 TM Transmembrane 144 LG: 7763039. 6 : 2002JAN18 470 559 TM Extracellular 144 LG: 7763039. 6 : 2002JAN18 560 582 TM Transmembrane 144 LG : 7763039. 6 : 2002JAN18 583 658 TM Cytosolic 144 LG : 7763039. 6 :2002JAN18 659 681 TM Transmembrane 144 LG : 7763039.6 : 2002JAN18 682 690 TM Extracellular 144 LG : 7763039. 6 :2002JAN18 691 713 TM Transmembrane 144 LG : 7763039. 6 : 2002JAN18 714 809 TM Cytosolic 144 LG: 7763039. 6: 2002JAN18 1 303 TM Extracellular 144 LG: 7763039. 6 : 2002JAN18 304 326 TM Transmembrane 144 LG: 7763039.6 : 2002JAN18 327 471 TM Cytosolic 144 LG : 7763039. 6 :2002JAN18 472 494 TM Transmembrane 144 LG : 7763039.6 : 2002JAN18 495 497 TM Extracellular 144 LG : 7763039. 6 :2002JAN18 498 520 TM Transmembrane 144 LG : 7763039. 6 :2002JAN18 521 568 TM Cytosolic 144 LG: 7763039. 6 : 2002JAN18 569 591 TM Transmembrane 144 LG : 7763039, 6: 2002JAN18 592 809 TM Extracellular 144 LG :7763039. 6 :2002JAN18 1704 1763 forward 3 SP 145 LG : 7763254. 5 :2002JAN18 1 98 TM Extracellular 145 LG :7763254. 5 : 2002JAN18 99 121 TM Transmembrane 145 LG : 7763254, 5 : 2002JAN18 122 313 TM Cytosolic 145 LG : 7763254, 5: 2002JAN18 1 102 TM Cytosolic 145 LG :7763254.5:2002JAN18 103 125 TM Transmembrane 145 LG: 7763254. 5:2002JAN18 126 312 TM Extracellular 145 LG : 7763254, 5: 2002JAN18 303 347 forward 3 SP 146 LG : 7763421. 8 :2002JAN18 1 9 TM Extracellular 146 LG : 7763421.8 : 2002JAN18 10 32 TM Transmembrane 146 LG : 7763421, 8 : 2002JAN18 33 96 TM Cytosolic 146 LG : 7763421. 8 :2002JAN18 97 119 TM Transmembrane 146 LG:7763421. 8 2002JAN18 120 158 TM Extrscellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 146 LG : 7763421, 8 : 2002JAN18 159 181 TM Transmembrane 146 LG : 7763421. 8: 2002JAN18 182 192 TM Cytosolic 146 LG:7763421.8:2002JAN18 1 6 TM Cytosolic 146 LG :7763421.8:2002JAN18 7 29 TM Transmembrane 146 LG : 7763421.8 : 2002JAN18 30 38 TM Extracellular 146 LG : 7763421. 8 : 2002JAN18 39 61 TM Transmembrane 146 LG :7763421. 8 : 2002JAN18 62 191 TM Cytosolic 146 LG : 7763421. 8 2002JAN18 1 162 TM Extracellular 146 LG: 7763421, 8 : 2002JAN18 163 185 TM Transmembrane 146 LG : 7763421.8 : 2002JAN18 186 191 TM Cytosolic 146 LG : 7763421. 8 : 2002JAN18 2278forward I SP 146 LG : 7763421.8 : 2002JAN18 22 81 forward 1 SP 146 LG: 7763421, 8 : 2002JAN18 22 90 forward 1 SP 146 LG: 7763421, 8: 2002JAN18 22 72 forward 1 SP 146 LG : 7763421.8 : 2002JAN18 22 84 forward 1 SP 146 LG : 7763421, 8: 2002JAN18 22 84 forward 1 SP 146 LG : 7763421. 8: 2002JAN18 22 87 forward 1 SP 147 LG: 7763437.104 : 2002JAN18 1 655 TM Extracellular 147 LG : 7763437. 104 2002JAN18 656 678 TM Transmembrane 147 LG : 7763437.104 : 2002JAN18 679 710 TM Cytosolic 147 LG : 7763437. 104 : 2002JAN18 711 733 TM Transmembrane 147 LG : 7763437, 104: 2002JAN18 734 1279 TM Extracellular 147 LG: 7763437, 104: 2002JAN18 709 768 forward 1 SP 147 LG : 7763437, 104: 2002JAN18 709 762 forward 1 SP 147 LG : 7763437, 104 : 2002JAN18 709 783 forward 1 SP 147 LG : 7763437.104 : 2002JAN18 709 762 forward 1 SP 147 LG: 7763437.104 : 2002JAN18 49 132 forward 1 SP 147 LG: 7763437.104 : 2002JAN18 709 765 forward 1 SP 147 LG: 7763437. 104 : 2002JAN18 709 783 forward 1 SP 147 LG : 7763437, 104: 2002JAN18 709 777 forward 1 SP 147 LG: 7763437. 104 : 2002JAN18 1916 1996 forward 2 SP 147 LG: 7763437.104 : 2002JAN18 1364 1456 forward 2 SP 147 LG : 7763437.104 : 2002JAN18 1131 1181 forward 3 SP 148 LG: 7770095. 2: 2002JAN18 1 54 TM Cytosolic 148 LG: 7770095.2 : 2002JAN18 1 54 TM Cytosolic 149 LG : 7770589.6 : 2002JAN18 1 274 TM Cytosolic 149 LG :7770589. 6 :2002JAN18 275 297 TM Transmembrane 149 LG : 7770589. 6 :2002JAN18 298 475 TM Extracellular 149 LG: 7770589. 6 : 2002JAN18 160 228 forward 1 SP 149 LG : 7770589. 6 : 2002JAN18 160 228 forward 1 SP 149 LG:7770589. 6 : 2002JAN18 136 228 forward 1 SP 149 LG : 7770589. 6 : 2002JAN18 160 222 forward 1 SP 149 LG: 7770589, 6 : 2002JAN18 136 219 forward 1 SP 149 LG: 7770589, 6: 2002JAN18 160 234 forward 1 SP 149 LG: 7770589, 6: 2002JAN18 806 880 forward 2 SP 149 LG : 7770589.6 : 2002JAN18 806 862 forward 2 SP 149 LG : 7770589.6 : 2002JAN18 806 886 forward 2 SP 150 LG:7770618.6:2002JAN18 1 406 TM Extracellular 150 LG:7770618.6:2002JAN18 407 429 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type. 150 LG : 7770618. 6 : 2002JAN18 430 467 TM Cytosolic 150 LG : 7770618.6 : 2002JAN18 1 95 TM Extracellular 150 LG : 7770618.6 : 2002JAN18 96 118 TM Transmembrane 150 LG: 7770618. 6: 2002JAN18 119 130 TM Cytosolic 150 LG : 7770618. 6 : 2002JAN18 131 153 TM Transmembrane 150 LG : 7770618. 6: 2002JAN18 154 167 TM Extracellular 150 LG : 7770618.6 : 2002JAN18 168 185 TM Transmembrane 150 LG: 7770618.6 : 2002JAN18 186 396 TM Cytosolic 150 LG: 7770618. 6 : 2002JAN18 397 419 TM Transmembrane 150 LG : 7770618. 6 : 2002JAN18 420 466 TM Extracellular 150 LG : 7770618.6 : 2002JAN18 1 419 TM Etracellular 150 LG: 7770618.6 : 2002JAN 18 420 442 TM Transmembrane 150 LG: 7770618. 6: 2002JAN18 443 466 TM Cytosolic 150 LG : 7770618. 6 : 2002JAN18 440 487 forward 2 SP 150 LG : 7770618.6 : 2002JAN18 440 493 forward 2 SP 150 LG: 7770618.6 : 2002JAN18 275 340 forward 2 SP 150 LG: 7770618.6 : 2002JAN18 440 499 forward 2 SP 150 LG: 7770618. 6 : 2002JAN18 440 493 forward 2 SP 151 LG : 7770900. 9 : 2002JAN18 1 156 TM Cytosolic 152 LG: 7771513.22 : 2002JAN18 1 23 TM Extracellular 152 LG: 7771513. 22: 2002JAN18 24 46 TM Transmembrane 152 LG : 7771513.22 : 2002JAN18 47 348 TM Cytosolic 152 LG: 7771513. 22: 2002JAN18 349 371 TM Transmembrane 152 LG : 7771513. 22: 2002JAN18 372 413 TM Extracellular 152 LG: 7771513. 22: 2002JAN18 1 358 TM Extracellular 152 LG : 7771513. 22: 2002JAN18 359 381 TM Transmembrane 152 LG : 7771513.22 : 2002JAN18 382 413 TM Cytosolic 152 LG: 7771513. 22 : 2002JAN18 1 22 TM Extracellular 152 LG : 7771513.22 : 2002JAN18 23 45 TM Transmembrane 152 LG : 7771513. 22 : 2002JAN18 46 347 TM Cytosolic 152 LG: 7771513. 22 : 2002JAN18 348 370 TM Transmembrane 152 LG: 7771513. 22 : 2002JAN18 371 389 TM Extracellular 152 LG : 7771513.22 : 2002JAN18 390 407 TM Transmembrane 152 LG : 7771513.22 : 2002JAN18 408 413 TM Cytosolic 153 LG : 899402. 3: 2002JAN18 1 800 TM Extracellular 153 LG : 899402.3 : 2002JAN18 801 823 TM Transmembrane 153 LG : 899402.3 : 2002JAN18 824 835 TM Cytosolic 153 LG : 899402.3 : 2002JAN18 836 858 TM Transmembrane 153 LG: 899402.3 : 2002JAN 18 859 886 TM Extracellular 153 LG : 899402.3 : 2002JAN 18 887 909 TM Transmembrane 153 LG: 899402.3 : 2002JAN18 910 1096 TM Cytosolic 153 LG : 899402.3 : 2002JAN18 1097 1119 TM Transmembrane 153 LG : 899402. 3: 2002JAN18 1120 1609 TM Extracellular 153 LG: 899402. 3 : 2002JAN18 1610 1632 TM Transmembrane 153 LG: 899402.3 : 2002JAN18 1633 1671 TM Cytosolic 153 LG : 899402.3 : 2002JAN18 1672 1691 TM Transmembrane 153 LG: 899402.3 : 2002JAN18 1692 1776 TM Extracellular 153 LG : 899402.3 : 2002JAN18 1 126 TM Cytosolic 153 LG : 899402.3 : 2002JAN18 127 149 TM Transmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO: Type 153 LG : 899402.3 : 2002JAN18 150 1574 TM Extracellular 153 LG : 899402, 3 : 2002JAN18 1575 1597 TM Transmembrane 153 LG : 899402, 3 : 2002JAN18 1598 1668 TM Cytosolic 153 LG : 899402.3 : 2002JAN18 1669 1691 TM Transmembrane 153 LG :899402. 3 :2002JAN18 1692 1720 TM Extracellular 153 LG : 899402, 3: 2002JAN18 1721 1743 TM Transmembrane 153 LG : 899402. 3: 2002JAN18 1744 1775 TM Cytosolic 153 LG : 899402, 3: 2002JAN18 1 713 TM Extracellular 153 LG : 899402.3 : 2002JAN18 714 733 TM Transmembrane 153 LG : 899402.3 : 2002JAN18 734 873 TM Cytosolic 153 LG : 899402. 3 : 2002JAN18 874 896 TM Transmembrane 153 LG : 899402. 3 :2002JAN18 897 979 TM Extracellular 153 LG : 899402. 3: 2002JAN18 980 1002 TM Transmembrane 153 LG : 899402. 3 : 2002JAN18 1003 1057 TM Cytosolic 153 LG: 899402. 3: 2002JAN18 1058 1080 TM Transmembrane 153 LG : 899402. 3 : 2002JAN 18 1081 1775 TM Extracellular 153 LG: 899402, 3 : 2002JAN18 3271 3339 forward 1 SP 153 LG: 899402.3 : 2002JAN18 3280 3339 forward 1 SP 153 LG: 899402, 3 : 2002JAN18 299 352 forward 2 SP 153 LG : 899402. 3 : 2002JAN18 4119 4193 forward 3 SP 153 LG: 899402, 3 : 2002JAN18 4842 4898 forward 3 SP 154 LG :902699.29::2002JAN18 1 252 TM Extracellular 154 LG : 902699, 29 : 2002JAN18 253 272 TM Transmembrane 154 LG: 902699, 29: 2002JAN18 273 438 TM Cytosolic 154 LG : 902699, 29 : 2002JAN18 439 461 TM Transmembrane 154 LG : 902699.29 : 2002JAN18 462 529 TM Extracellular 155 LG : 977532, 3 : 2002JAN18 1 71 TM Cytosolic 155 LG :977532. 3 : 2002JAN18 72 93 TM Transmembrane 155 LG: 977532.3 : 2002JAN 18 94 400 TM Extracellular 155 LG : 977532, 3: 2002JAN18 401 423 TM Transmembrane 155 LG : 977532.3 : 2002JAN18 424 540 TM Cytosolic 155 LG : 977532. 3 :2002JAN18 541 563 TM Transmembrane 155 LG : 977532.3 : 2002JAN18 564 613 TM Extracellular 155 LG : 977532. 3 :2002JAN18 614 633 TM Transmembrane 155 LG : 977532.3 : 2002JAN18 634 645 TM Cytosolic 155 LG : 977532. 3 : 2002JAN18 646 668 TM Transmembrane 155 LG : 977532. 3 : 2002JAN 18 669 864 TM Extracellular 155 LG :977532. 3 :2002JAN18 1 611 TM Extracellular 155 LG : 977532.3 : 2002JAN18 612 634 TM Transmembrane 155 LG: 977532, 3 : 2002JAN18 635 770 TM Cytosolic 155 LG:977532. 3 : 2002JAN18 771 793 TM Transmembrane 155 LG : 977532, 3 : 2002JAN18 794 817 TM Extracellular 155 LG:977532. 3 : 2002JAN18 818 840 TM Transmembrane 155 LG : 977532, 3: 2002JAN18 841 863 TM Cytosolic 155 LG : 977532, 3 : 2002JAN18 1 37 TM Extracellular 155 LG : 977532. 3 : 2002JAN18 38 60 TM Transmembrane 155 LG: 977532, 3: 2002JAN18 61 402 TM Cytosolic 155 LG:977532.3:2002JAN18 403 425 TM Transmembrane 155 LG:977532.3:2002JAN18 426 538 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 155 LG : 977532. 3 :2002JAN18 539 561 TM Transmembrane 155 LG : 977532.3 : 2002JAN18 562 607 TM Cytosolic 155 LG : 977532. 3 : 2002JAN18 608 627 TM Transmembrane 155 LG :977532. 3 :2002JAN18 628 646 TM Extracellular 155 LG : 977532, 3 : 2002JAN18 647 669 TM Transmembrane 155 LG : 977532. 3 : 2002JAN18 670 769 TM Cytosolic 155 LG :977532. 3 :2002JAN18 770 792 TM Transmembrane 155 LG : 977532. 3 : 2002JAN18 793 821 TM Extracellular 155 LG :977532. 3 : 2002JAN18 822 844 TM Transmembrane 155 LG : 977532, 3 : 2002JAN18 845 863 TM Cytosolic 155 LG : 977532, 3: 2002JAN18 1744 1806 forward 1 SP 155 LG : 977532.3 : 2002JAN18 407 472 forward 2 SP 155 LG : 977532.3 : 2002JAN18 407 472 forward 2 SP 155 LG: 977532. 3: 2002JAN18 407 481 forward 2 SP 155 LG: 977532, 3: 2002JAN18 407 463 forward 2 SP 155 LG: 977532, 3: 2002JAN18 407 481 forward 2 SP 155 LG : 977532. 3 :2002JAN18 407 466 forward 2 SP 155 LG: 977532. 3 : 2002JAN18 407 469 forward 2 SP 156 LG :978729. 5 :2002JAN18 1 373 TM Extracellular 156 LG :978729. 5 : 2002JAN18 374 396 TM Transmembrane 156 LG: 978729. 5 : 2002JAN18 397 557 TM Cytosolic 157 LG: 980200, 9: 2002JAN18 1 569 TM Extracellular 157 LG : 980200.9 : 2002JAN18 570 592 TM Transmembrane 157 LG : 980200. 9 :2002JAN18 593 737 TM Cytosolic 157 LG : 980200.9 : 2002JAN18 738 760 TM Transmembrane 157 LG : 980200. 9 :2002JAN18 761 769 TM Extracellular 157 LG : 980200. 9 :2002JAN18 770 792 TM Transmembrane 157 LG : 980200. 9: 2002JAN18 793 822 TM Cytosolic 157 LG: 980200, 9 : 2002JAN18 1 14 TM Extracellular 157 LG: 980200, 9 : 2002JAN18 15 37 TM Transmembrane 157 LG: 980200.9 : 2002JAN18 38 364 TM Cytosolic 157 LG:980200. 9 : 2002JAN18 365 384 TM Transmembrane 157 LG : 980200. 9 :2002JAN18 385 428 TM Extracellular 157 LG: 980200, 9: 2002JAN18 429 448 TM Transmembrane 157 LG : 980200. 9: 2002JAN18 449 571 TM Cytosolic 157 LG : 980200, 9::2002JAN18 572 594 TM Transmembrane 157 LG : 980200, 9 : 2002JAN18 595 660 TM Extracellular 157 LG : 980200. 9 :2002JAN18 661 680 TM Transmembrane 157 LG : 980200.9 : 2002JAN18 681 737 TM Cytosolic 157 LG:980200. 9 : 2002JAN18 738 760 TM Transmembrane 157 LG : 980200. 9 : 2002JAN 18 761 822 TM Extracellular 157 LG : 980200.9 : 2002JAN18 1 564 TM Extracellular 157 LG : 980200. 9 : 2002JAN18 565 587 TM Transmembrane 157 LG: 980200. 9: 2002JAN18 588 738 TM Cytosolic 157 LG : 980200. 9 : 2002JAN18 739 756 TM Transmembrane 157 LG: 980200. 9 : 2002JAN18 757 759 TM Extracellular 157 LG : 980200. 9 : 2002JAN18 760 779 TM Transmembrane 157 LG : 980200, 9: 2002JAN18 780 821 TM Cytosolic 158 LG : 980859. 5: 2002JAN18 1 88 TM Cytosolic Table 2 SEQ ID |Template ID Start Stop Frame Domain Topology NO: T e 158 LG: 980859. 5 : 2002JAN18 89 108 TM Transmembrane 158 LG : 980859. 5 : 2002JAN18 109 555 TM Extracellular 158 LG : 980859.5 : 2002JAN18 1498 1572 forward 1 SP 158 LG : 980859. 5 : 2002JAN18 1598 1642 forward 2 SP 158 LG : 980859. 5: 2002JAN18 1106 1186 forward 2 SP 159 LG : 982723. 4 : 2002JAN18 1 118 TM Cytosolic 159 LG : 982723.4 : 2002JAN18 119 141 TM Transmembrane 159 LG: 982723.4 : 2002JAN18 142 185 TM Extracellular 159 LG: 982723.4 : 2002JAN18 186 208 TM Transmembrane 159 LG: 982723. 4 : 2002JAN18 209 363 TM Cytosolic 159 LG : 982723.4 : 2002JAN18 364 386 TM Transmembrane 159 LG : 982723. 4: 2002JAN18 387 769 TM Extracellular 159 LG : 982723.4 : 2002JAN 18 1 116 TM Cytosolic 159 LG : 982723. 4 : 2002JAN18 117 139 TM Transmembrane 159 LG : 982723. 4: 2002JAN18 140 186 TM Extracellular 159 LG : 982723.4 : 2002JAN18 187 209 TM Transmembrane 159 LG: 982723.4 : 2002JAN18 210 304 TM Cytosolic 159 LG: 982723.4 : 2002JAN18 305 327 TM Transmembrane 159 LG: 982723. 4 : 2002JAN18 328 362 TM Extracellular 159 LG : 982723.4 : 2002JAN18 363 385 TM Transmembrane 159 LG : 982723. 4: 2002JAN18 386 477 TM Cytosolic 159 LG: 982723. 4 : 2002JAN18 478 497 TM Trsnsmembrane 159 LG : 982723.4 : 2002JAN18 498 769 TM Extracellular 159 LG : 982723. 4 : 2002JAN18 1 184 TM Cytosolic 159 LG : 982723. 4: 2002JAN18 185 207 TM Transmembrane 159 LG: 982723.4 : 2002JAN18 208 769 TM Extracellular 159 LG: 982723.4 : 2002JAN18 884 967 forward 2 SP 160 LG : 986427.1 : 2002JAN18 1 264 TM Cytosolic 160 LG : 986427. 1 : 2002JAN18 265 284 TM Transmembrane 160 LG: 986427. 1: 2002JAN18 285 298 TM Extracellular 160 LG : 986427. 1: 2002JAN18 299 321 TM Transmembrane 160 LG : 986427. 1: 2002JAN18 322 352 TM Cytosolic 160 LG : 986427. 1: 2002JAN18 353 375 TM Transmembrane 160 LG: 986427. 1: 2002JAN18 376 387 TM Extracellular 160 LG: 986427. 1: 2002JAN18 388 405 TM Transmembrane 160 LG: 986427. 1: 2002JAN18 406 425 TM Cytosolic 160 LG : 986427. 1: 2002JAN18 426 448 TM Transmembrane 160 LG: 986427. 1 : 2002JAN18 449 502 TM Extracellular 160 LG : 986427. 1: 2002JAN18 503 522 TM Transmembrane 160 LG: 986427.1 : 2002JAN18 523 528 TM Cytosolic 160 LG : 986427. 1 : 2002JAN18 529 548 TM Transmembrane 160 LG : 986427. 1 : 2002JAN18 549 582 TM Extracellular 160 LG : 986427. 1 : 2002JAN18 583 605 TM Transmembrane 160 LG: 986427. 1 : 2002JAN18 606 718 TM Cytosolic 160 LG: 986427. 1 : 2002JAN18 1 504 TM Extracellular 160 LG: 986427. 1: 2002JAN18 505 527 TM Transmembrane 160 LG : 986427.1 : 2002JAN18 528 581 TM Cytosolic 160 LG : 986427.1 : 2002JAN18 582 604 TM Transmembrane 160 LG: 986427. 1 : 2002JAN18 605 77 TM Extracellular Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : T e 161 LG : 996868. 32: 2002JAN18 1 47 TM Cytosolic 161 LG : 996868.32 : 2002JAN18 48 70 TM Transmembrane 161 LG:996868. 32 : 2002JAN18 77 T54 TM Extracellular 161 LG : 996868. 32 : 2002JAN18 155 177 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 178 441 TM Cytosolic 161 LG : 996868. 32 2002JAN18 442 461 TM Transmembrane 161 LG :996868.32:2002JAN18 462 921 TM Extracellular 161 LG : 996868.32 : 2002JAN18 922 944 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 945 964 TM Cytosolic 161 LG : 996868.32 : 2002JAN18 965 984 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 985 1022 TM Extracellular 161 LG: 996868.32 : 2002JAN18 1023 1045 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 1046 1084 TM Cytosolic 161 LG : 996868.32 : 2002JAN18 1085 1107 TM Transmembrane 161 LG : 996868. 32: 2002JAN18 1108 1110 TM Extracellular 161 LG : 996868. 32 :2002JAN18 1111 1133 TM Transmembrane 161 LG:996868. 32: 2002JAN18 1134 1139 TM Cytosolic 161 LG : 996868.32 : 2002JAN18 1140 1162 TM Transmembrane 161 LG : 996868. 32 :2002JAN18 1163 1430 TM Extracellular 161 LG : 996868.32 : 2002JAN18 1431 1453 TM Transmembrane 161 LG : 996868. 32: 2002JAN18 1454 1464 TM Cytosolic 161 Lu 996868. 32 : 2002JAN 18 1465 1487 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 1488 1536 TM Extracellular 161 LG : 996868. 32 :2002JAN18 1537 1559 TM Transmembrane 161 LG: 996868. 32:2002JAN18 1560 1616'TM Cytosolic 161 LG: 996868.32 :2002JAN18 1617 1639 TM Transmembrane 161 LG: 996868.32 : 2002JAN18 1640 1812 TM Extracellular 161 LG : 996868. 32: 2002JAN18 1 830 TM Extracellular 161 LG : 996868. 32 : 2002JAN18 31 853 TM Transmembrane 161 LG: 996868.32 : 2002JAN18 854 906 TM Cytosolic 161 LG : 996868. 32 : 2002JAN18 907 929 TM Transmembrane 161 LG : 996868. 32: 2002JAN18 930 959 Tm Extracellular 161 LG : 996868. 32 : 2002JAN18 960 982 TM Transmembrane 161 LG:996868. 32: 2002JAN18 983 1025 TM Cytosolic 161 LG : 996868. 32 :2002JAN18 1026 1045 TM Transmembrane 161 LG: 996868. 32: 2002JAN18 1046 1087 TM Extracellular 161 LG : 996868.32 : 2002JAN18 1088 1110 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 1111 1129 TM Cytosolic 161 LG : 996868. 32 : 2002JAN18 1130 1152 TM Transmembrane 161 LG : 996868. 32 :2002JAN18 1153 1533 TM Extracellular 161 LG : 996868. 32 : 2002JAN18 1534 1556 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 1557 1576 TM Cytosolic 161 LG : 996868. 32 : 2002JAN18 1577 1599 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 1600 1618 TM Extracellular 161 LG: 996868.32 : 2002JAN18 1619 1641 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 1642 1761 TM Cytosolic 161 LG : 996868. 32 : 2002JAN18 1762 1784 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 1785 1787 TM Extracellular 161 LG:996868. 32 : 2002JAN18 1788 1810TMTransmembrane Table 2 SEQ ID Template ID Start Stop Frame Domain Topology NO : Type 161 LG: 996868. 32: 2002JAN 18 1811 1811 TM Cytosolic 161 LG: 996868, 32: 2002JAN18 1 47 TM Extracellular 161 LG : 996868. 32 :2002JAN18 48 70 TM Transmembrane 161 LG : 996868, 32: 2002JAN18 71 76 TM Cytosolic 161 LG : 996868. 32: 2002JAN18 77 99 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 100 835 TM Extracellular 161 LG :996868. 32 : 2002JAN18 836 858 TM Transmembrane 161 LG: 996868, 32 : 2002JAN18 859 896 TM Cytosolic 161 LG :996868. 32 : 2002JAN18 897 916 TM Transmembrane 161 LG : 996868, 32: 2002JAN18 917 920 TM Extracellular 161 LG :996868.32:2002JAN18 921 943 TM Transmembrane 161 LG : 996868, 32: 2002JAN18 944 963 TM Cytosolic 161 LG :996868. 32 ; 2002JAN18 964 982 TM Transmembrane 161 LG : 996868.32 : 2002JAN18 983 1018 TM Extracellular 161 LG :996868. 32 : 2002JAN18 1019 1041 TM Transmembrane 161 LG:996868. 32: 2002JAN18 1042 1120 TM Cytosolic 161 LG:996868. 32 :2002JAN18 1121 1143 TM Transmembrane 161 LG:996868. 32 : 2002JAN18 1144 1152 TM Extracellular 161 LG :996868. 32 : 2002JAN18 1153 1175 TM Transmembrane 161 LG: 996868. 32: 2002JAN18 1176 1468 TM Cytosolic 161 LG :996868. 32 : 2002JAN18 1469 1486 TM Transmembrane 161 LG : 996868. 32 : 2002JAN18 1487 1533 TM Extracellular 161 LG: 996868, 32: 2002JAN18 1534 1556 TM Transmembrane 161 LG : 996868. 32: 2002JAN18 1557 1575 TM Cytosolic 161 LG :996868. 32 :2002JAN18 1576 1598 TM Transmembrane 161 LG:996868. 32 : 2002JAN18 1599 1612 TM Extracellular 161 LG: 996868, 32 : 2002JAN18 1613 1635 TM Transmembrane 161 LG : 996868, 32 : 2002JAN18 1636 1723 TM Cytosolic 161 LG:996868. 32 : 2002JAN18 1724 1746 TM Transmembrane 161 LG : 996868, 32: 2002JAN18 1747 1760 TM Extracellular 161 LG :996868. 32 : 2002JAN18 1761 1783 TM Transmembrane 161 LG : 996868. 32 :2002JAN18 1784 1811 TM Cytosolic 161 LG : 996868, 32: 2002JAN18 3266 3349 forward 2 SP 161 LG:996868. 32 :2002JAN18 3266 3337 forward 2 SP 161 LG: 996868, 32: 2002JAN18 2493 2573 forward 3 SP 161 LG : 996868.32 : 2002JAN18 2493 2564 forward 3 SP 161 LG : 996868. 32 : 2002JAN18 2493 2555 forward 3 SP 161 LG : 996868. 32 :2002JAN18 2493 2558 forward 3 SP 161 LG :996868. 32 :2002JAN18 2493 2564 forward 3 SP 161 LG : 996868. 32 2002JAN18 2493 2573 forward 3 SP 161 LG :996868. 32 : 2002JAN18 2754 2813 forward 3 SP 161 LG :996868. 32 : 2002JAN18 2493 2561 forward 3 SP Table 3 SEQ ID NO:/Template ID Component Spans 1/LG:021674.23:2002JAN18 1-687,91-792,455-1026,552-1118,553-912,583-722,593-1149,598- 830,635-930,677-924,677-952,682-1237,683-755,683- 1156,703-950,823-1233,912-1204,930-1645,942-1571,948-1131,94 8-1375,949-1559,962-1405,977-1433,979-1152,985- 1433,1002-1376,1017-1293,1019-1485,1033-1137,1035-1320,1037- 1297,1041-1583,1055-1228,1079-1335,1085- 1609,1193-1417,1195-1463,1215-1647,1220-1647,1317-1895,1324- 1505,1324-1858,1325-1821,1329-1610,1331- 1703,1355-1524,1408-1658,1445-1652,1450-1645,1485-1756,1524- 1811,1545-1794,1566-1822,1596-1815,1620- 2236,1645-2114,1654-1908,1657-1879,1684-1862,1724-1963,1724- 1974,1724-2232,1726-1960,1743-2156,1759- 1972,1765-1908,1781-2013,1796-2060,1798-2061,1872-2094,1884- 2092,1893-2156,1905-2156,1921-2156,1924- 2156,1927-2524,1933-2149,1937-2156,1939-2156,1939-2172,1939- 2407,1947-2156,1947-2488,1963-2412,1993- 2267,2006-2153,2006-2240,2006-2249,2006-2262,2021-2414,2024- 2270,2025-2156,2026-2321,2044-2549,2072- 2361,2072-2514,2073-2316,2073-2693,2093-2693,2094-2354,2101- 2693,2167-2286,2174-2442,2182-2353,2182- 2365,2182-2369,2182-2404,2182-2427,2182-2475,2182-2480,2182- 2494,2182-2561,2182-2565,2182-2613, 2182-2617,2182-2745,2193-2427,2196-2826,2197-2474,2197-2521, 2197-2562,2197-2659,2200-2432,2209-2370,2214- 2443,2231-2464,2232-2732,2240-2467,2241-2493,2249-2805,2256- 2796,2266-2391,2266-2693,2267-2795,2267- 2795,2276-2508,2287-2495,2325-2790,2350-2838,2355-2806,2372- 2798,2377-2472,2385-2658,2388-2623,2394- 2610,2396-2566,2399-2842,2400-2833,2418-2678,2426-2832,2427- 2600,2427-2836,2435-2835,2436-2836,2456- 2830,2462-2842,2466-2813,2466-2845,2467-2833,2467-2842,2468- 2838,2473-2841,2492-2693,2513-2842,2514- 2837,2515-2841,2525-2835,2527-2693,2529-2782,2530-2836,2532- 2843,2534-2784,2535-2838,2538-2816,2549- 2835,2604-2802,2608-2833,2611-2835,2621-2830,2640-2845,2718- 3318,2722-2812,2737-2823,2737-2842,2737- 2848,2737-3209,2737-3285,2738-2838,2738-2835,2770-2829 2/LG:1500085.9:2002JAN18 1-181; 1-208; 1-143 3/LG:201545.7:2002JAN18 1-526; 1-456; 1-277; 66-259; 67-267; 70-347; 85-139; 91-293; 99-477; 136-368; 146-365; 148-363; 192-385; 171-576; 234- 509; 233-436; 237-470; 206-922; 246-499; 239-872; 269-509; 240-932; 277-509; 277-742; 256-534; 257-436; 292-509; 300- 808; 274-524; 284-445; 316-509; 323-510; 330-617; 330-581; 347-764; 395-667; 396-680; 397-636; 369-926; 399-946; 413- 683; 428-727; 431-1090; 431-818; 433-682; 433-708; 520-1005; 491-1031; 540-1001; 559-935; 511-930; 527-729; 527- 711; 527-680; 565-1040; 530-932; 528-819; 567-1036; 569-977; 572-1040; 537-1027; 541-802; 545-1014; 545-1031; 551- 771; 524-984; 525-979; 525-983; 552-1203; 533-980; 559-711; 541-979; 572-1031; 549-980; 551-977; 552-974; 558-980; 540-969; 561-985; 562-982; 607-798; 579-985; 580-981; 581-983; 612-875; 613-894; 588-983; 620-820; 620-814; 591-938; 591-988; 617-851; 594-980; 612-984; 613-980; 616-982; 618-977; 622-980; 631-985; 633-979; 600-1008; 635-928; 663- 926; 641-985; 641-980; 641-974; 646-983; 648-979; 647-978; 680-908; 653-974; 653-979; 711-1006; 656-978; 672-981; 723-1051; 708-980; 710-974; 712-978; 749-976; 729-981; 729-941; 758-1035; 736-984; Table 3 SEQ ID NO:/Template ID Component Spans 737-972; 751-978; 753-978; 753-925; 785-1036; 760-981; 766-982; 771-976; 774-987; 779-973; 783-978; 845-1173; 831- 980; 843-983; 845-982; 866-980; 892-1159; 909-1154; 9813-1178; 915-1212; 970-1031; 972-1218; 975-1210; 1044-1317; 1050-1361; 1050-1344; 1055-1225; 1078-1337; 1085-1348; 1101-1340; 1132-1364; 1134-1358 4/LG:228868.32:2002JAN18 1-191; 1-139; 71-304; 71-690; 326-948; 333-564; 398-689; 401-689; 406-659; 419-948; 609-1009; 611-1004; 631-1004; 745-1009; 745-1040; 923-1009 5/LG:231319.2:2002JAN18 1-189; 1-160; 9-260; 13-215; 16-267; 20-232; 24-232; 25-194; 30-489; 30-590; 34-264; 36-232; 39-218; 40-232; 44-357; 44- 220; 44-244; 45-217; 45-211; 45-205; 48-363; 46-236; 45-244; 45-597; 45-268; 45-341; 45-188; 48-330; 45-242; 45-373; 48- 341; 48-419; 48-117; 49-646; 49-655; 49-181; 49-353; 48-138; 50-159; 50-230; 48-593; 49-341; 48-159; 51-234; 50-212; 53- 456; 56-232; 58-237; 59-232; 61-235; 61-423; 61-189; 61-263; 61-191; 61-157; 61-167; 61-111; 64-521; 63-613; 77-263; 79- 489; 94-630; 94-232; 96-232; 100-366; 100-340; 101-242; 110-361; 121-399; 123-652; 125-256; 130-376; 132-426; 132- 340; 139-393; 140-683; 143-383; 145-372; 146-368; 147-694; 150-667; 150-361; 155-406; 159-363; 159-655; 162-393; 165- 645; 167-233; 172-373; 177-430; 200-263; 205-417; 211-473; 220-399; 235-692; 253-383; 256-656; 256-689; 271-693; 281- 689; 287-682; 288-678; 289-694; 289-655; 289-695; 289-693; 289-521; 289-486; 289-609; 289-422; 289-473; 289-421; 289- 742; 289-698; 291-693; 294-546; 296-382; 300-693; 301-372; 307-695; 319-491; 319-600; 331-695; 332-698; 338-595; 339-605; 342-689; 345-534; 356-698; 367-693; 379-612; 381-693; 383-695; 388-691; 393-695; 393-658; 396-657; 398-605; 400-664; 404-692; 403-694; 413-486; 416-664; 418-697; 419-664; 420-693; 422-643; 422-689; 422-630; 422-594; 424-679; 425-700; 446-625; 446-689; 459-691; 466-600; 467-539; 467-693; 489-695; 507-695; 570-695; 612-693; 611-693 6/LG:245164.1:2002JAN18 1-658; 546-840; 590-1212; 794-1423; 907-1341; 974-1470; 974-1226; 1040-1497; 1068-1531; 1091-1718; 1089-1359; 1434-2013; 1478-1720; 1518-1995; 1602-2014; 1602-2159; 1622-1873; 1662-2122; 1662-1951; 1683-2215; 1723-1983; 1740-2271; 1740-1988; 1814-2153; 1901-2463; 1962-2461; 1981-2233; 2057-2492; 2057-2275; 2068-2296; 2092-2266; 2092-2243; 2103-2365; 2117-2396; 2227-2375; 2257-2584; 2266-2760; 2299-2606; 2300-2602; 2313-2582; 2355-2896; 2375-2922; 2405-2605; 2413-2677; 2419-2912; 2514-2587; 2535-2808; 2540-2809; 2544-2742; 2544-2932; 2556-3003; 2595-2809; 2615-2888; 2747-3270; 2759-2985; 2782-3070; 2855-3401; 2894-3339; 2894-3141; 2898-3455; 2898-3132; 2898-3416; 2926-3548; 2944-3146; 2955-3189; 2967-3247; 2981-3265; 3013-3488; 3080-3696; 3158-3390; 3163-3413; 3163-3628; 3178-3439; 3180-3606; 3190-3575; 3197-3712; 3210-3713; 3210-3477; 3212-3678; 3357-3628; 3362-3740; 3379-3851; 3387-3644; 3405-3812; 3408-3860; 3408-3621; 3408-3679; 3412-3627; 3417-3661; 3422-4004; 3422-3780; 3422-3669; 3430-4047; 3450-3935; 3450-3718; 3481-4056; 3501-4050; 3520-3933; 3521-4035; 3522-3775; 3548-4089; 3548-3802; 3560-3974; 3567-4047; 3595-4058; 3614-3877; 3641-4098; 3640-4050; 3642-4098; 3645-4030; 3647-4055; 3650-4088; 3665-4093; 3670-4093; 3710-4093; 3721-4099; 3746-4099; 3752-4089; 3754-4093; 3755-4049; 3756-4087; 3755-4040; 3765-4008; 3786-4060; 3811-4130; 3811-4011; 3832-4093; 3853-4089; 3859-4108; 3859-4090; 3861-4093; 3986-4098; 3992-4054 Table 3 SEQ ID NO:/Template ID Component Spans 7/LG:7685619.6:2002JAN18 1-650; 50-143; 57-204; 49-572; 74-550; 74-277; 74-591; 78-608; 208-591; 435-903; 437-689; 441-582; 425-989; 425-844; 426-670; 461-738; 492-1232; 498-1117; 499-1082; 472-771; 517-729; 544-762; 497-866; 493-1002; 541-1104; 683-945; 696-908; 719-1067; 760-1331; 789-1561; 802-1330; 802-1128; 807-1266; 807-1013; 820-1278; 838-1389; 839-1617; 841- 1084; 844-1614; 895-1242; 917-1241; 893-1209; 923-1185; 917-1186; 912-968; 930-1109; 984-1484; 951-1498; 1003- 1266; 1028-1449; 982-1379; 999-1239; 1000-1202; 990-1337; 990-1138; 991-1258; 1020-1268; 1020-1234; 1034-1264; 1089-1248; 1050-1545; 1109-1368; 1065-1544; 1069-1688; 1069-1577; 1069-1552; 1116-1699; 1066-1302; 1122-1331; 1124-1356; 1128-1392; 1084-1544; 1093-1378; 1095-1544; 1123-1540; 1125-1462; 1137-1548; 1157-1474; 1179-1419; 1179-1454; 1191-1465; 1191-1464; 1232-1542; 1239-1545; 1252-1450; 1312-1541; 1255-1431; 1316-1541; 1323-1555; 1351-1615; 1311-1540; 1376-1615; 1376-1537; 1326-1499; 1353-1545; 1394-1506; 1401-1540 8/LG:7771153.7:2002JAN18 1-689; 198-791; 233-858; 326-770 9/LG:978820.7:2002JAN18 1-609; 183-448; 391-566; 529-1087; 794-1032; 822-1094; 830-1089; 859-1498; 865-1102; 868-1135; 958-1237; 1025- 1222; 1125-1436; 1329-1554; 1363-1824; 1441-1948; 1441-1704; 1533-1777; 1537-2182; 1586-2038; 1610-2165; 1648- 2203; 1669-1996; 1749-2217; 1757-2221; 1761-2222; 1775-2222; 1783-2220; 1799-2219; 1825-2012; 1847-2151; 1872- 2216; 1950-2220; 2095-2218; 2123-2218; 2145-2220 10/LG:024189.1:2002JAN18 1-254,1-590,162-703,600-1194,596-1049,630-1224,651-1230,1035 -1288,1035-1278,1035-1629,1035-1270,1035- 1562,1037-1810,1338-1887,1365-1810,1375-1497,1405-1633,1416- 1954,1557-1950,1675-1945,1834-2036 11/LG:222798.12:2002JAN18 1-473; 262-731; 289-449; 365-734; 368-1012; 370-537; 433-872; 932-1288; 1185-1463; 1185-1401; 1185-1555; 1244- 1512; 1277-1523; 1276-1719; 1345-1671; 1447-1993; 1461-1684; 1724-1967; 1896-2005; 1897-2008; 1188-1896 12/LG:233706.19:2002JAN18 1-451; 60-559; 62-600; 75-465; 139-363 13/LG:404417.1:2002JAN18 1-539; 48-776; 197-769; 259-749; 285-951; 354-878; 364-563; 398-529; 429-838; 442-803; 442-704; 503-893; 519-888; 692-851; 699-888; 702-888; 734-888 14/LG:005369.4:2002JAN18 1-224,24-270,29-726,117-360,117-362,202-419,240-499,270-348, 280-376,293-610,296-410,330-461,391-658,392-746,392- 748,409-621,417-677,424-948,517-1064,546-1125,548-864,578-86 7,578-1079,623-866,639-975,658-1182,658-1198,673- 1094,684-960,715-1274,791-1212,800-1073,835-1583,840-1534,86 8-1108,889-1191,889-1202,889-1337,913-1563,994- 1129,994-1317,1043-1266,1050-1275,1071-1805, 1100-1163, 1100-1490,1117-1818,1139-1615,1155-1497,1180-1445,1198- 1490,1204-1487,1218-1455,1218-1603,1218-1699,1228-1802,1255- 1547,1258-1787,1271-1789,1361-1784,1362- 1826,1370-1789,1374-1430,1374-1605,1374-1786,1374-1823,1374- 1823,1374-1885,1880-1823,1399-1826,1402- 1613,1405-1783,1422-1785,1424-1669,1424-1828,1429-1796,1432- 1713,1444-1826,1451-1830,1453-2035,1454- 1926,1478-1830,1478-1832,1482-1926,1486-1827,1493-1925,1500- 1762,1500-1790,1500-1830,1510-1925,1515- 1744,1517-1827,1524-1771,1547-1821,1547-1823,1567-1826,1575- 1800,1588-1816,1588-1847,1611-1826,1626- 1800,1646-1840,1649-1910,1655-1928,1657-1874,1713-1774,1728- 1828,1812-1926,1891-2164, 1971-2723,1984-2632,2193-2819 Table 3 SEQ ID NO:/Template ID Component Spans 15/LG:008334.1:2002JAN18 1-360,110-218,128-517 16/LG:022943.14:2002JAN18 1-310,1-357,1-398,115-189,115-584,123-306,123-309,186-380 17/LG:026981.4:2002JAN18 1-517,37-200,215-685,229-685,229-685,235-651,250-519,284-684 ,325-685,332-684,333-684,358-684,361-917,382- 671,391-545,391-669,391-676,391-676,399-685,432-652,441-647, 516-651,530-686,652-896,699-1030,728-990,729- 1044,734-1079,877-1222 18/LG:054807.6:2002JAN18 1-534,1-614,47-2490,152-489,217-924,537-808,1075-1474,1248-1 408,1297-1569,1373-1385,1375-1609,1506-1784,1619- 1779,1621-1785,1624-1779,1682-2240,2237-240 19/LG:063690.11:2002JAN18 1-254,1-349,80-187,80-826,139-499,289-848,750-1017,796-1536, 1060-1615,1170-1620,1175-1622,1526-2138,1528- 1965,1685-1833,1699-2127,1699-2127,1716-2127,1994-2896,2567- 3086,2609-3176,2751-3216 20/LG:068514.8:2002JAN18 1-349,80-826,80-187,139-499,289-848,750-1017,796-1536,1060-1 615,1170-1620,1175-1622,1526-2138,1528-1965,1685- 1833,1699-2127,1699-2127,1716-2127,1994-2896,2567-3086,2609- 3176,2751-3216 21/LG:097147.4:2002JAN18 1-486,29-389,49-317,304-757,667-994,667-1002,667-1201,828-10 52,862-1407,894-1466,932-1175,973-1445,982- 1442,983-1442,984-1448,992-1442,1025-1383,1043-1450,1079-116 6,1079-1405,1081-1380,1095-1390,1117-1390,1173- 1256,1273-1390,1288-1553,1306-1445,1306-1445,1312-1445,1395- 1878,1564-1947,1573-1975,1573-2035,1573- 2079,1575-1854,1701-2144,1908-2401,1925-2176 22/LG:099622.1:2002JAN18 1-416,26-114,33-547,412-519 23/LG:1005046.2:2002JAN18 1-604; 265-894; 269-4573; 280-660; 623-1237; 2177-2697; 2271-2804; 2350-2671; 2351-2412; 2392-2909; 2392-2661; 2424-2894; 2463-2614; 2574-3271; 2574-3114; 2630-3192; 2630-3305; 2630-3122; 2651-2839; 2677-3063; 2754-3294; 2854-5517; 3164-3917; 3165-3521; 3236-3663; 3236-3506; 3376-3891; 3415-3707; 3415-3843; 3431-3961; 3463-4564; 3601-4168; 3628-3908; 3664-3837; 3796-4290; 3796-4074; 3800-4028; 3818-4491; 3840-4361; 3840-4329; 3845-4275; 3845-4249; 3854-4083; 3859-4482; 3875-4144; 3880-4621; 3944-4185; 3944-4423; 3988-4533; 3995-4524; 4029-4267; 4051-4528; 4062-5517; 4085-4572; 4087-4525; 4087-4520; 4093-4460; 4095-4566; 4113-4535; 4167-4565; 4195-4572; 4198-4573; 4208-4468; 4208-4442; 4209-4418; 4217-4563; 4234-4527; 4234-4572; 4293-4571; 4312-4565; 4319-4573; 4319-5090; 4327-4572; 4364-4563; 4620-5157; 4723-4986; 4724-4975; 4767-5049; 4775-5413; 4802-4909; 4831-5437; 4850-5069; 4855-5108; 4856-5432; 4852-5373; 4854-5589; 4835-5043; 4860-5335; 4862-5011; 4854-5063; 4857-5371; 4862-5410; 4863-5488; 4869-5286; 4870-5144; 4882-5035; 4882-5065; 4881-5323; 4882-5129; 4882-4999; 4882-4993; Table 3 SEQ ID NO:/Template ID Component Spans 4882-4984; 4882-4981; 4882-4975; 4882-4936; 4882-4934; 4882-4933; 4872-5151; 4873-5107; 4875-5411; 4857-5602; 4880-5118; 4882-5322; 4882-5207; 4882-5127; 4882-5124; 4882-5098; 4882-4948; 4883-5288; 4882-5095; 4882-5079; 4882-5066; 4882-5064; 4882-5061; 4882-5077; 4882-5032; 4882-5025; 4882-5022; 4882-5023; 4882-5013; 4882-5456; 4887-5126; 4891-5129; 4902-5117; 4902-5008; 4902-4987; 4891-5113; 4891-5110; 4894-5155; 4894-5120; 4882-5039; 4882-5078; 4882-4962; 4897-5130; 4899-5218; 4899-5096; 4899-5203; 4898-4990; 4900-5105; 4902-5347; 4902-5077; 4902-5070; 4902-5062; 4902-5061; 4902-5059; 4902-5054; 4902-5044; 4902-5043; 4902-5042; 4902-5039; 4902-5034; 4902-5031; 4902-4974; 4902-5163; 4902-5120; 4905-5209; 4907-5387; 4907-5367; 4909-5411; 4909-5176; 4909-5132; 4909-5092; 4898-5044; 4910-5504; 4912-5178; 4899-5020; 4914-5181; 4902-5027; 4902-5024; 4902-5022; 4902-5021; 4902-4976; 4902-4975; 4902-4960; 4919-5140; 4923-5130; 4924-5157; 4926-5173; 4940-5008; 4959-5414; 4943-5024; 4935-5180; 4936-5202; 4937-5174; 4939-5187; 4931-5123; 4945-5199; 4947-5437; 4947-5175; 4947-5477; 4954-5186; 4956-5210; 4954-5510; 4952-5480; 4959-5205; 4961-5250; 4961-5244; 4961-5246; 4966-5462; 4961-5579; 4970-5218; 4971-5208; 4971-5493; 4973-5265; 4978-5476; 4981-5479; 4982-5254; 4981-5252; 4986-5265; 4986-5237; 4994-5573; 4996-5477; 4995-5493; 4999-5170; 4997-5265; 5002-5509; 5014-5265; 5018-5268; 5022-5324; 5025-5267; 5025-5276; 5030-5334; 5031-5253; 5073-5357; 5046-5326; 5045-5468; 5048-5292; 5053-5320; 5054-5517; 5062-5308; 5060-5512; 5061-5319; 5061-5442; 5062-5302; 5066-5512; 5070-5302; 5071-5297; 5073-5364; 5073-5517; 5074-5314; 5073-5218; 5076-5276; 5078-5508; 5079-5512; 5079-5520; 5080-5333; 5082-5521; 5087-5516; 5089-5512; 5090-5360; 5092-5517; 5097-5520; 5098-5517; 5100-5617; 5103-5517; 5104-5512; 5106-5517; 5106-5518; 5107-5512; 5109-5517; 5112-5519; 5114-5380; 5114-5519; 5116-5520; 5116-5517; 5117-5513; 5119-5512; 5120-5518; 5124-5512; 5138-5517; 5138-5512; 5142-5411; 5158-5406; 5149-5401; 5156-5425; 5157-5517; 5159-5416; 5173-5440; 5174-5518; 5188-5452; 5182-5510; 5179-5517; 5181-5517; 5183-5518; 5183-5517; 5184-5520; 5187-5516; 5190-5407; 5192-5434; 5192-5422; 5195-5512; 5198-5520; 5199-5520; 5199-5517; 5209-5517; 5206-5461; 5218-5517; 5216-5510; 5218-5510; 5218-5491; 5219-5517; 5222-5460; 5225-5519; 5224-5488; 5224-5463; 5227-5517; 5230-5517; 5233-5519; 5239-5510; 5233-5510; 5233-5474; 5233-5463; 5236-5517; 5236-5490; 5234-5427; 5235-5503; 5235-5440; 5246-5467; 5255-5488; 5262-5505; 5267-5499; 5270-5510; 5272-5516; 5279-5503; 5285-5517; 5291-5517; 5295-5512; 5302-5523; 5306-5517; 5312-5527; 5312-5517; 5331-5495; 5332-5518; 5332-5523; 5337-5517; 5333-5519; 5354-5524; 5362-5517; 5370-5517; 5384-5517; 5393-5521; 5397-5510; 5416-5517; 5420-5472; 5425-5517; 5427-5517; 5427-5509; 5451-5510; 5458-5517 24/LG:1040736.16:2002JAN18 1-612; 28-630; 190-630; 232-729; 250-763; 297-959; 360-922; 366-633; 387-935; 402-1084; 402-937; 417-932; 458-1227; 476-693; 569-936; 569-921; 675-1150; 1022-1241; 1021-1416; 1213-1720; 1480-1738 Table 3 SEQ ID NO:/Template ID Component Spans 25/LG:105937.16:2002JAN18 1-555; 1-728; 1-689; 15-450; 451-1071; 537-1163; 606-1170; 893-1413; 919-1405; 945-1555; 946-1321; 1061-1341; 1097- 1692; 1152-1568; 1144-1715; 1152-1493; 1152-1698; 1158-1715; 1167-1332; 1194-1715; 1223-1792; 1275-1806; 1291- 1723; 1322-1574; 1322-1871; 1336-1883; 1344-1635; 1349-1900; 1373-1822; 1405-1725; 1414-1762; 1433-1834; 1465- 1731; 1479-1584; 1507-2121; 1551-2042; 1624-2195; 1692-2207; 1722-2235; 1716-2236; 1718-1994; 1722-2305; 1722- 2155; 1722-2280; 1722-2337; 1722-2332; 1722-2245; 1722-2312; 1722-2279; 1722-2304; 1722-2086; 1723-2190; 1724- 2269; 1810-2208; 1815-2207; 2004-2318; 2042-2647; 2102-2319; 2113-2620; 2194-2645; 2297-2738; 2297-2629; 2297- 2547; 2308-2660; 2373-2737; 2377-2738; 2422-2732; 2451-2691; 2471-2751; 2477-2693; 2487-2551; 2512-2737; 2544- 2779; 2641-2782; 2638-2732; 2645-2760; 2653-2737; 2666-2737 26/LG:1077405.2:2002JAN18 1-360; 132-586; 477-641; 480-1017; 489-999; 480-694; 480-558; 603-1032; 709-1099; 722-1096; 747-1090 27/LG:1084716.4:2002JAN18 1962-2482; 1963-2357; 2145-2344; 1998-2274; 1733-2015; 1549-2015; 1542-2010; 1567-2010; 1666-2008; 1562-2007; 1549-2007; 1643-2007; 1521-1965; 1518-1961; 1585-1955; 1522-1934; 1342-1907; 1316-1896; 1815-1863; 1266-1825; 1585-1824; 1670-1821; 1523-1816; 1525-1814; 1608-1780; 1656-1738; 1544-1727; 1269-1394; 916-1355; 1069-1356; 968- 1288; 821-1129; 384-1068; 508-1011; 660-886; 397-777; 402-726; 494-692; 1-609; 46-308; 45-308 28/LG:1091759.1:2002JAN18 1-208; 30-404; 34-168; 34-516; 53-155; 87-168; 100-172; 437-614; 441-526; 441-506; 441-514; 472-834; 488-705; 512- 770; 529-834; 533-614; 541-593; 541-637; 572-703; 572-636; 572-675; 572-626; 751-807 29/LG:1095157.16:2002JAN18 1-183; 93-682; 106-552; 106-184; 109-459; 111-243; 111-308; 111-288; 111-162; 112-289; 123-665; 216-287; 216-289; 268-653; 422-998; 588-1118; 698-954; 698-1118; 771-1238; 797-1055; 849-1126; 855-1410; 878-1390; 878-1076; 892- 1462; 945-1062; 959-1055; 1039-1431; 1047-1462; 1047-1583; 1063-1197; 1065-1197; 1083-1599; 1083-1350; 1083-1375; 1083-1255; 1088-1642; 1114-1197; 1124-1656; 1143-1587; 1171-1438; 1197-1806; 1242-1530; 1251-1474; 1283-1761; 1283-1681; 1283-1479; 1336-1623; 1348-1582; 1349-1889; 1451-1718; 1464-2017; 1482-1749; 1560-1969; 1587-1860; 1625-1728; 1645-2075; 1673-2075; 1721-2013; 1762-1985; 1797-2017; 1865-2075; 1932-2075; 1932-2373; 2225-2382; 2225-2358; 2241-2529; 2337-2945; 2337-2601; 2372-2748; 2420-2681; 2425-2535; 2434-2538; 2716-2960; 2773-3006; 2938-3163; 2944-3120; 2765-3015; 2458-2842; 2703-2898; 2787-2960; 2776-2935; 1799-1943; 2781-2870; 1769-1846; 2513-2586; 2464-2518; 2712-2761 30/LG:1096601.118:2002JAN18 1-228; 1-291; 210-486; 219-498 31/LG:1099356.5:2002JAN18 1-589; 6-274; 10-437; 20-279; 28-282; 28-494; 52-530; 52-318; 22-527; 70-301; 81-601; 82-329; 91-630; 99-338; 349-436; 447-947; 486-1018; 486-630; 495-630; 538-947; 538-812; 657-948; 665-1065; 665-1036; 676-955; 723-1056; 733-862; 761- 1065; 765-1065; 774-1065; 801-1066; 825-1067; 890-1065; 912-1068; 935-1065; 946-1065; 955-1065; 1006-1065 Table 3 SEQ ID NO:/Template ID Component Spans 32/LG:1100807.18:2002JAN18 1927-2146; 1945-2143; 1385-2042; 1826-2018; 1702-2018; 1728-2017; 1618-2014; 1649-2013; 1731-2013; 1553-2012; 1712-2012; 1815-2016; 1820-2012; 1828-2012; 1748-2013; 1558-2011; 1752-2014; 1433-2012; 1910-2012; 1623-2011; 1624-2011; 1542-2010; 1735-2013; 1891-2010; 1538-2008; 1724-2008; 1549-2007; 1591-2007; 1654-2010; 1794-2007; 1796-2007; 1823-2007; 1542-2008; 1543-2008; 1556-2006; 1567-2006; 1685-2007; 1652-2006; 1553-2007; 1551-2004; 1620-2005; 1681-2004; 1894-2003; 1655-2003; 1658-2001; 1665-2002; 1654-2003; 1724-2002; 1835-2002; 1918-2002; 1726-2003; 1649-2002; 1659-2004; 1565-2002; 1625-2002; 1827-1999; 1848-1997; 1410-1992; 1435-1992; 1517-1988; 1738-1986; 1495-1974; 1557-1965; 1634-1957; 1381-1937; 1447-1948; 1685-1943; 1238-1927; 1591-1924; 1469-1902; 1185-1900; 1734-1892; 1618-1874; 1307-1870; 1585-1841; 1585-1838; 1240-1826; 1278-1810; 1680-1810; 1238-1775; 1345-1761; 1557-1770; 1344-1760; 1308-1755; 1479-1736; 1115-1691; 1348-1649; 1368-1623; 1310-1559; 1223-1532; 1310-1504; 1221-1501; 1218-1501; 1004-1501; 1228-1471; 786-1463; 974-1458; 1165-1455; 1190-1448; 1082-1435; 1168-1432; 1150-1427; 1224-1424; 1229-1393; 863-1387; 1216-1390; 1233-1376; 1064-1359; 1130-1357; 1102-1356; 1089-1337; 1102-1298; 1005-1292; 904-1284; 1043-1280; 1004-1207; 953-1193; 1017-1193; 780-1173; 786-1134; 787- 1101; 838-1089; 987-1085; 851-1071; 766-1057; 390-1006; 679-961; 642-880; 644-880; 204-832; 329-789; 452-702; 554- 661; 1-643 33/LG:1116310.38:2002JAN18 1-591; 29-134; 76-474; 93-582; 90-659; 183-450; 190-589; 213-483; 213-466; 213-456; 213-765; 229-483; 244-507; 265- 696; 274-509; 303-571; 318-615; 319-638; 319-566; 374-590; 411-666; 414-863; 447-914; 647-816; 718-987; 742-897; 750- 998; 757-1279; 1045-1279; 1086-1330; 283-520; 103-587; 76-560 34/LG:1132386.23:2002JAN18 1-476; 8-533; 79-334; 99-586; 331-475; 506-795; 529-819; 530-618; 618-911; 716-1438; 782-884; 790-1049; 796-1454; 810-1587; 815-1449; 821-1085; 842-1415; 857-1107; 860-1066; 867-1575; 897-1200; 904-1229; 920-1184; 932-1041; 932- 1099; 944-1678; 955-1574; 966-1468; 968-1180; 978-1389; 978-1232; 1008-1293; 1024-1232; 1061-1294; 1063-1310; 1063-1293; 1065-1314; 1065-1496; 1067-1317; 1071-1335; 1071-1290; 1072-1394; 1087-1580; 1089-1403; 1094-1407; 1119-1362; 1124-1469; 1126-1663; 1137-1778; 1135-1358; 1140-1382; 1139-1379; 1154-1423; 1155-1716; 1155-1419; 1161-1403; 1177-1809; 1182-1477; 1186-1494; 1191-1616; 1209-1775; 1216-1479; 1243-1496; 1246-1491; 1247-1871; 1259-1521; 1285-1777; 1284-1722; 1313-1776; 1315-1481; 1318-1574; 1318-1540; 1322-1843; 1334-1582; 1337-1591; 1338-1772; 1347-1609; 1356-1678; 1373-1802; 1385-1589; 1391-1670; 1392-1899; 1392-1727; 1395-1658; 1396-1630; 1396-1626; 1396-1802; 1398-1646; 1412-1689; 1421-1731; 1432-1649; 1432-1651; 1432-1706; 1434-1713; 1443-1705; 1445-1679; 1492-1634; 1496-1656; 1512-1792; 1514-1808; 1515-1975; 1525-2061; 1532-2064; 1533-2061; Table 3 SEQ ID NO:/Template ID Component Spans 1536-1720; 1538-1799; 1537-1722; 1538-1787; 1537-1776; 1559-1780; 1582-1746; 1583-1869; 1586-1877; 1588-1863; 1590-2360; 1595-1865; 1599-2025; 1601-1924; 1617-2124; 1617-1827; 1627-1891; 1629-1890; 1641-1825; 1645-2173; 1647-1895; 1649-1921; 1649-1901; 1659-2236; 1658-1880; 1665-2331; 1672-1949; 1685-1960; 1686-1966; 1700-1955; 1703-2259; 1713-1970; 1713-2253; 1730-1996; 1731-1937; 1733-1962; 1741-1985; 1751-2223; 1745-2281; 1749-2279; 1752-2053; 1752-2063; 1753-2048; 1755-2192; 1755-2004; 1755-2001; 1756-2012; 1782-2184; 1761-1949; 1761-1947; 1760-2308; 1767-1993; 1772-1986; 1777-1981; 1777-1896; 1777-2300; 1779-1990; 1789-2266; 1795-2216; 1799-2280; 1800-2202; 1803-2055; 1805-2320; 1805-2254; 1824-2280; 1841-2291; 1831-2052; 1830-2048; 1830-2035; 1830-2047; 1837-2111; 1847-2077; 1850-2281; 1851-2320; 1849-2060; 1863-2323; 1865-2272; 1866-2329; 1870-2325; 1872-2089; 1886-2317; 1922-2332; 1898-2320; 1904-2205; 1904-2330; 1904-2322; 1904-2315; 1904-2286; 1910-2217; 1908-2274; 1910-2319; 1910-2280; 1910-2175; 1911-2169; 1914-2119; 1933-2168; 1939-2082; 1941-2200; 1945-2322; 1950-2325; 1955-2244; 1960-2221; 1961-2322; 1964-2323; 1965-2319; 1968-2249; 1972-2216; 1976-2303; 1984-2305; 1990-2260; 2013-2325; 2017-2298; 2019-2209; 2022-2278; 2028-2297; 2032-2322; 2051-2278; 2052-2320; 2067-2323; 2071-2330; 2084-2318; 2092-2324; 2112-2328; 2123-2323; 2145-2323; 2148-2325; 2150-2323; 2153-2320; 2180-2330; 2197-2321; 2206-2323; 2208-2320; 2216-2320; 2221-2328; 2221-2320; 2221-2323; 2224-2330; 2226-2323; 2203-2320; 2228-2320; 2232-2323; 2258-2330; 2264-2323; 575-1083; 1664-2294; 1037-1293; 878-1218; 1697-2061; 526-1057 35/LG:1134869.44:2002JAN18 1-184; 12-184 36/LG:1135675.15:2002JAN18 1-489; 44-297; 45-433; 45-342; 45-302; 64-210; 76-514; 96-152; 96-147; 109-256; 112-560; 114-425; 114-366; 123-383; 139-489; 139-370; 170-326; 170-400; 170-330; 170-322; 170-288; 227-619; 254-322; 296-750; 296-533; 302-489; 339-804; 339-819; 338-438; 339-489; 339-511; 339-463; 339-459; 339-451; 339-447; 339-434; 345-508; 350-489; 352-981; 352-489; 366-489; 372-489; 385-489; 391-489; 392-489; 394-489; 458-898; 541-877; 541-885; 560-778; 564-854; 591-854; 596-885; 612-854; 623-885; 623-854; 624-854; 632-1000; 635-961; 664-828; 674-995; 676-747; 682-983; 682-899; 682-868; 682- 864; 682-748; 682-736; 682-777; 689-1000; 684-748; 696-968; 697-999; 727-945; 727-854; 739-995; 754-995; 755-928; 755-920; 761-854; 764-974; 764-928; 79--854; 805-957; 805-928; 805-854; 805-995; 805-943; 805-959; 805-958; 814-970; 809-894; 819-1103; 828-928; 832-1022; 839-928; 872-945; 888-994; 985-1473; 991-1446; 991-1055; 999-1055; 1003- 1055; 1020-1088; 1198-1381; 1214-1788; 1213-1621; 1213-1608; 1214-1683; 1213-1480; 1215-1684; 1219-1680; 1220- 1517; 1220-1362; 1226-1451; 1252-1477; 1259-1413; 1259-1526; 1259-1408; 1259-1326; 1272-1686; Table 3 SEQ ID NO:/Template ID Component Spans 1284-1570; 1300-1584; 1312-1567; 1312-1898; 1324-1909; 1334-1915; 1334-1711; 1340-1907; 1341-1590; 1349-1742; 1372-1473; 1415-1657; 1451-1662; 1448-2001; 1467-1661; 1472-1965; 1501-1805; 1507-1768; 1513-1765; 1526-1892; 1541-2010; 1547-1966; 1571-2012; 1570-1904; 1579-1907; 1578-2010; 1594-2015; 1597-1974; 1604-2010; 1604-1848; 1613-1888; 1625-2010; 1632-1954; 1636-1954; 1641-1985; 1646-2008; 1651-2010; 1654-2010; 1653-1908; 1653-2010; 1684-1929; 1705-1954; 1704-2010; 1706-2011; 1709-2010; 1714-2004; 1717-2010; 1768-2013; 1769-2010; 1771-2188; 1776-2037; 1780-1961; 1781-1972; 1783-2014; 1789-2009; 1815-2012; 1820-2011; 1840-2010; 1852-2102; 1855-1965; 1860-2011; 1861-2132; 1864-2010; 1900-2175; 1917-2165; 2034-2499; 2034-2213; 2141-2764; 2168-2716; 2168-2761; 2173-2741; 2209-2797; 2212-2500; 2322-2566; 2591-3128; 2636-2752; 2784-3128 37/LG:1285109.14:2002JAN18 1-212; 6-497; 97-676; 284-899; 290-988; 297-777; 438-726; 466-661; 471-735; 491-1081; 496-972; 503-594; 503-593; 503- 910; 503-694; 503-720; 503-621; 504-724; 503-675; 504-732; 505-614; 505-922; 505-567; 505-851; 505-641; 505-643; 505- 658; 505-617; 517-727; 517-673; 518-830; 517-620; 517-576; 518-907; 518-610; 518-1030; 520-792; 523-1048; 524-766; 524-764; 524-1045; 534-1121; 535-837; 534-822; 545-638; 550-843; 559-1115; 562-803; 562-804; 563-813; 572-819; 612- 881; 613-879; 614-855; 617-850; 623-1182; 641-914; 658-1200; 683-829; 686-803; 689-979; 693-1007; 697-902; 702-869; 703-856; 704-1193; 709-1337; 716-937; 718-1042; 738-1000; 738-1346; 764-997; 788-1111; 789-1077; 806-968; 819-956; 830-1400; 831-1073; 858-1251; 877-1409; 887-1417; 896-1324; 892-1452; 904-1270; 910-1171; 935-1446; 939-1168; 955- 1440; 998-1318; 1004-1437; 1023-1439; 1023-1438; 1035-1280; 1039-1437; 1044-1441; 1066-1276; 1075-1438; 1075- 1333; 1077-1440; 1081-1451; 1094-1367; 1095-1451; 1094-1289; 1101-1353; 1101-1260; 1101-1188; 1102-1362; 1102- 1411; 1103-1285; 1105-1438; 1120-1374; 1126-1437; 1146-1327; 1156-1422; 1160-1440; 1163-1345; 1184-1445; 1184-1387; 1186-1442; 1222-1449; 1234-1437; 1237-1438; 1257-1336; 1264-1445; 1275-1437; 1304-1449; 1332-1451 38/LG:1329818.9:2002JAN18 1-315; 1-128; 1-219; 1-193; 11-506; 27-265; 31-413; 46-428; 52-278; 61-434; 59-198; 59-172; 47-328; 50-483; 50-271; 52- 205; 73-211; 61-217; 62-389; 61-211; 65-209; 66-212; 67-391; 119-677; 105-541; 126-341; 152-336; 156-386; 158-389; 158-395; 171-445; 225-555; 237-497; 265-526; 266-623; 268-518; 271-668; 282-469; 292-454; 312-853; 319-570; 336-665; 342-767; 342-597; 342-573; 341-620; 369-952; 393-620; 413-645; 421-983; 485-549; 488-734; 498-945; 498-784; 508- 1069; 519-609; 519-723; 534-785; 535-1055; 539-668; 542-1006; 543-603; 549-661; 557-811; 557-799; 557-797; 568-791; 585-1196; 591-853; 593-831; 597-1202; 597-868; 602-669; 611-869; 611-858; 649-910; 650-907; 654-907; 678-966; 680- 893; 681-953; 683-1307; 698-1066; 707-1292; 735-982; 773-1099; 795-1030; 821-1130; 853-1124; 861-1166; 880-1491; 890-1140; 890-1146; 903-1038; 908-1124; 915-1459; 927-1428; 938-1074; 952-1225; 959-1568; 962-1456; 968-1591; 980- 1223; 988-1226; 1007-1565; 995-1578; 991-1457; 997-1468; 997-1247; 1023-1259; 1028-1429; 1029-1449; 1029-1384; 1037-1307; 1051-1480; 1052-1311; 1055-1442; 1063-1310; 1075-1326; 1084-1358; 1101-1657; Table 3 SEQ ID NO:/Template ID Component Spans 1122-1632; 1122-1656; 1143-1655; 1152-1383; 1157-1670; 1158-1400; 1172-1593; 1172-1441; 1174-1627; 1184-1473; 1185-1618; 1189-1674; 1205-1670; 1205-1476; 1222-1670; 1223-1669; 1226-1671; 1228-1676; 1228-1670; 1226-1565; 1231-1676; 1247-1677; 1255-1511; 1259-1544; 1255-1476; 1266-1654; 1265-1674; 1267-1510; 1272-1674; 1277-1671; 1277-1405; 1278-1516; 1277-1510; 1282-1674; 1282-1670; 1292-1670; 1294-1626; 1294-1624; 1304-1674; 1304-1524; 1312-1569; 1318-1670; 1319-1670; 1319-1532; 1320-1670; 1324-1676; 1324-1675; 1326-1674; 1329-1671; 1334-1536; 1330-1668; 1341-1670; 1351-1583; 1351-1457; 1357-1668; 1359-1670; 1362-1645; 1362-1671; 1367-1580; 1370-1675; 1378-1670; 1386-1942; 1389-1624; 1393-1670; 1403-1670; 1407-1670; 1407-1588; 1422-1670; 1424-1670; 1429-1651; 1434-1629; 1434-1669; 1436-1674; 1438-1670; 1446-1671; 1447-1667; 1458-1670; 1470-1670; 1496-1762; 1513-1763; 1518-1811; 1527-1908; 1532-1763; 1538-1802; 1538-1629; 1538-1670; 1547-1668; 1567-1672; 1593-1901; 1615-1794; 1681-2429; 1684-2155; 1683-2070; 1689-1923; 1695-1966; 1700-1911; 1700-1754; 1700-1980; 1703-1975; 1708-2220; 1710-2188; 1722-1972; 1731-2215; 1733-2212; 1743-2362; 1762-2176; 1767-2054; 1771-1990; 1772-2211; 1771-2118; 1771-2003; 1775-2210; 1778-2243; 1781-2243; 1783-2247; 1784-2240; 1786-2239; 1779-2247; 1796-2246; 1794-1916; 1796-2012; 1795-2071; 1801-2245; 1802-2217; 1807-2240; 1817-2211; 1821-2212; 1825-2101; 1826-2248; 1825-2240; 1823-2211; 1834-2247; 1847-2089; 1847-2086; 1863-2218; 1855-2239; 1867-2098; 1872-2199; 1875-2246; 1875-2152; 1877-2248; 1880-2131; 1889-2250; 1901-2055; 1904-2239; 1907-2013; 1911-2240; 1916-2240; 1912-2188; 1917-2205; 1919-2171; 1936-2154; 1938-2210; 1941-2191; 1944-2155; 1951-2220; 1955-2155; 1952-2228; 1969-2217; 1982-2240; 1982-2184; 1989-2240; 1997-2239; 2002-2276; 2001-2178; 2024-2239; 2033-2123; 2035-2247; 2071-2267; 2143-2240; 787-1293; 1281-1543; 1279-1652; 709-1227 39/LG:1377451.48:2002JAN18 1-453; 146-820; 434-844; 688-1267; 805-1059; 805-934; 922-1380; 965-1375; 974-1123; 1005-1380; 1018-1376; 1024- 1349; 1035-1307; 1063-1378; 1071-1380; 1075-1378; 1090-1374; 1112-1374; 1116-1374; 1134-1337; 1136-1526; 1136- 1382; 1136-1375; 1139-1382; 1140-1367; 1144-1356; 1147-1487; 1159-1364; 1177-1413; 1221-1380; 1258-1534; 1260- 1374; 1260-1336; 1282-1374; 1284-1380; 1304-1382; 1333-1525; 1377-1534 40/LG:1383694.5:2002JAN18 1-127; 12-127 Table 3 SEQ ID NO:/Template ID Component Spans 41/LG:1383725.3:2002JAN18 1-628; 235-650; 248-742; 250-832; 400-657; 460-963; 809-1357; 809-1419; 814-1637; 988-1654; 1102-1484; 1532-2283; 1592-1864; 1600-1687; 1595-1844; 1638-1829; 1645-2224; 1638-1828; 1648-1913; 1656-2083; 1686-1971; 1702-2000; 1703-1976; 1708-2118; 1725-2001; 1742-2039; 1755-2279; 1772-2044; 1784-2269; 1800-2166; 1805-2381; 1807-2500; 1811-2052; 1812-2203; 1826-2459; 1819-2192; 1820-2020; 1825-2073; 1828-2181; 1829-2247; 1836-2456; 1847-2504; 1867-2569; 1867-2350; 1878-2008; 1867-2521; 1877-2271; 1926-2190; 1924-2218; 1956-2229; 1956-2428; 2012-2641; 2044-2294; 2047-2304; 2050-2295; 2065-2315; 2060-2289; 2089-2641; 2091-2320; 2103-2315; 2109-2350; 2128-2401; 2136-2435; 2151-2614; 2151-2682; 2167-2641; 2177-2409; 2181-2881; 2194-2410; 2200-2687; 2200-2456; 2205-2443; 2210-2504; 2217-2941; 2219-2559; 2230-2786; 2231-2475; 2253-2531; 2253-2495; 2262-3240; 2252-2370; 2272-2575; 2277-2533; 2262-2362; 2284-2550; 2286-2529; 2291-2570; 2293-2524; 2300-3017; 2306-2560; 2309-2880; 2314-2933; 2324-2491; 2328-2739; 2327-2545; 2337-2938; 2338-2612; 2336-2586; 2343-2883; 2347-2586; 2351-2795; 2368-2474; 2383-2829; 2395-2622; 2406-2640; 2407-2577; 2429-2749; 2451-2673; 2453-2703; 2458-2706; 2458-2995; 2470-2667; 2488-2787; 2498-2744; 2499-3165; 2498-2719; 2501-3169; 2500-2666; 2521-3096; 2522-2778; 2528-2818; 2526-3120; 2536-2762; 2554-2785; 2573-3165; 2590-2792; 2590-3025; 2590-3094; 2605-2868; 2605-2864; 2616-2752; 2626-2881; 2626-2879; 2629-2928; 2645-3192; 2657-3124; 2659-3126; 2668-3198; 2673-3198; 2676-2939; 2678-3165; 2688-2958; 2692-2945; 2692-3195; 2692-3123; 2703-3163; 2701-3166; 2708-3169; 2710-3167; 2715-2972; 2715-3158; 2720-3168; 2724-2983; 2726-2993; 2734-3001; 2735-3163; 2738-2966; 2741-3259; 2744-3165; 2744-2856; 2747-3168; 2747-3167; 2747-3163; 2754-3165; 2756-3170; 2756-3165; 2759-3025; 2758-3165; 2758-3012; 2760-3165; 2762-3245; 2761-3170; 2763-2955; 2764-3171; 2770-3240; 2774-3243; 2780-3240; 2786-3071; 2788-3170; 2788-3071; 2792-3240; 2792-3170; 2795-3170; 2796-3189; 2799-2995; 2800-3243; 2803-3246; 2805-3001; 2807-3165; 2814-3240; 2815-3321; 2817-3232; 2819-3092; 2825-3238; 2825-3240; 2826-3240; 2831-3255; 2832-3168; 2837-3240; 2837-3166; 2840-3168; 2842-3165; 2844-3082; 2846-3194; 2848-3170; 2848-3165; 2854-3114; 2854-3162; 2855-3109; 2857-3166; 2858-3153; 2860-3037; 2861-3079; 2861-3046; 2861-3245; 2861-3040; 2862-3207; 2862-3245; 2862-3241; 2863-3221; 2865-3151; 2872-3159; 2877-3232; 2880-3167; 2887-3220; 2884-3240; 2885-3240; 2885-3233; 2890-3176; 2894-3159; 2901-3243; 2901-3139; 2902-3243; 2913-3241; 2913-3178; 2913-3200; 2918-3240; 2919-3165; 2920-3148; 2920-3245; 2926-3165; 2931-3170; 2933-3181; 2932-3034; 2934-3158; 2936-3168; 2936-3240; 2937-3240; 2949-3205; 2957-3220; 2961-3221; 2962-3159; 2970-3217; 3003-3225; 3012-3167; 3024-3240; 3025-3241; 3034-3165; 3040-3165; 3050-3168; 3064-3158; 3073-3209; 3089-3255; 3100-3165; 3175-3241 42/LG:1394903.37:2002JAN18 1-303; 246-736; 543-905; 738-1205; 896-1227; 900-1501; 895-1319; 944-1205; 945-1150; 937-1389; 1016-1451; 1025- 1785; 1073-1588; 1092-1517; 1165-1767; 1666-2257; 1786-1870; 1665-1906 Table 3 SEQ ID NO:/Template ID Component Spans 43/LG:1398274.13:2002JAN18 1-437; 1-223; 40-297; 70-761; 53-386; 53-441; 53-305; 53-298; 73-275; 127-214; 200-403; 216-442; 298-555; 345-893; 371- 940; 381-527; 410-872; 445-689; 460-617; 479-737; 486-693; 529-1072; 559-838; 571-1060; 623-839; 664-1100; 701-960; 701-943; 701-908; 751-1477; 752-1354; 769-1179; 785-1574; 830-1289; 830-1253; 855-1180; 975-1492; 978-1169; 978- 1072; 983-1072; 993-1072; 1104-1279; 1120-1356; 1149-1567; 1155-1617; 1155-1419; 1213-1510; 1220-1524; 1250-1433; 1260-1392; 1273-1566; 1298-1550; 1368-1559; 1380-1659; 1399-1490; 1439-1717; 1469-1557; 1604-2141; 1625-1868; 1686-1838; 1692-1959; 1693-2043; 1693-1941; 1706-1895; 1720-2423; 1740-2310; 1745-2557; 1747-2316; 1768-2042; 1780-2316; 1778-2077; 1793-2327; 1803-2353; 1815-2476; 1827-2366; 1846-2389; 1845-2636; 1883-2202; 1904-2367; 1904-2139; 1933-2495; 1933-2354; 1952-2162; 1957-2233; 1984-2270; 2001-2080; 2014-2706; 2023-2303; 2026-2622; 2030-2412; 2033-2798; 2059-2337; 2055-2714; 2087-2328; 2136-2420; 2137-2336; 2162-2303; 2165-2869; 2166-2783; 2166-2741; 2176-2741; 2176-2722; 2232-2356; 2279-2590; 2281-2615; 2284-2463; 2288-2987; 2287-2923; 2287-2540; 2292-2545; 2296-2503; 2307-2568; 2308-2565; 2319-2573; 2324-2956; 2333-2583; 2345-2868; 2372-2627; 2375-2642; 2381-2890; 2386-2840; 2389-2841; 2410-2650; 2418-2663; 2445-3089; 2452-3080; 2469-2721; 2472-2860; 2478-2841; 2526-3070; 2518-2801; 2520-2742; 2531-2747; 2535-2833; 2572-2821; 2594-2864; 2640-3040; 2640-2901; 2640-2877; 2643-3039; 2643-2879; 2643-2846; 2643-2833; 2645-2905; 2647-2935; 2658-2911; 2660-2934; 2664-2903; 2664-2799; 2681-2950; 2684-2808; 2700-3231; 2700-2949; 2728-2883; 2734-2853; 2744-3452; 2745-2999; 2753-3024; 2753-3012; 2755-3030; 2755-2931; 2766-3000; 2767-2975; 2768-2982; 2779-3280; 2780-3022; 2791-3018; 2793-3043; 2801-3044; 2804-3350; 2804-3076; 2808-2860; 2814-3175; 2815-3035; 2816-3072; 2828-2886; 2853-3117; 2851-3009; 2860-3097; 2861-3418; 2866-3357; 2893-3148; 2904-3184; 2913-3192; 2918-3057; 2921-3136; 2926-3519; 2928-3138; 2934-3213; 2940-3035; 2945-3447; 2945-3214; 2946-3332; 2960-3434; 2955-3214; 2964-3265; 2966-3230; 2974-3230; 2979-3465; 3007-3228; 3012-3427; 3013-3573; 3020-3289; 3027-3233; 3032-3238; 3041-3289; 3043-3508; 3049-3566; 3052-3465; 3053-3599; 3065-3465; 3086-3517; 3086-3312; 3092-3324; 3105-3634; 3106-3530; 3117-3384; 3121-3474; 3132-3649; 3132-3400; 3137-3353; 3145-3486; 3143-3610; 3158-3730; 3179-3735; 3180-3674; 3182-3375; 3185-3410; 3196-3551; 3196-3479; 3212-3457; 3212-3474; 3214-3410; 3215-3296; 3217-3575; 3218-3727; 3225-3466; 3229-3471; 3235-3759; 3238-3481; 3247-3495; 3247-3470; 3271-3734; 3271-3731; 3308-3384; 3359-3692; 3432-3773; 3527-3735; 3706-4190; 3706-4106; 3728-4192; 3729-4193; 3737-4197; 3737-4193; 3739-4197; 3741-4194; 3751-4193; 3753-4193; 3774-4125; 3764-4015; 3772-4196; 3777-4190; 3785-4193; 3789-4190; 3789-4105; 3813-4193; 3819-4190; 3859-4198; 3874-4190; 3875-4190; 3879-4190; 3886-4106; 3900-4194; 3900-4190; 3900-4195; 3903-4194; 3907-4064; 3910-4190; 3911-4054; 3921-4193; 3933-4190; 3939-4176; 3951-4198; 3955-4190; 3954-4106; 3973-4189; 3984-4190; 3987-4194; 3989-4190; 3993-4194; 4030-4190; 4059-4186; 4099-4191; 4105-4232; 4115-4190; 4123-4195; 4121-4189; 4121-4184; 4125-4178; 4131-4190; 4159-4493; 4200-4262; 4200-4331; 4200-4334; 4200-4257; 4200-4355; 4331-4600; 4531-4747; 4571-4831; 4286-4448; 742-903; 1111-1298; 1104-1377; 1417-1765; 4652-4725; 3267-3649; 273-657; Table 3 SEQ ID NO:/Template ID Component Spans 247-648; 239-657; 242-657; 441-897; 457-1072 44/LG:1398646.12:2002JAN18 1-377; 1-227; 274-526; 293-888; 330-776; 330-523; 448-713; 458-1146; 462-511; 469-600; 486-714; 496-965; 501-1066; 540-720; 621-1189; 626-892; 626-899; 637-908; 688-934; 710-1254; 752-820; 757-999; 766-1010; 771-1069; 770-1004; 770-996; 791-1346; 808-1335; 804-1035; 812-1485; 829-1448; 829-1084; 849-1448; 858-1383; 881-1555; 885-1176; 897- 1461; 920-1290; 933-1277; 935-1153; 943-1507; 943-1212; 962-1281; 962-1230; 962-1171; 967-1252; 989-1114; 1009- 1667; 1009-1200; 1059-1338; 1061-1167; 1065-1338; 1085-1315; 1085-1317; 1085-1313; 1085-1283; 1103-1215; 1107- 1537; 1123-1638; 1125-1405; 1160-1413; 1165-1437; 1167-1414; 1170-1636; 1176-1348; 1195-1641; 1199-1471; 1205- 1458; 1216-1804; 1226-1538; 1226-1462; 1238-1908; 1244-1819; 1246-1512; 1252-1487; 1256-1531; 1261-1538; 1279- 1537; 1283-1494; 1284-1553; 1285-1549; 1285-1512; 1288-1537; 1291-1360; 1307-1537; 1308-1547; 1326-1545; 1333- 1426; 1357-1537; 1375-2088; 1384-1648; 1395-1537; 1400-1537; 1414-1660; 1414-1537; 1472-2079; 1560-2258; 1567- 1673; 1573-2105; 1595-2016; 1648-1995; 1690-2221; 1703-1918; 1716-2062; 1721-1989; 1731-2208; 1750-1945; 1777-2246; 1793-2414; 1793-2186; 1798-2080; 1798-2174; 1800-2173; 1813-2249; 1824-2066; 1824-2038; 1824-2015; 1832-2246; 1833-2205; 1833-2088; 1837-2246; 1839-2250; 1846-2240; 1845-2241; 1845-2112; 1850-2244; 1855-2255; 1860-2244; 1866-2244; 1869-2250; 1874-2130; 1883-2141; 1885-2265; 1885-2208; 1890-2280; 1902-2121; 1902-2164; 1909-2153; 1911-2240; 1910-2124; 1912-2149; 1913-2199; 1921-2150; 1921-2131; 1922-2181; 1923-2257; 1923-2177; 1923-2150; 1923-2105; 1929-2167; 1930-2211; 1939-2436; 1941-2246; 1942-2250; 1972-2246; 1974-2246; 1979-2198; 1993-2244; 2039-2261; 2399-2658 45/LG:1398955.2:2002JAN18 1-227; 1-560; 2-274; 1-87; 3-239; 6-130; 12-659; 40-230; 495-1110; 498-771; 510-1114; 525-894; 525-764; 571-1139; 766- 1101; 919-1393; 1055-1222; 1083-1435; 1154-1900; 1182-1799; 1227-1520; 1385-1904; 1385-1511; 1385-1500; 1552- 2261; 1658-2490; 1901-2137; 1991-2677; 2013-2734; 2023-2452; 2029-2247; 2142-2405; 2143-2652; 2143-2380; 2163- 2869; 2309-2859; 2416-2947; 2448-2859; 2497-3195; 2511-2859; 2597-4853; 2615-2869; 2646-3289; 2703-3333; 2706- 2755; 2716-2979; 2788-3254; 2883-3138; 3107-3349; 3182-3448; 3234-3384; 3238-3924; 3254-3462; 3254-3634; 3312- 3497; 3370-3906; 3370-3620; 3379-3737; 3531-3896; 3533-3794; 3537-3764; 3554-4047; 3573-4340; 3686-3968; 3688- 3923; 3696-3941; 3742-4187; 3742-4000; 3746-4222; 3746-3997; 3752-4007; 3753-3876; 3765-4010; 3779-4062; 3803- 4063; 3819-4025; 3822-4025; 3832-3900; 3834-4045; 3842-4025; 3849-4266; 3861-4363; 3864-4148; 3869-4182; 3944- 4524; 3947-4025; 4070-4621; 4074-4328; 4074-4524; 4094-4217; 4099-4182; 4101-4655; 4148-4737; 4157-4328; 4174- 4752; 4189-4278; 4222-4834; 4258-4856; 4271-4328; 4279-4530; 4279-4328; 4281-4975; 4288-4750; 4289-4818; Table 3 SEQ ID NO:/Template ID Component Spans 4299-4355; 4299-4349; 4364-4827; 4373-4819; 4376-4508; 4377-4811; 438004644; 4381-4691; 4394-4864; 4399-4968; 4406-4851; 4407-4851; 4406-4642; 4408-4865; 4413-4669; 4417-4864; 4421-4808; 4421-4802; 4421-4790; 4421-4636; 4421-4549; 4421-4526; 4421-4512; 4433-4718; 4452-4734; 4467-4864; 4478-4864; 4495-4864; 4498-4864; 4505-4753; 4514-4684; 4524-4741; 4531-4865; 4552-4784; 4567-5078; 4566-4797; 4572-4772; 4589-5084; 4595-4880; 4603-4864; 4605-4805; 4609-4856; 4615-5075; 4614-4851; 4632-4872; 4652-4845; 4664-4124; 4665-5126; 4667-5124; 4675-5124; 4679-4898; 4685-5114; 4687-5083; 4696-5139; 4697-5121; 4704-5124; 4708-5064; 4714-5124; 4720-5117; 4720-4865; 4736-4864; 4747-5126; 4773-5085; 4803-5090; 4850-4957; 4868-5117; 4887-5124; 4914-5122; 4945-5139; 4953-5139; 4958-5123; 5010-5121; 5040-5123 46/LG:1452762.26:2002JAN18 1-115; 1-76; 54-677; 364-954; 581-1007; 663-1090; 664-1099; 680-1081; 722-1134; 722-1125; 722-1124; 722-975; 728- 1128; 735-837; 737-985; 760-1128; 761-1134; 791-134; 811-1132; 832-1123; 843-1046; 871-1125 47/LG:1452783.7:2002JAN18 1-289; 18-384; 18-135; 18-270; 134-732; 2317-638; 244-328; 561-1239; 623-1073; 595-1112; 613-1131; 635-1070; 640- 1128; 653-1133; 660-1118; 699-1110; 699-1180; 706-1123; 728-1139; 736-1140; 742-1081; 745-1182; 756-1183; 766- 1146; 766-1189; 786-1190; 787-1181; 787-1183; 791-1175; 792-1140; 825-1047; 898-1179; 903-1152 915-1365; 920- 1155; 922-1128; 933-1173; 953-1191; 960-183; 967-1109; 970-1040; 979-1189; 991-1180; 996-1714; 1020-1179; 1020- 1098; 1028-1143; 1039-1131; 1039-1103; 1039-1143; 1042-1143; 1173-1642; 1621-1901; 1621-1926; 1624-1941; 1624- 1804; 1713-1894; 1853-2306; 1856-2133; 1870-2120; 1891-2041; 1892-2253; 1913-2257; 2030-2460; 2205-2469; 2205- 2581; 2220-2548; 2251-2471; 2311-3007; 2517-3078; 2518-3078; 2602-2790; 2632-3078; 2632-30712; 2647-3085; 2649- 3078; 2747-3078; 878-1016 48/LG:1453027.28:2002JAN18 1-585; 126-330; 256-505; 327-610; 354-813; 493-830; 537-805; 545-804; 565-813; 565-816; 570-813; 571-813; 583-808; 584-819; 588-813; 591-745; 595-813; 625-813; 627-772; 631-813; 635-813; 655-771; 660-818; 662-813; 664-813; 682-813; 767-820 49/LG:1454967.12:2002JAN18 1-236; 47-303; 136-682; 138-387; 139-402; 161-412; 170-673; 207-731; 436-898; 460-1013; 495-993; 685-1313; 807-1284; 866-1131; 934-1158; 1004-1209; 1005-1265; 1009-1412; 1013-1508; 1013-1461; 1052-1654; 1052-1318; 1053-1368; 1059- 1357; 1071-1430; 1099-1296; 1126-1346; 1142-1403; 1153-1325; 1174-1347; 1180-1569; 1266-1422; 12278-1533; 1280- 1875; 1376-1844; 1407-1642; 1435-1966; 1435-1714; 1437-1802; 1450-2110; 1459-1710; 1508-1978; 1509-1746; 1534- 1710; 1553-1781; 1570-1845; 1623-2131; 1646-1873; 1662-2219; 1662-1839; 1663-1921; 1681-1854; 1688-1942; 1695- 1969; 1697-1944; 1699-1969; 1704-1963; 1714-1998; 1721-2029; 1752-2002; 1752-1996; 1759-2003; 1779-1891; 1799- 2106; 1836-1958; 1867-2355; 1867-2085; 1954-2355; 1959-2355; 1981-2078; 1981-2036; 1984-2078; 1988-2380; 1988- 2203; 1994-2169; 1996-2247; 2005-2226; 2021-2576; 2131-2339; 2137-2714; 2168-2417; 2169-2413; 2193-2414; 2204- 2550; 2204-2414; 2249-2785; 2262-2835; 2266-2523; 2282-2473; 2295-2868; 23012-2511 2299-3025; 2307-2730; 2319- 2609; 2328-2597; 2366-2558; 2431-2930; 24312-2691; 2431-2689; 2433-2866; 2433-2666; 2437-2714; Table 3 SEQ ID NO:/Template ID Component Spans 2449-2912; 2466-2839; 2474-23002; 2477-3003; 2486-2730; 2480-2998; 2489-2760; 2507-2880; 2508-2739; 2501-2799; 2536-2953; 2536-2743; 2557-2918; 2558-2868; 2592-2879; 2585-2875; 2587-3124; 2589-2994; 2591-2991; 2610-3040; 2610-3044; 2610-2845; 2610-2843; 2610-2820; 2611-2687; 2622-3042; 2624-3047; 2631-3047; 2632-3037; 2636-3007; 2636-3039; 2636-3041; 2637-3046; 2640-3041; 2648-3042; 2648-3201; 2648-2894; 2659-3043; 2667-3044; 2679-3040; 2683-3041; 2685-3040; 2702-3032; 2701-2899; 2717-3037; 2712-3226; 2721-3053; 2731-3241; 2734-3431; 2737-3044; 2740-3041; 2743-3040; 2759-3046; 2760-3040; 2760-3038; 2776-3037; 2781-3044; 2791-3020; 2819-3037; 2832-3035; 2841-2902; 2889-3350; 2891-3303; 2905-3008; 2907-3154; 2915-3595; 2980-3163; 2980-3376; 2980-3282; 2981-3181; 2981-3428; 2981-3256; 2981-3257; 2982-3450; 2983-3380; 2983-3351; 2983-3227; 2983-3039; 2984-3453; 2985-3340; 2986-3434; 2986-3419; 2986-3347; 2985-3351; 2986-3287; 2987-3238; 2989-3226; 2989-3182; 2991-3391; 2995-3273; 2995-3285; 2998-3336; 3005-3444; 3005-3119; 3014-3261; 3023-3452; 3024-3233; 3025-3356; 3038-3180; 3036-3804; 3047-3781; 3055-3297; 3072-3320; 3081-3332; 3084-3350; 3087-3492; 3101-3241; 3103-3577; 3111-3607; 3144-3779; 3172-3408; 3251-3528; 3254-3573; 3282-3526; 3328-3494; 3332-3533; 3353-3577; 3370-3633; 3376-3579; 3383-3646; 3390-3440; 3415-3857; 3644-3708; 3706-4287; 3710-4288; 3731-4287; 3761-4287; 3762-4288; 3767-4287; 3798-4288; 3813-4287; 3863-4288; 3997-4288 50/LG:1466307.1:2002JAN18 1-501 51/LG:149121.24:2002JAN18 3315-3655; 3264-3644; 3337-3644; 3528-3644; 3049-3380; 3040-3379; 3029-3379; 3033-3352; 3035-3328; 3034-3266; 3017-3266; 3022-3186; 3022-3171; 2509-3103; 2192-2655; 2490-2673; 2127-2673; 2260-2636; 2256-2649; 2402-2649; 2317-2636; 2250-2636; 2275-2636; 2348-2636; 2353-2636; 2334-2636; 2101-2636; 2386-2624; 1766-2514; 2022-2497; 2015-2497; 2026-2497; 2276-2497; 2074-2495; 2220-2481; 2289-2474; 2051-2473; 2074-2468; 2011-2467; 2250-2463; 2284-2458; 1946-2431; 2047-2428; 2284-2428; 2284-2427; 2025-2424; 2020-2424; 2092-2424; 2220-2424; 2284-2424; 1782-2386; 1787-2384; 1979-2401; 1988-2401; 2026-2401; 2091-2401; 251-2399; 1977-2399; 2253-2401; 1767-2398; 2284-2395; 2048-2392; 2163-2391; 2265-2381; 1977-2378; 1932-2361; 2034-2358; 1835-2345; 1960-2323; 12951-2255; 2075-2235; 1936-2203; 1951-2202; 1967-2187; 1800-2167; 1917-2181; 2057-2167; 1721-2167; 1974-2162; 1877-2152; 1452-2050; 1432-2050; 17612-1973; 1800-1890; 1635-1891; 1292-1876; 1639-1877; 1535-1840; 1487-1740; 1479-1739; 1216-1713; 1388-1639; 1453-1582; 1341-1579; 967-1548; 1015-1548; 934-1548; 1200-1387; 1102-1248; 953-1218; 882-1053; 889-1053; 565-1042; 439-973; 430-966; 497-965; 522-962; 463-924; 763-888; 565-842; 45-590; 1-533 52/LG:1500347.11:2002JAN18 1-436; 62-650 53/LG:1500433.15:2002JAN18 1-580; 54-192; 57-459; 154-401; 153-404 165-439; 397-663; 562-1014; 618-1017 Table 3 SEQ ID NO:/Template ID Component Spans 54/LG:1500434.6:2002JAN18 1-774; 36-429; 188-417; 195-849; 216-739; 701-1169; 701-1290; 861-1017; 1095-1567; 1095-1630; 1107-1601; 1165- 1601; 1488-1832; 1600-2170; 1600-1991; 1603-1885; 1618-2381; 1638-2094; 1687-2132; 1688-2153; 1698-2050; 1701- 1968: 1742-2150; 1763-2521; 1792-2375; 1847-2133; 1866-2102; 1893-2122; 1895-2155; 1959-2211; 2067-2191; 2087- 2467; 2089-2318; 2088-2700; 2104-2375; 2117-2697; 2206-2871; 2330-2795; 2349-2613; 2351-2708; 2390-2593; 2433- 2657; 2452-3112; 2458-3037; 2501-2806; 2511-3015; 2514-2735; 2514-2734; 2562-2803; 2570-3081; 2570-2792; 2602- 2874; 2703-2985; 2719-3193; 2753-3031; 2777-3026; 2811-3190; 2816-3139; 2839-3146; 2864-3142; 2875-3139; 2882- 3089; 2902-3166; 2925-3184; 2938-3637; 2983-3151; 3088-3599; 3131-3338; 3149-3328; 3169-3443; 3237-3478; 3237- 3382; 3307-3560; 3307-3700; 3307-3511; 3524-3606; 3317-3887; 3362-3656; 3363-3571; 3374-3477; 3414-3642; 3476- 3705; 3484-4055; 3501-3730; 3499-4011; 3511-4245; 3536-3792; 3549-4161; 3611-3886; 3658-3895; 3658-4005; 3663- 3949; 3670-4355; 3686-3881; 3720-4005; 3721-3993; 3751-4004; 3759-4079; 3759-4008; 3759-3996; 3768-4324; 3786-4027; 3819-4042; 3837-4084; 3846-4097; 3849-4146; 3854-4327; 3854-4207; 3857-4300; 3869-4441; 3875-4062; 3876-4086; 3876-4257; 3876-4062; 3878-4110; 3895-4206; 3923-4154; 3943-4527; 3943-4468; 3947-4202; 3967-4203; 3968-4522; 3930-4367; 3930-4358; 4026-4510; 4040-4244; 4080-4504; 4080-4308; 4083-4546; 4084-4547; 4095-4546; 4098-4554; 4099-4510; 4101-4547; 4110-4547; 4127-4540; 4127-4357; 4127-4580; 4128-4520; 4146-4484; 4168-4551; 4178-4546; 4185-4546; 4187-4566; 4195-4546; 4201-4362; 4204-4415; 4215-4511; 4224-4546; 4232-4540; 4241-4544; 4269-4547; 4231-4546; 4287-4539; 4287-4546; 4290-4443; 4308-4541; 4309-4517; 4283-4583; 4344-4506; 4323-4543; 4335-4547; 4357-4550; 4423-4506; 4430-4546; 4430-4540; 4449-4531; 4460-4544; 4463-4546; 4439-4538 55/LG:1601028.9:2002JAN18 1-323; 1-408; 1-559;L 1-595: 54-114 56/LG:1501710.32:2002JAN18 1-591; 178-320; 271-850; 347-557; 348-956; 471-936; 498-644; 613-951; 723-1325; 733-1206; 737-986; 783-1143; 822- 1420; 829-937; 861-1187; 892-1105; 954-1227; 963-1042; 978-1496; 995-1284; 12152-1306; 1163-1374; 1213-1670; 1270- 1510; 1281-1518; 1281-1522; 1325-1889; 1331-1486; 1344-1832; 1364-1921; 1364-1631; 1365-1630; 1414-1698; 1426- 1917; 1445-1716; 1499-1746; 1507-1775; 1519-1780; 1519-1763; 1526-1746; 1527-1772; 1532-1746; 1550-1798; 1622- 1885; 1625-2056; 1681-1937; 1695-2094; 1698-1967; 1727-2068; 1727-2100; 1763-2076; 1789-2377; 1810-2102; 1892- 2102; 1898-2287; 1896-2264; 1898-2146; 1898-2110; 1926-2018; 1952-2188; 1956-2151; 1968-2242; 1984-2220; 1985- 2334; 2001-2496; 2029-2523; 2029-2296; 2031-2201; 2055-2260; 2071-2302; 2089-2332; 2090-2634; 2126-2309; 2141- 2900; 2161-2415; 2170-2374; 2183-2423; 2190-2743; 2248-2773; 2262-2521; 2289-2527; 2303-2901; 2308-2901; 2325- 2572; 2325-2775; 2353-2593; 2410-2522; 2413-2893; 2413-2634; 2420-2961; 2420-2634; 2453-2961; 2453-2963; 2458- 2614; 2461-2634; 2462-2638; 2484-2738; 2503-2904; 2506-2965; 2509-2965; 2510-2966; 2516-2661; 2531-2997; Table 3 SEQ ID NO:/Template ID Component Spans 2543-3005; 2554-2997; 2559-3003; 2563-3006; 2568-2854; 2575-2742; 2580-3001; 2586-3008; 2638-2986; 2639-3004; 2644-2963; 2656-2967; 2656-2959; 2656-2938; 2656-3003; 2663-2891; 2663-2968; 2663-2853; 2673-2941; 2687-2954; 2693-3014; 2693-2854; 2704-2994; 2702-3003; 2739-3003; 2758-2985; 2767-2966; 2776-2997; 2787-2998; 2832-3002; 2855-3422; 2855-3003; 2858-3003; 2866-2997; 2891-3003; 2894-3003; 2895-3003; 3247-3846; 3245-3784; 3249-3754; 3252-3802; 3254-3754; 3275-3742; 3286-3800; 3314-3843; 3332-3832; 3360-3755; 3376-3664; 3495-3784; 3521-3792; 3525-3676; 3537-3810; 3576-3799; 3578-3829; 3686-3792; 3717-3798; 3719-3833; 3719-3800; 57/LG:1502217.12:2002JAN18 1-269; 68-703; 130-5612; 185-247; 671-1165; 671-1328; 671-791; 851-1116; 901-1112; 910-1118; 945-1178 1040-1103; 1087-1248 58/LG:1502272.38:2002JAN18 1-522; 47-608; 295-584; 314-511; 314-628; 414-1029; 435-1030; 499-1091; 768-1009; 908-1381; 1173-1329; 1203-1844; 1261-1780; 1283-1551; 1282-1663; 1284-1442; 1500-2120; 1691-2258; 1750-2361; 2001-2767; 2038-2607; 2154-2693; 2162-2885; 2187-2783; 2224-2396; 2282-2518; 2317-2741; 2329-2889; 2376-2786; 2378-2566; 2442-2823; 2442-2613; 2447-2987; 2471-2851; 2543-2974; 2598-3164; 2729-3382; 2741-3331; 2815-3404; 2818-2979; 2833-3397; 2883-3397; 2866-3603; 2878-3448; 2903-3174; 2950-3536; 2958-3189; 2969-3603; 2995-3173; 2997-3297; 2986-3627; 3008-3184; 2995-3181; 3029-3173; 3029-3319; 3040-3332; 3045-3328; 3049-3362; 3062-3277; 3062-3323; 3064-3329; 3048-3338; 3088-3356; 3089-3334; 3089-3367; 3103-3378; 3103-3333; 3082-3274; 3092-3666; 3089-3387; 3090-3532; 3114-3369; 3098-3311; 3097-3178; 3103-3338; 3123-3320; 3113-3687; 3121-3395; 3222-3646; 3224-3281; 3222-3385; 3222-3358; 3226-3391; 3211-3482; 3211-3402; 3222-3457; 3222-3448; 3257-3578; 3247-3318; 3250-3417; 3300-3579; 3326-3583; 3316-3451; 3310-3774; 3360-3598; 2684-2978 59/LG:1502313.3:2002JAN18 1-458; 3-2912; 18-161; 146-866; 372-956; 389-746; 397-746; 411-566; 418-746; 426-745; 426-747; 426-736; 515-673 60/LG:1502474.57:2002JAN18 1563-1757; 1515-1746; 1515-1668; 1218-1668; 1023-1656; 646-1376; 848-1305; 894-953; 336-800; 1-571; 194-508 61/LG:1502663.27:2002JAN18 1-581; 1-578; 29-655; 32-536; 39-565; 40-572; 45-637; 50-1511; 50-577; 50-323; 51-567; 56-609; 60-578; 63-668; 79-511; 79-683; 163-419; 220-775; 321-797; 330-596; 342-684; 368-745; 419-935; 574-1196; 574-824; 608-991; 658-1266; 660- 942; 6997-1068; 745-1263; 783-1251; 786-1349; 850-1313; 863-1004; 885-1320; 91-1305; 891-1152; 915-1171; 929-1473; 929-1360; 938-1412; 957-1432; 962-1301; 984-1301; 996-1499; 1046-1513; 1062-1511; 1061-1513; 1083-1512; 1084- 1511; 1098-1520; 1103-1391; 1120-1504; 1129-1732; 1129-1511; 1136-1561; 1134-1511; 1157-1517; 1177-1517; 1197- 1512; 1197-1479; 1228-1509; 1239-1520; 1239-1492; 1239-1480; 1253-1549; 1253-1511; 1256-1511; 1271-1512; 1263- 1511; 1280-1444; 1331-1511; 1379-1511; 1413-1951; 1413-1510; 1429-1506; 1440-1998; 1453-1755; 1515-1899; 1653- 2143; 1625-2136; 1631-2122; 1666-1771; 1668-2232; 1665-2169; 1685-2208; 1699-1837; 1725-2371; 1858-2431; 1890- 2153; 1915-2102; 1915-2128; 1923-2232; 1925-2418; 1941-2396; 1968-2200; 1970-2429; 2028-4002; 2029-2422; 2029- 2386; 2028-2338; 2122-2337; 2125-2408; 2136-2479; 2134-2404; 2136-2442; 2137-2429; 2141-2426; 2182-2413; Table 3 SEQ ID NO:/Template ID Component Spans 2205-2433; 2214-2752; 2324-2834; 2324-2542; 2376-2960; 2380-2631; 2452-2620; 2458-2629; 2477-2712; 2533-3095; 2575-2818; 2617-2914; 2617-2863; 2632-3158; 2734-3130; 2786-3149; 2763-2990; 2775-3268; 2780-2893; 2784-3127; 2785-3192; 2819-3101; 2834-3095; 2840-3023; 2864-3100; 2909-3399; 2911-3190; 2911-3204; 2926-3364; 2930-3549; 2946-3224; 2976-3234; 2999-3133; 3013-3369; 3013-3289; 3013-3269; 3013-3341; 3034-3545; 3068-3578; 3112-3583; 3112-3418; 3112-3310; 3128-3378; 3150-3427; 3151-3456; 3154-3423; 3158-3436; 3169-3567; 3197-3617; 3218-3449; 3234-3283; 3235-3483; 3237-3489; 3237-3480; 3241-3476; 3245-3701; 3245-3455; 3265-3518; 3285-3808; 3288-3688; 3288-3488; 3332-3633; 3335-3581; 3346-3526; 3358-3960; 3358-3427; 3361-3793; 3364-3959; 3365-3825; 3366-3676; 3366-3618; 3378-3617; 3378-3523; 3379-3626; 3382-3959; 3456-3686; 3468-3836; 3469-3690; 3480-3755; 3480-3726; 3515-3750; 3541-4002; 3543-4085; 3543-3797; 3544-3782; 3548-3641; 3545-3857; 3558-3838; 3570-3763; 3577-4002; 3592-4002; 3617-3809; 3630-3807; 3632-4003; 3663-3825; 3669-3827; 3726-3996; 3724-4123; 3740-4123; 3747-4143; 3756-3999; 3755-3942; 3758-4005; 3762-3999; 3776-4026; 3774-4002; 3776-4007; 3779-4047; 3816-3995; 3820-3995; 3850-3995; 3870-4116; 3870-3998; 3874-4022; 3875-4291; 3875-4125; 3875-4097; 3875-4083; 3875-4002; 3872-4123; 3872-4105; 3872-4125; 3920-4125; 3973-4144; 3976-4131; 3979-4128; 3979-4083; 3977-4123; 4070-4310; 4143-4388; 4145-4428; 4145-4492; 4145-4451; 4148-4415; 4151-4608; 4159-4412; 4159-4358; 4219-4299; 4222-4679; 4223-4468; 4223-4404; 4229-4679; 4232-4678; 4243-4680; 4260-4488; 4260-4498; 4305-4679; 4307-4571; 4330-4682; 4332-4679; 4338-4679; 4354-4501; 4364-4679; 4415-4524; 4415-4679; 4453-4710; 4466-4705; 4489-4638; 4501-4632; 4501-4679; 4507-4679; 4540-4675 62/LG:154608.1:2002JAN18 1-563; 180-418; 180-434; 180-642; 232-520; 262-553 407-933; 407-563; 478-909; 716-936; 791-1101 63/L:170235.124:2002JAN18 1-520; 1-533; 1-431; 18-478 64/LG:170604.1:2002JAN18 1-266; 175-693; 426-9124; 444-1009; 639-921; 663-1217; 666-925; 1027-1355; 1229-1469; 1230-1652 65/LG:171629.1:2002JAN18 1-426; 70-426; 188-441; 1288-737; 304-426; 419-994; 423-1054 66/LG:172411.1:2002JAN18 3243-3719; 3115-3686; 3204-3646; 3056-3458; 3011-3458; 2872-3165; 2799-3160; 2914-3150; 2690-3109; 2509-2953; 2301-2878; 2382-2762; 2386-2591; 1967-2580; 2114-2445; 2320-2436; 1983-2396; 1942-2346; 1983-2161; 1730-2152; 1778-2038; 1737-2037; 1550-1878; 1505-1878; 1510-1689; 1343-1595; 1163-1521; 654-1244; 384-1124; 313-547; 52-475; 201-473; 1-211 67/LG:173356.1:2002JAN18 1-226; 10-426; 39-504; 204-501; 273-490; 296-471; 389-862; 399-804; 530-700; 557-893; 573-1111; 628-1082; 634-1083; 638-1087; 638-865; 640-1079; 642-1083; 709-1085; 710-1088; 771-1430; 851-1082; 879-1062; 953-1524; 1347-1978; 1387-1625; 1510-1913; 1671-2084; 1671-1889; 1741-2019; 1745-1922; 1885-2132; 1965-2343; 1968-2311; 1976-2248; 2001-2281; 2007-2223; 2040-2292; 2102-2510; 2132-2323; 2191-2834; 2328-2661; 2366-3000; 2421-2867; 2442-2694; 2483-2665; 2591-3032; 2605-3046; 2649-3029; 2692-3029; 2693-3289; 2735-3029; 2765-3019; 2847-2987 Table 3 SEQ ID NO:/Template ID Component Spans 68/LG:193755.18:2002JAN18 1-188; 8-536; 63-569; 89-576; 106-603; 132-306; 135-496; 135-553; 145-306; 161-307; 155-393; 170-593; 170-269; 175- 825; 192-484; 2012-483; 216-576; 209-687; 223-576; 223-596; 239-515; 249-500; 280-557; 285-674; 289-488; 305-533; 332- 612; 339-555; 346-534; 358-801; 377-848; 392-531; 407-692; 403-657; 412-765; 429-934; 427-665; 423-593; 453-1127; 461-770; 465-1033; 471-707; 478-566; 505-676; 504-717; 540-1125; 572-1094; 592-851; 597-806; 598-1042; 598-981; 599- 1010; 606-1000; 606-912; 606-791; 606-759; 606-744; 606-793; 611-842; 613-1294; 617-1218; 616-1197; 639-1201; 639- 650; 639-870; 644-1177; 645-884; 647-834; 650-763; 650-1146; 650-888; 650-860; 650-897; 650-878; 656-814; 668-1042; 672-934; 675-1230; 678-937; 680-915; 686-1113; 686-901; 690-934; 690-896; 697-961; 697-932; 711-1291; 715-853; 724- 1291; 721-925; 721-997; 721-1000; 723-966; 723-1122; 725-1268; 732-1063; 735-1073; 737-989; 738-990; 737-898; 740- 1171; 749-1023; 765-1002; 770-1016; 769-882; 779-1040; 787-1293; 791-1013; 796-1053; 796-1032; 796-1015; 811-1056; 818-1085; 825-1250; 830-1297; 837-1292; 840-1292; 842-1293; 842-1091; 843-1099; 843-1271; 846-1107; 850-1294; 851-1291; 852-1094; 852-1070; 852-1149; 856-1288; 860-1141; 860-1173; 859-1157; 860- 1176; 860-1113; 861-1165; 860-1143; 860-1142; 861-1150; 861-1146; 861-1142; 861-1143; 861-1122; 861-1176; 861- 1140; 861-1155; 862-1135; 861-1116; 863-1295; 864-1143; 865-1123; 866-1108; 8661-1105; 867-1288; 878-1142; 878- 1292; 881-1297; 882-1291; 904-1176; 907-1309; 907-1119; 910-1098; 910-1291; 910-1151; 910-1306; 911-1130; 930- 1208; 934-1220; 939-1154; 941-1228; 962-1220; 962-1247; 975-1560; 975-1445; 975-1510; 975-1500; 975-1540; 975- 1470; 982-1286; 975-1443; 985-1258; 989-1091; 994-1230; 996-1563; 1005-1288; 1015-1269; 1069-1545; 1039-1484; 1039-1227; 1044-1288; 1043-1296; 1044-1308; 1056-1238; 1061-1266; 1074-1360; 1090-1299; 1090-1291; 1092-1291; 1095-1667; 1096-1292; 1098-1395; 1100-1379; 1109-1288; 1109-1380; 1115-1272; 1116-1291; 1123-1377; 1127-1291; 1131-1388; 1134-1386; 1141-1370; 1144-1295; 1145-1234; 1149-1433; 1156-1292; 1156-1297; 1170-1291; 1173-1438; 1174-1261; 1181-1382; 1181-1291; 1184-1315; 1184-1278; 1188-1291; 1192-1476; 1192-1447; 1196-1291; 1206-1798; 1209-1472; 1214-1602; 1220-1472; 1230-1770; 1240-1448; 1251-1481; 1251-1489; 1258-1521; 1272-1726; 1269-1410; 1279-1501; 1283-1525; 1284-1856; 1292-1587; 1294-1581; 1302-1551; 1311-1946; 1304-1936; 1335-1931; 1327-1961; 1328-1562; 1341-1625; 1343-1553; 1343-1582; 1345-1856; 1353-1596; 1357-1626; 1361-1599; 1392-1851; 1363-1604; 1368-1567; 1371-1814; 1380-1739; 1381-1625; 1387-1665; 1394-2013; 1414-1653; 1416-1651; 1419-1679; 1430-1667; 1450-1729; 1453-1697; 1468-1676; 1478-1712; 1478-1759; 1483-1744; 1485-1780; 1489-1769; 1494-1773; 1508-1745; 1533-1865; 1520-1691; 1521-1801; 1524-1812; 1514-2051; 1529-1747; 1531-1778; 1535-1776; 1538-1767; 1542-1801; 1563-1772; 1582-2069; 1571-1839; 1571-1817; 1573-1833; 1573-1847; 1573-1807; 1589-2091; 1610-1832; 1612-1788; 1626-1941; 1639-1880; 1623-2150; 1655-2015; 1664-1872; 1688-1982; 1680-1946; 1709-1764; 1699-1830; 1689-2007; 1705-1863; 1710-1949; 1709-1938; 1696-2223; 1710-2166; 1702-1916; 1719-1954; 1722-1940; 1722-2047; 1722-1974; 1745-1987; 1764-1988; 1745-1982; 1777-1939; 1751-2008; 1789-2166; 1790-2300; 1762-2011; 1764-2131; Table 3 SEQ ID NO:/Template ID Component Spans 1774-2297; 1806-2096; 1789-2441; 1825-2090; 1799-2099; 1800-2048; 1800-2047; 1806-1998; 1803-2416; 1842-2427; 1859-2028; 1861-2093; 1869-2111; 1859-2127; 1868-2142; 1894-2365; 1879-2394; 1884-2159; 1903-2120; 1904-2126; 1893-2161; 1894-2120; 1893-2099; 1894-2155; 1894-2136; 1910-2151; 1912-2027; 1912-2029; 1923-2155; 1931-2197; 1937-2401; 1951-2136; 1944-2228; 1970-2138; 1970-2250; 1986-2137; 1986-2247; 2007-2341; 2006-2192; 2018-2261; 2022-2519; 2032-2599; 2044-2137; 2085-2371; 2086-2783; 2093-2443; 2102-2363; 2102-2324; 2105-2246; 2104-2380; 2104-2376; 2114-2336; 2114-2343; 2116-2584; 2117-2355; 2120-2422; 2124-2326; 2140-2351; 2134-2393; 2139-2375; 2138-2376; 2138-2423; 2139-2315; 2139-2304; 2143-2356; 2146-2313; 2152-2698; 2152-2684; 2151-2606; 2154-2719; 2153-2423; 2153-2424; 2154-2395; 2161-2470; 2164-2408; 2167-2415; 2170-2801; 2181-2722; 2186-2681; 2180-2767; 2186-2661; 2193-2412; 2197-2794; 2201-2361; 2204-2444; 2211-2786; 2215-2435; 2217-2473; 2221-2661; 2229-2497; 2232-2445; 2232-2410; 2238-2744; 2241-2774; 2241-2480; 2255-2530; 2258-2567; 2258-2514; 2262-2510; 2264-2714; 2265-2538; 2264-2539; 2265-2507; 2265-2530; 2272-2510; 2281-2544; 2284-2746; 2290-2480; 2295-2633; 2295-2608; 2296-2521; 2296-2534; 2296-2615; 2308-2663; 2311-2481; 2317-2555; 2319-2700; 2325-2798; 2333-2598; 2336-2656; 2336-2540; 2339-2794; 2346-2601; 2352-2797; 2356-2799; 2359-2797; 2359-2602; 2361-2553; 2369-2798; 2370-2793; 2372-2619; 2370-2643; 2737-2794; 2375-2631; 2378-2768; 2381-2794; 2384-2598; 2386-2618; 2389-2794; 2388-2792; 2390-2794; 2410-2627; 2414-2685; 2421-2794; 2421-2660; 2445-2773; 2461-2731; 2466-2756; 2466-2754; 2466-20807; 2477-2680; 2478-2799; 2490-2683; 2559-2794; 2702-2789; 2702-2794; 2716-2795; 1049-1296; 1045-1292; 316-563; 907- 1123; 130-267; 1017-1291; 1010-1292; 1008-1289; 1003-1291; 1470-1755; 996-1292; 985-1288; 965-1292; 972-1291; 974- 1292; 955-1292; 914-1258; 946-1291;953-1294; 755-1107; 2319-2672; 901-1258; 2329-2674; 911-1291; 1-266; 901-1290; 852-1293; 2360-2794; 1284-1760; 2260-2772; 1679-12215; 1351-1913; 1679-2261; 2053-2770; 1894-2596; 1053-1293; 88- 265; 1050-1258; 1078-1295; 92-267; 920-1113; 1098-1291; 684-857; 1235-267; 1130-1291; 1130-1290; 283-401; 1151-1291; 87-187; 208-307; 1130-118 69/LG:196620.12:2002JAN18 1-700; 89-520; 103-660; 116-382; 123-511; 172-432; 214-783; 232-782; 239-782; 381-719; 431-834; 508-834; 591-1080; 700-1237; 717-834; 741-1052; 765-1305; 863-1394; 899-1452; 976-1448; 992-1322; 1041-1344; 1065-1492; 1065-1333; 1091-1365; 1114-1688; 1115-1656; 1143-1648; 1220-1460; 1218-1411; 1259-1767; 1275-1474; 1322-1525; 1322-1626; 1379-1875; 1382-1913; 1416-1636; 1463-1645; 1464-1755; 1515-1788; 1515-1929; 1524-1929; 1528-2148; 1538-1853; 1541-1851; 1564-1862; 1570-1920; 1578-1926; 1578-1872; 1578-1746; 1587-1828; 1587-1986; 1592-1926; 1596-1936; 1605-1879; 1664-1929; 1703-2031; 1714-1922; 1737-1926; 1793-2011; 1810-2434; 1859-2470; 1859-1929; 1927-2499; 2001-2658; 2015-2572; 2017-2582; 2019-2295; 2028-2561; 2054-2596; 2073-2409; 2074-2567; 2083-2675; 2098-2377; 2107-2368; 2126-2582; 2137-2750; 2142-2691; 2142-2362; 2169-2439; 2181-2561; 2181-2807; 2202-2461; 2205-2493; 2239-2465; 2260-2538; 2269-2633; 2269-2507; 2405-3028; 2459-3064; 2485-3025; 2520-3127; 2534-3120; 2560-2798; 2580-3080; 2583-2843; 2617-3002; 2622-3123; 2649-3070; 2654-3225; 2670-3124; 2670-3130; 2676-3077; 2689-3122; Table 3 SEQ ID NO:/Template ID Component Spans 2693-3129; 2726-2941; 2729-3097; 2739-3127; 2748-3128; 2750-3128; 2751-3129; 2773-3126; 2782-3128; 2785-3102; 2789-3107; 2793-3129; 2812-3128; 2813-3118; 2816-3044; 2816-3122; 2859-3130; 2861-3122; 2897-3122; 2919-3129; 2975-3122; 2991-3129; 3034-3127; 3065-3568; 3120-3191; 3195-3615; 3208-4002; 3244-3827; 3271-3724; 3271-3546; 3284-3440; 3276-4050; 3284-3911; 3283-4032; 3293-3539; 3293-3934; 3295-3866; 3293-3929; 3304-4051; 3299-4073; 3305-4068; 3376-3559; 3436-4131; 3486-3671; 3525-4161; 3649-3863; 3712-3826; 3777-4252; 3802-4137; 3991-4252; 3994-4265; 4062-4349; 4141-4349; 4175-4349; 4185-4349; 4258-4349; 4271-4349 70/LG:197624.1:2002JAN18 1161-1301; 1096-1298; 846-1292; 1096-1291; 869-1290; 935-1287; 871-1285; 1077-1285; 798-1283; 1131-1280; 1097- 1283; 1111-1280; 909-1280; 883-1280; 864-1281; 1018-1280; 876-1275; 996-1275; 877-1275; 1129-1274; 1061- 1252; 976-1251; 648-1251; 650-1236; 850-1228; 852-1152; 618-1090; 622-1090; 629-1090; 640-1090; 644-1090; 631- 1083; 531-1083; 663-1083; 691-1083; 801-1083; 872-1083; 350-1082; 912-1071; 795-1066; 526-1019; 932-1010; 705-964; 669-944; 737-924; 449-917; 389-885; 390-878; 629-861; 543-824; 577-801; 577-781; 559-780; 559-774; 373-765; 526-764; 58-719; 546-718; 78-704; 70-692; 61-692; 99-630; 80-624; 85-628; 71-589; 21-539; 35-439; 90-385; 206-319; 71-305; 1- 165 71/LG:197634.69:2002JAN18 407-781; 501-781; 505-781 573-781; 648-781; 507-780; 594-780; 480-779; 566-779; 573-779; 589-779; 726-779; 572-778; 489-777; 503-777; 407-701; 573-701; 407-671; 195-613; 135-609; 117-610; 278-607; 128-609; 129-609; 152-609; 129-598; 130-599; 129-597; 129-599; 145-599; 143-599; 123-599; 137-593; 188-594; 129-592; 129-583; 129-576; 122-572; 129-570; 309-569; 129-565; 191-552; 54-561; 1-565; 19-561; 1-562; 268-558; 311550; 119-521; 159-469; 162-411; 165-409; 182- 382 118-368; 168-365; 133-342 72/LG:198680.1:2002JAN18 1-546; 216-931; 388-931; 711-1015; 777-1398; 774-1156; 774-1012; 821-1106; 878-1305; 948-1639; 1045-1436; 1110- 1777; 1135-1723; 1193-1638; 1218-1970; 1250-1748; 1251-1756; 1282-1491; 1463-1767; 1506-2213; 1513-2154; 1598- 2055; 1608-2053; 1609-2059; 1613-2056; 1641-2053; 1649-1930; 1651-2055; 1673-2055; 1699-2014; 1762-2061; 1822- 2055; 1856-2056; 1874-2110; 1985-2078; 2089-2474; 2089-2250; 2181-2445; 2279-2497; 2338-2956; 2356-2474; 2379- 2445; 2409-2927; 2411-2474; 2732-2995; 2734-3085; 2761-2919; 2761-2861; 2761-2857; 2761-2826; 2763-2899; 2761- 3343; 2761-3347; 2784-3051; 2788-3060; 2861-3227; 2861-3102; 2868-3126; 2894-3129; 2908-3547; 2908-3449; 2934- 3506; 2934-3472; 2949-3173; 2949-3194; 2973-3175; 2973-3150; 2978-3212; 2998-3271; 3039-3315; 3087-3694; 3094- 3317; 3104-3318; 3129-3515; 3136-3374; 3141-3515; 3181-3676; 3191-3472; 3245-3497; 3245-3483; 3258-3602; 3277- 3508; 3285-3695; 3292-3692; 3303-3539; 3303-3540; 3303-3427; 3333-3738; 3333-3736; 3338-3602; 3340-3737; 3346- 3735; 3382-3735; 3397-3741; 3453-3675; 3457-3701; 3551-3602; 3554-3735; 3588-3735; 3631-3741 Table 3 SEQ ID NO:/Template ID Component Spans 73/LG:201188.2:2002JAN18 400-4306; 3479-4069; 3505-4022; 3805-4008; 3723-4008; 3517-4009; 3571-4008; 569-4008; 3522-4008; 521-4009; 3508-4008; 3538-4008; 3517-4008; 3509-4008; 3600-4008; 3772-4008; 3699-4008; 3529-4008; 3515-4008; 3520-3999; 3558-3999; 3491-3997; 3464-3995; 3511-3990; 3540-3990; 3525-3988; 3526-3988; 3765-3982; 3366-3936; 3760-3939; 3841-3914; 3673-3915; 3620-3901; 3336-3845; 3568-3808; 3464-3799; 3279-3750; 3167-3717; 3482-3702; 3193-3687; 3501-3679; 3409-3668; 3180-3648; 3355-3632; 3161-3624; 3354-3565; 3319-3562; 3144-3562; 3470-3556; 3146-3545; 3142-3468; 3142-3414; 3307-3412; 3142-3359; 3189-3345; 3082-3329; 3112-3329; 3082-3302; 2818-3254; 2923-3226; 3084-3184; 2911-3154; 2744-3154; 2818-3136; 2643-3034; 2776-3077; 2643-3034; 2472-2944; 2516-2917; 2473-2894; 2404-2883; 2479-2684; 2478-2670; 1883-2560; 1909-2560; 1773-2317; 1835-2275; 1835-2254; 1394-2059; 1612-2053; 821-1517; 822-1460; 490-961; 185-774; 489-755; 185-685; 333-420; 1-267 74/LG:201887.16:2002JAN18 1-584; 1-579; 4-581; 71-659; 78-333; 92-550; 102-393; 102-388; 118-323; 132-580; 138-696; 155-581; 160-696; 179-442; 181-581; 191-467; 193-581; 196-580; 197-373; 200-534; 202-569; 214-548; 228-509; 228-498; 233-521; 236-551; 256-569; 261-733; 277-733; 279-553; 280-691; 282-733; 285-737; 289-586; 302-564; 313-733; 314-733; 318-508; 331-733; 348-733; 353-581; 358-710; 361-577; 368-597; 375-573; 377-569; 380-727; 383-736; 397-569; 404-581; 413-717; 420-733; 430-825; 436-581; 441-715; 444-682; 454-735; 454-733; 454-573; 456-581; 507-733; 513-902; 514-569; 558-694; 599-733; 600-733; 601-734; 601-1130; 625-842; 642-89; 651-889; 654-1148; 723-1238; 750-1230; 757-914; 762-953; 762-941; 762-977; 764- 1143; 769-1278; 773-1059; 777-1054; 793-1386; 796-1219; 829-1031; 832-966; 898-1493; 916-1166; 970-1466; 970-1185; 971-1166; 983-1214; 1000-1278; 1012-1181; 1048-1288; 1055-1316; 1044-1117; 1057-1345; 1108-1389; 1111-1787; 1134- 1577; 1127-1359; 1148-1773; 1163-1385; 1169-1278; 1202-1775; 1203-1432; 1198-1947; 1201-1457; 1213-1740; 1202- 1553; 1206-1479; 1263-1507; 1266-1544; 1276-1783; 1283-1822; 1285-1376; 1300-1456; 1294-1451; 1295-1790; 1297-1551; 1300-1553; 1304-1607; 1312-1539; 1320-1486; 1334-1449; 1349-1575; 1373-1583; 1377-1646; 1401-1865; 1401-1751; 1415-1663; 1422-1634; 1431-1672; 1434-1709; 1440-1714; 1456-1701; 1466-1714; 1472-1702; 1477-1769; 1477-1766; 1479-1772; 1479-1716; 1481-1903; 1485-2235; 1491-1721; 1492-1732; 1504-1903; 1508-1787; 1514-1786; 1543-1799; 1567-1797; 1571-1842; 1604-1783; 1612-1854; 1633-1915; 1635-1890; 1634-1840; 1642-1907; 1642-1881; 1647-1927; 1661-1885; 1684-1936; 1700-1986; 1722-1932; 1745-1981; 1758-1958; 1769-2032; 1800-2057; 1806-2015; 1844-2410; 1852-2421; 1870-2108; 1883-2423; 1920-2065; 1933-2166; 1997-2458; 2002-2455; 2001-2406; 2005-2457; 2007-2457; 2011-2234; 2030-2429; 2051-2234; 2057-2450; 2071-2330; 2084-2455; 2113-2388; 2116-2455; 2155-2455; 2156-2455; 2164-2455; 2174-2429; 2177-2455; 2185-2461; 2194-2444; 2212-2394; 2219-2455; 2236-2456; 2236-2421; 2263-2455; 2305-2455; 2315-2453; 2346-2456 Table 3 SEQ ID NO:/Template ID Component Spans 75/LG:208134.1:2002JAN18 1-733; 9-664; 94-237; 99-353; 118-813; 136-396; 173-569; 178-904; 260-843; 415-716; 476-739; 500-609; 534-780; 554- 814; 564-824; 673-880; 699-948; 732-1144; 746-1242; 839-1051; 851-1126; 858-1221; 859-998; 878-1130; 930-1512; 949- 1352; 1133-1505; 1133-1426; 1175-1398; 1182-1947; 1208-1348; 1248-1864; 1252-1429; 1311-1580; 1336-1855; 1352- 1816; 1358-1728; 1357-1611; 1357-1500; 1370-1635; 1435-1712; 1463-1681; 1501-1860; 1501-1712; 1506-1883; 1506- 1735; 1538-1853; 1537-1856; 1546-1822; 1546-1806; 1560-2057; 1560-1818; 1648-1844; 1655-2157; 1676-2015; 1694- 1855; 1699-1956; 1713-1977; 1709-1855; 1727-1965; 1764-2046; 1763-1976; 1783-2217; 1901-2119; 1901-2082; 1901- 2247; 1903-2443; 1901-2401; 1905-2167; 1905-2572; 1909-2123; 1925-2750; 1931-2218; 1952-2192; 1962-2324; 1970- 2358; 1971-2444; 1989-2487; 1999-2174; 2005-2298; 2016-2245; 2020-2229; 2023-2111; 2022-2265; 2039-2375; 2042- 2585; 2042-2773; 2042-2405; 2042-2272; 2042-2313; 2061-2322; 2071-2532; 2071-2286; 2089-2374; 2089-2350; 2090- 2235; 2101-2357; 2108-2192; 2111-2351; 2127-2882; 2137-2452; 2135-2390; 2135-2367; 2157-2692; 2195-2450; 2204-2441; 2204-2693; 2210-2457; 2212-2351; 2215-2794; 2218-2801; 2245-2498; 2248-2496; 2252-2789; 2304-2603; 2313-2802; 2336-2802; 2349-2795; 2359-2840; 2360-2597; 2368-2632; 2370-2840; 2374-2841; 2379-2840; 2384-2833; 2388-2842; 2387-2840; 2388-2650; 2394-2840; 2399-2847; 2401-2657; 2403-2633; 2410-2821; 2410-2804; 2410-2728; 2421-2870; 2423-2700; 2423-2667; 2426-2840; 2427-2840; 2441-2854; 2442-2840; 2442-2601; 2451-2712; 2452-2843; 2453-2846; 2455-2729; 2456-2840; 2457-2840; 2462-2838; 2458-2840; 2459-2839; 2462-2802; 2469-2840; 2475-2840; 2478-2840; 2491-2841; 2492-2714; 2496-2863; 2501-2755; 2503-2840; 2513-2819; 2519-2845; 2530-2838; 2528-2811; 2533-2840; 2534-2840; 2534-2682; 2536-2801; 2540-2840; 2543-2840; 2546-2840; 2549-2841; 2551-2828; 2553-2796; 2556-2840; 2558-2845; 2571-2847; 2579-2808; 2588-2840; 2590-2712; 2594-2818; 2608-2840; 2618-2840; 2625-2802; 2633-2840; 2685-2840; 2690-2840; 2690-2801; 2692-2841; 2703-2818; 2706-2840; 2714-2840; 2716-2840; 2732-2843; 2775-2840 76/LG:209924.5:2002JAN18 1-312; 1-177; 8-200; 12-223; 12-255; 15-257; 33-88; 62-562; 70-347; 83-375; 102-253; 107-364; 108-400; 122-415; 127- 452; 127-379; 131-371; 131-233; 132-234; 134-409; 134-406; 145-328; 146-419; 146-418; 146-388; 148-470; 148-424; 148- 410; 148-395; 148-329; 149-405; 150-407; 150-382; 162-437; 209-650; 212-467; 265-968; 291-880; 321-892; 361-521; 375- 649; 377-914; 406-642; 459-921; 463-960; 466-746; 487-928; 493-657; 559-1132; 573-836; 573-780; 589-1010; 601-1128; 650-942; 703-993; 726-939; 721-969; 745-1154; 788-1173; 842-997; 878-999; 879-1171; 897-1105; 1049-1165 77/LG:223060.1:2002JAN18 1-759; 255-886; 255-577; 543-1177; 582-1187; 596-813; 679-974; 798-998; 811-929; 933-1209; 938-1504; 1050-1712; 1101-1336; 1141-1252; 1172-1591; 1216-1508; 1258-1544; 1395-1650; 1427-1845; 1496-2045; 1496-1726; 1522-1782; 1552-2041; 1552-2005; 1681-1942; 1734-2002; 1764-2294; 1838-1988; 1881-2187; 1885-2421; 1917-2443; 1931-2241; 2028-2554; 2033-2262; 2071-2404; 2106-2364; 2118-2361; 2144-2617; 2190-2633; 2191-2389; 2219-2443; 2233-2443; 2289-2404; 2308-2573; 2310-2578; 2329-2443; 2383-2578; 2420-2617; 2421-2617; 2437-2577; 2458-2555 78/LG:227583.2:2002JAN18 1-744; 3-162; 165-294; 365-863; 1-176; 481-1024; 586-833; 606-939; 626-994; 627-970; 669-1034; 754-1001 79/LG:230149.12:2002JAN18 483-748; 374-745; 405-744; 391-744; 146-729; 400-708; 378-706; 410-705; 1-659; 172-564; 6-442; 6-273 Table 3 SEQ ID NO:/Template ID Compoent spans 80/LG:230509.30:2002JAN18 1-335, 29-682; 32-720; 33-731; 56-258; 77-537; 77-314; 99-702; 109-814; 124-2735; 156-698; 148-436; 161-478; 220-601; 229-652; 237-1047; 260-522; 279-528; 288-806; 295-1021; 296-749; 302-749; 341-582; 361-1109; 383-1110; 405-490; 471- 618; 496-733; 503-1038; 518-989; 535-1076; 537-700; 537-894; 541-739; 591-10151; 625-1238; 634-1111; 646-824; 646- 848; 646-890; 697-974; 706-930; 729-1180; 733-1371; 731-1172; 741-1379; 749-1012; 749-1223; 804-1098; 810-1163; 810-1289; 810-1450; 813-1452; 825-1193; 826-1113; 845-1020; 856-1217; 857-1007; 858-995; 861-1378; 937-1251; 945- 1516; 954-1515; 977-1399; 1025-1175; 1025-1264; 1047-1297; 1054-1266; 1119-1424; 1134-1552; 1158-1404; 1159-1525; 1207-1747; 1207-1460; 1206-2735; 1211-1430; 1214-1464; 1223-1911; 1225-1625; 1229-1338; 1229-1457; 1234-1417; 1246-2735; 1259-1632; 1280-1349; 1297-1556; 1309-1766; 1315-1562; 1315-1547; 1315-1868; 1328-1562; 1337-1626; 1345-1951; 1345-1570; 1353-1477; 1358-1871; 1379-1766; 1385-2142; 1393-1746; 1403-1822; 1408-1655; 1411-1665; 1416-1668; 1422-1959; 1429-1803; 1435-1950; 1464-1667; 1480-2055; 1492-1754; 1494-1735; 1496-1645; 1495-1680; 1508-1883; 1510-1887; 1510-1896; 1511-1894; 1519-1757; 1525-1882; 1525-1887; 1534-2319; 1531-1739; 1533-2245; 1534-1767; 1534-1787; 1531-1969; 1538-1770; 1542-1769; 1551-1773; 1561-1769; 1564-2271; 1571-1769; 1572-1882; 1575-2307; 1583-2184; 1589-1955; 1613-1830; 1622-1939; 1636-1810; 1643-2309; 1655-2338; 1699-2155; 1715-2332; 1747-2253; 1793-2498; 1816-2214; 1799-1973; 1799-2336; 1799-1979; 1800-1974; 1800-2149; 1800-2247; 1800-1969; 1800-2192; 1800-1991; 1800-2025; 1800-1852; 1800-2026; 1803-2070; 1803-2069; 1805-2071; 1820-2059; 1824-2016; 1830-2358; 1834-2312; 1846-2176; 1851-2549; 1871-2111; 1871-2454; 1877-2122; 1909-2135; 1922-2180; 1957-2202; 1959-2332; 1959-2349; 1975-2439; 1978-2219; 1983-2335; 1984-2358; 1990-2572; 1991-2225; 2007-2209; 2007-2213; 2013-2320; 2021-2222; 2024-2725; 2034-2286; 2035-2285; 2043-2295; 2074-2257; 2084-2320; 2085-2327; 2095-2343; 2111-2514; 2120-2357; 2134-2378; 2134-2406; 2134-2413; 2135-2314; 2193-2444; 2193-2353; 2193-2351; 2207-2353; 2218-2437; 2225-2477; 2266-2735; 2282-2735; 2284-2427; 2286-2741; 2301-2735; 2315-2723; 2327-2723; 2348-2714; 2383-2662; 2394-2735; 2395-2696; 2402-2689; 2404-2737; 2428-2723; 2442-2735; 2467-2735; 2472-2595; 2479-2725; 2481-2733; 2481-2737; 2486-2736; 2501-2725; 2520-2717; 2530-2737; 2537-2723; 2573-2723; 2607-2735; 2629-2820; 2631-2735; 2757-2958 Table 3 SEQ ID NO:/Template ID Component Spans 81/LG:230923.1:2002JAN18 1-677; 20-577; 29-292; 27-163; 30-571; 36-796; 275-933; 309-933; 344-911; 363-911; 394-883; 593-3412; 636-1242; 752- 1324; 877-1082; 1129-1385; 1726-1962; 1881-2304; 1883-2084; 1993-2229; 1993-2454; 1994-2302; 1995-2320; 2019- 2536; 2022-2224; 2022-2623; 2025-2605; 2025-2568; 2025-2288; 2033-2220; 2036-2115; 2060-2473; 2085-2286; 2152- 2423; 2234-2434; 2237-2514; 2267-2499; 2345-2788; 2363-2623; 2363-2568; 2363-2556; 2370-2627; 2372-2485; 2408- 2509; 2410-2891; 2408-2879; 2408-2679; 2418-2542; 2422-2651; 2451-2879; 2453-2658; 2491-2733; 2497-2847; 2511- 2728; 2524-2752; 2536-2877; 2537-2827; 2541-2784; 2556-2879; 2560-2752; 2568-3025; 2568-2733; 2626-2875; 2629- 3044; 2634-2879; 2656-3094; 2667-3172; 2709-2879; 2733-2879; 2750-3290; 2770-2879; 2772-3000; 2775-3063; 2775- 3009; 2782-3374; 2795-3043; 2815-3390; 2931-3147; 2931-3373; 2942-3412; 2951-3225; 2962-3412; 2967-3416; 2992- 3412; 2993-3412; 2993-3409; 2997-3315; 3007-3415; 3012-3415; 3017-3412; 3042-3416; 3042-3409; 3043-3364; 3044- 3331; 3078-3352; 3080-3384; 3089-3416; 3114-3342; 3114-3412; 3116-3412; 3118-3327; 3121-3413; 3122-3368; 3145-3412; 3166-3393; 3205-3407; 3205-3415; 3215-3409; 3223-3410; 3246-3374; 3259-3411; 3303-3412 82/LG:232307.11:2002JAN18 1-525; 51-662; 51-496; 69-662; 74-663; 142-712; 188-975; 232-423; 271-562; 271-830. 293-559; 326-573; 326-633; 325- 529; 431-958; 634-1241; 1046-1250; 1115-1613; 1115-1742; 1121-1684; 1172-1467; 1228-1894; 1228-1697; 1287-1545; 1287-1883; 1416-1542; 1521-2280; 1677-2281; 1677-2200; 1689-2071; 174-2216; 1935-2717; 1990-2222; 1990-2346; 2048-2653; 2083-2726; 2130-2844; 2227-2809; 2260-3010; 2291-2801; 2302-2595; 2297-22777; 2391-2639; 2425-2945; 2440-2998; 2470-2909; 2471-3177; 2563-2834; 2563-3046; 2585-3029; 2614-2823; 2630-2711; 2648-2810; 2678-3177; 2699-2951; 2763-3190; 2768-3049; 2771-3274; 2771-3001; 2771-3002; 2800-2985; 2815-3008; 2817-2984; 2849-3446; 2852-3105; 2885-3270; 2922-3258; 2939-3277; 2939-3363; 2952-3109; 3042-3267; 3089-3270; 3110-3372; 3133-3616; 3149-3270; 3173-3702; 3179-3429; 3179-3584; 3183-3472; 3184-3492; 3220-3744; 3310-3684; 3307-3672; 3319-3473; 3332-3539; 3344-3899; 3409-3757; 3450-3699; 3477-3830; 3510-3766; 3579-3797; 3581-3985; 3580-3857; 3583-3857; 3592-3927; 3597-3842; 3601-4189; 3624-3886; 3638-3903; 3650-4171; 3650-4162; 3656-3934; 3659-3952; 3666-3899; 3734-3924; 3738-3947; 3738-3942; 3742-3941; 3757-3842; 3768-3852; 3789-3946; 3793-4058; 3822-3939; 3872-4138; 3882-4246; 3890-4584; 3943-4558; 3953-4561; 3976-4220; 3985-4513; 3988-4586; 3992-4254; 4010-4644; 4006-4591; 4032-4628; 4044-4582; 4065-4649; 4085-4295; 4086-4631; 4085-4425; 4100-4628; 4108-4628; 4113-4218; 4111-4566; 4120-4664; 4124-4564; 4163-4398; 4189-4659; 4204-4667; 4208-4663; 4210-4666; 4213-4672; 4215-4649; 4215-4670; 4217-4672; 4217-4659; 4220-4664; 4222-4672; 4241-4663; 4249-4669; 4246-4671; 4247-4661; 4259-4664; 4259-4663; 4264-4667; 4273-4634; 4277-4672; 4278-4672; 4282-4665; 4287-4666; 4287-4671; 4297-4664; 4313-4669; 4316-4665; 4318-4667; 4319-4661; 4320-4665; 4321-4669; 4321-4672; 4326-4663; 4342-4665; 4361-4669; 4378-4665; 4389-4665; 4397-4666; 4420-4663; 4454-4663; 4455-4663; 4466-4598; 4470-4585; 4506-4666; 4529-4671; 4545-4661; 4565-4670; 4577-4669; 4581-4669 83/LG:232415.30:2002JAN18 265-904; 444-902; 1-548; 1-192 Table 3 SEQ ID NO:/Template ID Component Spans 84/LG:234121.5:2002JAN18 1-318; 162-500; 214-1041; 456-1020; 456-703; 778-1499; 954-1656; 959-1335; 961-1232; 1026-1578; 1482-1644; 1482- 1656; 1495-1653; 1500-1653; 1506-1563; 1511-1653; 1565-1806; 1583-2025; 1804-2035; 1804-2139; 1985-2503; 2062- 2519; 2108-2602; 2116-2436; 2124-2714; 2135-2466; 2256-2595; 2448-2719; 2492-2702; 2631-2885; 2655-3450; 2659- 2923; 2744-2940; 2745-3354; 2864-3204; 2871-3118; 2883-3479; 2954-3223; 2969-3403; 3001-3272; 3023-3264; 3023- 3466; 3036-3574; 3046-3568; 3084-3329; 3092-3365; 3095-3590; 3106-3552; 3106-3465; 3106-3366; 3116-3196; 3119- 3584; 3128-3584; 3139-3309; 3181-3541; 3272-3906; 3288-3789; 3323-3570; 3325-3575; 3315-3789; 3318-3771; 3325- 3922; 3323-3797; 3346-3472; 3333-3789; 3339-3785; 3411-3785; 3440-3572; 3444-3871; 3480-3985; 3510-3788; 3546- 3998; 3550-3786; 3570-4028; 3581-3989; 3592-4034; 3609-4026; 3612-4028; 3620-4028; 3655-3915; 3657-3786; 3703- 4028; 3810-4028; 3816-4028; 3862-4028; 3916-4181; 3958-4026; 4000-4181 85/LG:235713.10:2002JAN18 1-250; 18-495; 27-595; 28-717; 32-460; 36-472; 44-299; 44-423; 45-311; 46-732; 51-554; 50-307; 52-339; 54-348; 54-300; 54-296; 55-490; 55-294; 52-745; 51-168; 57-793; 57-497; 64-286; 65-751; 66-547; 66-460; 67-542; 64-144; 70-2444; 72- 641; 70-286; 70-266; 72-302; 73-456; 73-305; 75-341; 77-328; 83-802; 85-328;86-335; 86-262; 89-377; 101-643; 100-443; 126-533; 182-679; 182-682; 190-813; 235-688; 274-677; 342-496; 371-794; 418-676; 418-652; 421-1016; 427-676; 453- 1100; 482-1146; 716-1286; 746-971; 757-1041; 786-1062; 927-1097; 936-1122; 1217-1720; 1276-1545; 1307-1529; 1308- 1569; 1324-1569; 1334-1569; 1358-1569; 1381-1569; 1410-2141; 1416-1495; 1592-2098; 1603-2105; 1612-2366; 1622- 2081; 1651-2131; 1651-1921; 1676-1955; 1676-1942; 1708-2004; 1719-2020; 1719-1933; 1755-2378; 1766-2010; 1769- 2224; 1769-2004; 1774-2403; 1796-2435; 1803-2317; 1811-2407; 1814-2445; 1834-1982; 1837-1950; 1840-2436; 1841- 2389; 1870-2442; 1894-2444; 1907-2401; 1922-2398; 1936-2406; 1956-2444; 1972-2397; 1981-2338; 1983-2445; 1985- 2444; 1987-2451; 1990-2442; 1990-2444; 1992-2448; 1990-2408; 1994-2448; 1994-2444; 1996-2450; 1996-2449; 1996-2445; 1999-2444; 2002-2450; 2004-2450; 2009-2443; 2021-2388; 2031-2445; 2032-2444; 2036-2444; 2043-2417; 2051-2311; 2058-2408; 2058-2443; 2068-2444; 2084-2444; 2096-2441; 2098-2406; 2100-2448; 2109-2445; 2133-2444; 2129-2443; 2141-2448; 2151-2383; 2151-2444; 2157-2406; 2160-2444; 2166-2428; 2171-2388; 2174-2446; 2183-2441; 2191-2443; 2192-2447; 2192-2444; 2197-2433; 2252-2444; 2268-2444; 2270-2444; 2271-2444 Table 3 SEQ ID NO:/Template ID Component Spans 86/LG:236340.12:2002JAN18 1-560; 11-161; 131-757; 166-723; 183-538; 186-428; 165-380; 168-359; 168-928; 175-889; 183-646- 185-555; 188-450; 193-889; 222-889; 257-525; 266-801; 273-761; 392-595; 403-891; 431-1278; 443-1133; 446-951; 455-1139; 459-710; 489- 1221; 488-1153; 507-2971; 508-766; 526-701; 548-1142; 651-1248; 718-978; 1331-1949; 1388-2095; 1492-2007; 1525- 2110; 1599-2016; 1704-2001; 1705-2007; 1706-1905; 1740-1948; 1789-1887; 1789-2005; 1793-1881; 1818-2085; 1831- 2017; 1837-1995; 1848-2005; 1937-2007; 1940-2020; 1940-2404; 2022-2510; 2138-2498; 2165-2588; 2267-2498; 2270- 2536; 2274-2759; 2290-2512; 2291-3013; 2291-2706; 2291-2693; 2291-2680; 2291-2503; 2291-2535; 2291-2369; 2302- 2758; 2303-2498; 2303-2439; 2305-2903; 2310-2501; 2318-2801; 2321-2562; 2332-2971; 2335-2559; 2338-2744; 2350- 2951; 2350-2650; 2390-2635; 2404-2753; 2414-2888; 2415-2923; 2437-2660; 2446-2753; 2456-2739; 2486-2921; 2496- 2929; 2501-2715; 2504-2778; 2509-2967; 2515-2972; 2515-2967; 2514-2915; 2517-2967; 2518-2968; 2542-2970; 2544- 2966; 2555-2796; 2576-2801; 2579-2966; 2596-2801; 2604-2758; 2631-2967; 2648-2801; 2661-2801; 2664-2964; 2667-2801; 2678-2967; 2680-2966; 2690-2894; 2701-2966; 2711-2899; 2830-2882; 2860-2952; 2864-3013; 2883-2968; 2918-3175; 3072-3402; 3218-3704; 3222-3704; 3234-3460; 3454-3705; 3462-3884; 3490-3919; 3490-3741; 3590-3842; 3633-3882; 3634-4047; 3751-4223; 3753-4245; 3807-4053; 3877-4097; 4091-4271 87/LG:236386.2:2002JAN18 1-482; 1-225; 4-276; 16-266; 28-309; 29-321; 30-155; 30-318; 67-487; 109-487; 122-330; 145-485; 183-481; 202-481; 235- 472; 389-744; 389-738; 568-818; 575-993; 579-996; 581-817; 585-988; 605-988; 624-988; 630-996; 634-949; 651-996; 650- 982; 684-993; 686-988; 690-996; 693-976; 705-993; 708-988; 741-993; 754-983; 765-993; 767-998; 774-996; 777-980; 779- 953; 797-939; 860-988; 865-988; 890-996; 890-999; 890-1513; 908-988; 1036-1320; 1109-1660; 1589-2173; 1790-2616; 2014-2448; 2121-2353; 2137-2789; 2318-2897; 2353-3085; 2450-3897; 2460-3026; 2508-3074; 2513-3085; 2564-2868; 2610-2955; 2787-3302; 2814-3233; 2814-3053; 2822-3069; 2879-3539; 2894-3129; 2922-3068; 3030-3228; 3086-3346; 3184-3432; 3184-3355; 3198-3447; 3282-3553; 3339-3890; 3339-3574; 3351-3984; 3353-3775; 3424-3630; 3612-4154; 3640-4223; 3670-4002; 3676-3880; 3676-3979; 3733-4217; 3763-4211; 3765-4049; 3823-3914; 3822-4301; 3823-4373; 3829-4440; 3843-4314; 3860-4052; 3877-4035; 3861-4089; 3918-4647; 3949-4064; 3948-4570; 3995-4576; 3986-4232; 3986-4233; 3990-4531; 3997-4596; 4017-4513; 4045-4294; 4053-4257; 4073-4636; 4086-4499; 4086-4282; 4100-4581; 4106-4362; 4128-4587; 4121-4628; 4174-4386; 4168-4617; 4176-4614; 4179-4627; 4185-4397; 4197-4614; 4201-4618; 4210-4450; 4212-4619; 4258-4671; 4261-4617; 4279-4663; 4298-4620; 4327-4590; 4346-4666; 4350-4671; 4357-4673; 4378-4614; 4421-4547 Table 3 SEQ ID NO:/Template ID Componetn Spans 88/LG:239601.22:2002JAN18 2479-3026; 2668-2987; 2608-2983; 2598-2981; 2749-2981; 2607-2981; 2646-2981; 2539-2979; 2596-2978; 2722-2979; 2498-2977; 2503-2976; 2521-2976; 2525-2976; 2705-2974; 2870-2975; 2717-2975; 2441-2956; 2441-2955; 2441-2943; 2439-2942; 2429-2939; 2192-2881; 2479-2880; 2567-2872; 2479-2861; 2479-2859; 2479-2852; 2610-2840; 2479-2836; 2499-2836; 2525-2836; 2593-2836; 2572-2836; 2658-2836; 2665-2836; 2743-2836; 2612-2821; 2610-2791; 2476-2766; 2479-2734; 2441-2722; 2175-2714; 2479-2688; 2462-2667; 2479-2660; 2440-2656; 2437-2655; 2441-2647; 2448-2578; 2145-2295; 1848-2213; 1767-2138; 1741-2129; 1848-2112; 1780-2109; 1944-2081; 1793-2062; 1737-2016; 1694-1988; 1268-1902; 1696-1881; 1489-1894; 1709-1812; 1450-1794; 1534-1695; 1014-1600; 1331-1568; 1076-1443; 1092-1345; 816-1292; 1024-1293; 704-1247; 9461180; 660-1125; 685-1120; 576-1099; 658-1105; 663-1105; 1012-1104; 718-1103; 976-1103; 630-1102; 714-1102; 719-1102; 744-1101; 761-1102;850-1102; 655-1101; 690-1101; 711-1101; 681-1099; 906- 1101; 753-1100; 751-1099; 934-1100; 937-1099; 630-1099; 683-1099; 692-1099; 713-1099; 721-1099; 750-1099; 778-1099; 792-1099; 800-1099; 797-1099; 823-1097; 852-1099; 672-1101; 875-1099; 891-1099; 895-1099; 909-1099; 976- 1099; 984-1099; 1003-1099; 1019-1099; 915-1099; 726-1099; 649-1097; 698-1097; 711-1097; 782-1096; 792-1096; 817- 1096; 816-1096; 858-1096; 897-1096; 763-1095; 784-1095; 960-1096; 832-1094; 962-1095; 454-1099; 962-1087; 891- 1092; 634-1091; 814-1091; 656-1087; 847-1089; 599-1087; 742-1087; 653-1077; 356-1076; 899-1073; 933-1072; 681- 1071; 988-1069; 963-1067; 825-1064; 660-1064; 586-1061; 870-1062; 649-1061; 811-1060; 649-1058; 5643-1056; 774- 1056; 873-1055; 617-1042; 767-1035; 819-1024; 709-982; 686-982; 715-966; 689-965; 656-962; 664-947; 656-914; 632- 914; 645-903; 616-894; 644-888; 632-887; 607-882; 656-882; 644-881; 656-880; 618-876; 618-876; 602-864; 637-856; 506-821; 577- 821; 634-823; 252-798; 359-782; 552-783; 509-774; 155-772; 607-772; 520-758; 394-7455; 509-743; 491-730; 483-708; 421- 660; 395-645; 359-631; 363-605; 383-524; 7-520; 191-512; 182-379; 1-155 89/LG:239673.8:2002JAN18 1-207; 55-207; 79-205; 79-207; 112-445; 237-732; 240-717; 240-486; 240-467; 240-579; 240-582; 240-507; 240-482; 240- 500; 240-592; 240-540; 240-502; 255-460; 265-564; 439-879; 439-815; 439-760; 439-512; 621-882; 621-903; 822-1081; 907-1195; 912-1059; 916-1476; 974-1166; 974-1173; 974-1201; 1016-1166; 1052-1608; 1056-1199; 1073-1607; 1102- 1166; 1219-1633; 1251-1652; 1300-1529; 1319-1580; 1329-1467; 1331-1785; 1332-1718; 1332-1657; 1331-1648; 1331- 1559; 1331-1518; 1331-1451; 1331-1399; 1329-1557; 1331-2010; 1336-1414; 1340-1610; 1344-1741; 1355-1935; 1376- 1608; 1381-1542; 1426-1967; 1426-1965; 1426-1874; 1435-2014; 1435-1974; 1441-2052; 1442-1686; 1504-1735; 1519- 1815; 1523-1775; 1550-1743; 1556-1805; 1564-1789; 1568-1856; 1570-2155; 1584-1804; 1586-1840; 1605-1872; 1614- 1807; 1616-1920; 1616-1887; 1616-1874; 1626-1887; 1629-1888; 1640-2166; 1649-2032; 1650-2289; 1674-1878; 1680- 1966; 1685-2173; 1698-1966; 1719-2156; 1720-2167; 1756-1987; 1771-2039; 1773-2036; 1807-2087; 1842-2373; 1853- 2110; 1857-2173; 1871-2575; 1884-2155; 1904-2029; 1917-2147; 1928-2522; 1929-2187; 1984-2501; 1991-2565; 2001-2619; 1994-2230; 1999-2637; 2013-2450; 2039-2532; 2041-2291; 2040-2298; 2045-2567; 2052-2195; 2059-2306; 2091-2371; 2100-2747; 2103-2605; 2117-2383; 2169-2417; 2178-2776; 2262-2752 Table 3 SEQ ID NO:/Template ID Component Spans 90/LG:249905.45:2002JAN18 1-573; 1-211; 4-580; 11-244; 47-247; 514-1128; 519-655; 539-638; 948-1603; 1110-1481; 1404-1601; 1457-1707; 1459- 1697; 1465-1730; 1467-1729; 1610-1902; 1659-2176; 1708-2207; 1800-2442; 1800-2507; 1842-2134; 1845-2066; 1860- 2164; 1903-2214 91/LG:250038.3:2002JAN18 1-357; 9-346; 9-459; 9-464; 9-832; 1-249; 15-540; 14-162; 18-758; 22-262; 24-257; 51-314; 51-300; 61-311; 59-372; 59- 551; 65-458; 99-358; 102-468; 163-537; 243-391; 550-1139; 574-854; 619-862; 710-1289; 877-1477; 987-1537; 989-1224; 1103-1508; 1198-1702; 1415-2151; 1461-1712; 1499-2135; 1526-2052; 1661-2272; 1665-2154; 1699-2159; 1711-2250; 1714-2250; 1788-2094; 1999-2250; 2077-2357; 2179-2625; 2179-2412; 2199-2704; 2236-2499; 2267-5881; 2344-2910; 2361-2966; 2361-2786; 2361-2728; 2361-2599; 2447-2679; 2553-2706; 2567-2819; 2670-2972; 2673-3253; 2708-3165; 2722-3290; 2724-3232; 2730-3193; 2732-3131; 2752-2971; 2921-3292; 2942-3291; 2953-3212; 3081-3291; 3101-3381; 3120-3392; 3131-3359; 3176-3665; 3176-3393; 3242-3743; 3242-3776; 3245-3468; 3267-3858; 3268-3761; 3269-3477; 3338-3605; 3370-3898; 3426-3685; 3476-3684; 3458-4174; 3512-3962; 3520-3971; 3527-3741; 3552-4016; 3554-3756; 3559-3786; 3577-3691; 3579-4168; 3635-4286; 3646-3784; 3648-3884; 3716-3983; 3772-4078; 3783-4065; 3783-4027; 3820-4051; 3833-4408; 3875-4150; 3898-4109; 3898-4077; 3944-4153; 3947-4289; 3950-4289; 3973-4426; 3983-4225; 3997-4242; 4018-4289; 4023-4264; 4033-4350; 4032-4542; 4068-4321; 4079-4544; 4078-4320; 4085-4355; 4094-4841; 4105-4395; 4109-4632; 4130-4316; 4134-4236; 4143-4760; 4140-4678; 4148-4613; 4148-4746; 4155-4725; 4166-4521; 4175-4743; 4194-4459; 4207-4488; 4230-4524; 4231-6885; 4261-4728; 4281-4751; 4285-4748; 4288-4750; 4287-4704; 4306-4750; 4306-4747; 4306-4687; 4308-4719; 4311-4750; 4311-4672; 4311-4462; 4311-4747; 4315-4747; 4324-4727; 4332-4547; 4337-4788; 4338-4849; 4318-4713; 4341-4747; 4352-4844; 4368-4748; 4368-4747; 4382-4728; 4384-4642; 4383-4852; 4388-4997; 4393-4848; 4394-4536; 4398-4747; 4402-4752; 4404-4750; 4404-4747; 4405-4676; 4406-4849; 4408-4852; 4394-5034; 4411-4707; 4419-4748; 4438-4744; 4437-4682; 4462-4730; 4505-4847; 4507-4850; 4509-4850; 4525-4847; 4526-4725; 4528-4747; 4528-4708; 4540-4747; 4543-4827; 4548-5183; 4551-4718; 4552-5191; 4554-4747; 4556-5207; 4560-4852; 4615-5233; 4565-4748; 4583-4747; 4583-4749; 4679-5433; 4646-4908; 4698-4747; 4761-4995; 4770-5265; 4773-5026; 4852-5479; 4853-5068; 4877-5443; 4957-5283; 4958-5508; 5082-5317; 5020-5270; Table 3 SEQ ID NO:/Template ID Component Spans 5114-5335; 5114-5315; 5114-5296; 5114-5287; 5114-5262; 5114-5260; 5114-5256; 5045-5338; 5098-5234; 5127-5669; 5127-5494; 5128-5285; 5091-5743; 5130-5559; 5136-5393; 5133-5242; 5124-5674; 5128-5400; 5172-5627; 5172-5646; 5172-5626; 5173-5440; 5191-5319; 5146-5768; 5183-5629; 5183-5631; 5185-5630; 5192-5625; 5200-5643; 5202-5629; 5169-5540; 5169-5410; 5215-5646; 5216-5660; 5230-5625; 5240-5645; 5240-5625; 5245-5625; 5194-5532; 5250-5600; 5253-5625; 5180-5543; 5266-5727; 5282-5601; 5246-5488; 5258-5412; 5217-5549; 5217-5529; 5228-5650; 5234-5660; 5281-5831; 5255-5570; 5258-5547; 5265-5565; 5318-5793; 5321-5542; 5445-5721; 5478-5733; 5445-5760; 5450-5606; 5455-5643; 5464-5643; 5466-5743; 5468-5644; 5470-5642; 5479-5644; 5491-5675; 5443-5660; 5458-5538; 5460-5686; 5541-5701; 5673-5793; 5663-5910; 5695-5969; 5705-5789; 5715-5947; 5722-5977; 5766-5983; 5769-5983; 5791-5983; 5800-6247; 5803-5983; 5835-5983; 5891-5983; 6179-6497; 6183-6367; 6183-6402; 6184-6458; 6184-6398; 6184-6379; 6184-6270; 6203-6690; 6203-6447; 6209-6504; 6211-6620; 6241-6503; 6247-6586; 6248-6533; 6253-6731; 6298-6540; 6300-6559; 6315-6565; 6329-6628; 6384-6647; 6509-6622; 6548-6737 93/LG:252800.19:2002JAN18 353-605; 344-602; 353-602; 276-600; 353-599; 500-599; 343-599; 353-593; 221-583; 332-580; 107-551; 353-544; 1-540; 201-500; 353-452; 12-254 93/LG:253580.6:2002JAN18 1-650; 19-607; 151-559; 237-612; 237-491; 253-1298; 254-833; 302-874; 337-619; 353-591; 407-820; 371-651; 404-648; 443-895; 458-973; 527-1081; 592-964; 604-1064; 627-1070; 696-920; 716-1144; 717-984; 719-845; 760-937; 851-1242; 887-1098; 893-1288; 922-1355; 937-1277; 941-1427; 936-1354; 975-1404; 975-1265; 980-1266; 1044-1363; 1044-1265; 1048-1314; 1056-1712; 1060-1352; 1060-1363; 1065-1722; 1092-1459; 1094-1353; 1114-1400; 1128-1687; 1125-1366; 1131-1361; 1144-1373; 1178-1444; 1189-1668; 1189-1450; 1192-1465; 1196-1371; 1200-1495; 1201-1360; 1218-1468; 1222-1446; 1227-1359; 1232-1492; 1242-1496; 1243-1369; 1246-1536; 1261-1714; 1286-1337; 1297-1523; 1298-1525; 1299-1572; 1329-1406; 1369-1647; 1377-1714; 1382-1816; 1383-1622; 1385-1621; 1385-1616; 1385-1602; 1385-1603; 1385-2083; 1389-1618; 1394-1634; 1405-1603; 1408-1651; 1412-1656; 1421-1849; 1425-1575; 1428-1668; 1436-1705; 1441-1708; 1448-1712; 1458-1821; 1481-1723; 1491-1708; 1507-1669; 1540-1813; 1540-1772; 1547-1837; 1547-1800; 1548-1812; 1561-1801; 1563-1852; 1565-1843; 1568-1785; 1575-1847; 1577-1831; 1578-1829; 1579-1840; 1585-1858; Table 3 SEQ ID NO:/Template ID Component Spans 1588-1871; 1593-2020; 1597-1870; 1604-1870; 1604-1872; 1610-1933; 1650-1887; 1651-1874; 1651-1844; 1654-1873; 1663-1927; 1664-1893; 1664-1884; 1667-2243; 1667-1940; 1684-2147; 1688-1901; 1688-1876; 1690-1954; 1696-1982; 1697-1922; 1701-1915; 1702-1941; 1703-1920; 1704-1766; 1707-1965; 1711-2213; 1719-2263; 1719-1984; 1720-2013; 1729-1973; 1732-2042; 1741-1963; 1760-1910; 1766-2336; 1766-1911; 1772-2301; 1771-2013; 1772-2013; 1773-1977; 1775-1986; 1776-1983; 1777-2065; 1777-2043; 1802-2315; 1805-2010; 1805-2009; 1805-2007; 1805-1975; 1820-1991; 1821-2198; 1832-2201; 1836-2076; 1840-2092; 1843-2120; 1847-2069; 1849-2077; 1855-2113; 1857-2162; 1859-2089; 1862-2110; 1864-2035; 1863-2029; 1870-2256; 1870-2140; 1870-2121; 1870-2112; 1875-2120; 1877-2804; 1877-2165; 1881-2526; 1881-2146; 1888-2175; 1895-2454; 1902-2132; 1904-2053; 1910-2250; 1912-2508; 1912-2143; 1913-2024; 1914-2256; 1930-2560; 1937-2171; 1937-2199; 1939-2195; 1940-2222; 1947-2199; 1955-2202; 1961-2076; 1965-2236; 1974-2480; 1974-2485; 1980-2124; 1981-2241; 1994-2124; 1998-2260; 2019-2290; 2044-2339; 2046-2305; 2049-2316; 2054-2378; 2055-2322; 2055-2283; 2059-2579; 2059-2292; 2059-2291; 2067-2729; 2067-2514; 2089-2329; 2095-2332; 2095-2284; 2096-2359; 2096-2786; 2101-2521; 2102-2752; 2103-2355; 2105-2513; 2106-2513; 2105-2382; 2109-2374; 2113-2373; 2115-2368; 2122-2382; 2126-2377; 2128-2261; 2129-2406; 2133-2698; 2110-2804; 2137-2284; 2143-2621; 2154-2405; 2156-2455; 2172-2377; 2176-2513; 2193-2766; 2198-2477; 2198-2464; 2196-2463; 2201-2804; 2211-2479; 2215-2765; 2228-2493; 2229-2463; 2230-2471; 2239-2483; 2253-2502; 2257-2547; 2261-2536; 2260-2548; 2254-2804; 2262-2571; 2276-2801; 2279-2514; 2283-2571; 2289-2543; 2289-2539; 2289-2528; 2291-2544; 2292-2524; 2297-2394; 2299-2744; 2307-2762; 2311-2565; 2330-2583; 2334-2766; 2337-2560; 2341-2804; 2341-2628; 2341-2538; 2342-2801; 2349-2803; 2355-2801; 2361-2804; 2359-2801; 2360-2801; 2377-2803; 2365-2808; 2368-2809; 2368-2807; 2371-2811; 2373-2456; 2374-2801; 2375-2810; 2384-2477; 2383-2810; 2383-2801; 2384-2682; 2386-2633; 2387-2804; 2386-2583; 2389-2806; 2389-2594; 2390-2594; 2391-2658; 2393-2768; 2396-2470; 2395-2804; 2397-2615; 2398-2594; 2400-2648; 2407-2594; 2410-2804; 2414-2800; 2416-2594; 2417-2807; 2430-2804; 2430-2636; 2432-2785; 2432-2804; 2432-2660; 2439-2717; 2442-2629; 2444-2801; 2449-2817; 2449-2799; 2456-2804; 2456-2654; 2464-2802; 2466-2749; 2466-2698; 2469-2662; 2481-2689; 2488-2797; 2484-2800; 2484-2680; 2485-2804; 2485-2680; 2489-2805; 2490-2804; 2501-2773; 2508-2805; 2510-2776; 2509-2764; 2511-2801; 2510-2732; 2512-2747; 2513-3058; 2515-2763; 2515-2760; 2515-2804; 2517-2801; 2518-2771; 2518-2594; 2520-2571; 2522-2806; 2523-2800; 2525-2749; 2530-2810; 2535-2756; 2540-2817; 2542-2721; 2552-2798; 2567-2804; 2567-2781; 2570-2689; 2583-3064; 2590-2800; 2595-3095; 2595-2870; 2628-2801; 2640-2799; 2655-3098; 2655-2931; 2665-3099; 2668-3099; 2685-2804; 2686-2804; 2689-3086; 2691-2801; 2732-2801; 2749-2804; 2776-3045; 2821-3426; 2829-3099; 2858-3089; 2863-3109; 2970-3205; 3006-3292; 3006-3102; 3334-3729; 3334-3604; 3433-3792; 3434-3781; 3573-3805; 3601-3704; 3634-4188; 3963-4657; 4000-4225; 4086-4327; 4120-4630; 4137-4445; 4203-4675; 4215-4669; 4238-4668; 4245-4670; 4263-4670; 4263-4624; 4267-4669; 4281-4526; 4282-4536; Table 3 SEQ ID NO:/Template ID Component Spans 4284-4668; 4294-4669; 4294-4567; 4300-4668; 4311-4668; 4342-4668; 4372-4668; 4373-4596; 4383-4665; 4399-4669; 4422-4668; 4432-4668; 4447-4668; 4455-4668; 4482-4668; 4525-4668; 4612-4766; 4683-4748; 1845-2203; 2383-2888; 2229-2787; 1709-2321; 173-785; 1768-2384; 1585-2274; 1464-2235; 1959-2690; 104-265; 3837-4011 94;LG:271509.8:2002JAN18 1-452; 151-717; 201-404; 254-906; 285-687; 300-807; 348-949; 351-927; 350-628; 663-1360; 763-1350; 792-1479; 817- 1353; 825-1361; 916-1479; 1396-2032; 1561-2078; 1615-2289; 1722-2297; 1765-2365; 1765-2347; 2040-2650; 2047-2509; 2109-2216; 2277-2639; 2556-3251; 2760-3377; 2763-3380; 2792-3496; 2840-3427; 2924-3496; 2924-3517; 3000-3517; 3084-3496; 3330-4203; 3328-3906 95/LG:277161.30:2002JAN18 1-645; 38-453; 53-716; 126-453; 212-453; 359-840; 364-453; 386-891; 538-827; 545-763; 599-1164; 630-1419; 632-774; 682-897; 779-1137; 971-1586; 1072-1666; 1075-1319; 1135-1678; 1187-1752; 1196-1685; 1557-1751; 1569-2211; 1767- 2019; 1781-2023; 1783-2300; 1798-2451; 1961-2172; 2008-2230; 2060-2245; 793-1076; 815-1119 96;LG:330739.4:2002JAN18 657-1142; 659-1142; 654-1142; 730-1142; 773-1142; 716-1140; 688-1108; 510-1085; 510-1055; 733-1022; 542-871; 542- 797; 470-790; 270-740; 542-692; 336-548; 381-487; 1-458; 1-155 97;LG:331470.6:2002JAN18 1-434; 1-564; 14-446; 30-238; 30-299; 37-235; 44-297; 48-308; 50-466; 90-638; 213-695; 253-880; 288-527; 297-787; 382- 653; 399-695; 409-805; 448-730; 511-797; 512-1036; 602-1006; 588-1100; 691-958; 670-997; 671-997; 670-993; 703- 1093; 747-1284; 812-1125; 877-1604; 883-1078; 928-1421; 928-1384; 934-1561; 932-1126; 935-1582; 1060-1621; 1026- 1785; 1056-1421; 1077-1382; 1176-1417; 1185-1421; 1704-4207; 1760-2029; 1760-2199; 2213-2756; 2269-2839; 2269- 2515; 2269-2499; 2271-2443; 2275-2388; 2313-2609; 2363-3088; 2422-2611; 2444-2687; 2469-2700; 2591-3195; 2607- 2801; 2664-2916; 2691-3089; 2691-2954; 2701-2987; 2710-3134; 2717-3453; 2743-2896; 2748-3062; 2759-3261; 2767- 3028; 2778-3040; 2787-3005; 2826-3047; 2835-3029; 2855-3257; 2880-3101; 2882-3122; 2905-3503; 2923-3244; 2937- 3451; 2940-3228; 2953-3185; 2972-3372; 2998-4207; 3000-3275; 3007-3246; 3077-3350; 3077-3268; 3077-3459; 3077- 3637; 3077-3627; 3077-3533; 3095-3275; 3098-3379; 3110-3680; 3143-3249; 3147-3423; 3152-3744; 3152-3406; 3152- 3401; 3153-3401; 3185-3459; 3184-3456; 3201-3414; 3203-3475; 3203-3476; 3205-3789; 3204-3464; 3244-3373; 3250-3518; 3252-3817; 3260-3558; 3280-3546; 3306-3538; 3311-3528; 3312-3803; 3351-3804; 3352-3636; 3359-3899; 3360-3664; 3365-3782; 3389-3685; 3390-3810; 3397-3802; 3429-3897; 3429-3667; 3430-3640; 3445-3708; 3445-3657; 3450-3912; 3453-4133; 3454-3674; 3461-3749; 3462-3912; 3456-3879; 3487-4091; 3508-3775; 3530-4155; 3530-3789; 3539-4104; 3547-3857; 3548-3816; 3560-3817; 3568-4080; 3617-3900; 3625-4019; 3625-3893; 3628-3897; 3633-4115; 3637-3809; 3638-3904; 3642-3996; 3652-3908; 3653-4115; 3670-4148; 3672-4084; 3672-4012; 3672-3977; 3672-3945; 3672-3824; 3672-3811; 3672-4076; 3672-3831; 3673-4086; 3673-3830; 3674-3783; 3863-3925; 3692-3828; 3706-4275; 3704-4095; 3710-3973; 3720-3956; 3731-3979; 3731-3973; 3731-3972; 3737-4107; 3746-4064; 3745-3992; 3753-4038; 3749-4065; 3749-4040; 3754-4164; 3760-3954; 3774-3947; 3773-4286; 3772-3979; 3785-3930; 3781-4057; 3783-4333; 3801-4338; 3804-4059; 3804-4201; 3803-4012; 3808-4202; 3808-4101; 3814-4206; 3815-4201; 3819-4073; 3819-4006; 3832-4101; 3827-4105; 3835-4114; 3839-4305; 3847-4685; 3847-4094; 3850-3999; 3849-4447; 3858-4203; 3863-4103; Table 3 SEQ ID NO:/Template ID Component Spans 3868-4458; 3884-4181; 3884-4150; 3856-4043; 3860-4426; 3858-4090; 3901-4207; 3902-4179; 3922-4214; 3917-4546; 3929-4170; 3931-4172; 3932-4319; 3935-4180; 3947-4188; 3945-4514; 3954-4612; 3960-4407; 3960-4354; 3954-4097; 3932-4010; 3976-4646; 3994-4240; 3990-4464; 4009-4101; 4013-4191; 4027-4494; 4036-4506; 4046-4529; 4048-4292; 4053-4243; 4056-4566; 4056-4340; 4058-4340; 4057-4332; 4064-4531; 4081-4522; 4077-4557; 4078-4273; 4074-4199; 4080-4521; 4082-4348; 4088-4514; 4092-4558; 4095-4567; 4107-4219; 4103-4330; 4111-4375; 4113-4563; 4114-4563; 4115-4319; 4120-4571; 4121-4563; 4122-4558; 4123-4571; 4125-4567; 4126-4557; 4127-4564; 4134-4566; 4131-4376; 4144-4563; 4142-4684; 4146-4375; 4147-4563; 4151-4569; 4151-4563; 4154-4567; 4154-4226; 4157-4563; 4169-4576; 4162-4711; 4172-4570; 4174-4574; 4174-4570; 4175-4565; 4180-4577; 4170-4254; 4185-4443; 4137-4926; 4183-4457; 4133-4421; 4156-4511; 4218-4778; 4214-4758; 4160-4501; 4169-4500; 4228-4558; 4169-4402; 4224-4459; 4170-4509; 4230-4425; 4237-4331; 4251-4499; 4198-4416; 4201-4504; 4208-4514; 4259-4519; 4205-4505; 4208-4505; 4213-4500; 4269-4538; 4307-4582; 4307-4576; 4307-4528; 4293-4788; 4316-4581; 4319-4585; 4324-4582; 4324-4584; 4327-4573; 4305-4866; 4330-4585; 4318-4588; 4337-4566; 4273-4500; 4277-4505; 4336-4566; 4337-4622; 4349-4573; 4297-4501; 4426-4575; 4377-4611; 4390-5084; 4394-4613; 4458-4653; 4559-4863p 4703-5331; 4991-5452; 5031-5634; 5405-5948; 5616-6223; 6008-6191; 6107-6684; 6315-6889; 6460-6785; 6630-7203; 6870-7229; 7109-7195; 2800-3308; 5415-6223; 2207-2977; 52-831; 2019-2279; 2418-3106; 44-742; 2583-3255; 2365-3021; 2944-3603; 15-665; 2713-3355; 1072-1408; 3099-3254; 724-890; 1217-1410; 6498-6603; 5634-5738; 4315-4672; 4315-4682; 4009-4409; 3248-3678; 4523-4995; 2238- 2849; 3017-3619; 2684-3267 98;LG:331661.1:2002JAN18 1-613; 1-573; 1-515; 218-830; 509-983; 509-1178; 522-664; 774-1195; 1023-1305; 1157-1679; 1189-1646; 1234-1715; 1235-1351; 1235-1445; 1263-1338; 1607-2018; 1656-1929; 1661-1913; 1726-2293; 1746-2033; 1748-1988; 1758-2233; 1773-2396; 1781-2019; 1790-2252; 1856-2080; 1884-2503; 1885-2444; 1905-2402; 1955-2340; 1955-2574; 1959-2157; 1959-2474; 1961-2096; 1990-2232; 1994-2239; 2024-2129; 2025-2353; 2037-2158; 2029-2557; 2046-2307; 2046-2332; 2065-2313; 2065-1308; 2081-2516; 2077-2781; 2111-2297; 2105-2625; 2105-2628; 2150-2434; 2178-2844; 2221-2824; 2235-2803; 2236-2673; 2236-2450; 2241-2855; 2277-2885; 2289-2562; 2299-3000; 2299-2907; 2307-2850; 2392-2887; 2423-2926; 2469-2933; 2471-2680; 2479-2925; 2488-2926; 2489-2886; 2488-2728; 2510-2922; 2541-2888; 2544-2788; 2576-2926; 2577-2848; 2626-2925; 2686-2922; 2742-2926; 2749-2878; 2773-2929 99/LG:332032.17:2002JAN18 1-239; 5-560; 14-187; 15-616; 22-259; 39-570; 42-509; 43-407; 42-319; 46-279; 47-311; 122-662; 142-406; 149-732; 213- 384; 217-447; 300-835; 318-566; 333-774; 363-640; 367-851; 375-664; 412-857; 418-854; 426-862; 434-702; 440-711; 444- 683; 460-711; 478-591; 502-871; 525-785; 545-851; 561-850; 602-847; 609-711; 620-851; 632-851; 726-853 Table 3 SEQ ID NO:/Template ID Component Spans 100/LG:332431.2:2002JAN18 1-728; 450-708; 493-1169; 511-732; 511-811; 522-781; 535-1147; 540-710; 559-909; 597-1132; 597-858; 608-1244; 663- 1169; 684-973; 736-1214; 737-1135; 737-1269; 747-1162; 747-1205; 765-1232; 765-1033; 765-1240; 766-1207; 771-1216; 797-1172; 797-1009; 797-1223; 797-1227; 797-1230; 797-1236; 797-1231; 797-1094; 799-973; 799-1155; 903-1451; 908- 1478; 932-1400; 947-1508; 947-1404; 950-1404; 1003-1404; 1007-1404; 1030-1407; 1035-1478; 1031-1510; 1039-1404; 1044-1466; 1051-1509; 1052-1403; 1108-1497; 1118-1472; 1123-1387; 1148-1594; 1187-1581; 1207-1498; 1221-1440; 1233-1498; 1258-1661; 1272-1594; 1275-1799; 1305-2069; 1315-1524; 1360-1580; 1507-2281; 1583-1804; 1588-1793; 1705-2285; 1762-2018; 1771-2050; 1836-2057; 1976-2182; 2137-2369 101/LG:335173.4:2002JAN18 1241-1464; 1033-1378; 1187-1373; 1222-1329; 1264-1323; 880-1243; 880-1243; 1020-1243; 886-1129; 535-988; 29-765; 36-762; 1- 4728; 36-736 102/LG:336529.3:2002JAN18 1-631; 393-938; 610-1125; 616-4637; 620-1004; 627-1043; 636-1024; 647-1203; 661-1231; 751-1083; 754-976; 758-1083; 803-1292; 807-1278; 814-1381; 819-1381; 1028-1671; 1123-1671; 1163-1831; 1188-1849; 1319-1689; 1319-1608; 1327- 1766; 1369-1831; 1371-1725; 1427-1483; 1647-2252; 1647-2372; 1911-2436; 1979-2193; 2265-2706; 2266-2540; 2283- 2425; 2357-2754; 2356-2925; 2357-2997; 2418-3059; 2726-3367; 2767-3277; 2797-2997; 2814-3050; 2833-3087; 2853- 3018; 3022-3292; 3026-3483; 3038-3363; 3173-3300; 3191-3369; 3387-3830; 3387-3821; 3388-3778; 3389-3709; 3389- 3785; 3392-3800; 3392-3861; 3392-3847; 3392-3822; 3393-3727; 3395-3830; 3395-3829; 3396-3819; 3399-3687; 3435- 3682; 3441-3624; 3441-3905; 3453-3669; 3453-3866; 3453-3574; 3453-3601; 3456-3694; 3559-4015; 3615-3943; 3624- 4106; 3624-3890; 3679-3894; 3702-4337; 3712-4053; 3725-4057; 3747-4183; 3767-4355; 3784-4053; 3838-4053; 3860- 4057; 3866-4059; 3899-4019; 3906-4055; 3907-4057; 3923-4244; 3923-4079; 3951-4426; 3954-4174; 3954-4180; 3954- 4175; 3954-4177; 3955-4185; 3960-4091; 3970-4105; 4024-4480; 4111-4561; 4114-4415; 4114-4267; 4114-4482; 4114-4344; 4114-4321; 4114-4400; 4138-4374; 4156-4570; 4165-4319; 4166-4750; 4166-4803; 4186-4432; 4210-4417; 4226-4481; 4228-4517; 4261-4648; 4294-4531; 4300-4538; 4315-4571; 4331-2579; 4341-4717; 4428-4639; 4428-4655; 4433-4999; 4452-4599; 4452-4637; 4454-5058; 4470-4710; 4478-4801; 4482-4635; 4497-5071; 4500-4716; 4503-4557; 4512-4782; 4515-4811; 4524-4690; 4540-4638; 4568-4829; 4582-5124; 4610-5161; 4681-5161; 4692-5162; 4699-5163; 4700-5157; 4705-5157; 4706-5163; 4727-5157; 4731-5162; 4735-5098; 4743-4982; 4748-5162; 4790-5162; 4807-4998; 4810-5157; 4811-5023; 4811-5123; 4811-5110; 4811-5156; 4841-5162; 4849-5162; 4881-5123; 4895-5162; 4897-5146; 4915-5157; 4951-5108; 4988-5177; 5000-5162; 5010-5478; 5013-5318; 5029-5601; 5053-5469; 5064-5160; 5084-5162; 5088-5336; 5088-5390; 5096-5444; 5096-5500; 5097-5204; 5113-5417; 5133-5689; 5136-5677; 5138-5402; 5158-5385; 5166-5429; 5172-5399; 5202-5670; 5219-5427; 5219-5450; 5224-5785; 5258-5659; 5418-5670; 5533-5809; 5549-5776; 5555-5829; 5567-5811; 5581-5806; 5606-5890; 5626-5858; 5656-5964; 5713-6185; 5736-6008; 5944-6185; 5957-6185; 6099-6369; 6120-6693; 6127-6825; 6141-6259; 6158-6413; 6324-6585; 6364-6807; 6366-6747; 6455-6868; 6462-6739; 6497-6784; 6511-6935; 6722-7307; 6743-6977; 6793-6977; 6823-7182; 6909-7144; 6994-7173; 7075-7277; 7180-7811; 7311-7923; 7321-7811; 7558-7811; 7572-7974 Table 3 SEQ ID NO:/Template ID Component Spans 103/LG:338001.2:2002JAN18 1-444; 1-265; 12-275; 27-458; 73-464; 81-458; 155-458; 221-473; 238-966; 732-1240; 737-844; 769-1044; 769-1151; 769- 1214; 769-848; 769-861; 769-911; 769-948; 769-1116; 772-924; 772-945; 772-1118; 772-894; 778-1002; 780-1052; 788- 1311; 804-1069; 828-1450; 855-1057; 974-1652; 1003-1247; 1013-1638; 1040-1278; 1061-1384; 1088-1638; 1096-1664; 1214-1660; 1223-1538; 1293-1432; 1294-1687; 1298-1735; 1314-1738; 1315-1537; 1340-1698; 1342-1735; 1347-1738; 1345-1735; 1364-1623; 1365-1634; 1407-1738; 1411-1734; 1416-1738; 1428-1742; 1453-1700; 1476-1738; 1525-1742 104/LG:338469.4:2002JAN18 1-552; 457-711; 625-1152; 698-1277; 928-1193; 953-1543; 972-1212; 984-1384; 1102-1276; 1167-1353; 1169-1419; 1178- 1446; 1207-1747; 1207-1262; 1219-1722; 1219-1665; 1235-1490; 1254-1587; 1269-1499; 1271-1660; 1274-1510; 1296- 1932; 1300-1894; 1334-1750; 1361-1666; 1365-1724; 1370-1610; 1386-1786; 1422-1677; 1445-1725; 1452-1706; 1470- 1584; 1474-1741; 1475-1729; 1476-1732; 1490-2015; 1490-1773; 1490-1743; 1490-1855; 1512-1930; 1547-1821; 1568- 1889; 1582-1848; 1591-1895; 1591-1832; 1608-2028; 1615-2088; 1616-1882; 1621-2086; 1656-1913; 1657-1957; 1658- 1924; 1662-1863; 1674-1756; 1697-1977; 1719-1987; 1726-1972; 1734-2213; 1738-2426; 1738-2371; 1749-1981; 1751- 2012; 1763-2069l 1768-2008; 1772-2037; 1791-2038; 1841-2066; 1868-2089; 1886-2184; 1888-2131; 1898-2087; 1958- 2211; 1999-2232; 2020-2275; 2035-2294; 2037-2531; 2038-2323; 2054-2452; 2055-2318; 2054-2291; 2061-2617; 2065- 2322; 2071-2326; 2070-2305; 2070-2264; 2075-2526; 2075-2318; 2082-2227; 2084-2319; 2094-2195; 2096-2306; 2105- 2331; 2105-2217; 2140-2378; 2140-2293; 2164-2638; 2175-2435; 2175-2465; 2181-2470; 2188-2399; 2193-2707; 2206-2473; 2213-2420; 2220-2449; 2231-2830; 2245-2452; 2248-2494; 2254-2530; 2257-2497; 2273-2464; 2275-2496; 2275-2502; 2282-2581; 2287-2468; 2291-2533; 2293-2892; 2299-2571; 2314-2871; 2328-2523; 2330-2605; 2333-2567; 2337-2779; 2340-2911; 2349-2577; 2350-2626; 2369-2693; 2373-2589; 2377-2871; 2386-2887; 2392-2625; 2396-2689; 2404-2889; 2405-2891; 2409-2679; 2466-2641; 2468-2599; 2469-2935; 2476-2931; 2479-2933; 2480-2773; 2483-2933; 2487-2931; 2501-2764; 2501-2758; 2512-2931; 2515-2923; 2515-2754; 2515-2745; 2516-2930; 2516-2892; 2534-2931; 2543-2833; 2563-2930; 2564-2926; 2567-2930; 2575-2887; 2574-2829; 2581-2930; 2585-2834; 2606-2925; 2605-2925; 2620-2930; 2621-2888; 2621-2765; 2646-2925; 2650-2925; 2667-2929; 2690-2931; 2695-2896; 2701-2934; 2703-2934; 2729-2926; 2731-2932; 2738-2853; 2753-2914; 2762-2926; 2822-2937; 2831-2930; 2875-2930 Table 3 SEQ ID NO:/Template ID Component Spans 105/LG:344659.1:2002JAN18 8-671; 1-781; 9-757; 9-732; 9-550; 9-776; 30-614; 34-787; 52-479; 61-348; 197-717; 297-584; 297-919; 315-781; 347-848; 343-782; 391-819; 411-665; 411-781; 431-817; 464-823; 480-803; 510-820; 565-1130; 587-781; 592-1158; 665-1165; 687- 818; 835-1193; 835-1109; 849-1134; 888-1340; 885-1324; 908-1144; 1171-1628; 1185-1639; 1295-1885; 1355-1628; 1355- 1602; 1355-1593; 1423-1673; 1535-1932; 1601-2142; 1608-1768; 1621-2117; 1701-1797; 1985-2299; 1989-2203; 2001- 2251; 2069-2364; 2069-2288; 2163-2423; 2163-2836; 2356-2633; 2505-3010; 2505-2719; 2537-2749; 2559-2837; 2564- 2684; 2588-3212; 2642-2748; 2651-2913; 2704-2913; 2749-3008; 2764-3236; 2838-3089; 2854-3094; 2859-3374; 2907- 3572; 2919-3148; 2928-3201; 2985-3502; 2985-3397; 2985-3191; 2985-3181; 2985-3148; 2985-2075; 2986-3170; 2989- 3275; 2989-3192; 2989-3129; 3062-3306; 3081-3649; 3981-3593; 3081-3308; 3081-3292; 3102-3675; 3119-3710; 3118- 3390; 3133-3382; 3190-3275; 3192-3446; 3201-3666; 3236-3495; 3236-3488; 3236-3475; 3236-3391; 3237-3795; 3248- 3514; 3278-3497; 3311-3558; 3319-3905; 3372-3636; 3378-3830; 3381-3621; 3387-3638; 3420-3835; 3422-3858; 3435-3850; 3435-3905; 3435-3693; 3441-3875; 3447-3713; 3447-3907; 3460-3905; 3462-3711; 3469-3905; 3469-3911; 3481-3907; 3486-3658; 3488-3805; 3503-3909; 3503-3907; 3503-3902; 3510-3905; 3519-3775; 3535-3905; 3544-3831; 3565-3904; 3625-3875; 3670-3865; 3715-3865; 3759-3865 106/LG:345278.38:2002JAN18 1-574; 7-582; 126-564; 257-805; 336-582; 364-621; 369-656; 389-836; 396-919; 508-996; 567-953; 567-845; 602-740; 607- 875; 625-1159; 706-951; 706-945; 710-1123; 710-919; 730-967; 736-996; 809-1074; 855-1320; 855-1105; 891-1337; 890- 1073; 914-1133; 948-1200; 961-1235; 962-1554; 972-1238; 999-1276; 1020-1621; 1033-1294; 1036-1267; 1037-1292; 1070-1318; 1109-1506; 1109-1338; 1115-1606; 1115-1611; 1119-1358; 1133-1680; 1188-1451; 1206-1459; 1212-1453; 1229-1511; 1252-1466; 1275-1599; 1275-1514; 1282-1519; 1288-1579; 1293-1602; 1296-1852; 1296-1477; 1318-1855; 1345-1797; 1357-1594; 1362-1593; 1368-1934; 1383-1964; 1395-1932; 1416-1637; 1431-1708; 1433-1676; 1464-1756; 1466-1715; 1486-1771; 1532-1658; 1543-1858; 1550-1816; 1554-1795; 1567-1816; 1570-1914; 1572-1820; 1577-1886; 1593-2178; 1593-1838; 1608-1871; 1621-1900; 1623-1854; 1638-1890; 1688-2291; 1698-1948; 1719-1972; 1726-1982; 1739-1960; 1751-2349; 1786-2374; 1786-2373; 1810-2199; 1811-2338; 1825-2342; 1887-1965; 1888-1968; 1892-2356; 1896-2368; 1903-2330; 1915-2374; 1932-2374; 1964-2378; 1986-2260; 2017-2374; 2036-2593; 2066-2358; 2058-2589; 2089-2343; 2090-2347; 2107-2377; 2124-2374; 2162-2622; 2163-2353; 2179-2360; 2183-2374; 2192-2592; 2201-2592; 2218-2374; 2220-2592; 2276-2337; 2276-2374; 2306-2372; 2312-2621; 1525-2269; 86-237; 1243-1797 Table 3 SEQ ID NO:/Template ID Component Spans 107/LG:346657.13:2002JAN18 1-241; 1-578; 1-301; 42-547; 35-610; 40-454; 44-608; 42-205; 46-450; 48-659; 59-609; 58-261; 62-354; 61-507; 62-241; 66- 239; 71-501; 71-465; 71-391; 71-268; 71-254; 71-244; 71-241; 71-201; 72-270; 72-276; 72-200; 72-185; 98-241; 102-247; 141-251; 166-241; 170-637; 178-517; 179-284; 181-491; 181-1389; 182-593; 209-286; 244-515; 312-652; 332-622; 332- 656; 335-619; 335-397; 356-634; 358-586; 358-502; 358-466; 358-461; 358-459; 358-656; 358-636; 358-534; 392-662; 462- 839; 463-647; 466-661; 466-652; 466-609; 468-808; 479-661; 540-802; 549-1310; 639-1158; 642-905; 667-907; 668-907; 668-1182; 668-1018; 807-1153; 834-1349; 869-924; 1071-1390; 1080-1196; 1083-1389; 1083-1330; 1084-1184; 1084; 1392; 1084-1390; 1084-1389; 1084-1350; 1084-1396; 1095-1390; 1100-1197; 1121-1389; 1123-1348; 1128-1387; 1191- 1389 108/LG:348101.16:2002JAN18 1-612; 545-1298; 1138-1350; 1144-1450; 1166-1800; 1166-1646; 1404-1905; 1510-1995; 1653-2086; 1731-2081; 1735- 2081; 1753-2087; 1889-2370; 1891-2174; 1927-2519; 1927-2181; 1927-2044; 1927-2071; 2036-2726; 2523-2784; 2605- 3190; 2634-3178; 2667-3157; 2748-3005; 2754-2918; 2784-3016; 2935-3507; 2946-3498; 2979-3185; 2983-3598; 3015- 3583; 3051-3611; 3078-3600; 3085-3341; 3103-3694; 3103-3319; 3113-3264; 3143-3425; 3154-3416; 3189-3347; 3333- 3666; 3355-3649; 3355-3615; 3371-3880; 3393-3576; 3437-3955; 3437-3689; 3446-3933; 3446-3738; 3446-3706; 3446- 3656; 3454-3822; 3454-3534; 3483-3628; 3487-3734; 3546-3905; 3612-3880; 3614-3844; 3634-3900; 3634-3883; 3634- 3714; 3640-3903; 3647-3916; 3682-3859; 3695-3939; 3699-3954; 3739-3986; 3745-4020; 3745-4006; 3746-4286; 3777- 4038; 3788-3845; 3791-4242; 3807-4350; 3814-4531; 3832-4503; 3835-4412; 3837-4129; 3838-4121; 3860-4396; 3860- 4257; 3860-4079; 3868-4144; 3868-4143; 3868-4099; 3868-4072; 3868-4067; 3868-4129; 3870-4079; 3871-4109; 3871- 4105; 3883-4497; 3885-4105; 3890-4197; 3909-4134; 3909-4139; 3916-4178; 3926-4433; 3940-4477; 3990-4517; 4020-4502; 4041-4273; 4045-4478; 4054-4522; 4059-4339; 4064-4514; 4065-4521; 4069-4513; 4071-4523; 4069-4350; 4074-4522; 4077-4523; 4081-4513; 4085-4528; 4089-4352; 4094-4477; 4114-4518; 4115-4524; 4124-4518; 4124-4517; 4125-4411; 4127-4465; 4148-4509; 4146-4553; 4148-4517; 4149-4518; 4152-4517; 4162-4525; 4169-4516; 4176-4522; 4185-4523; 4211-4501; 4210-4523; 4257-4515; 4270-4417; 4283-4526; 4351-4528; 4377-4515; 4392-4515; 4433-4526 Table 3 SEQ ID NO:/Template ID Component Spans 109/LG:350827.10:2002JAN18 1-340; 1-184; 1-414; 1-255; 3-251; 4-250; 6-219; 7-301; 22-432; 13-169; 15-564; 17-217; 17-539; 18-129; 18-583; 17-532; 22-265; 22-353; 22-547; 21-243; 22-107; 22-447; 22-163; 22-199; 22-108; 22-128; 22-95; 22-114; 22-169; 22-181; 22-551; 22-102; 22-160; 25-240; 22-119; 22-74; 22-490; 24-222; 30-630; 31-240; 30-312; 32-308; 35-280; 35-500; 36-312; 44-551; 46-239; 45-288; 46-581; 53-371; 65-581; 84-336; 93-349; 99-364; 101-576; 113-584; 114-577; 117-576; 123-588; 123-573; 123-582; 126-413; 126-312; 127-568; 134-372; 135-244; 137-359; 143-617; 144-583; 147-581; 149-533; 152-576; 154-369; 158-671; 159-576; 160-576; 162-581; 168-576; 171-581; 175-521; 177-576; 178-577; 183-472; 183-420; 185-573; 187-538; 187-604; 187-428; 187-390; 187-444; 195-582; 205-540; 217-589; 217-583; 219-572; 224-468; 227-576; 230-492; 231-587; 238-475; 238-509; 240-496; 244-498; 244-470; 259-476; 269-578; 259-364; 262-515; 264-576; 271-573; 306-511; 315-571; 333-581; 338-564; 338-503; 338-441; 356-544; 356-610; 356-470; 356-597; 357-575; 360-1007; 391-581; 394-627; 396- 752; 397-576; 405-747; 413-713; 418-571; 424-577; 443-573; 446-656; 446-722; 471-581; 481-575; 483-539; 483-576; 486-710; 490-685; 515-713; 518-578; 521-573; 523-598; 529-749; 557-799; 563-691; 580-749; 583-738; 587-712; 587-749; 591-697; 598-721; 656-752; 759-1310; 942-1246; 1225-1489; 1251-1604; 1251- 1462; 1251-1479; 1355-1604; 1362-1602; 1400-1602; 1459-1664; 1476-1602; 1502-1639 110/LG:354580.28:2002JAN18 1-584; 24-169; 112-638; 229-654; 276-777; 282-559; 406-766; 406-929; 451-861; 451-740; 487-945; 501-1044; 526-1004; 551-1023; 558-860; 688-939; 688-801; 705-1005; 737-1084; 743-1317; 749-1183; 785-882; 808-1063; 865-1013; 867- 1057; 873-1394; 873-1396; 922-1398; 936-1165; 976-1398; 1043-1314; 1075-1450; 1157-1778; 1167-1780; 1243-1780; 1254-1913; 1540-1828; 1540-1663; 1540-1633; 1559-1776 111/LG:356006.3:2002JAN18 412-811; 1-574; 230-543 112/LG:370212.10:2002JAN18 1-440; 1-611; 1-260; 5-553; 49-588. 204-616; 206-616; 211-482; 280-582; 394-608; 416-608; 517-707; 523-726; 523-766; 526-726; 551-737; 603-918; 633-817; 692-918; 700-941; 716-897; 720-901; 751-828; 760-918; 773-1001; 779-1074; 853- 1317; 853-1096; 966-1025; 1076-1657; 1076-1567; 1084-1419; 1128-1420; 1139-1657; 1467-2073; 1488-1955; 1495-1651; 1715-2301; 2078-2331; 2259-2779; 2264-3318; 2336-2962; 2347-2977; 2361-2939; 2372-2838; 2388-2995; 2391-2945; 2452-3077; 2455-2570; 2466-2863; 2466-2904; 2475-2913; 2476-3008; 2482-2711; 2483-3245; 2490-3058; 2492-2776; 2496-2932; 2498-3013; 2510-3136; 2513-3142; 2512-2702; 2514-3091; 2516-2796; 2518-3077; 2520-2836; 2527-2753; 2529-3302; 2542-3081; 2562-3107; 2564-3335; 2546-3031; 2566-2857; 2571-3092; 2571-2989; 2573-2859; 2575-2686; 2580-2862; 2583-3219; 2587-3246; 2589-3217; 2598-3076; 2597-3010; 2597-2823; 2597-2821; 2598-2796; 2600-3083; 2616-3202; 2619-2891; 2629-2886; 2632-3323; 2641-3213; 2634-2900; 2633-3247; 2636-2870; 2643-3247; 2646-2878; 2647-3193; 2650-3184; 2660-2873; 2660-2887; 2662-3105; 2669-2809; 2677-3099; 2675-2898; 2679-3313; Table 3 SEQ ID NO:/Template ID Component Spans 2682-3097; 2684-2994; 2685-3214; 2684-3294; 2686-3101; 2685-2922; 2688-3098; 2710-3236; 2709-2968; 2711-2806; 2717-2951; 2737-3280; 2739-3018; 2741-2960; 2742-3013; 2743-3069; 2763-3195; 2760-2908; 2764-3276; 2764-3009; 2763-3105; 2767-3257; 2774-2995; 2777-3300; 2780-3038; 2784-3099; 2792-3316; 2792-3216; 2795-3098; 2797-3390; 2797-3045; 2801-3216; 2800-2940; 2805-3031; 2808-2935; 2816-3197; 2814-3033; 2821-3319; 2833-3273; 2835-3319; 2842-3324; 2844-3320; 2847-3316; 2848-3313; 2849-3315; 2851-3322; 2853-3106; 2858-3282; 2857-3318; 2857-3280; 2858-3319; 2859-3311; 2866-3323; 2868-3317; 2874-3089; 2882-3175; 2882-3320; 2882-3216; 2882-3319; 2882-3318; 2893-3319; 2891-3318; 2896-3318; 2900-3322; 2901-3318; 2901-3319; 2904-3315; 2907-3291; 2907-3318; 2908-3097; 2909-3212; 2909-3166; 2910-3248; 2910-3319; 2914-3291; 2915-3173; 2918-3318; 2922-3324; 2925-3213; 2925-3085; 2927-3268; 2929-3162; 2930-3275; 2931-3318; 2950-3318; 2960-3318; 2969-3306; 2975-3099; 2979-3228; 2980-3099; 3042-3321; 3052-3192; 3052-3249; 3053-3241; 3060-3292; 3061-3318; 3061-3301; 3068-3318; 3072-3321; 3075-3315; 3084-3318; 3088-3467; 3088-3642; 3092-3387; 3092-3319; 3134-3317; 3140-3317; 3187-3906; 3233-3318; 3251-3318; 3258-3410; 3398-3797; 3428-3995; 3460-4159; 3535-3840; 3599-3817; 3724-3798; 3736-3938; 3736-4290; 3736-4251; 3736-4214; 3736-3951; 3757-4214; 3870-4183; 3891-4330; 3894-4138; 3992-4259; 3994-4291; 3997-4076; 4189-4843; 4190-4260; 4222-4326; 4247-4471; 4269-4523; 4348-4583; 4367-4887; 4390-4883; 1584-2238; 1223-1475; 2308-2605 113/LG:373219.13:2002JAN18 1-547; 26-383; 70-605; 72-247; 95-264; 131-692; 197-449; 229-384; 321-573; 366-622; 384-826; 384-656; 413-728; 446- 925; 453-903; 467-622; 467-924; 467-885; 475-1002; 482-650; 484-945; 486-750; 538-874; 564-711; 706-1279; 715-970; 730-1274; 741-1389; 744-1147; 788-989; 890-1068; 902-1082; 924-1116; 939-1375; 961-1407; 1027-1290; 1032-1558; 1032-1342; 1060-1340; 1062-1114; 1143-1407; 1155-1776; 1197-1407; 1246-1407; 1273-1677; 1273-1532; 1430-1698; 1437-1609; 1446-1749; 1486-2104; 1536-1754; 1562-1824; 1561-2263; 1573-1821; 1578-1820; 1579-1828; 1605-1791; 1608-1856; 1617-1844; 1614-1918; 1638-1818; 1642-2191; 1642-1860; 1650-2193; 1661-1904; 1664-1893; 1699-1979; 1699-1972; 1727-2197; 1727-1997; 1739-2140; 1739-1994; 1742-2001; 1741-1995; 1742-2003; 1743-1822; 1781-1999; 1806-2410; 1835-1905; 1840-2076; 1850-2271; 1881-2123; 1883-2394; 1903-2156; 1913-2084; 1915-2195; 1923-2156; 1939-2187; 1998-2275; 2001-2222; 2007-2193; 2014-2305; 2035-2556; 2045-2311; 2047-2303; 2053-2325; 2058-2456; 2066-2304; 2066-2312; 2099-2369; 2112-2316; 2140-2374; 2142-2648; 2147-2400; 2150-2433; 2152-2423; 2165-2395; 2199-2736; 2199-2308; 2204-2463; 2206-2446; 2225-2463; 2253-2959; 2247-2647; 2247-2463; 2250-2463; 2252-2650; 2253-2724; 2253-2647; 2285-2647; 2285-2575; 2323-2464; 2325-2568; 2368-2643; 2368-2463; 2381-2586; 2397-2628; 2411-2658; 2414-2463; 2422-2742; 2481-2647; 2481-2650; 2481-2645; 2481-2897; 2484-2893; 2484-2897; 2503-2896; 2508-2896; 2509-2647; 2511-2636; 2521-2754; 2523-2890; 2531-2639; 2540-2761; 2550-2647; 2555-2850; 2560-2645; 2570-2891; 2589-2897; 2590-2871; 2664-2896; 2667-2896; 2667-2886; 2667-2736; 2670-2896; 2672-2893; 2667-2834; 2675-2896; 2704-2891; 2699-2895; 2710-2798; 2711-2891; 2712-2857; 2712-2886; 2754-2896; 2751-2902; 2776-2886; 2777-2877; 2786-2893; 1793-2608; 2103-2439 Table 3 SEQ ID NO:/Template ID Component Spans 114/LG:399821.22:2002JAN18 1-460; 99-460; 223-711; 416-1036; 524-806; 908-1187; 925-1111; 1082-1570; 1186-1415; 1462-1856; 1538-1783; 1702- 2106; 1702-1908; 1716-2023; 1721-2343; 1841-2080; 1951-2491; 1986-2348; 1986-2229; 2030-2276; 2039-2700; 2054- 2330; 2132-2410; 2293-2820; 2299-2882; 2306-2520; 2333-2604; 2332-2867; 2328-2479; 2486-3084; 2510-2936; 2521- 2857; 2561-2819; 2570-2819; 2586-2990; 2586-2831; 2596-3246; 2636-3216; 2644-2941; 2819-3025; 3005-3270; 3020- 3513; 3034-3705; 3132-3385; 3166-3413; 3265-3712; 3288-3517; 3290-3786; 3290-3544; 3290-3384; 3329-3518; 3364- 3567; 3373-3476; 3375-3634; 3375-3978; 3375-3556; 3424-3665; 3452-3716; 3524-4059; 3589-4096; 3613-3894; 3615- 3879; 3638-3883; 3646-3885; 3646-3858; 3653-4003; 3697-3939; 3708-4158; 3719-3980; 3751-3985; 3776-4019; 3785- 3890; 3786-4329; 3815-4033; 3852-4077; 3878-4091; 3885-4194; 3966-4535; 3967-4518; 3979-4198; 3989-4182; 4001- 4367; 4001-4251; 4006-4263; 4039-4297; 4046-4135; 4055-4349; 4080-4312; 4104-4558; 4105-4368; 4110-4288; 4114- 4323; 4120-4587; 4151-4423; 4165-4345; 4169-4400; 4224-4705; 4236-4727; 4266-4567; 4292-4505; 4310-4605; 4310-4588; 4313-4559; 4313-4701; 4329-4629; 4335-4590; 4335-4591; 4343-4584; 4358-4635; 4385-4659; 4398-4717; 4407-4672; 4408-4666; 4416-4730; 4424-4645; 4443-4695; 4444-4703; 4483-4741; 4483-5020; 4497-4912; 4506-4947; 4505-4717; 4506-4727; 4567-4911; 4605-4715; 4605-4830; 4605-4856; 4605-4980; 4616-5257; 4638-5253; 4633-4922; 4667-4937; 4667-5015; 4668-5269; 4719-4958; 4721-5200; 4735-4976; 4748-5015; 4758-4884; 4758-5341; 4767-5012; 4770-4951; 4779-5028; 4785-5310; 4796-5247; 4789-5045; 4800-5312; 4804-5317; 4809-5337; 4816-5348; 4816-5329; 4816-5053; 4817-5063; 4822-5356; 4822-5319; 4826-5358; 4830-5391; 4832-5196; 4839-5312; 4849-5337; 4855-5309; 4855-5109; 4858-5317; 4875-5313; 4881-5352; 4888-5165; 4891-5355; 4893-5353; 4893-5356; 4894-5062; 4895-5356; 4896-5310; 4899-5352; 4901-5361; 4915-5351; 4917-5339; 4917-5356; 4919-5240; 4919-5356; 4925-5356; 4928-5356; 4941-5310; 4945-5356; 4945-5368; 4954-5357; 4958-5358; 4960-5223; 4960-5301; 4961-5362; 4962-5221; 4962-5150; 4967-5356; 4968-5347; 4963-5242; 4964-5178; 4969-5351; 4970-5356; 4975-5306; 4979-5354; 4982-5317; 4989-5357; 4990-5371; 4991-5351; 4993-5359; 4993-5356; 4993-5355; 5005-5352; 5007-5357; 5011-5211; 5016-5354; 5016-5356; 5027-5362; 5054-5360; 5057-5356; 5058-5275; 5059-5305; 5060-5356; 5083-5351; 5081-5357; 5078-5355; 5083-5356; 5083-5355; 5095-5377; 5111-5363; 5114-5355; 5135-5263; 5143-5390; 5151-5399; 5149-5355; 5169-5356; 5176-5356; 5177-5356; 5184-5356; 5189-4334; 5218-5432; 5220-5347; 5222-5315; 1574-5356; 1183-1973; 2840-3579; 1187-1939; 3685-4426; 2933-3657; 2988-3707; 1721-1983; 4943-5216; 3894-4346; 4608-5062 Table 3 SEQ ID NO:/Template ID Component Spans 115/LG:400519.1:2002JAN18 3-490; 3-399; 1-410; 28-220; 34-526; 48-796; 77-293; 80-362; 95-612; 131-856; 311-582; 507-1135; 533-1168; 682-1034; 830-1327; 830-1402; 948-1420; 960-1392; 1018-1464; 1036-1823; 1132-1371; 1188-1376; 1219-1805; 1219-1425; 1244- 2040; 1351-1903; 1544-1957; 1544-1791; 1556-1806; 1705-2231; 1842-1953; 1919-2167; 1935-2021; 2043-2425; 2119- 2380; 2123-2503; 2172-2600; 2194-2712; 2196-2413; 2300-2579; 2381-3043; 2437-2876; 2482-2574; 2601-2804; 2621- 2985; 2666-3051; 2669-2915; 2679-2866; 2679-2960; 2704-3132; 2718-3135; 2718-2969; 2777-3201; 2861-3102; 3034- 3337; 3034-3290; 3073-3381; 3161-3728; 3164-3482; 3227-3744; 3247-3478; 3263-3486; 3302-3480; 3314-3440; 3417- 3502; 3440-3727; 3513-3730; 3535-3727; 3567-3974; 3579-3974; 3599-3974; 3616-3865; 3669-3976; 3669-3898; 3670- 3897; 3670-3893; 3775-3974; 3776-3972; 3779-4243; 3850-4245; 3852-4108; 3973-4262; 4020-4284; 4049-4275; 4076- 4245 116/LG:402797.1:2002JAN18 1-668; 1-718; 16-563; 515-772; 520-1084; 597-1052; 600-849; 766-1280; 1057-1392; 1059-1334; 1151-1496; 1222-1464; 1245-1579; 1323-1835 117/LG:402974.1:2002JAN128 1-493; 3-287; 36-223; 146-519; 205-554; 234-555; 347-519; 375-1057; 570-1224; 615-976; 940-1110; 845-973; 940-1343; 937-1175; 981-1412; 1134-1220; 1353-1829; 1356-1637; 1392-1604; 1407-2100; 1473-2062; 1523-2023; 1523-1766; 1531- 2160; 1571-2108; 1570-2139; 1574-1876; 1585-2136; 1609-2153; 1699-2179; 1718-2178; 1720-2178; 1722-1872; 1781- 2179; 1785-2176; 1785-2055; 1785-1998; 1809-2147; 1811-2180; 1842-2179; 1850-2179; 1911-2180; 1947-2179; 1947- 2157; 1947-2134; 1958-2179; 1962-2176; 1978-2177; 2049-2180; 2082-2181; 2091-2182 118/LG:403397.7:2002JAN18 1-637; 1-383; 352-988; 478-927; 522-758; 727-1011; 817-1528; 893-1520; 1030-1180; 1110-1679; 1238-1427; 1255-1511; 1287-1592; 1292-1870; 1290-1576; 1290-1794; 1330-1695; 1356-1777; 1363-1656; 1482-1846; 1482-1714; 1521-1764; 1559-1799; 1565-1974; 1579-1824; 1639-2192; 1649-1899; 1669-1888; 1670-1926; 1683-1927; 1715-1957; 1718-2271; 1734-2242; 1745-2017; 1760-2464; 1783-2359; 1810-2111; 1816-2253; 1859-2598; 1859-2539; 1882-2242; 1882-2145; 1889-2186; 1935-2297; 1935-2206; 1937-2171; 1999-2708; 2029-2299; 2080-2656; 2090-2635; 2094-2636; 2103-2655; 2102-2341; 2107-2655; 2143-2630; 2158-2675; 2215-2674; 2228-2676; 2243-2671; 2258-2671; 2266-2517; 2273-2671; 2274-2676; 2273-2517; 2291-2517; 2297-2673; 2297-2671; 2299-2675; 2423-2942; 2522-2676; 2544-2942; 2584-2746 119/LG:404199.4:2002JAN18 1-693; 1-276; 76-581; 77-513; 79-389; 79-374; 298-535; 328-604; 329-749; 345-882; 345-587; 357-1130; 470-1038; 470- 973; 472-693; 520-692; 557-1114; 571-1175; 656-816; 757-861; 772-1226; 787-1237; 792-1235; 799-1237; 815-1225; 886- 1237; 889-1655; 901-1190; 907-1234; 936-1103; 941-1124; 941-1229; 941-1181; 976-1236; 1071-1225; 1309-1646; 1309- 1640; 1309-1511; 1405-2020, 1554-1698; 1554-1860; 1906-2059; 1909-1988; 1968-2471; 1986-2316; 1989-2266; 2231- 2482; 2231-2575; 2254-2632; 2576-2813 Table 3 SEQ ID NO:/Template ID Component Spans 120/LG:404482.7:2002JAN18 1-291; 12-608; 17-242; 25-526; 34-705; 38-659; 38-576; 48-503; 48-411; 49-296; 53-549; 52-296; 53-302; 55-506; 55-310; 58-344; 61-265; 62-609; 63-859; 63-627; 64-638; 64-302; 58-330; 65-673; 67-367; 72-285; 74-313; 81-294; 86-535; 86- 337; 90-382; 93-342; 98-348; 99-274; 110-532; 182-576; 193-461; 196-272; 266-488; 311-557; 317-572; 361-731; 463-705; 516-731; 518-890; 600-860; 630-1180; 852-1306; 972-1210; 972-1155; 1024-1272; 1203-1663; 1203-1437; 1423- 1604; 1487-1790; 1491-1791; 1570-1874; 1576-2101; 1578-1989; 1582-1777; 1727-2034; 1787-2020; 1787-2108; 1826- 2108; 1832-2044; 1841-2054; 1900-2103; 1900-2310; 2011-2286; 2222-2445; 2222-2399; 2222-2312; 2340-2822; 2342- 2647; 2441-2989; 2448-2686; 2466-3008; 2515-2761; 2521-2979; 2523-2994; 2522-2772; 2526-2915; 2526-2793; 2541- 3009; 2558-3025; 2577-2831; 2593-3044; 2596-2907; 2617-2899; 2684-2935; 2721-2943 121/LG:406239.1:2002JAN18 1-348; 1-590; 203-654; 226-746; 226-471; 288-488; 289-655; 343-897; 344-888; 523-974; 579-985; 579-651; 636-976; 667- 824; 669-927; 674-1273 122/LG:407055.6:2002JAN18 1-289; 11-444; 13-461; 15-186; 15-461; 15-470; 15-474; 17-226; 17-133; 17-208; 17-396; 20-400; 36-199; 38-307; 62-689; 80-316; 84-435; 92-641; 121-655; 158-874; 205-630; 327-588; 357-630; 376-630; 376-983; 447-558; 475-1038; 547-634; 594-886; 675-1044; 674-955; 714-1006; 755-1044; 759-1168; 795-1097; 837-1097; 855-1118; 872-1134; 940-1122; 972-1607; 1044- 1096; 1044-1097; 1100-1475; 1117-1580; 1153-1403; 1181-1585; 1228-1517; 1232-1601; 1265-1950; 1265-1975; 1296- 1543; 1296-1539; 1322-1710; 1371-1612; 1425-1943; 1529-1781; 1569-2141; 1621-1927; 1638-2199; 1640-1989; 1640- 2193; 1641-1989; 1648-1918; 1647-1783; 1681-2087; 1708-2181; 1784-2088; 1787-2238; 1822-2010; 1841-2086; 1873- 2107; 1993-2233; 2011-2379; 2093-2367; 2094-2659; 2118-2561; 2131-2699; 2140-2386; 2134-2714; 2168-2581; 2172- 2440; 2174-2475; 2189-2508; 2188-2577; 2192-2523; 2194-2745; 2205-2479; 2237-2443; 2245-2794; 2253-2369; 2271- 2485; 2278-2503; 2283-2767; 2293-2554; 2313-2837; 2388-2851; 2391-2966; 2399-2919; 2445-2697; 2448-2670; 2450- 2906; 2463-2677; 2465-2705; 2469-2949; 2492-2780; 2496-2734; 2508-3098; 2516-2756; 2523-2912; 2523-2719; 2541-3075; 2547-2807; 2550-2909; 2568-2843; 2577-2820; 2577-3046; 2581-2845; 2582-3284; 2586-2822; 2587-3030; 2587-2718; 2592-2846; 2600-2863; 2630-2872; 2680-2894; 2688-2938; 2720-3230; 2713-3139; 2721-2983; 2721-2928; 2724-2998; 2729-3241; 2746-3301; 2754-2988; 2755-2995; 2783-3030; 2791-3380; 2815-2923; 2822-3044; 2826-3358; 2848-3106; 2854-3321; 2856-3145; 2864-3403; 2866-2966; 2894-3150; 2903-3143; 2907-3148; 2924-3618; 2965-3775; 2981-3052; 2981-3258; 2982-3648; 2999-3269; 2999-3461; 3030-3738; 3027-3687; 3035-3518; 3038-3288; 3055-3356; 3070-3295; 3070-3296; 3076-3384; 3094-3332; 3098-3378; 3102-3383; 3130-3412; 3138-3767; 3156-3742; 3163-3417; 3176-3399; 3184-3459; 3197-3740; 3202-3871; 3209-3839; 3209-3478; 3223-3480; 3236-3471; 3236-3511; 3236-3493; 3236-3601; 3243-3824; 3258-3740; 3281-3810; 3286-3572; 3298-3541; 3299-3501; 3308-3798; 3318-3806; 3352-3822; 3363-3843; 3375-3849; 3390-3525; 3398-3841; 3404-3842; 3408-3843; 3419-3842; 3424-3844; 3429-3845; 3449-3743; 3449-3845; 3459-3680; 3465-3735; 3467-3843; 3477-3842; 3488-3872; 3494-3847; 3498-3847; 3512-3767; Table 3 SEQ ID NI:/Template ID Component Spans 3524-3818; 3527-3844; 3528-3848; 3534-3842; 3539-3840; 3545-3842; 3562-3787; 3575-3840; 3584-3838; 3583-3846; 3584-3848; 3587-3842; 3590-3846; 3595-3822; 3601-3845; 3605-3844; 3650-3847; 3660-3844; 3676-3805; 3677-3844; 3677-3834; 3688-3843; 3696-3838; 3698-3844; 3705-3842; 3708-3843; 3737-3840; 3781-3847 123/LG:407485.1:2002JAN18 1-501; 6-695; 22-711; 24-436; 167-548; 167-652; 167-591; 333-1028; 542-1028; 821-1295; 893-1566; 913-1555; 1035- 1292; 1096-1698; 1450-1709; 1613-2058; 1708-2058; 1796-2055; 1890-2226; 1890-2123; 1930-2032; 1964-2241; 2002- 2624; 2019-2229; 2171-2446; 2192-2446; 2212-2439; 2270-2654; 2308-2827; 2429-2840; 2525-3257; 2548-3078; 2575- 3069; 2577-2671; 2804-3084; 2804-3083; 2804-3073; 2804-2925; 2805-3081; 3104-3456; 3155-3336; 3187-3744; 3303- 3749; 3307-3724; 3311-3721; 3398-4007; 3402-4165; 3410-4092; 3446-3682; 3468-3748; 3506-3761; 3515-3724; 3557- 3783; 3558-4033; 3694-3870; 3703-4453; 3780-4083; 3796-3993; 3886-4482; 3886-4042; 3902-4111; 4027-4664; 4067- 4418; 4057-4315; 4066-4380; 4091-4334; 4095-4191; 4156-4459; 4157-4580; 4180-4616; 4230-4368; 4296-4447; 4336- 4730; 4338-4626; 4400-4854; 4425-4807; 4443-4730; 4487-4938; 4496-4781; 4520-5028; 4634-5128; 4634-4911; 4650- 4908; 4659-4922; 4699-5257; 4711-5207; 4712-4947; 4707-5113; 4733-5444; 4747-4952; 4839-5411; 4847-5072; 4873- 5390; 4938-5038; 4951-5159; 5022-5462; 5034-5257; 5049-5303; 5088-5312; 5095-5374; 5103-5308; 5163-5361; 5205-5482; 5218-5449; 5230-4738; 4232-5497; 5239-5418; 5241-5456; 5241-5478; 5241-5453; 5241-5429; 5241-5346; 5241-5351; 5254-5449; 5314-5634; 5315-5657; 5327-5661; 5327-5572; 5345-5749; 5357-5638; 5373-5580; 5397-5673; 5408-5615; 5413-5616; 5425-5684; 5427-5629; 5432-5664; 5450-5815; 5450-5701; 5457-5736; 5478-5749; 5483-6094; 5492-5602; 5499-6028; 5535-6030; 5534-5762; 5545-5779; 5564-5824; 5578-6016; 5585-6129; 5585-5998; 5585-5825; 5588-6101; 5606-6087; 5614-5847; 5616-5873; 5631-6048; 5653-6094; 5677-5946; 5680-6132; 5702-6132; 5708-5916; 5717-5955; 5731-6139; 5752-6150; 5754-6139; 5759-6090; 5758-5871; 5769-6134; 5781-6132; 5782-6131; 5806-6081; 5807-6060; 5859-6132; 5898-6112; 5903-6144; 5911-6055; 5908-6135; 5923-6078; 5930-6135; 5952-6140; 5982-6139; 5994-6243; 6082-6150 124/LG:422048.46:2002JAN18 8-347: 1-234; 1-412; 1-228; 66-584; 67-505; 71-498; 84-662; 84-630; 134-504; 137-493; 141-499; 145-499; 159-496; 205- 500;287-454; 293-499; 293-463; 307-433; 311-491; 312-499; 312-454; 314-498; 314-491; 334-491; 378-491; 378- 453; 405-482; 420-644; 587-1102; 587-1129; 587-1063; 260-504; 238-504; 500-754; 503-783; 502-785; 201-490; 94-388; 198-504; 514-811; 162-489; 500-841; 500-835; 32-380; 92-492; 79-504; 1-173; 331-491; 310-465; 1-165; 1-141; 1-183; 1- 132; 1-128; 303-416; 1-87; 405-491; 1-83; 1-75; 425-499; 1-56 Table 3 SEQ ID NO:/Template ID Component Spans 125/LG:425448.18:2002JAN18 3813-4351; 4015-4339; 3954-4312; 3756-4181; 3881-4181; 3561-4175; 3671-4038; 3754-4035; 3358-3887; 3084-3525; 3254-3491; 3045-3479; 3149-3392; 2900-3238; 2885-3224; 2884-3198; 2887-3086; 2601-3075; 2887-3049; 2932-3048; 2768-3032; 2667-3001; 2761-2994; 2768-2994; 2603-2988; 2464-2986; 2618-2987; 2676-2964; 2686-2964; 2728-2964; 2660-2962; 2175-2956; 2508-2859; 2562-2855; 2275-2829; 2348-2785; 2171-2723; 2174-2696; 2427-2682; 2118-2596; 2217-2490; 1998-2412; 2154-2393; 2135-2349; 2019-2328; 2065-2326; 1642-2276; 1990-2262; 1904-2257; 1798-2215; 1847-2159; 1946-2159; 1685-2143; 1856-2118; 1684-2072; 1869-2061; 1786-2041; 1676-2006; 1821-1974; 1684-1928; 1519-1915; 1586-1903; 1640-1900; 1665-1861; 1500-1849; 1511-1807; 1598-1799; 1603-1799; 1478-1757; 1485-1724; 1264-1702; 1480-1688; 1577-1683; 1515-1678; 1344-1655; 1433-1653; 1389-1632; 1341-1619; 1339-1598; 1307-1587; 932-1562; 975-1552; 1036-1539; 1259-1541; 1247-1533; 995-1511; 967-1507; 1275-1459; 931-1456; 1178-1399; 932- 1390; 915-1360; 965-1358; 956-1354; 930-1345; 926-1332; 1040-1324; 928-1321; 1038-1322; 932-1316; 1178-1314; 921-1296; 930-1293; 926-1292; 930-1292; 930-1283; 925-1280; 1008-1264; 944-1263; 929-1262; 983-1252; 945-1249; 930-1237; 1177-1234; 944-1220; 949-1218; 1059-1215; 930-1209; 1128-1206; 953-1198; 936-1113; 625-1008; 921-1001; 592-817; 488-814; 565-813; 573-813; 567-813; 574-813; 587-813; 639-812; 647-811; 625-811; 430-810; 510-809; 588-809; 354-808; 384-808; 455-808; 422-808; 426-807; 451-807; 494-807; 498-807; 504-807; 470-807; 519-807; 572-807; 578-807; 480-807; 381-806; 328-807; 617-806; 656-805; 658-805; 676-806; 419-805; 420-805; 476-805; 463-805; 493-805; 540-807; 357-804; 382-803; 394-803; 404-807; 415-804; 430-805; 497-805; 357-803; 396-803; 410-805; 466-803; 570-804; 84-808; 437-803; 450-802; 512-801; 574-802; 604-801; 350-799; 425-799; 512-799; 531-799; 627-799; 480-798; 581-799; 393-799; 570-798; 582-796; 395-797; 296-786; 393-781; 126-777; 26-775; 126-766; 404-760; 528-757; 454-754; 477-753; 179-739; 356-738; 168-737; 434-736; 319-730; 480-731; 447-731; 185-729; 179-732; 413-725; 432-729; 125-723; 251-720; 418-721; 296-720; 486-716; 483-711; 156-708; 470-709; 97-700; 249-700; 124-705; 403-699; 464-679; 200-659; 232-653; 382-655; 403-644; 392-638; 360-633; 48-629; 7-586; 7-572; 458-554; 255-550; 279-543; 280- 538; 264-534; 285-530; 250-508; 231-495; 357-485; 237-482; 15-454; 184-440; 73-393; 153-374; 1-339; 79-322; 105-285; 1-245; 35-242; 67-239; 70-204; 1-156; 17-136 Table 3 SEQ ID NO:/Template ID Component Spans 126/LG:435717.5:2002JAN18 1-144; 7-374; 7-372; 7-126; 7-83; 18-380; 27-528; 27-332; 59-572; 70-353; 82-589; 173-603; 179-435; 212-637; 230-611; 240-615; 236-456; 322-620; 340-600; 408-607; 422-614; 422-607; 465-1089; 469-1072; 526-595; 892-1328; 915-1667; 914- 1194; 918-1368; 917-1458; 919-1087; 924-1337; 924-1226; 924-1003; 924-1305; 927-1150; 950-1246; 954-1240; 960- 1301; 967-1458; 976-1278; 976-1201; 976-1199; 977-1458; 977-1174; 983-1458; 1011-1180; 1020-1291; 1045-1458; 1051- 1438; 1051-1298; 1087-1458; 1088-1347; 1088-1314; 1088-1291; 1088-1277; 1088-1240; 1089-1290; 1095-1343; 1095- 1332; 1118-1458; 1123-1251; 1129-1297; 1134-1306; 1140-1350; 1140-1458; 1141-1410; 1159-1398; 1174-1387; 1176- 1458; 1189-1414; 1199-1458; 1199-1431; 1221-1834; 1258-1431; 1259-1458; 1263-2073; 1265-1429; 1297-1458; 1298- 1458; 1321-1954; 1322-1458; 1334-1458; 1338-1458; 1369-1458; 1372-1458; 1382-1458; 1387-1458; 1388-1458; 1404- 1458; 1718-2264; 1716-1957; 1716-2231; 1720-2316; 1726-1979; 1720-2065; 1720-2264; 1724-2252; 1724-2242; 1726- 1885; 1726-1828; 1726-1818; 1726-1778; 1726-2345; 1726-2080; 1726-2051; 1726-2112; 1729-1844; 1735-1973; 1737-1841; 1738-2003; 1743-1930; 1744-2315; 1745-1996; 1760-1890; 1755-2021; 1755-2005; 1755-1990; 1755-1808; 1755-2290; 1755-2259; 1755-2229; 1755-2169; 1760-1961; 1763-2040; 1775-2059; 1785-2073; 1785-2078; 1790-2085; 1796-2322; 1792-2013; 1799-2344; 1805-2365; 1811-1997; 1808-2369; 1809-2183; 1812-2268; 1816-2042; 1816-2073; 1821-2066; 1821-1950; 1827-2254; 1828-2320; 1846-2121; 1848-2331; 1849-2152; 1866-2324; 1867-2338; 1883-2332; 1893-2390; 1901-2139; 1931-2364; 1947-2363; 1953-2365; 1958-2369; 1977-2365; 1981-2367; 1992-2364; 1993-2289; 1995-2368; 1997-2368; 1998-2363; 2001-2364; 2003-2368; 2003-2365; 2006-2204; 2020-2368; 2021-2357; 2025-2363; 2026-2301; 2027-2284; 2031-2273; 2041-2365; 2049-2368; 2050-2369; 2050-2366; 2060-2179; 2064-2366; 2063-2287; 2069-2365; 2073-2217; 2110-2365; 2118-2365; 2123-2370; 2123-2368; 2123-2332; 2145-2368; 2147-2366; 2154-2365; 2159-2370; 2168-2363; 2186-2369; 2189-2365; 2216-2336; 2229-2365; 2233-2365; 2243-2368; 2255-2365; 2306-2883; 2319-2890; 2365-2890; 2395-2925; 2438-2702; 2529-2757; 2547-2889; 2560-2881; 2564-2797; 2573-2890; 2595-2792; 2608-2880; 2720-2882; 2757-2890 127/LG:451858.13:2002JAN18 1-258; 45-516; 76-627; 83-590; 82-292; 83-576; 83-323; 83-311; 108-622; 118-381; 121-610; 137-623; 151-519; 163-428; 167-625; 175-621; 218-627; 221-622; 227-625; 233-628; 236-478; 239-621; 242-625; 253-516; 253-455; 258-509; 258-508; 294-525; 298-619; 305-532; 320-621; 325-583; 325-581; 332-627; 332-572; 333-617; 431-621; 459-623; 532-849; 532-621; 572-621; 651-1186; 654-862; 651-1012; 651-838; 653-847; 655-847; 654-792; 657-847; 666-862; 669-848; 870-1281; 870- 1227; 873-1454; 935-1565; 935-1292; 1091-1357; 1091-1378; 1109-1696; 1121-1367; 1152-1528; 1180-1464; 1568-1735; 1574-1962; 1574-1783; 1576-1864; 1588-1820; 1593-2114; 1596-1801; 1596-1732; 1596-1652; 1596-1717; 1596-1678; 1596-1668; 1606-1742; 1606-1736; 1616-2062; 1618-1733; 1645-1841; 1646-1914; 1744-2665; 1780-2417; 1787-2052; 1787-2044; 1787-2014; 1790-2280; 1801-2297; 1825-2354; 1828-2418; 1879-2479; 1880-2135; 1817-2494; 1921-2493; 1926-2571; 1956-2555; 1971-2557; 1968-2578; 1989-2317; 1997-2133; 2061-2491; 2081-2357; 2107-2566; 2154-2775; 2241-2796; 2286-2565; 2290-2392; 2293-2572; 2295-2624; 2318-2641; 2323-2642; 2326-2775; 2328-2670; Table 3 SEQ ID NO:/Template ID Component Spans 2328-2656; 2340-2574; 2352-2624; 2384-3119; 2387-2583; 2390-2566; 2434-2776; 2442-2668; 2591-2665; 2614-2663; 2719-2774; 2749-2989; 2890-3519; 2961-3462; 3076-3323; 3089-3174; 3093-3471; 3268-3471; 3268-3433; 3268-3334; 3274-3444; 3284-3504; 3308-3473; 3308-3370; 3310-3471; 3315-3471; 3357-3471; 3423-3667; 3552-3677 128/LG:462233.20:2002JAN18 1-285; 1-242; 12-317; 12-131; 12-205; 21-328; 28-304; 28-158; 28-134; 28-188; 41-306; 73-303; 75-325; 112-257; 170- 307; 186-322; 192-454; 342-860; 345-599; 394-792; 398-792; 414-860; 446-785; 464-855; 516-860; 538-860; 590-819; 614- 1024; 641-896; 705-860; 711-855; 719-862; 723-873; 739-855; 774-860; 792-860; 793-1475; 795-860; 1147-1486; 1148- 1676; 1149-1751; 1155-1579; 1155-1323; 1156-1253; 1155-1214; 1166-1380; 1170-1373; 1180-1464; 1177-1741; 1193- 1879; 1193-1415; 1251-1746; 1271-1541; 1302-1439; 1316-1687; 1319-1717; 1323-1797; 1337-1608; 1359-1601; 1355- 1858; 1374-1958; 1379-1958; 1396-1692; 1418-1681; 1422-1883; 1469-1934; 1534-1811; 1549-1935; 1555-2116; 1556- 2043; 1564-1934; 1566-1935; 1578-2019; 1584-1786; 1589-2240; 1601-1831; 1637-2190; 1637-1934; 1663-2198; 1800- 2351; 1815-1934; 1835-2315; 1843-2165; 1862-2443; 1868-2304; 1872-1931; 1928-2389; 1946-2031; 1947-2473; 1980- 2679; 1999-2537; 2020-2672; 2027-2515; 2037-2635; 2042-2253; 2045-2537; 2071-2167; 2080-2435; 2081-2379; 2103- 2263; 2112-2671; 2113-2645; 2147-2331; 2171-2351; 2177-2783; 2189-2720; 2196-2462; 2212-2575; 2214-2441; 2242-2486; 2278-2512; 2381-2644; 2400-3020; 2428-3069; 2439-2665; 2439-2634; 2440-3034; 2464-2924; 2464-2580; 2477-2843; 2480-2797; 2498-2757; 2619-2871; 2660-3263; 2679-2923; 2679-2994; 2682-2788; 2679-2881; 2701-3104; 2703-3259; 2713-2892; 2721-3008; 2721-2994; 2709-2905; 2740-3032; 2746-3245; 2746-2950; 2748-2839; 2794-2997; 2810-3399; 2847-3113; 2868-3124; 2868-3406; 2867-3482; 2876-3106; 2879-3463; 2906-3172; 2929-3206; 2940-3133; 2980-3271; 2985-3243; 2996-3282; 3032-3658; 3033-3320; 3035-3309; 3035-3271; 3058-3357; 3072-3521; 3072-3320; 3078-3356; 3082-3323; 3100-3720; 3116-3238; 3138-3526; 3149-3213; 3154-3308; 3159-3391; 3171-3357; 3182-3312; 3184-3458; 3187-3473; 3187-3420; 3202-3797; 3202-3461; 3207-3496; 3224-3418; 3227-3758; 3230-3653; 3232-3706; 3231-3479; 3235-3543; 3294-3884; 3303-3865; 3330-3774; 3343-3831; 3349-3611; 3351-3848; 3358-3834; 3355-3834; 3355-3583; 3354-3611; 3364-3669; 3365-3650; 3388-4067; 3388-3744; 3388-3600; 3414-3516; 3427-3705; 3437-3834; 3486-3741; 3493-3957; 3505-3767; 3509-3757; 3517-3773; 3547-3830; 3566-3830; 3566-3823; 3578-3771; 3616-3863; 3633-3814; 3622-3830; 3624-3863; 3632-3834; 3638-3818; 3638-3834; 3639-3798; 3641-3834; 3667-3828; 3722-3861; 3701-3833; 3701-3831; 3781-3831; 12-354; 1578-1934; 1194-1666; 3309-3834; 2669-3401; 2661-3391; 3035-3753; 2920- 3616; 1739-1933 129/LG:473880.41:2002JAN18 1-407; 1-578; 3-256; 151-764; 388-644; 410-815; 420-535; 420-682; 422-658; 429-691; 430-711; 431-713; 436-684; 436- 734; 436-492; 437-628; 441-494; 441-545; 441-569; 441-510; 441-627; 454-525; 456-804; 479-719 130/LG:474421.5:2002JAN18 1-271 Table 3 SEQ ID NO:/Template ID Component Spans 131/LG:481462.4:2002JAN18 1-238; 1-524; 1-235; 5-289; 6-272; 7-269; 12-263; 182-65; 26-326; 26-298; 26-221; 28-349; 28-510; 28-289; 28-264; 33- 456; 33-289; 45-445; 46-343; 47-340; 47-303; 47-288; 47-261; 47-208; 48-265; 81-478; 84-590; 88-262; 122-588; 121-310; 132-290; 163-624; 167-419; 170-626; 178-627; 210-627; 220-626; 227-462; 227-620; 227-620; 227-583; 283-20; 388-447; 412-952; 423-952; 450-624; 450-588; 451-587; 453-626; 490-620; 629-1039; 629-709; 932-1035; 971-1042. 132/LG:7684981.2:2002JAN18 1-388; 208-623; 208-611; 341-611; 363-758; 370-759; 610-869; 664-970; 740-966; 752-1146; 750-1212; 806-855; 876- 1128; 885-1207; 896-1353; 921-1160; 952-1239; 1050-1204; 1064-1203; 1276-1882; 1293-1719; 1438-1553; 1599-1887; 1655-1931; 1751-1870; 1751-2213; 1770-1949; 1846-2009; 1847-2090; 1844-2394; 1897-2179; 1938-2133; 1988-2532; 2000-2299; 2014-2384; 2014-2272; 2105-2292; 2215-2775; 2229-2723; 2231-2436; 2226-2567; 2262-2891; 2255-2899; 2259-2899; 2261-2517; 2261-2525; 2260-2784; 2308-2602; 2307-2895; 2306-2909; 2310-2897; 2309-2958; 2376-2636; 2369-2689; 2405-2947; 2469-2961; 2535-2895; 2588-2834; 2588-2990; 2636-2995; 2665-3006; 2688-2976; 2702-2950; 2705-3034; 2717-3149; 3735-2990; 2741-2997; 2791-3082; 2800-3082; 2811-3082; 2818-3082; 2840-2964; 2862-2997 133/LG:7690420.1:2002JAN18 1-254; 1-284; 1-226; 1-248; 26-263 134/LG:7691425.2:2002JAN18 1-510; 1-263; 294-678; 294-566; 294-537; 492-1014; 628-901; 682-1011; 694-844; 694-859 135/LG:7692702.1:2002JAN18 497-1082; 754-976; 441-916; 467-916; 689-916; 517-916; 485-897; 372-872; 1-602 136/LG:7694388.21:2002JAN18 646-849; 335-784; 323-775; 358-775; 517-775; 357-775; 424-775; 376-775; 520-775; 284-775; 546-762; 268-738; 195-738; 292-730; 218-711; 482-697; 94-635; 90-634; 477-626; 1-629; 386-610; 295-565; 210-557; 288-548; 311-553; 45-533; 182- 496; 167-452; 149-416; 77-355; 52-228; 668-768; 680-770; 668-769; 411-773; 361-773 137/LG:7697322.7:2002JAN18 1-250; 72-330; 72-573; 79-350; 109-496; 110-312; 114-357; 165-467; 212-463; 292-986; 322-929; 329-569; 329-901; 329- 687; 377-841; 471-943; 487-1060; 493-940; 517-795; 615-983; 671-1242; 677-923; 679-1126; 679-886; 678-894; 687-983. 705-896; 791-989; 1137-1771; 1231-1628; 1291-1727; 1291-1536; 1350-1619; 1361-1616; 1361-1787; 1421-1518; 1503- 1902; 1503-1739; 1508-1706; 1561-1771; 1569-1686; 1569-1670; 1669-1926; 1675-2219; 1779-2031; 1810-2401; 1858- 2363; 1870-2402; 1870-2030; 1870-1995; 1873-2355; 1889-2359; 1919-2367; 1929-2381; 1958-2402; 1969-2399; 1978- 2405; 1988-2401; 1995-2400; 1994-2262; 2027-2399; 2058-2332; 2174-2359; 2246-2397 138/LG:7697347.3:2002JAN18 1-91; 26-396; 234-689; 241-345; 256-498; 311-984; 375-818; 389-906; 425-922; 434-784; 434-671; 468-728; 468-712; 480- 937; 508-816; 528-826; 54-865; 770-867; 808-941 139/LG:7698451.18:2002JAN18 1-475 140/LG:7698705.7:2002JAN18 1-279; 2-283 141/LG:7731829.1:2002JAN18 1-691 142/LG:7761659.11:2002JAN18 1-761 Table 3 SEQ ID NO:/Template ID Component Spans 143/LG:7761806.33:2002JAN18 1-301; 170-465; 216-794; 293-917; 429-964; 823-1064; 841-1131; 867-1229; 877-1274; 877-1074; 905-1097; 962-1610; 930-1156; 953-1193; 966-1545; 971-1093; 971-1190; 975-1102; 1003-1388; 1003-1209; 1038-1492; 1053-1661; 1075- 1268; 1083-1287; 1101-1742; 1177-1804; 1239-1515; 1341-1627; 1341-1600; 1342-1882; 1342-1806; 1342-1631; 1342- 1614; 1342-1520; 1343-1790; 1343-1585; 1344-1592; 1344-1469; 1350-1466; 1350-1834; 1353-1518; 1354-1884; 1354- 1802; 1359-1569; 1364-1634; 1370-1835; 1377-1836; 1377-1713; 1378-1772; 1378-1479; 1380-1899; 1381-1722; 1384- 1647; 1386-1878; 1387-1671; 1392-2098; 1421-1684; 1427-1672; 1427-2192; 1430-1681; 1464-1648; 1524-2294; 1543- 1820; 1561-1770; 1579-1836; 1586-1837; 1586-1924; 1599-2173; 1637-1926; 1664-2315; 1747-2272; 1754-2267; 1768- 2310; 1762-2183; 1776-2077; 1900-2310; 1942-2057; 1944-2087; 1989-2094; 2177-2309; 2189-2497; 2192-2497; 2205- 2304; 2227-2546; 1341-1599; 1382-1638; 1377-1639; 1799-2031; 1716-1989; 1354-1646; 1364-1654; 1496-1857; 1426- 2067; 1665-1908; 1494-1657; 1485-1643 144/LG:7763039.6:2002JAN18 1-556; 15-309; 182-796; 183-435; 543-1127; 543-771; 620-900; 620-787; 1036-1606; 1069-1367; 1518-1706; 1518-1699; 1523-2118; 1533-1705; 1650-2236; 1722-2197; 1738-1943; 1757-1907; 1835-2430; 1844-2074; 1851-2081; 1925-2115; 2002-2261; 2016-2292; 2020-2266; 2044-2315; 2087-2250; 2171-2260 145/LG:7763254.5:2002JAN18 1-599; 62-592; 418-940; 490-756 146/LG:7763421.8:2002JAN18 1-576 147/LG:7763437.104:2002JAN1 4-417; 1-269; 4-252; 4-291; 4-148; 4-182; 6-341; 15-253; 17-276; 35-655; 117-316; 169-401; 193-291; 205-582; 242-766; 249-483; 302-867; 361-604; 375-539; 444-1034; 613-823; 612-1062; 635-818; 662-905; 712-951; 778-1313; 796-1005; 922- 1042; 922-1067; 942-1411; 1062-1336; 1075-1411; 1081-1372; 1188-E1411; 1198-1411; 1198-1252; 1202-1580; 1202-1822 1207-1707; 1228-1803; 1249-1838; 1302-1578; 1289-1611; 1289-1611; 1347-1411; 1408-1664; 1404-1656; 1431-1719; 1492-1689; 1505-1958; 1508-1769; 1508-1858; 1508-1621; 1530-1912; 1513-1761; 1509-1851; 1524-1662; 1524-1663; 1524-2021; 1585-2275; 1585-1819; 1570-1805; 1612-2193; 1660-1891; 1701-2008; 1701-2066; 1701-1961; 1701-1931; 1712-1901; 1748-2195; 1749-1857; 1785-2115; 1884-2092; 1929-2475; 2010-2455; 2186-2470; 2234-2571; 2272-2527; 2275-2514; 2275-2728; 2552-2809; 2602-2953; 2602-2805; 2667-2971; 2894-3142; 2895-3137; 2920-3137; 2941-3130; 3071-3609; 3082-3141; 3210-3840; 3298-3614; 3317-3494; 3410-3840; 3697-3829; 4-240; 2888-3144; 1524-1909; 1524- 2169; 2932-3130; 2932-3043 148/LG:7770095.2:2002JAN18 1-165 149/LG:7770589.6:2002JAN18 1-466; 159-466; 299-855; 299-765; 301-555; 302-577; 302-566; 302-511; 305-548; 310-562; 324-532; 377-637; 406-625; 412-690; 435-705; 451-680; 473-1145; 473-743; 474-725; 474-773; 511-688; 540-744; 59-786; 575-718; 611-860; 619- 840; 629-868; 663-848; 664-880; 680-555; 685-937; 688-924; 751-992; 884-1403; 1212-1428 150/LG:770618.6:2002JAN18 1-605; 363-838; 363-833; 363-644; 363-628; 363-627; 607-1331; 840-1401; 848-1258 150/LG:770900.9:2002JAN18 1-264; 8-282; 31-420; 44-321; 44-133; 260-470 TAble 3 SEQ ID NO:/Template ID Component Spans 152/LG:7771513.22:2002JAN18 1-255; 1-281; 42-339; 64-336; 89-662; 146-361; 201-490; 235-444; 277-908; 277-568; 353-642; 415-611; 416-990; 425- 710; 441-708; 480-730; 500-897; 501-714; 557-015; 562-747; 588-780; 637-790; 684-799; 881-1241 153/LG:899402.3:2002JAN18 1-268; 1-586; 36-620; 40-397; 45-277; 52-533; 38-743; 53-566; 97-574; 384-493; 404-1096; 408-816; 426-931; 496-714; 507-1111; 516-701; 594-776; 716-953; 727-1334; 769-1016; 792-883; 794-1228; 840-1244; 840-939; 846-1128; 883-1159; 913-1311; 913-1164; 934-1486; 942-1176; 954-1629; 1013-1302; 1020-1508; 1042-1209; 1079-1354; 1101-1538; 1117- 1388; 1211-1408; 1216-1499; 1220-1586; 1237-1492; 1255-1738; 1254-1465; 1254-1443; 1266-1721; 1266-1459; 1269- 1688; 1276-1541; 1300-1556; 1301-1560; 1300-1536; 1319-1598; 1320-1583; 1319-1547; 1326-1621; 1333-1589; 1340- 1976; 1355-1813; 1355-1594; 1373-1956; 1437-1993; 1444-1565; 1453-2106; 1454-1750; 1459-1709; 1465-1754; 1486- 2050; 1489-1637; 1503-1867; 1503-1690; 1506-1746; 1512-2102; 1533-2190; 1529-2130; 1537-2126; 1550-2104; 1555- 1843; 1561-1936; 1560-1829; 1560-1814; 1589-1995; 1594-1871; 1594-2068; 1596-2137; 1597-1904; 1597-1871; 1605- 2169; 1614-2169; 1615-2139; 1621-2171; 1623-1907; 1643-2169; 1648-1906; 1654-2035; 1663-2173; 1667-2241; 1682- 2209; 1719-2201; 1719-1976; 1721-1803; 1728-1904; 1728-1994; 1751-2164; 1762-2169; 1762-2209; 1761-2092; 1764-2209; 1765-2052; 1774; 2209 1785-2210; 1790-2209; 1791-2207; 1796-2035; 1823-2209; 1826-2459; 1844-2209; 1846-2158; 1874-2209; 1881-2209; 1884-2209; 1886-2213; 1889-2155; 1893-2216; 1896-2279; 1898-2164; 1903-2206; 1920-2206; 1920-2213; 1920-2173; 1921-2209; 1933-2165; 1943-2634; 1956-2203; 1956-2212; 1960-2269; 1994-2203; 1969-2209; 1976-2206; 1988-2209; 1995-2260; 1995-2209; 2009-2209; 2030-2281; 2041-2215; 2049-2209; 2073-3180; 2078-2332; 2118-2209; 2137-2277; 2148-2209; 2183-2311; 2205-2503; 2209-2657; 2209-2656; 2211-2696; 2212-2546; 2212-2667; 2212-2539; 2212-2521; 2212-2492; 2212-2488; 2214-2590; 2215-2645; 2230-2697; 2250-2659; 2252-2732; 2253-2702; 2255-2463; 2265-2629; 2276-2618; 2292-2768; 2340-2778; 2363-2818; 2363-2586; 2373-2464; 2424-2675; 2420-2705; 2430-2703; 2444-2857; 2443-2700; 2459-3167; 2483-3160; 2528-3165; 2550-2808; 2572-2868; 2625-2732; 2644-3247; 2660-2993; 2675-2732; 2690-2920; 2786-3107; 2789-3186; 2793-3079; 2801-3047; 2858-3105; 2870-3265; 2873-3502; 2876-3117; 2910-3172; 2936-3186; 2958-3627; 3055-3402; 3058-3618; 3060-3265; 3068-3428; 3070-3382; 3072-3374; 3127-3379; 3173-3295; 3192-3509; 3214-3428; 3221-3362; 3225-3440; 3252-3474; 3253-3496; 3261-3663; 3272-3502; 3281-3684; 3293-3767; 3336-3588; 3358-3608; 3487-3766; 3492-3748; 3579-3659; 3594-3840; 3607-3739; 3606-4243; 3616-4192; 3679-4192; 4025-4579; 4034-4363; 4047-4237; 4047-4216; 4053-4364; 4053-4314; 4053-4237; 4053-4214; 4053-4174; 4053-4110; 4054-4197; 4055-4352; 4055-4414; 4054-4306; 4055-4228; 4088-4640; 4105-4778; 4133-4646; 4226-4685; 4234-4576; 4276-4685; 4270-4685; 4274-4847; 4313-4684; 4323-4553; 4325-4644; 4339-4690; 4348-4689; 4346-4685; 4433-4689; 4440-4685; 4466-4690; 4476-4692; 4531-4685; 4549-4685; 4575-5328; 4715-4991; 4715-5231; 4961-5349 154/LG:902699.29:2002JAN18 1-517; 387-553; 410-672; 410-644; 410-626; 410-585; 410-541; 409-1079; 477-1096; 562-1059; 657-1103; 683-1101; 695- 949; 697-1103; 730-1190; 734-1190; 773-1190; 989-1224; 1134-1433; 1355-1590 Table 3 SEQ ID NO:/Template ID Component Spans 155/LG:977532.3:2002JAN18 1-261; 49-609; 82-287; 82-328; 82-329; 82-334; 438-715; 445-1086; 456-934; 495-964; 502-707; 513-662; 522-1004; 557- 722; 581-862; 653-915; 791-1038; 836-999; 954-1187; 996-1300; 1031-1344; 1091-1655; 1101-1658; 1107-1371; 1171- 1404; 1274-1869; 1286-1802; 1289-1812; 1337-1907; 1349-1598; 1357-1560; 1410-1981; 1442-1890; 1445-1711; 1463- 1796; 1485-1722; 1514-2004; 1544-2059; 1560-2059; 1698-1972; 1776-2051; 1777-2110; 1790-2377; 1798-2039; 1798- 2021; 1813-2059; 1820-2108; 1817-2282; 1831-2462; 1839-2017; 1867-2431; 1873-2132; 1877-2110; 1877-2080; 1918- 2206; 1946-2572; 1961-2096; 1963-2059; 1971-2059; 1972-2444; 1977-2519; 1986-2059; 2021-2135; 2021-2091; 2077- 2459; 2174-2526; 2232-2351; 2236-2567; 2266-2533; 2269-2513; 2270-2572; 2272-2572; 2275-2573; 2279-2575; 2279- 2569; 2279-2570; 2279-2573; 2279-2572; 2279-2592; 2279-2564; 2279-2566; 2279-2442; 2279-2392; 2279-2477; 2283- 2569; 2299-2553; 2299-2524; 2299-2569; 2312-2568; 2314-2553; 2313-2519; 2362-2572; 2408-2564 156/LG:978725.5:2002JAN18 1614-1674; 1225-1663; 1278-1663; 1193-1661; 1334-1659; 1394-1632; 1148-1606; 1053-1557; 1022-1423; 808-1309; 1022-1273; 1034-1179; 694-1163; 693-1132; 650-1107; 746-1099; 820-1099; 603-1005; 674-947; 1-720 157/LG:980200.9:2002JAN18 1-359; 3-591; 159-707; 175-321; 180-579; 192-742; 191-975; 201-579; 201-966; 201-795; 213-346; 218-747; 424-581; 596- 1019; 597-999; 645-998; 802-1065; 804-1080; 869-1529; 1032-1435; 1033-1160; 1033-1113; 1153-1523; 1206-1927; 1249- 1484; 1432-1656; 1447-1789; 1597-2150; 1598-1847; 1598-1992; 1600-1844; 1683-1930; 1754-2107; 1757-2001; 1775- 1992; 1803-1908; 1829-2364; 1826-2417; 1831-2200; 1888-2214; 1899-2468; 1943-2394; 1945-2214; 1979-2424; 1979- 2340; 1995-2470; 2026-2467; 2068-2228; 2071-2467; 2182-2466; 2272-2467; 2275-2467; 2275-2468; 2292-2449; 2334- 2467; 2356-2467; 2386-2467 158/LG:980859.5:2002JAN18 1-560; 125-660; 136-453; 223-464; 243-680; 283-659; 283-518; 378-575; 389-603; 421-656; 518-1011; 519-668; 532-781; 533-623; 553-751; 766-968; 878-1578; 889-1427; 889-1176; 903-1357; 919-1547; 941-1636; 959-1640; 957-1321; 963- 1160; 963-1433; 958-1560; 965-1377; 993-1639; 1069-1616; 1166-1590; 1193-1656; 1193-1624; 1200-1664; 1221-1655; 1225-1651; 1233-1660; 1240-1603; 1233-1658; 1235-1656; 1239-1666; 1276-1368; 1293-1660; 1294-1622; 1293-1562; 1307-1629; 1308-1655; 1314-1589; 1319-1657; 1319-1621; 1321-1656; 1362-1658; 1375-1658; 1374-1588; 1487-1658; 1303-1656; 1570-1667 159/LG:982723.4:2002JAN18 1-559; 354-781; 711-1070; 711-1043; 711-799; 727-1014; 727-979; 855-1545; 978-1232; 979-1175; 996-1533; 1022-1231; 1177-1583; 1265-1565; 126-1985; 1349-2036; 1352-1595; 1352-1577; 1381-1604; 1388-1577; 1403-1577; 1455-1577; 1474-1577; 1487-1577; 1491-1582; 1527-1577; 1871-2242; 1873-2183; 1872-2146; 1879-2149; 1885-2095; 1885-2017; 1885-1975; 1904-2073; 1944-2285; 1946-2166; 1995-2231; 2000-2284; 2057-2243; 2123-2309 Table 3 SEQ ID NO:/Template ID Component Spans 160/LG:986427.1:2002JAN18 1-236; 1-641; 112-648; 337-928; 482-845; 492-652; 499-998; 515-964; 515-998; 515-625; 515-640; 515-655; 515-620; 515- 2154; 515-565; 515-575; 521-811; 524-999; 522-1002; 521-1023; 524-791; 523-784; 527-725; 537-998; 539-748; 538-824; 545-763; 548-800; 594-904; 611-893; 626-1035; 630-989; 654-879; 659-911; 692-1037; 711-995; 719-1015; 719-981; 720- 928; 734-1335; 745-952; 745-970; 755-1022; 758-893; 766-943; 768-1076; 775-1027; 780-1003; 832-998; 835-1027; 846- 1093; 846-1173; 866-1098; 886-1078; 889-1085; 930-1027; 931-1180; 938-1270; 941-1027; 941-1296; 942-1157; 948- 1281; 954-1157; 975-1272; 1001-1273; 1006-1268; 1022-1524; 1022-1690; 1028-1308; 1031-1205; 1048-1350; 1059-1620; 1060-1269; 1074-1544; 1068-1336; 1074-1774; 1079-1335; 1097-1357; 1104-1323; 1109-1375; 1117-1762; 1133-1423; 1135-1384; 1144-1410; 1142-1406; 1142-1530; 1154-1435; 1157-1367; 1173-1410; 1176-1351; 1183-1425; 1186-1453; 1202-1403; 1207-1449; 1209-1383; 1207-1684; 1219-1474; 1219-1481; 1237-1437; 1274-1543; 1276-1538; 1283-1546; 1295-1785; 1295-1554; 1306-1792; 1321-1543; 1355-1870; 1376-2154; 1377-2040; 1386-1656; 1395-1688; 1396-1543; 1425-1851; 1426-1661; 1437-1677; 1439-1786; 1439-1994; 1439-1651; 1453-1709; 1456-1705; 1456-1851; 1462-1889; 1481-1614; 1486-1734; 1488-1700; 1490-1767; 1581-2031; 1587-2071; 1581-2104; 1583-2075; 1585-1732; 1585-1817; 1585-1745; 1585-1894; 1585-2042; 1585-1807; 1585-1763; 1608-2104; 1642-2090; 1648-1892; 1654-2109; 1685-1927; 1687-2148; 1688-2153; 1710-2148; 1717-1976; 1737-2154; 1739-2155; 1743-2148; 1748-2148; 1753-2153; 1755-2154; 1756-2154; 1756-1996; 1759-2145; 1759-2116; 1759-2040; 1767-2098; 1763-2148; 1767-1998; 1773-2052; 1773-2148; 1787-2062; 1795-2025; 1798-2152; 1798-2154; 1800-2154; 1803-2148; 1805-2154; 1836-2154; 1839-2154; 1842-2154; 1842-2110; 1843-2153; 1844-2106; 1845-2154; 1846-2051; 1854-2157; 1858-2157; 1864-2154; 1893-2124; 1965-2153; 1968-2160; 2007-2115; 2085-2154; 2092-2154; 161/LG:996868.32:2002JAN18 1-5391; 708-1242; 724-1201; 726-1410; 729-863; 1129-1396; 1295-1973; 1310-1930; 1323-1515; 1335-1603; 1357-1911; 1398-1640; 1497-1729; 1495-1601; 1497-2021; 1557-2144; 1557-1824; 1624-2186; 1763-1913; 1763-2184; 1765-2310; 1773-2136; 1790-2317; 1891-2251; 1908-2409; 1908-2293; 1910-2215; 1927-2152; 2094-2311; 2094-2294; 2101-2376; 2117-2337; 2119-2370; 2220-2466; 2232-2323; 2333-2602; 2347-2531; 2393-2787; 2425-2932; 2473-2614; 2483-2761; 2483-3012; 2553-2779; 2618-3188; 2789-3105; 2799-3091; 2802-3087; 2802-3262; 2826-3364; 2874-3070; 2885-3542; 2891-3065; 2920-3681; 2920-3525; 2959-3216; 2962-3361; 2982-3260; 3007-3070; 3009-3070; 3011-3440; 3011-3702; 3011-3257; 3083-3269; 3198-3467; 3207-3423; 3229-3743; 3235-3848; 3259-3479; 3267-3511; 3301-3782; 3325-3784; 3385-3904; 3394-3907; 3419-3818; 3420-3819; 3439-3698; 3459-3906; 3489-3923; 3501-3898; 3511-3964; 3528-3930; 3557-3763; 3566-3923; 3571-3923; 3586-3929; 3607-3925; 3616-3797; 3621-3940; 3623-3909; 3663-3893; 3690-3924; 3699-3937; 3702-3916; 3705-3926; 3782-3906; 3786-4241; 3855-4141; 3892-4143; 3952-4494; 3976-4336; 4053-4625; Table 3 SEQ ID NO :/Template ID Component Spans 4161-4614 ; 4164-4442 ; 4208-4360 ; 4287-4579 ; 4319-4644 ; 4320-4621 ; 4333-5107 ; 4456-5006 ; 4482-4956 ; 4482-4732 ; 4492-4750 ; 4552-4752 ; 4656-4855 ; 4664-5238 ; 4691-5299 ; 4724-5484 ; 4742-5296 ; 4741-5081 ; 4784-5295 ; 4792-5046 ; 4809-5295 ; 4906-5187 ; 4937-5392 ; 4949-5392 ; 4973-5392 ; 5034-5392 ; 5039-5391 ; 5048-5392 ; 5046-5408 ; 5071-5396 ; 5092-5356 ; 5119-5391 ; 5126-5392 ; 5143-5422 ; 5159-5436 ; 5162-5392 ; 5186-5295 ; 5185-5391 ; 5186-5383 ; 5190-5382 ; 5242-5392 ; 5246-5404 ; 5318-5411 ; 5318-5404 Table 4 SEQ ID Template ID Tissue Distribution NO: 1 LG:021674.23:2002JAN18 Gem Cells -17%, Unclassified/Mixed - 12%, Exocrine Glands - 10% 2 LG:1500085.9:2002JAN18 Endocrine System - 67%, Female Genitalia - 33% 3 LG:201545.7:2002JAN18 Skin - 13%, Sense Organs - 12%, Unclassified/Mixed - 10% 4 LG:228868.3:22002JAN18 Female Genitalla - 27%, Unclassified/Mixed - 23%, Cardiovascular System - 18% 5 LG:231319.2:2002JAN18 Skin - 15%, Endocrine System - 12% 6 LG:245164.1:2002JAN18 Respiratory System - 11%, Female Genitalia - 11%, Embryonic Structures - 10% 7 LG:7685619.6:2002JAN18 Germ Cells - 19%, Respiratory System - 13%, Hemic and Immune System - 12% 8 LG:7771153.7:2002JAN18 Hemic and Immune System - 50%, Nervous System - 50% 9 LG:978820.7:2002JAN18 Germ Cells - 18%, Endocrine System - 17%, Unclassified/Mixed - 13% 10 LG:024189.1:2002JAN18 Nervous System - 69%, Endocrine System - 31% 11 LG:222798.12:2002JAN18 Digestive system - 17%, Musculoskeletal System - 15%, Respiratory System - 12%, Unclassified/Mixed - 12% 12 LG:233706.19:2002JAN18 Embryonic Structures - 47%, Endocrine System - 27%, Digestive System - 13%, Nervous System - 13% 13 LG:404417.1:2002JAN18 Nervous System - 27%, Endocrine System - 18%, Exocrine Glands - 14%, Urinary Tract - 14% 14 LG:005369.4:2002JAN18 Unclassified/Mixed - 17%, Endocrine System - 12% 15 LG:008434.1:2002JAN18 Male Genitalia - 67%, Nervous System - 33% 16 LG:022943.14:2002JAN18 Nervous System - 75%, Digestive System - 25% 17 LG:026981.4:2002JAN18 Unclassified/Mixed - 37%, Respiratory System - 17%, Exocrine Glands - 12% 18 LG:054807.6:2002JAN18 Pancreas - 26%, Liver - 21, Hemic and Immune System - 12%, Nervous System - 12% 19 LG:063690.11:2002JAN18 Digestive System - 100% 20 LG:068514.8:2002JAN18 Germ Cells - 65%, Unclassified/Mixed - 11% 21 LG:097147.4:2002JAN18 Urinary Tract - 22%, Unclassified/Mixed - 20%, Cardiovascular System - 19% 22 LG:099622.1:2002JAN18 Respiratory System - 67%, Hemic and Immun System - 33% 23 LG:1005046.2:2002JAN18 widely distributed 24 LG:1040736.16:2002JAN18 Female Genitalia - 23%, Connective Tissue - 20%, Musculoskeletal System - 17% 25 LG:105937.16:2002JAN18 Skin - 19%, Musculoskeletal System - 15%, Nervous System - 13% 26 LG:1077405.2:2002JAN18 Female Genitalia - 38%, Endocrine System - 19%, Urinary Tract - 14%, Exocrine Glands - 14% 27 LG:1084716.4:2002JAN18 Unclassified/Mixed - 30%, Urinary Tract - 23%, Nervous System - 11% 28 LG:1091759.1:2002JAN18 Sense Organs - 42%, Connective Tissue - 17%, Digestive System - 12% 29 LG:1095157.16:2002JAN18 Female Genitalia - 24%, Exocrine Glands - 14%, Male Genitalia - 12% 30 LG:1096601.118:2002JAN18 Endocrine System - 67%, Female Genitalia - 33% 31 LG:1099356.5:2002JAN18 Female Genitalia - 231%, Pancreas - 16%, Hemic and Immune System - 16% Table 4 SEQ ID Template ID Tissue Distribution NO: 32 LG:1100807.18:2002JAN18 Sense Organs - 24%, Unclassified/Mixed - 20% 33 LG:1116310.38:2002JAN18 Exocrine Glands - 15%, Pancreas - 11% 34 LG:1132386.23:2002JAN18 Embryonic Structures - 12%, Nervous System -12% 35 LG:1134869.44:2002JAN18 Unclassified/Mixed - 100% 36 LG:1135675.15:2002JAN18 Unclassified/Mixed - 13%, Liver - 10% 37 LG:1285109.14:2002JAN18 Cardiovascular System - 17%, Connective Tissue - 11%, Digestive System - 11% 38 LG:1329818.9:2002JAN18 wiedely distributed 39 LG:e1377451.48:2002JAN18 Germ Cells - 51%, Nervous System - 35% 40 LG:1383694.5:2002JAN18 Unclassified/Mixed - 100% 41 LG:1383725.3:2002JAN18 Germ Cells - 11% 42 LG:1394903.37:2002JAN18 Embryonic Structures - 27%, Skin - 22%, Digestive System - 13% 43 LG:1398274.13:2002JAN18 Skin - 12% 44 LG:1398646.12:2002JAN18 Unclassified/Mixed - 12% 45 LG:1398955.2:2002JAN18 widely distributed 46 LG:1452762.26:2002JAN18 Embryonic Structures - 41%, Female Genitalia - 11% 47 LG:1452783.7:2002JAN18 Urinary Tract - 16%, Connective Tissue - 15%, Embryonic Structures - 14% 48 LG:1453027.28:2002JAN18 Cardiovascular System - 25%, Male Genitalia -14%, Endocrine System - 14% 49 LG:1454967.12:2002JAN18 Germ Cells - 15%, Pancreas - 10% 50 LG:1466307.1:2002JAN18 Hemic and Immune system - 100% 51 LG:149121.24:2002JAN18 widely distributed 52 LG:1500347.11:2002JAN18 Liver - 70%, Urinary Tract - 30% 53 LG:1500433.15:2002JAN18 Sense Organs - 71%, Hemic and Immune System - 16% 54 LG:1500434.6:2002JAN18 Stomatognathic System - 22%, Sense Organs - 15% 55 LG:1501028.9:2002JAN18 Endocrine System - 36%, Hemic and Immune ystem - 27%, Male Genitalia - 18%, Respiratory System - 18% 56 LG:1501710.3:2002JAN18 Nervous System - 17% 57 LG:1502217.12:2002JAN18 Digestive System - 43%, Unclassified/Mixed - 24%, male Genitalia - 19% 58 LG:1502272.38:2002JAN18 Stomatognathic System - 21%, Sense Organs - 10% 59 LG:1502313.3:2002JAN18 Digestive System - 76% 60 LG:1502474.57:2002JAN18 Embryonic Structures - 32%, Unclassified/Mixed - 23%, Digestive System - 14%, Nervous System - 14% 61 LG:1502663.27:2002JAN18 Nervous System - 17%, Germ Cells - 15%, Unclassified/Mixed - 11% Table 4 SEQ ID Template ID Tissue Distribution NO: 62 LG:154608.1:2002JAN18 Musculoskeletal System - 35%, Urinary Tract - 18%, Henic and Immune System - 18%, Nervous System - 18% 63 LG:170235.14:2002JAN18 Nervous System - 100% 64 LG:170604.1:2002JAN18 Embryonic Structures - 23%, Liver - 23%, Respiratory System - 17%, Unclassified/Mixed - 17% 65 LG:171629.1:2002JAN18 Hemic and Immune System - 83%, Nervous System - 17% 66 LG:172411.1:2002JAN18 Hemic and Immune System - 32%, Unclassified/Mixed - 18%, Pancreas - 16% 67 LG:173356.1:2002JAN18 Skin - 30%, Unclassified/Mixed - 13%, Urinary Tract - 10% 68 LG:193755.18:2002JAN18 Exocrine Glands - 10% 69 LG:196620.12:2002JAN18 Embryonic Structures - 19%, Nervous System - 12%, Liver - 11% 70 LG:197624.1:2002JAN18 Skin - 19%, Urinary Tract - 15%, Germ Cells - 11% 71 LG:197634.69:2002JAN18 Unclassified/Mixed - 23%, Digestive System - 23%, Germ Cells - 11% 72 LG:198680.1:2002JAN18 Liver - 18%, Hemic and immune System - 13% 73 LG:201188.2:2002JAN18 Sense Organs - 38%, Respiratory System - 12%, Germ Cells - 12% 74 LG:201887.16:2002JAN18 Sense Organs - 15%, Embryonic Structures - 13% 75 LG:208134.1:2002JAN18 Unclassified/Mixed - 22% 76 LG:209924.5:2002JAN18 Connective Tissue - 42% 77 LG:223060.1:2002JAN18 Liver - 30%, Germ Cells -13%, Pancreas - 10% 78 LG:227583.2:2002JAN18 Connective Tissue - 41%, Exocrine Glands - 18%, Male Genitalia - 12%, Digestive System - 12%, Female Genitalia - 12% 79 LG:230149.12:2002JAN18 Unclassified/Mixed - 31%, Connective Tissue - 22%, Endocrine System - 13% 80 LG:230509.30:2002JAN18 Unclassified/Mixed -12% 81 LG:230923.1:2002JAN18 Skin - 16% 82 LG:232307.11:2002JAN18 Nervous System - 18%, Germ Cells - 11% 83 LG:232415.30:2002JAN18 Cardiovascular System - 67%. Digestive System - 33% 84 LG:234121.5:2002JAN18 Germ Cells - 20%, Nervous System -15%, Skin - 11% 85 LG:235713.10:2002JAN18 Stomatognathic System - 13% 86 LG:236340.12:2002JAN18 Skin - 15%, Germ Cells - 10% 87 LG:236386.2:2002JAN18 Connective Tissue - 18%, Female Genitalla - 11%, Urlnary Tract - 10% 88 LG:239601.22:2002JAN18 Pancreas - 11%, Unclassified/Mixed - 11% 89 LG:239673.8:2002JAN18 Nervous System - 15%, Embryonic Structures - 14%, Digestive System - 12% 90 LG:249905.45:2002JAN18 Endocrine System - 33%, Unclassified/Mixed - 17%, Liver - 12%, Exocrine Glands - 12% Table 4 SEQ ID Template ID Tissue Distribution NO: 91 LG:250038.3:2002JAN18 Stomatognathic System - 12%, Germ Cells - 11% 92 LG:252800.19:2002JAN18 Stomatognathic System - 58%, Embryonic Structures - 19% 93 LG:253580.6:2002JAN18 widely distributed 94 LG:271509.8:2002JAN18 Germ Cells - 31%, Musculoskeletal System - 16%, Unclassified/Mixed - 15% 95 LG:277161.30:2002JAN18 Sense Organs - 39% 96 LG:330739.4:2002JAN18 Embryonic Structures - 37%, Exocrine Glands - 22% 97 LG:331470.6:2002JAN18 widely distributed 98 LG:331661.2:2002JAN18 Nervous System - 44%. Sense Organs - 29%, Endocrine System - 15% 99 LG:332032.17:2002JAN18 Germ Cells - 18%, Unclassified/Mixed - 13% 100 LG:332431.2:2002JAN18 Germ Cells - 39%, Unclassified/Mixed -11%, Respiratory System - 10% 101 LG:335173.4:2002JAN18 Musculoskeletal System - 54%, Embryonic Structures - 17% 102 LG:336529.3:2002JAN18 Sense Organs - 16%, Digestive System - 11%, Germ Cells - 10% 103 LG:338001.2:2002JAN18 Liver - 24%, Pancreas - 12%, Digestive System - 11% 104 LG:338469.4:2002JAN18 Nervoius System - 20%, Stomatognathic System - 15% 105 LG:344659.1:2002JAN18 Sense Organs - 32%, Germ Cells - 21% 106 LG:345278.38:2002JAN18 widely distributed 107 LG:346657.13:2002JAN18 Unclassified/Mixed - 20%, Endocrine System - 10% 108 LG:348101.16:2002JAN18 Germ Cells - 23%, Connective Tissue - 15% 109 LG:350827.10:2002JAN18 Germ Cells - 17% 110 LG:354580.28:2002JAN18 Exocrine Glands - 26%, Urinary Tract - 15%, Female Genitalla - 10% 111 LG:356006.3:2002JAN18 Female Genitalia - 67%, Nervous System - 33% 112 LG:370212.10:2002JAN18 Unclassified/Mixed - 11% 113 LG:373219.13:2002JAN18 Respiratory System - 18%. Exocrine Glands - 11% 114 LG:399821.22:2002JAN18 Germ Cells - 22% 115 LG:400519.1:2002JAN18 Skin - 15%, Sense Organs - 14% 116 LG:402797.1:2002JAN18 Connective Tissue - 33%, Respiratory System - 33%, Urinary Tract - 14% 117 LG:402974.1:2002JAN18 Sense Organs - 25%, Nervous System - 13%, Unclassified/Mixed - 12% 118 LG:403397.7:2002JAN18 Urinary Tract - 16%, Liver - 13%, Germ Cells - 10% 119 LG:404199.4:2002JAN18 Unclassified/Mixed - 23%, Embryonic Structures - 20%, Connective Tissue - 12%, Exocrine Glands - 12% 120 LG:404482.7:2002JAN18 Hemic and Immune System - 14%, Female Genitalia - 13%, Connective Tissue - 11%, Endocrine System - 11% Table 4 SEQ ID Template ID Tissue Distribution NO: 121 LG:406239.1:2002JAN18 GErm Cells - 54%. Cardiovascular System - 18% 122 LG:407056.6:2002JAN18 Sense Organs - 11% 123 LG:407485.1:2002JAN18 Stomatognathic System - 13%, Embryonic Structures - 13% 124 LG:422048.46:2002JAN18 Sense Organs - 27%, Unclassified/Mixed - 13% 125 LG:425448.18:2002JAN18 Sense Organs - 13% 126 LG:435717.5:2002JAN18 Skin - 11%, Endocrine System - 11%, Sense Organs - 10% 127 LG:451858.13:2002JAN18 Hemic and Immune System - 15%, Unclassified/Mixed - 14%, Nervous System - 12% 128 LG:462233.20:2002JAN18 widely distributed 129 LG:4733880.41:2002JAN18 Connective Tissue - 33%, Skin - 15%, Pancreas - 12% 130 LG:474421.5:2002JAN18 Digestive System - 100% 131 LG:481462.4:2002JAN18 Connective Tissue - 31%, Germ Cells - 14%, Unclassified/Mixed - 10% 132 LG:7684981.2:2002JAN18 Sense Organs - 27%, Germ Cells - 17% 133 LG:7690420.1:2002JAN18 Digestive System - 100% 134 LG:7691425.2:2002JAN18 Stomatognathic System - 98% 135 LG:7692702.1:2002JAN18 Germ Cells - 88% 136 LG:7694388.21:2002JAN18 Unclassified/Mixed - 27%, Exocrine Glands - 19% 137 LG:7697322.7:2002JAN18 Germ Cells - 18%, Skin - 15%, Sense Organs - 14% 138 LG:7697347.3:2002JAN18 Fermale Genitalia - 17%, Connective Tissue - 15%, Male Genitalia -13%, Musculoskeletal System 13% 139 LG:7698451.18:2002JAN18 Endocrine System - 100% 140 LG:7698705.7:2002JAN18 Hemic and Immune System - 100% 141 LG:7731829.1:2002JAN18 Nervous System - 100% 142 LG:7761659.11:2002JAN18 Hemic and Immune System - 100% 143 LG:7761806.33:2002JAN18 Sense Organs - 13%, Exocrine Glands - 11% 144 LG:7763039.6:2002JAN18 Liver - 27%, REspiratory System - 22%, Hemic and Immune System - 18% 145 LG:7763254.5:2002JAN18 Male Genitalia - 40%, REspiratory System - 40%, Nervous System - 20% 146 LG:7763421.8:2002JAN18 Respiratory System - 100% 147 LG:7763437.104:2002JAN18 Female Genitalia - 11%, Endocrine System - 10% 148 LG:7770095.2:2002JAN18 Female Genitalia - 100% 149 LG:7770589.6:2002JAN18 Skin - 32%, Connective Tissue - 18% 150 LG:7770618.6:2002JAN18 Endocrine System - 47%, Pancreas - 26%, Liver - 21% 151 LG:7770900.9:2002JAN18 Embryonic Structures - 50%, Respiratory System - 36% Table 4 SEQ ID Template ID Tissue Distribution NO: 152 LG:7771513.22:2002JAN18 Musculoskeletal System - 28%, Connective Tissue - 16%, Pancreas - 11% 153 LG:899402.3:2002JAN18 widely distributed 154 LG:902699.29:2002JAN18 Germ Cells - 68% 155 LG:977532.3:2002JAN18 Female Genitalia - 13%, Endocrine System - 12%, Unclassified/Mixed - 11% 156 LG:978729.5:2002JAN18 Unclassified/Mixed - 44%, Male Genitalia - 31%, Respiratory System - 11% 157 LG:980200.9:2002JAN18 Liver - 24%,Musculoskeletal System -17%, EmbryonicStructures - 11% 158 LG:980859.5:2002JAN18 Endocrine System - 42% 159 LG:982723.4:2002JAN18 EmbryonicStructures - 19%, Hemic and Immune System - 17%, Digestive System -15% 160 LG:986427.1:2002JAN18 Connective Tissue -15%, Cardiovascular System -13%, Stomatognathic System - 12% 161 LG:996868.32:2002JAN18 Female Genitalia - 11%, Germ Cells - 11%. Connective Tissue - 10% Table 5 SEQ ID NO: Frame LengthStart Stop GI Number Probability Score Annotation 172 3 124 345 716 g784990 7.0E-62 5-HT5A serotonin receptor 172 3 124 345 716 g20379144 7.0E-62 5-hydroxytryptaminereceptor 5A 172 3 124 345 716 g6064324 3.0E-59 GENE DURECEPTEUR 5HT5A HUMAN 174 3 199 3 599 g15866260 1.0E-113 MRIP2 174 3 199 3 599 g18916856 1.0E-103KIAA1975 protein 174 3 199 3 599 g5689535 4.0E-90 KIAA1099 protein 177 1 84 91 342 g12838451 1.0E-26 evidence:NAS-hypothetical protein-putative 177 1 84 91 342 g12860112 1.0E-26 evidence:NAS-hypothetical protein-putative 177 1 84 91 342 g12854374 1.0E-26 evidence:NAS-hypothetical protein-putative 180 2 167 1592 2092 g21756737 9.0E-27 unnamed protein product 180 2 167 1592 2092 g114934831.0E-20 PRO2550 180 2 167 1592 2092 g7020440 1.0E-19 unnamed protein product 182 3 84 3 254 g4589570 3.0E-06 KIAA0963 protein 182 3 84 3 254 g3399676 3.0E-06 R31180_1 182 3 84 3 254 g18676552 3.0E-06 FLJ00173 protein 183 1 782 4 2349 g22316595 0 unnamed protein product 183 1 782 4 2349 g22316593 0 unnamed protein product 183 1 782 4 2349 g17644260 0 bB206121.1 (ATPase, Class VI, type 11C) 184 2 193 344 922 g23270794 1.0E-68 Unknown (protein forMGC:20553) 184 2 193 344 922 g22713609 1.0E-68 Similar to KIAA1548 protein 184 2 193 344 922 g21753309 1.0E-68 unnamed protein product 185 1 101 79 381 g21708029 1.0E-18 similar to Alu subfamily SQ sequence contamination warming entry 185 1 101 79 381 g16041132 4.0E-15 hypothetical protein 185 1 101 79 381 g7959923 9.0E-15 PRO2738 186 3 1277 3 3833 g20521982 0 KIAA1742 protein 186 3 1277 3 3833 g24324266 0 dispatched B 186 3 1277 3 3833 g23092587 0 DISP1 187 2 417 5 1255 g21619770 0 Unknown (protein for MGC:45404) 187 2 417 5 1255 g21655217 6.0E-23 TAB2 187 2 417 5 1255 g13435951 6.0E-23 Similar to TAK1-binding protein 2; KIAA0733 protein 188 2 587 116 1876 g22255880 0 folliculin 188 2 587 116 1876 g19387935 0 similar to Unknown (protein for MGC:23445) (H. sapiens) Table 5 SEQ ID NO: Frame LengthStart Stop GI Number Probability Score Annotation 188 2 587 116 1876 g160417021.0E-122 Unknown (protein foir MGC:17998) 191 1 78 268 501 g9955914 6.0E-06 platelet glycoprotein VI-3 194 2 113 134 472 g21619220 3.0E-13 Unknown (protein for IMAGE:4707214) 194 2 113 134 472 g1869901 3.0E-13XIAP associated factor-1 (ZAP-1) 196 3 105 3 317 g453132 4.0E-55 p130 196 3 105 3 317 g416031 4.0E-55 130K protein 196 3 105 3 317 g397148 4.0E-55 Rb2/p130 protein 197 1 134 1 402 g15620863 1.0E-71 KIAA1902 protein 197 1 134 1 402 g21740085 7.0E-71 hypothetical protein 197 1 134 1 402 g22209048 4.0E-51 Unknown (protein for MGC:43177) 204 2 175 1520 2044 g5360115 8.0E-97 NY-REN-45 antigen 204 2 175 1520 2044 g21740071 8.0E-97 hypothetical protein 204 2 175 1520 2044 g18093151 8.0E-97 bA275K8.1 (NY-REN-45 antigen) 205 2 175 1196 1720 g2707770 2.0E-91 nuclear receptro coactivator 205 2 175 1196 1720 g2584880 2.0E-91 thyroid hormone receptor activator molecule 205 2 175 1196 1720 g2331250 2.0E-91 Amplified in Breast Cancer 207 2 438 311 1624 g21336134 0 unnamed protein product 207 2 438 311 1624 g10436645 0 unnamed protein product 207 2 438 311 1624 g13905156 1.0E-145 Unknown (protein for MGC:11798) 208 2 920 317 3076 g21732498 0 hypothetical protein 208 2 920 317 3076 g21750783 0 unnamed protein product 208 2 920 317 3076 g18676716 0 FLJ00257 protein 213 2 113 161 499 g12850722 2.0E-49 data source:SPTR, source key:Q9V5P5, evidence:ISS-putative-related toi CG12935 PROTEIN 213 2 113 161 499 g12842446 2.0E-49 data source:SPTR, source key:Q9V5P5, evidence:ISS-putative-related toi CG12935 PROTEIN 213 2 113 161 499 g12842369 2.0E-49 data source:SPTR, source key:Q9V5P5, evidence:ISS-putative-related toi CG12935 PROTEIN 214 1 242 1348 2073 g21439108 1.0E-125 unnamed protein product 214 1 242 1348 2073 g14042736 1.0E-125 unnamed protein product 214 1 242 1348 2073 g6841178 1.0E-123 HSPC264 217 3 179 1020 1556 g19683970 1.0E-108 Unknown (protein for MGC:33371) Table 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 217 3 179 1020 1556 g14198207 2.0E-52 Similar to CG4452 gene product 217 3 1791020 1556 g4200234 6.0E-52 hypothetical protein 219 2 226 161 838 g21757978 1.0E-124 unnamed protein product 219 2 226 161 838 g3882153 3.0E-95 KIAA0716 protein 219 2 226 161 838 g12321294 9.0E-10 unknown protein 220 1 128 793 1176 g7406621 2.0E-71 MUC4/X apomucin 220 1 128 793 1176 g7406619 2.0E-71 MUC4/Y apomucin 220 1 128 793 1176 g7406617 2.0E-71 sv8-MUC4 apomuch 221 3 185 2790 3344 g3334899 4.0E-65 autoantigen p542 221 3 185 2790 3344 g4938296 2.0E-64 dJ64K7.3.1 (heterogenous nuclear ribonucleoprotein RALY or autoantigen P542, isoform 1) 221 3 185 2790 3344 g6164674 6.0E-64 heterogeneous nuclear ribonucleoprotein, alternate transcript 224 2 333 206 1204 g12052928 0 hypothetical protein 224 2 333 206 1204 g21336340 0 unnamed proteinproduct 224 2 333 206 1204 g15030175 1.0E-146 Similar to hypothetical protein DKFZp566A1524 225 1 70 562 771 g12698182 5.0E-16 hypothetical protein 225 1 70 562 771 g21757056 8.0E-14 unnamed protein product 225 1 70 562 771 g70211646 8.0E-13 unnamed protein product 226 1 92 115 390 g21739842 1.0E-08 hypothetical protein 226 1 92 115 390 g12654795 1.0E-08 Similar to hypothetical protein FLJ10422 226 1 92 115 390 g10434125 1.0E-08 unnamed protein product 227 2 236 821 1528 g23342599 1.0E-128 unnamed protein product 227 2 236 821 1528 g21732498 7.0E-79 hypothetical protein 227 2 236 821 1528 g23342591 2.0E-75 unnamed protein product 230 3 239 3 719 g10437090 4.0E-86 unnamed protein product 230 3 239 3 719 g14573887 3.0E-19 Hypothetical protein C34D4.1 230 3 239 3 719 g8777580 2.0E-16 gene_id:F1D9.26-unknown protein 232 1 601 1 1803 g21757176 0 unnamed protein product 232 1 601 1 1803 g15020651 0 hypothetical protein 232 1 601 1 1803 g14017859 0 KIAA1821 protein Tabel 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 233 3 109 45 371 g12856787 2.0E-29 DNA binding domain with preference for A/T rich regions containing protein#data source:Pfam, source key:PF02178, evidence:ISS#putative 233 3 109 45 371 g12853099 2.0E-29 DNA binding domain with preference for A/T rich regions containing protein#data source:Pfam, source key:PF02178, evidence:ISS#putative 233 3 109 45 371 g12840402 4.0E-21 DNA binding domain with preference for A/T rich regions containing protein#data source:Pfam, source key:PF02178, evidence:ISS#putative 234 2 97 2 292 g7934572 1.0E-21 TACC2 234 2 97 2 292 g7542377 1.0E-21 anti zual-1 234 2 97 2 292 g19584438 1.0E-21 hypothetical protein 236 2 264 3512 4303 g2605967 2.0E-06 24 236 2 264 3512 4303 g6599134 4.0E-06 hypothetical protein 236 2 264 3512 4303 g6912009 9.0E-06 conserved hypothetical proteinSCE56.05c 239 2 193 32 610 g21439006 2.0E-86 unnamed protein product 239 2 193 32 610 g20987922 3.0E-84 RIKEN cDNA 1500005J14 gene 239 2 193 32 610 g15214767 3.0E-84 RIKEN cDNA 1500005J14 gene 240 1 152 1618 2073 g21739629 2.0E-11 hypothetical protein 240 1 152 1618 2073 g21739493 2.0E-11 hypothetical protein 240 1 152 1618 2073 g10437518 5.0E-11 unnamed protein product 241 2 98 245 538 g21751539 8.0E-24 unnamed protein product 241 2 98 245 538 g21750861 3.0E-23 unnamed protein product 21 2 98 245 538 g299471 3.0E-18 X-linked retinopathy protein 243 2 665 38 2032 g15529703 0 importin 9 243 2 665 38 2032 g14042277 0 unnamed protein product 243 2 665 38 2032 g22760379 0 unnamed protein product 244 3 192 1038 1613 g14249848 1.0E-111 hypothetical protein FLJ21276 244 3 192 1038 1613 g10437348 1.0E-111 unnamed protein product 245 1 294 1 882 g10440373 1.0E-170 FLJ00022 protein 245 1 294 1 882 g20379511 1.0E-111 Similar to hypothetical protein FLJ0001 245 1 294 1 882 g10440396 1.0E-106 FLJ00031 protein Table 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 246 2 219 233 889 g10862874 2.0E-84 dJ927M24.2 (KIAA1219) 246 2 219 233 889 g21740166 2.0E-83 hypothetical protein 246 2 219 233 8898 g20521798 2.0E-49 KIAA1219 protein 247 3 423 948 2216 g14042066 0 unnamed protein product 247 3 423 948 2216 g12860-337 1.0E-54 evidenen:NAS#hypothetical protein#putative 247 3 423 948 2216 g21755300 5.0E-33 unnamed protein product 248 1 647 397 2337 g7021047 0 unnamed protein product 248 1 647 397 2337 g12654801 0 hypothetical protein 248 1 647 397 2337 g15488990 0 Similar to hypothetical protein 249 3 457 3 1373 g7021062 0 unnamed protein product 249 3 457 3 1373 g20072202 0 hypothetical protein FLJ20729 249 3 457 3 1373 g10241710 0 hypothetical protein 253 2 153 1430 1888 g14250060 8.0E-54 Unknown (protein for MGC:14598) 253 2 153 1430 1888 g7578785 7.0E-53 NPD008 protein 253 2 153 1430 1888 g4929765 7.0E-53 CGI-148 protein 254 3 1248 522 4265 g5733726 0 gamma-synergin 254 3 1248 522 4265 g7341344 0 gamma-synergin 254 3 1248 522 4265 g5733728 0 gamma-synergin 257 2 759 1511 3787 g23194377 0 ALFY 257 2 759 1511 3787 g21750517 0 unnamed protein product 257 2 759 1511 3787 g22945705 1.0E-161 CG14001-PA 258 3 135 1944 2348 g18028934 7.0E-53 four-span transmembrane protein 3.2 258 3 135 1944 2348 g15778232 7.0E-53 MS4A6A 258 3 135 1944 2348 g18028932 2.0E-52 four-span transmembrane protein 3.1 260 1 628 1 1884 g21335589 0 unnamed protein product 260 1 628 1 1884 g21335587 0 unnamed protein product 260 1 628 1 1884 g3043708 0 KIAA0592 protein 262 2 223 98 766 g19263519 2.0E-69 RIKEN cDNA B230118H07 gene 262 2 223 98 766 g12861731 5.0E-69 evidence:NAS#hypothetical protein#putative 262 2 223 98 766 g12846529 5.0E-69 evidence:NAS#hypothetical protein#putative 263 1 148 532 975 g17390179 7.0E-61 Similar to RIKEN cDNA 9030409E16 gene 263 1 148 532 975 g12858225 7.0E-59 evidence:NAS#hypothetical protein#putative Table 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 263 1 148 532 975 g21627513 5.0E-13 CG12341-PA 264 3 210 9 638 g5924316 6.0E-31 carbon catabolite repression 4 protein homolog 264 3 210 9 638 g18314363 1.0E-30 Unknown (protein for MGC:1119) 264 3 210 9 638 g9885278 2.0E-25 NOCTURNIN 265 3 1025 51 3125 g21336252 0 unnamed protein product 265 3 1025 51 3125 g7243095 0 KIAA1357 protein 265 3 1025 51 3125 g15488869 1.0E-138 Unknown (protein for IMAGE:3591967) 266 2 133 185 583 g21757324 2.0E-06 unnamed protein product 268 1 246 1 738 g18676842 1.0E-144 unnamed protein product 268 1 246 1 738 g12653703 1.0E-130 Unknown (protein for MGC:3048) 268 1 246 1 738 g12856220 1.0E-129 data source:SPTR, source key:Q10079, evidence:ISS#putative#relative to HYPOTHETICAL 22.7 KDA PROTEIN C3H1.14 IN CHROMOSOME I 271 3 401 2415 3617 g15451309 8.0E-89 hypothetical protein 271 3 401 2415 3617 g6778922 4.0E-88 unnamed protein product 271 3 401 2415 3617 g6062874 4.0E-88 candldate tumor suppressor protein DICE1 273 1 94 1 282 g13278804 4.0E-09 Unknown (protein for MGC:2743) 273 1 94 1 282 g13097804 4.0E-09 Unknown (protein for MGC:4368) 273 1 94 1 282 g20072735 2.0E-08 Unknown (protein for MGC:37062) 274 3 161 3 485 g7381239 2.0E-57 p38 interacting protein 274 3 161 3 485 g6523258 2.0E-57 putative transcription factor 274 3 161 3 485 g5163089 2.0E-57 P38IP 275 1 348 250 1293 g18307966 0 splicing factor, arginine/serine-rich 12 275 1 348 250 1293 g7158880 1.0E-142 swerine-arginine-rich splicing regulatory protein SRRP86 275 1 348 250 1293 g23496658 1.0E-42 eukaryotic translation initiation factor 3 subunit 10. putative 277 3 1441 831 5153 g7243239 0 KIAA1429 protein 277 3 1441 831 5153 g13277584 0 RIKEN cDNA 1110037F02 gene 277 3 1441 831 5153 g10434568 0 unnamed protein product 278 2 404 170 1381 g13442786 1.0E-32 Drctnnbla 278 2 404 170 1381 g17511709 1.0E-130 down-regulated by Ctnnb1, a 278 2 404 170 1381 g16551687 1.0E-130 unnamed protein product 279 3 305 18 932 g12839444 1.0E-128 evidence:NAS#hypothetical protein#putative TAble 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 279 3 305 18 932 g21755294 4.0E-95 unnamed protein product 279 3 305 18 932 g23171899 3.0E-19 CG15498-PA 280 2 87 530 790 g21749185 9.0E-21 unnamed protein product 280 2 87 530 790 g10437485 2.0E-20 unnamed protein product 280 2 87 530 790 g21755850 1.0E-19 unnamed protein product 281 2 292 677 1552 g2224713 6.0E-40 KIAA0386 281 2 292 677 1552 g21748568 2.0E-31 FLJ00360 protein 281 2 292 677 1552 g21739918 9.0E-24 hypothetical protein 282 1 272 286 1101 g21336488 1.0E-149 unnamed protein product 282 1 272 286 1101 g15862410 1.0E-148 unnamed protein product 282 1 272 286 1101 g22800435 2.0E-67 Unknown (protein for MGC:17839) 283 3 214 3 644 g21438656 1.0E-115 unnamed protein product 283 3 214 3 644 g7018410 1.0E-110 hypothetical protein 283 3 214 3 644 g15012072 1.0E-110 Similkar to DKFZP566K023 protein 284 2 168 2 505 g21754639 2.0E-96 unnamed protein product 284 2 168 2 505 g21336414 2.0E-96 unnamed protein product 284 2 168 2 505 g18699567 2.0E-96 PGC-1-related estrogen receptor alpha coactivator short isoform 286 1 367 553 1653 g20380979 0 similar to putative 286 1 367 553 1653 g12855517 1.0E-162 data source:SPTR, source key:Q9VS60, evidence:ISS#putative#related to CG8576 PROTEIN 286 1 367 553 1653 g18044462 1.0E-131 Unknown (protein for MGC:30540) 288 3 188 3 566 g12313684 5.0E-06 hypothetical protein 288 3 188 3 566 g334068 6.0E-06 ORF2 288 3 188 3 566 g334072 8.0E-06 ORF-3 protein 289 1 124 562 933 g12698182 1.0E-29 hypothetical protein 289 1 124 562 933 g21751050 1.0E-25 unnamed protein product 289 1 124 562 933 g7020440 8.0E-24 unnamed protein product 293 3 89 3 269 g20379642 1.0E-15 hypothetical gene LOC136016 293 3 89 3 269 g21594456 5.0E-07 DNA segment, Chr 7, Wayne State University 86, expressed 293 3 89 3 269 g12851605 5.0E-07 DNA segment, Chr 7, Wayne State University 86, expressed#data source:MGD, source key:MGI:106442, evidence:ISS#putative 295 1 130 760 1149 g12698121 4.0E-12 hypothetical protein Table 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 295 1 130 760 1149 g16041152 3.0E-11 hypothetical protein 295 1 130 760 1149 g10435380 2.0E-06 unnamed protein product 296 3 87 3 263 g23450941 1.0E-30 cell death activator CIDE-3 296 3 87 3 263 g16877166 1.0E-30 Unknown (protein for MGC:16833) 296 3 87 3 263 g10188751 1.0E-30 unnamed protein product 298 3 137 396 806 g12860403 3.0E-21 evidence:NAS#hyothetical protein#putative 302 3 115 3 347 g9799931 6.0E-48 dJ621N11.4(A novel protein (containing transiation of EST DKFZp434N2022)) 302 3 115 3 347 g21752301 2.0E-47 unnamed protein product 302 3 115 3 347 g21739354 3.0E-18 hypothetical protein 304 3 101 339 641 g21756629 9.0E-19 unnamed protein product 304 3 101 339 641 g21757878 1.0E-11 unnamed protein product 304 3 101 339 641 g10435180 3.0E-11 unnamed protein product 307 1 114 2071 2412 g862407 3.0E-5 cbl-b 307 1 114 2071 2412 g23273909 3.0E-55 Cas-Br-M(murine) ecotropic retroviral transforming sequence b 307 1 114 2071 2412 g6467994 6.0E-50 CBL-B 308 1 109 508 834 g7023813 2.0E-30 unnamed protein product 308 1 109 508 834 g7018526 2.0E-30 hypothetical protein 308 1 109 508 834 g22852208 2.0E-30 beta-1,4N-acetylgalactosaminyltransferase 309 2 112 131 466 g21779824 5.0E-41 ABC transporter ABCA6 309 2 112 131 466 g21779782 5.0E-41 ABC transporter ABCA6 309 2 112 131 466 g17223622 5.0E-41 ATP-binding cassette A6 312 2 178 164 697 g10439565 2.0E-54 unnamed protein product 312 2 178 164 697 g2814367 5.0E-27 dJ5760B9.3 313 1 185 613 1167 g7573533 4.0E-50 dJ136O14.3 (novel protein) 315 3 243 165 893 g19584572 1.0E-132 RNA binding motif protein 9 315 3 243 165 893 g19264130 1.0E-132 RNA binding motif protein 9 315 3 243 165 893 g18461369 1.0E-132 hexaribonucleotide binding protein 2 316 2 452 233 1588 g10436681 0 unnamed protein product 316 2 452 233 1588 g5912126 0 hypothetical protein 316 2 452 233 1588 g2007345 1.0E-147 Similar to hypothetical gene supported by Ak024325; AL117573 317 2 180 905 1444 g3170174 7.0E-79 antigen NY-CO-1 Table 5 SEQ ID NO: Frame Length Start Stop GI Number Probability Score Annotation 317 2 180 905 1444 g18088535 7.0E-79 serologically defined colon cancer antigen 1 317 2 180 905 1444 g12855522 2.0E-41 data source:SPTR, source key:O60524, evidence:ISS#homolog to ANTIGEN NY-CO-1#putative 318 3 228 204 887 g7023747 1.0E-108 unnamed protein product 318 3 228 204 887 g21439208 1.0E-108 unnamed protein product 318 3 228 204 887 g21439206 1.0E-108 unnamed protein product 319 1 142 175 600 g23271393 2.0E-60 Similar to RIKEN cDNA 1700124B08 gene 319 1 142 175 600 g12840698 4.0E-18 data source:SPTR, source key:Q9FWH5, evidence:ISS#putative#related to MALATE DEHYDROGENASE 319 1 142 175 600 g20302744 5.0E-08 unknown 320 2 225 248 922 g18605738 1.0E-131 Unknown (protein for MGC:30052) 320 2 225 248 922 g14249949 6.0E-12 hypothetical protein DKFZp56410422 320 2 225 248 922 g12052740 6.0E-12 hypothetical protein 324 3 237 1257 1967 g6330772 1.0E-131 KIAA 1238 protein 324 3 237 1257 1967 g18314402 1.0E-131 Unknown (protein for IMAGE:3951537) 324 3 237 1257 1967 g21707208 6.0E-71 Similar to RIKEN cDNA 4933426K21 gene Table 6 Progra Description Reference Parameter Threshold ABI FACTURA A program that removes vector sequences and masks Applied Bosystems, Foster City, CA. ambignuous bases in nucleic acid sequences. ABI/PARACEL FDF A Fast Data Finder useful in comparing and Applied Biosytems, Foster City, CA; Paacel Mismatch <50% annotating amino acid or nucleic acid sequences. Inc., Pasdena, CA. ABI AutoAssembler A program that assembles nucleic acid sequences. Applied biosytems, Foster City, CA. BLAST A Basic Local alignment Search Tool useful in Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403- ESTs: Probability value= 1.0E-8 or less; sequence similarity search for amino acid and nucleic 410; Altschul, S.F. et al. (1997) Nucleic Acids Full Length sequences: Probability value= acid sequences. BLAST includes five functions: Res. 25:3389-3402. 1.0E-10 or less blastp, blastn, blastx, tblastn, and tblastx. FASTA A Pearson and Lipman algorithm that searches for Pearson, W.R. and D.J. Lipman (1988) Proc. $ESTs: fasta E value=1.06E-6; Assembled similarity betwen a query sequence and a group of Natl. Acad Sci. USA 85:2444-2448; Pearson, ESTs: fasta Identity=95% or greater and sequences of the same type. FASTA comprises as W.R. (1990) Methods Enzymol. 183:63-98; and Match length=200 bases or greater; fastx E least five functions: fasta, tfasta, fastx, tfastx, and Smith, T.F. and M.S. Waterman (1981) Adv. value=1.0E-8 or less; Full Length ssearch. Appl. Match. 2:482-489. sequences: fastx score=100 or greater BLIMPS A BLocks IMproved Searcher that matches a Henikoff, S. and J.g. Henikoff (1991) Nucleic Probability value= 1.0E-3 or less sequence against those in BLOCKS, PRINTS, Acids Res. 19:6565-6572; Henikoff, J.G. and S. DOMO, PRODOM, and PFAM databases to search Henikoff (1996) Methods Enzymol. 266:88-105; for gene families, sequence homology, and structural and Attwood, T.K. et al. (1997) J. Chem. Inf. fingerprint regions. Comput. Sci. 37:417-424. HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. 235:1501- PFAM hits: Probability value= 1.0E-3 or hidden Markov moel (HMM)-based databases of 1531; Sonnhammer, E.L.L. et al. (1988) Nucleic less; protein family consensus sequences, such as PFAM. Acids Res. 26:320-322; Durbin, R. et al. (1998) Signal peptide hits: Score=0 or greater Our World View, in a Nutsehll, Cambridge Univ. Press, pp. 1-350.

Table 6 Program Description eference Parameter Threshold profileScan An algorithm that searches for structural and Gribskov, M. et al. (1988) CABIOS 4:61-66; Normalized quality score#GCG-specified sequence motifs in protein sequences that match Gribskov, M. et al. (1989) Methods Enzymol. "HIGH" value for that particular Prosite sequence patterns defined in Prosite. 183:146-159; Bairoch, A. et al. (1997) Nucleic motif. Generally, score=1.4-2.1 Acids Res. 25:217-221. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) genome Res. 8:175-185; sequencer traces with high sensitivity and probability. wing, B. and P. Green (1998) Genome Res. 8:186-194. Phrap A Phils Revised Assembly Program including Smith, T."F. and M.S. Waterman (1981) Adv. Score= 120 or greater; SWAT and CrossMatch, programs based on efficient Appl. Math. 2:482-489; Smith, T.F. and M.S. Match length= 56 or greater implementation of the Smith-Waterman lagorithm, Waterman (1981) J. Mol. Biol. 147:195-197; useful in searching sequence homology and and Green, P., University of Washington, assembling DNA sequences. Seattle, WA. Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. 8;195- assemblies. 202. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score=3.5 or greater sequences for the presence of secretory signal 10:1-6; Claverie, J.M. and S. Audic (1997) peptides. CABIOS 12:431-439. TMAP A program that uses weight matrices to delneate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 2337:182-192; Persson, B. and P. Argos (1996) determine orientation. Protein Sci. 5:363-371. TMHMMER A program that uses a hidden Markov model (HMM) Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. to delineate transmembrane segments on protein conf. On Intelligent Systems for Mol. Biol., sequences and determine orientation. Glasgow et al., cds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, CA, and MIT press, Cambridge, MA, pp. 175-182.

Table 6 program Description Reference Parameter Threshold Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25:21-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, madison, WI.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 10 LG:024189.L1:2002JAN18 g21753280 0 Homo sapiens cNA FLJ36936 fis, clone BRACE2005395, highly similar to 5- HYDROXYTRYPTAMINE 5A RECEPTOR. 11 LG:222798. 12:2002JAN18 g21757986 0 Homo sapeins cDNA FLJ40738 fis, clone TKIDN2004185, weakly similar to GLOBIN. 12 LG:233706.19:2002JAN18 g15866259 0 Homo sapiens MRIP2 (MRIP2) mRNA, complete cds. 13 lg:404417.1:2002JAN18 G21755732 0 Homo sapiens cDNA FLJ38962 fis, clone NT2RI2000348, highly similar to GLYPICAN-2 PRECURSOR. 14 LG:005369.4:2002JAN18 g19584343 0 Homo sapiens mRNA; DNA DKFZp667D1012 (from clone DKFZp667D1012). 15 LG:008434.1:2002JAN18 g12838451 3.0E-26 evidence:NAS#hypothetical protein#putative (Mus musculus) 16 LG:022943.14:2002JAN18 g13699100 4.0E-18 Homo sapiens genomic DNA, chromosome 8q23, clone: KB1205A7. 17 LG:026981.4:2002JAN18 g14043835 0 Homo sapiens, clone MGC:14425 IMAGE:4302902, mRNA, complete cds. 18 LG:054807.6:2002JAN18 g21739502 0 Homo sapiens mRNA; cDNA DKFZp434M104 (from clone DFZp434M104). 19 LG:063690.11:2002JAN18 g4589569 5.0E-34 Homo sapiens mRNA for KIAA0963 protein, complete cds. 20 LG:068514.8:2002JAN18 g22316603 0 unnamed protein product (Homo sapiens) 21 LG:097147.4:2002JAN18 g22713608 0 Homo sapeins, Similar to KIAA1548 protein, clone MGC:35064 IMAGE:5166212, mRNA, complete cds. 22 LG:099622.1:2002JAN18 g7768687 1.0E-36 Homo sapiens genomic DNA, chronosome 21q, section 140/105. 23 LG:1005046.2:2002JAN18 g23092587 0 DISP1 (Mus musculus) 24 LG:1040736.16:2002JAN18 g21619770 0 Unknown (protein for MGC;45404) (Homo sapiens) 25 LG:105937.16:2002JAN18 g16041701 0 Homo sapiens, clone MGC:17998 IMAGE:3922049, mRNA, complete cds. 26 LG:1077405.2:2002JAN18 g5926688 1.0E-107 Homo sapiens genomic DNA, chromosome 8p11.2, clone:91h23 to 9-41. 27 LG:1084716.4:2002JAN18 g13529178 0 Homo sapiens, Similar to RIKEN cDNA 1700073K01 gene, clone MGC:12458 IMAGE:3511019, mRNA, complete cds. 28 LG:1091759.1:2002JAN18 g3327069 0 Homo sapiens mRNA for KIAA0628 protein, complete cds. 29 LG:1095157.16:2002JAN18 g16553847 0 Homo sapiens cDNA FLJ25147 fis,l clone CBR07369. 30 LG:1096601.118:2002JAN18 g16550389 3.0E-55 Homo sapiens cDNA FLJ31053 fis, clone HSYRA2000640, highly similar to Homo sapiens FRG1 mRNA. 31 LG:1099356.5:2002JAN18 g16552435 0 Homo sapiens cDNA FLJ32346 fis, clone PROST2006737, highly similar to H.sapiens mRNA for XIAP associated factor-1. 32 LG:1100807.18:2002JAN18 g21914240 5.0E-65 unknown (Homo sapiens) 33 LG:1116310.38:2002JAN18 g21759786 0 Homo sapiens, clone MGC:26535 IMAGE:4838444, mRNA, complete cds.

Table 7 SEQ ID NO: Template ID GI Number Prbability Annotation Score 34 LG:1132386.23:2002JAN18 g15680051 0 Homo sapiens, clone IMAGE:3839284, mRNA, partial cds. 35 LG:1134869.44:2002JAN18 g17511815 5.0E-61 Homo sapiens, Similar to RIKEN cDNA 1110032O22 gene, clone MGC:31967 IMAGE:4907976, mRNA, complete cds. 36 LG:1135675.15:2002JAN18 g21753769 0 Homo sapiens cDNA FLJ37344 fis, clone BRAMY2021139, highly similar to Seven in absentia. 37 LG:1285109.14:2002JAN18 g6453439 0 Homo sapiens mRNA: cDNA DKFZp434G171 (from clone DKFZp434G171). 38 LG:1329818.9:2002JAN18 g16549667 0 Homo sapiens cDNAFLJ30463 fis, clone BRACE2009517. 39 LG:1377451.48:2002JAN18 g9944290 0 Homo sapiens TTYH1 mRNA, complete cds. 40 LG:1383694.5:2002JAN18 g21750232 4.0E-48 Homo sapiens cDNA FLJ34461 fis, clone HLUNG2002949. 41 LG:1383725.3:2002JAN18 g10436852 0 Homo sapiens cDNA: FLJ20894 ifs, clone ADKA03469, highly similar to AF155110 Homo sapiens NY-REN-45 antigen mRNA. 42 LG:1394903.37:2002JAN18 g2565049 0 Homo sapiens CAGH16 mRNA, complete cds. 43 LG:1398274.13:2002JAN18 g10241768 0 Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244). 44 LG:1398646.12:2002JAN18 g7020975 0 Homo sapiens cDNA FLJ20707 fis, clone KAIA 1223. 45 LG:1398955.2:2002JAN18 g21733306 0 Homo sapiens mRNA; cDNA DKFZp313N099 (from clone DKFZp313N099). 46 LG:1452762.26:2002JAN18 g21619092 0 Homo sapiens, similar to putative, clone MGC:40405 IMAGE:5197918, mRNA, complete cds. 47 LG:1452783.7:2002JAN18 g7141124 0 Homo sapiens tissue-type heart Ellis-van Creveld syndrome proteln (EVC) mRNA, complete cds. 48 LG:1453027.28:2002JAN18 g14028371 0 Homo sapiens gene for mitochondrial ribosomal protein bMRP64, partial 49 LG:1454967.12:2002JAN18 g18606289 0 Homo sapiens, Similar to KIAA0800 gene product, clone MGC:23092 IMAGE:4853730, mRNA, complete cds. 50 LG:1466307.1:2002JAN18 g12834077 7.0E-65 data source:SPTR, source key:Q9v5P5, evidence:ISS-putative-related to CG12935 PROTEIN (Mus musculus) 51 LG:149121.24:2002JAN18 g16550530 0 Homo sapiens cDNA FLJ31167 fis, clone KIDNE1000145. 52 LG:1500347.11:2002JAN18 g2795924 4.0E-46 Homo sapiens clone 23596 mRNA sequence. 53 LG:1500433.15:2002JAN18 g21753716 0 Homo sapiens cDNA FLJ37304 fis, clone BRAMY2016070. 54 LG:1500434.6:2002JAN18 g1968969 0 Homo sapiens, clone MGC:33371 IMAGE:5270248, mRNA, complete cds. 55 LG:1501028.9:2002JAN18 g21752612 0 Homo sapiens cDNA FLJ36369 fis, clone THYMU2008035, highly similar to Homo sapiens DNA polymerase iota (POLI) mRNA. 56 LG:1501710.32:2002JAN18 g21757977 0 Homo sapiens cDNA FLJ40731 fis,clone TKIDN2000521.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 57 LG:1502217.12:2002JAN18 g22266116 0 Homo saplens partial MUC4 gene for mucin 4, exons 5-25. 58 LG:1502272.38:2002JAN18 g3334898 0 Homo sapiens autoantigen p542 mRNA, complete cds. 59 LG:1502313.3:2002JAN18 g16550586 4.0E-87 Homo sapiens cDNA FLJ31212 fis, clone KIDNE2003941. 60 LG:1502474.57:2002JAN18 g21702483 0 Homo sapiens chAB4 multisequence family and NF1-related multisequence family regions. 61 LG:1502663.27:2002JAN18 g12052927 0 Homo sapiens mRNa; cDNA DKFZp566A1524 (from clone DKFZp566A1524); complete cds. 62 LG:154608.1:2002JAN18 g22760448 2.0E-21 Homo sapiens cDNA FLJ90298 fis, clone NT2RP2000479. 63 LG:170235.14:2002JAN18 g10434124 7.0E-41 Homo sapiens cDNA FLJ12564 fis, clone NT2RM4000833. 64 LG:170604.1:2002JAN18 g21733306 0 Homo sapiens mRNa; cDNA DKFZp313N099 (from clone DKFZp313N099). 65 LG:171629.1:2002JAN18 g7959845 4.0E-41 PRO1925 (Homo sapiens) 66 LG:172411.1:2002JAN18 g20987805 0 Homo sapiens, LOc205472, clone MGC:40441 IMAGE:4385178, mRNA, complete cds. 67 LG:173356.1:2002JAN18 g10437090 3.0E-85 unnamed protein product (Homo sapiens) 68 LG:193755.18:2002JAN18 g16549483 0 Homo sapiens cDNA FLJ30302 fis, clone BRACE2003254. 69 LG:196620.12:2002JAN18 g21757175 0 Homo sapiens cDNA FLJ40105 fis, clone TESTI2006383. 70 LG:197624.1:2002JAN18 g12853099 2.0E-28 DNA binding domain with preference for A/Trich regions containing protein-data source:Pfam, source key:PF02178, evidence:ISS#putative (Mus musculus) 71 LG:197634.69:2002JAN18 g22760963 0 Homo sapiens cDNA FLJ90616 fis, clone PLACE1002153, highly similar to Homo sapiens TACC2 protein (TACC2) mRNA. 72 LG:198680.1:2002JAN18 g10432629 0 Homo sapiens cDNA FLJ11381 fis, clone HEMBA1000501. 73 LG:201188.2:2002JAN18 g15886647 0 Homo sapiens genomic sequence surrounding Noti site, clone NR1-OG18C. 74 LG:201887.16:2002JAN18 g7717304 0 Homo sapiens chromosome 21 sgement HS21C048. 75 LG:208134.1:2002JAN18 g21754264 0 Homo sapiens cDNA FLJ37755 fis, clone BRHIP2023762. 76 LG:209924.5:2002JAN18 g23241692 0 Homo sapiens, Similar to RIKEN cDNA 1500005J14 gene, clone IMAGE:4812334, mRNA. 77 LG:223060.1:2002JAN18 g21739629 6.0E-36 hypothetical protein (Homo sapiens) 78 LG:227583.2:2002JAN18 g7717257 6.0E-86 Homo sapiens chromosome 21 sgement HS21C008. 79 LG:230149.12:2002JAN18 g10439353 2.0E-32 Homo sapiens cDNA: FLJ22828 fis, clone KAIA4051, highly similar to HSU06631 Human (H326) mRNa.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 80 LG:230509.30:2002JAN18 g14042276 0 Homo sapiens cDNA FLJ14626 fis, clone NT2RP2000288. 81 LG:230923.1:2002JAN18 g14249847 0 Homo sapiens, hypothetical protein FLJ21276, clone MGC:14946 IMAGE:3532035, mRNA, complete cds. 82 LG:232307.11:2002JAN18 g10440372 0 Homo sapiens mRNA for FLJ00022 protein, partial cds. 83 LG:232415.30:2002JAN18 g21740165 0 Homo sapiens mRNa; cDNA DKFZp762M106 (from clone DKFZp762M106). 84 LG:234121.5:2002JAN18 g21758881 0 Homo sapiens cDNA FLJ25902 fis, clone CBR04408. 85 LG:235713.10:2002JAN18 g12654800 0 Homo sapiens, hypothetical protein, clone MGC:4948 IMAGE:3453136, mRNA, complete cds. 86 LG:236340.12:2002JAN18 g12060842 0 Homo sapiens serologically defined breast cancer antigen NY-BR-75 mRNa, partial cds. 87 LG:236386.2:2002JAN18 g21733629 0 Homo sapiens mRNa; cDNa DKFZp666B159 (from clone DKFZp666B159). 88 LG:239601.22:2002JAN18 g16740985 0 Homo sapiens, Similar to hypothetical protein DKFZp566A1524, clone MGC:24318 IMAGE:4041187, mRNa, complete cds. 89 LG:239673.8:2002JAN18 g2181825 1.0E-83 H.sapiens telomeric DNA sequence, clone 8QTEL004, read 90 LG:249905.45:2002JAN18 g15080393 0 Homo sapiens, cone MGC:8763 IMAGE:3860433, mRNa, complete cds. 91 LG:250038.3:2002JAN18 g5733725 0 Homo sapiens gamma-synergin mRNa, complete cds. 92 LG:252800.19:2002JAN18 g14572664 3.0E-34 Homo sapiens genomic DNa, chromosome 8q23, clone: KB1139G1. 93 LG:253580.6:2002JAN18 g17939581 0 Homo sapiens, clone MGC:13042 IMAGE:3625342, mRNa, complete cds. 94 LG:271509.8:2002JAN18 g21750516 0 Homo sapiens cDNA FLJ34700 fis, clone MESAN2002687. 95 LG:277161.30:2002JAN18 g13649404 0 Homo sapiens MS4A6A protein mRNa, complete cds. 96 LG:330739.4:2002JAN18 g24270882 0 Homo sapiens, Similar to RIKEN cDNA 2900084F20 gene, clone MGC:41939 IMAGE:5268756, mRNA, complete cds. 97 LG:331470.6:2002JAN18 g21335589 0 unnamed protein product (Homo sapiens) 98 LG:331661.1:2002JAN18 g11231088 0 Macaca fascicularis brain cDNa, clone:QccE-18536. 99 LG:332032.17:2002JAN18 g16306974 0 Homo sapiens, Similar to RIKEN cDNA B230118H07 gene, clone MGC:10116 IMAGE:3900485, mRNA, complete cds. 100 LG:332431.2:2002JAN18 g21754093 0 Homo sapiens cDNA FLJ37611 fis, clone BRCOC2011418. 101 LG:335173.4:2002JAN18 g18314362 0 Homo sapiens, clone MGC:1119 IMAGE:2959975, mRNa, complete cds. 102 LG:336529.3:2002JAN18 g10437845 0 Homo sapiens cDNA: FLJ21694 fis, clone COL09636. 103 LG:338001.2:2002JAN18 g14042055 0 Homo sapiens cDNA FLJ14497 fis, clone NT2RM1000039. 104 LG:338469.4:2002JAN18 g13676445 0 Macaca fascicularis brain cDNA clone:QflA-12278, full insert sequence.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 105 LG:344659.1:2002JAN18 g18676841 0 Homo sapiens cDNA FLJ23704 fis, clone HEP10851. 106 LG:345278.38:2002JAN18 g21752580 0 Homo sapiens cDNA FLJ36341 fis, clone THYMU2006505. 107 LG:346657.13:2002JAN18 g21740118 0 Homo sapiens mRNA; cDNA DKFZp547P234 (from clone DKFZp547P234). 108 LG:348101.16;2002JAN18 g21756063 0 Homo sapiens cDNA FLJ39225 fis, clone OCBBF2007224, highly similar to Homo sapiens candidate tumor suppressor protein DICE1 mRNA. 109 LG:350827.10:2002JAN18 g21751257 0 Homo sapiens cDNA FLJ35305 fis, clone PROST2009736. 110 LG:354580.28:2002JAN18 g21751565 0 Homo sapiens cDNA FLJ35546 fis, clone SPLEN2004078, weakly similar to CORNIFIN B. 111 LG:356006.3:2002JAN18 g7381239 3.0E-57 p38 interacting protein (Mus musculus) 112 LG:370212.10:2002JAN18 g18307966 0 splicing factor, arginine/serine-rich 12 (Homo sapiens) 113 LG:373219.13:2002JAN18 g21758331 0 Homo sapiens cDNA FLJ41019 fis, clone UTERU2019096. 114 LG:399821.22:2002JAN18 g7020907 0 Homo sapiens cDNA FLJ20661 fis, clone KAIA871. 115 LG:400519.1:2002JAN18 g10440231 0 Homo sapiens cDNA; FLJ23515 fis, clone LNG04761. 116 LG:402797.1:2002JAN18 g21755293 0 Homo sapiens cDNA FLJ38615 fis, clone HEART2006787. 117 LG:402974.1:2002JAN18 g13516382 1.0E-58 Homo sapiens genomic DNa, chromosome 8q23, clone: KB1589B1. 118 LG:403397.7:2002JAN18 g21748567 0 Homo sapiens mRNA for FLJ00360 protein. 119 LG:404199.4:2002JAN18 g21756386 0 Homo sapiens cDNA FLJ39494 fis, clone PROST2016444. 120 LG:404482.7:2002JAN18 g4884105 0 Homo sapiens mRNA; cDNA DKFZp566K023 (from clone DKFZp566K023). 121 LG:406239.1:2002JAN18 g21754638 0 Homo sapiens cDNA FLJ38072 fis, clone CTONG2015678, weakly similar to Rattus norvegicus PGC1 mRNA for PPAR gamma coactivator. 122 LG:407055.6:2002JAN18 g1663699 0 Human mRNA for KIAA0241 gene, partial cds. 123 LG:407485.1:2002JAN18 g21734245 0 Homo sapiens mRNA; cDNA DKFZp686E2367 (from clone DKFZp686E2367). 124 LG:422048.46:2002JAN18 g17066316 0 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 9657805. 125 LG:425448.18:2002JAN18 g15797276 3.0E-07 unnamed proteinproduct (Homo sapiens) 126 LG:435717.5:2002JAN18 g7768690 6.0E-73 Homo sapiens genomic DNA, chromosome 21@, section 14/105. 127 LG:451858.13:2002JAN18 g13937563 0 Homo sapiens, clone IMAGE:3454647, mRNa. 128 LG:462233.20:2002JAN18 g10436853 0 Homo sapiens cDNa; FLJ20895 fis, clone ADKA03483. 129 LG:473880.41:2002JAN18 g21753017 0 Homo sapiens cDNA FLJ36720 fis, clone UTERU2011261. 130 LG:474421.5:2002JAN18 g20379641 4.0E-87 Homo sapiens, hypothetical gene LOC136016, clone MGC:29720 IMAGE:5093832, mRNA, complete cds. 131 LG:481462.4:2002JAN18 g12247420 3.0E-23 Homo sapiens glioma-expressed antigen 2 (GLEA2) mRNA, partial cds.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 132 LG:7684981.2:2002JAN18 g21749200 0 Homo sapiens cDNA FLJ33622 fis, clone BRAMY2021388. 133 LG:7690420.1:2002JAN18 g16877165 1.0E-130 Homo sapiens, clone MGC:16833 IMAGE:3851667, mRNA, complete cds. 134 LG:7691425.2:2002JAN18 g247498 0 PBR1=proline-rich protein {intron 3} (human, Genomic, 898 nf). 135 LG:7692702.1:2002JAN18 g12860403 3.0E-23 evidence:NAS-hypothetical protein-putative (Mus musculus) 136 LG:7694388.21:2002JAN18 g1220304 7.0E-05 Homo sapiens dinucleotide repeat polymorphism. 137 LG:7697322.7:2002JAN18 g21754809 0 Homo sapiens cDNA FLJ38215 fis, clone FCBBF2000291. 138 LG:7697347.3:2002JAN18 g16553644 0 Homo sapiens cDNA FLJ33163 fis, clone UTERU2000541. 139 LG:7698451.18:2002JAN18 g21752300 1.0E-150 Homo sapiens cDNA FLJ36113 fis, clone TESTI2022179. 140 LG:7698705.7:2002JAN18 g21733368 1.0E-110 Homo sapiens mRNA; cDNA DKFZp667D2123 (from clone DKFZp667D2123). 141 LG:7731829.1:2002JAN18 g7768680 8.0E-26 Homo sapiens genomic DNA, chromosome 21q, section 72/105. 142 LG:7761659.11:2002JAN18 g21758885 9.0E-66 Homo sapiens cDNA FLJ25904 fis, clone CBR04573, highly similar to Homo sapiens PTD010 mRNA. 143 LG:7761806.33:2002JAN18 g21732657 0 Homo sapiens mRNA; cDNA DKFZp686C03103 (from clone DKFZp686C03103). 144 LG:7763039.6:2002JAN18 g862406 1.0E-173 Human cbl-b mRNA, complete cds. 145 LG:7763254.5:2002JAN18 g7023812 0 Homo sapiens cDNA FLJ11264 fis, clone PLACE1009111. 146 LG:7763421.8:2002JAN18 g21779781 0 Homo sapiens ABC transporter ABCA6 (ABCA6) mRNa, complete cds. 147 LG:7763437.104:2002JAN18 g13623424 0 Homo sapiens, Similar to KIAA0445 gene product, clone MGC:12760 IMAGE:4111573, mRNA, complete cds. 148 LG:7770095.2:2002JAN18 g551291 7.0E-66 Human DNa, novel tandem repeat sequence. 149 LG:7770589.6:2002JAN18 g7021183 0 Homo sapiens cDNA FLJ20852 fis, clone ADKA01414, highly similar to U28686 Human putative RNA binding protein RNPL mRNA. 150 LG:7770618.6:2002JAN18 g21749171 0 Homo sapiens cDNA FLJ33599 fis, clone BRAMY2013736, weakly similar to Homo sapiens gene for TU12B1-TY. 151 LG:7770900.9:2002JAN18 g21754854 1.0E-102 Homo sapiens cDNA FLJ38253 fis, clone FCBBF3000768, moderately similar to Homo sapiens general transcription factor 2-I (GTF2I) mRNa. 152 LG:7771513.22:2002JAN18 g19264129 0 Homo sapiens, RNA binding motif protein 9, clone MGC:39192 IMAGE:4555865, mRNa, complete cds. 153 LG:899402.3:2002JAN18 g21751166 0 Homo sapiens cDNA FLJ35227 fis, clone PRoST2001180. 154 LG:902699.29:2002JAN18 g3170174 1.0E-112 antigen NY-CO-1 (Homo sapiens) 155 LG:977532.3:2002JAN18 g7023746 0 Homo sapiens cDNA FLJ11219 fis, clone PLACE1008122.

Table 7 SEQ ID NO: Template ID GI Number Probability Annotation Score 156 LG:978729.5:2002JAN18 g23271392 0 Homo sapiens, Similar to RIKEN cDNA 1700124B08 gene, clone MGC:35262 IMAGE:5174046, mRNA, complete cds. 157 LG:980200.9:2002JAN18 g21733985 0 Homo sapiens mRNA; cDNA DKFZp686B2235 (from clone DKFZp686B2235). 158 LG:980859.5:2002JAN18 g21753338 0 Homo sapiens cDNA FLJ36985 fis, clone BRACE2006564. 159 LG:982723.4:2002JAN18 g10433764 0 Homo sapiens cDNA FLJ12317 fis, clone MAMMa1002058. 160 LG:986427.1:2002JAN18 g8518189 0 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076. 161 LG:996868.32:2002JAN18 g6330772 0 KIAA1238 protein (Homo sapiens)